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Summary 
Heart Failure (HF), a condition prevalent in older adults goes hand in hand with multiple 
concurrent diagnoses, polypharmacy and complex drug regimens. Consequently patients 
with HF need to develop effective strategies to care for themselves whilst managing the 
burden of multi-morbidities. Currently little is known about which factors influence 
adherence to medication in this population.  
To understand which factors consistently predict medication adherence in older people 
with HF a multi-methods study was undertaken. A systematic review of 21 studies 
reporting on interventions previously evaluated identified 8 which reported significant 
improvement in medication adherence. Interventions utilised a variety of approaches 
however heterogeneity in both intervention techniques and measurement methodology 
resulted in an inability to establish a clear effective approach.  
A rapid review of literature reporting on the perceptions and experiences of people with 
HF in relation to medicines proved equally inconclusive. Ten qualitative studies were 
reviewed highlighting non-adherent behaviour as multi-factorial and complex in nature. 
Individual beliefs, level of knowledge; environmental factors and the role played by 
significant others emerged as having the potential to influence medication adherence in 
both a positive and negative way. 
Utilising the information gleaned from the literature reviews a qualitative study was 
undertaken to explore beliefs around HF and its treatment. Using a purposive sampling 
strategy eight older HF patients and four nominated carers were recruited from a number 
of sites to participate in one to one structured interviews. Gender and recent admission 
to hospital were selected as key variables with carers directly nominated by the patients. 
Knowledge around both the condition and medication and the association between 
treatment and symptom control was found to be poor. While patients expressed a belief 
in the beneficial effects of medications, a wish to remain independent and trust in 
healthcare professionals were the main reasons given for adherence.  
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Finally, a prospective observational study of 60 community dwelling HF patients aged ≥ 
70years was undertaken. The primary outcome of adherence to medication was 
assessed using both direct and indirect methods. The secondary outcome of 
determinants of adherence were selected following analysis of the qualitative data and 
literature reviews. Adherence ranged from 74% to 100% depending on the method used 
however agreement between methods was found to be poor. No single determinant was 
found to consistently predict adherence across the different measures. 
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Chapter 1:  Introduction and overview 
1.1. Overview of chapter  
Heart failure (HF) has been defined as a ‟clinical syndrome of symptoms which may be 
as a result of structural or functional cardiac or non-cardiac disorder which impairs the 
ability of the heart to respond to physiological demands for increased cardiac output” (1) . 
The condition currently affects approximately 500,000 people in the UK (2); both incidence 
and prevalence increase steeply with age (3). HF is a major cause of disability, 
hospitalisation and death, particularly amongst older people. It is the most common 
hospital discharge diagnosis for patients over 65 years of age and is associated with 
symptoms (particularly fatigue and breathlessness), impaired physical function and poor 
quality of life (4). Given that patients with HF are typically older adults with multiple 
concurrent diagnoses, polypharmacy and complex drug regimens are common. Patients 
with HF consequently need to develop effective strategies to care for themselves whilst 
managing the burden of multi-morbidities that frequently result in polypharmacy. Non-
adherence in patients with HF may lead to worsening symptoms and eventually to 
hospitalization (5). 
Self-care for patients with HF is complex and often burdensome. For patients with HF it 
involves having to develop a range of skills across several domains including adherence 
to complex drug regimes, changing daily activities, ongoing monitoring of symptoms as 
well as modifications to dietary and fluid intake (6). According to European Society of 
Cardiology (ESC) guidelines multiple medications have been identified as being beneficial 
in HF and should be routinely prescribed (7). Improving medication adherence (‟the extent 
to which patients take medications as prescribed by their health care providers”) (8) has 
been identified as having the potential to impact on the health of the heart failure 
population in a greater way than improvement in any specific medical treatment (9).   
Enabling patients to adhere effectively to medications has been the subject of many 
studies in different long-term conditions such as hypertension and diabetes (10, 11). A 
systematic review carried out by Cramer (12) identified 20 published studies looking at 
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adherence in diabetic patients between 1966 and 2003 while a Cochrane review by Fahey 
et al (13) identified 38 studies conducted between 1975 and 2000 looking at interventions 
to increase adherence to blood pressure lowering medication in adults with essential 
hypertension. Little research however has been conducted in the context of HF (14).   
This chapter will describe the significance of the topic while defining the key terms of 
‘heart failure’ and ‘medication adherence’ used in this thesis. The background to the study 
as well as my previous experience as a nurse and researcher will be reflected on. The 
setting for the research will be discussed as will an overview of the research design 
including the research aims. Finally, the chapter will conclude with an outline of the 
content of subsequent chapters. 
1.2. Significance of the topic and context of the research  
1.2.1. Heart Failure 
The term ‟chronic heart failure” is defined in this thesis as:  
‟A complex clinical syndrome that can result from any structural or functional cardiac or 
non-cardiac disorder that impairs the ability of the heart to respond to physiological 
demands for increased cardiac output” (1) 
1.2.1.1. The burden of heart failure 
Chronic heart failure (CHF) has been described as an epidemic, particularly among the 
older population (15). Data from the Framingham heart study, a large cohort study from 
Massachusetts in the United States suggests that the incidence of heart failure doubles 
with every decade (16)pp17. HF is diagnosed in 1 to 2% of the population in developed 
countries (17). Currently around 60,000 people develop heart failure in the UK every year 
with prevalence expected to rise (18). In the UK the prevalence of HF is one in 35 people 
aged 65-74 years and increases to one in 15 of those aged 75-85 years. For those aged 
85 years and over prevalence is reported to be one in 7 (3).  In women the prevalence of 
HF is lower than in men at all ages. However, given the increase in incidence of HF with 
age, coupled with the proportionally larger number of elderly women in developed 
countries, the total number of men and women living with HF is similar (19). Overall, 
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survival rates among patients with HF do not appear to be improving (20) and it is predicted 
that the number of people with HF will continue to rise (21). While ongoing research in the 
development of cardiac devices, stem cell therapy and genetic treatment has and will 
assist patients with HF to live longer, the emergence of new medications has played a 
large part in the prolonging of life in those diagnosed with the condition (22). It is also 
important to highlight that most previous epidemiological studies reporting on the 
incidence of HF have included only patients displaying signs or symptoms and did not 
consist of the screening of an entire population where asymptomatic patients would be 
included. 
Despite recent improvements, prognosis for HF remains poor. The Hillingdon Heart Study 
found that of patients diagnosed with HF at the point of hospitalisation 40% had died 
within a year of that diagnosis while the Framingham Study and National Health and 
Nutrition Examination Survey (NHANES) survey reported high mortality and a prognosis 
of < 10 years (23). Although HF is considered a chronic or long-term condition, patients 
suffering from the condition can experience frequent decompensation which may lead to 
frequent hospital admissions. A three-year study of 570,000 hospitalisations found that 
patients hospitalised for HF were at high risk for all-cause re-hospitalisation, with the one 
month readmission rate estimated at 25% (24).  
Heart failure is an expensive condition currently accounting for 1-2% of all healthcare 
spending (25) and around 5% of all emergency hospital admissions in adults across 
Europe (26).  This significant burden on the National Health Service (NHS) budget is set 
to increase over the next few decades with hospital admissions projected to rise by over 
50%. The British Society for Heart Failure audit, carried out for the year 2014-2015, 
reported on nearly 57,000 hospital admissions for acute HF within England and Wales 
(27). Consequently this high number of hospital admissions has resulted in an estimated 
one million inpatient bed days (2% of the total) across the entire NHS (28). As well as heath 
care costs HF also places an additional burden on other agencies such as social services 
and the benefits system (25) and of course on people with HF, their families and caregivers.  
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Despite the prevalence of the condition, public awareness of HF is poor, with the condition 
commonly seen as a natural consequence of ageing. Perception of the illness was 
investigated by the Study group on HF Awareness and Perception in Europe (SHAPE) 
(29).  Researchers reported a high proportion of respondents believed that HF was a 
natural cause of ageing with one third wrongly believing that modern medication could 
not prevent its development (17, 30-32).  
Non-adherence to prescribed medication has been identified as a significant health 
challenge (33) and public health problem (34) with the World Health Organisation (WHO) 
identifying medication non-adherence as one of the major causes of preventable 
morbidity mortality and health care costs (35). Failure to take medication as it has been 
prescribed may result not only the attainment of suboptimal benefits for the patient 
themselves but may result in increased health costs for the population as a whole. 
Clinical guidelines have emphasised the need for HF patients to have a firm 
understanding of their condition and suggest that in order to avoid decompensation and 
maintain quality of life (QoL) patients should receive and make proper use of appropriate 
treatments, adopt lifestyle changes and receive ongoing advice from clinicians regarding 
medication adherence (36). In more general terms the management of long-term 
conditions such as HF poses a substantial challenge for health care services, particularly 
acute services. In order to reduce this burden those with long-term conditions require 
ongoing support in order to develop skills in self-management and be fully involved in all 
aspects of decision making regarding their health. 
1.2.2. Medication Adherence 
Non-adherence to medications has been documented to occur in >60% of cardiovascular 
patients (37).  Improving adherence to drug therapy therefore may offer an effective way to 
decrease costs. Importantly improvement in adherence has been shown to be possible. 
A recent randomised controlled trial (RCT) of sixty-two stroke survivors with an age range 
of 51-85 years concluded that implementation of a simple brief intervention, especially 
one which identified and addressed each individuals’ underlying beliefs, had the ability to 
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improve medication adherence not just among stroke survivors but within groups 
diagnosed with other long-term conditions (38). 
On a theoretical level, the nature and causes of non-adherent behaviour are complex and 
poorly understood.  The common-sense model (CSM) of illness cognitions and behavior 
by Leventhal et al (39) describes the factors involved in the processing of information by 
an individual regarding their disease or illness. The model identifies how this information 
is combined to provide a lay view of the illness and how this view guides coping 
behaviours and outcomes.  Given that patients not only hold personal thoughts around 
their illness but also about the treatment offered Horne has subsequently proposed that 
the CSM may also provide a framework for understanding intentional adherence (40). Self-
efficacy, the belief that one has the power to produce an effect by completing a given task 
or activity related to that competency, is the most important prerequisite for behaviour 
change thus any intervention aimed at improving medication adherence must consider 
factors that directly influence self-efficacy mainly behaviours, environment, and personal 
cognitive factors (41).  
1.3. Origins of the study and personal perspective 
My clinical nursing career has spanned nearly 30 years all spent working within medicine 
for the elderly services. Throughout that time, it became apparent to me that medication 
adherence in this age group was a significant problem, was difficult to address and that 
non-adherence frequently led to unwanted complications including hospital admission. 
My early journey into research brought me into contact with older HF patients many of 
whom, despite all having had a clinical diagnosis, had no idea they had HF and what that 
meant for them as individuals. While being able to describe the symptoms they 
experienced most were unable to relate these back to the underlying cause and in many 
cases explained these often unpleasant symptoms as simply a sign of advancing age. I 
realised that medical and nursing staff often assume that patients have had a previous 
explanation regarding any diagnosis and must therefore have developed an 
understanding of their medical condition. This was clearly not the case with these patients 
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with HF and it is therefore unsurprising that patients often don’t identify adherence to their 
medication with optimal management of their symptoms. 
In recent years members of the team of researchers within Ageing and Health at the 
University of Dundee with whom I worked completed a systematic review of the 
interventions available to enhance adherence to medications in patients with HF (42). The 
authors concluded that there was limited, high quality evidence evaluating the 
effectiveness of specific adherence enhancing interventions and recommended further 
research in order to identify the optimum strategies for implementation into clinical 
practice (42). Oosterom-Calo et al reached similar conclusions with their systematic review 
in this area (43).   
Analysis of data from a randomised controlled trial of exercise training in older HF patients 
was also conducted by the Dundee Ageing and Health team. Fifty-eight older outpatients 
with CHF had serum ACE levels measured and participants interviewed to assess beliefs 
about their illness. Whilst overall adherence to ACEI was 72%, participants who believed 
their illness to be a more chronic condition were more likely to be non-adherent to their 
medication and that a direct association could be made between medication adherence 
and beliefs about HF (44). 
It is clear therefore that gaps in existing research knowledge exist. There is an absence 
of data regarding which modifiable factors are associated with poor adherence in HF and 
a need to develop and test a theory-based intervention within this population. It was a 
desire to address these issues, coupled with my experience of working with older people 
(a group regularly under-represented in research studies) that led to the development of 
this PhD. 
1.4. Aims and objectives of the study 
The original aims of the research that underpins this PhD thesis were: 
1) To understand current beliefs around heart failure and medication in patients and 
spouses / informal caregivers. 
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2) To identify which factors around heart failure and medication consistently predict 
medication adherence, and which can be modified. 
3) To develop a brief deliverable psychological / psychosocial intervention to enhance 
medication adherence in heart failure patients for evaluation in a future randomised 
trial. 
1.5. Research setting and overview of research design 
The work for this PhD was conducted within NHS Tayside, an area with a combined 
population of over 400,000. Older patients with HF were recruited from across Dundee, 
Angus and Perthshire. Community based patients with HF were chosen rather than those 
in acute services as they were living with HF on a day to day basis and importantly were 
responsible for managing their own daily medication routine. Ethically it was also deemed 
less appropriate to ask patients about their understanding of their condition and 
medication when they were acutely unwell and in a potentially vulnerable position. 
As part of the work, a systematic review following Cochrane Review guidelines was 
conducted. Literature of key topics mainly: the nature and management of HF; factors 
believed to influence medication adherence particularly in HF and lay beliefs of illness, 
treatment and self-care in HF were reviewed.  
When considering the philosophical underpinning for any research study Creswell writes 
about the need to focus one’s attention on the research question while utilising 
heterogeneous approaches in order to develop knowledge about the problem (45). When 
learning about the social world the traditional view is that the paradigms of qualitative and 
quantitative research are underpinned by fundamentally different assumptions about 
ontology and epistemology and are thus incompatible. However, given the complexity of 
human phenomena multi-methods or mixed-methods research designs have increasingly 
been viewed as offering a third paradigm for research (46, 47).  
Despite having specific differences the terms mixed-methods and multi-methods 
research are often found to be used interchangeably (48). Mixed-methods research has 
been defined as ‟research in which the investigator collects and analyses data, integrates 
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the findings and draws inferences using both qualitative and quantitative approaches or 
methods in a single study” (49).  In mixed-methods research therefore it is suggested that 
by combining both quantitative and qualitative research methods researchers are 
provided with not only a richness from the qualitative enquiry but a scientific base for 
clinical practice.  
Alternatively, while a multi-method research design involves the undertaking of two or 
more research methods both qualitative and quantitative research approaches need not 
be involved (48). While driven by one overall research aim each study is planned and 
conducted independently using its own specific research question. Unlike mixed-methods 
were the results from each empirical study are integrated into the other assimilation in 
multi-method designs need not occur until conclusions are being made (47). Given that the 
work detailed within this thesis involved the undertaking of several different research 
methodologies with results triangulated to answer the overall research question a multi-
method research approach has been adopted. 
It is suggested that researchers seek to locate their research in a particular theoretical 
lens thus defining their epistemological, ontological and methodological stance (50).  In 
multi-methods research two philosophical positions direct the discussion. Qualitative 
researchers typically locate themselves within an interpretivist tradition while quantitative 
research is linked with positivism. While traditionally these paradigms have been deemed 
incompatible because of their differing ontological and epistemological stances it has 
been proposed that researchers may utilise an approach which seeks to bridge the gap 
between these opposing positions (51).  
The multi-methods paradigm is based on the belief that both scientific knowledge and 
common sense are relevant and neither are considered privileged (52). Rather than simply 
utilising one approach this paradigm is based around the belief that a better 
understanding of research problems can be achieved by the integration of both 
quantitative and qualitative data (53). In a similar manner, the philosophy of pragmatism 
points the researcher’s attention to operational rather than metaphysical concerns 
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advocating differing views and assumptions as well as use of multiple research methods 
(54).  
It is clear therefore that both HF, with its complicating presentation of symptoms and 
comorbid conditions and the topic of non-adherence to medications lend themselves to 
this method of research in order to explain both the qualitative and quantitative 
components. Additionally, when considering an intervention to improve adherence within 
the HF population, a multi-method methodology is a good precursor for the development 
and evaluation of a complex intervention as advocated by the Medical Research Council 
(MRC) framework (55).  
Using a research approach which encompasses of more than one method is not however 
without its weakness. A critical review of mixed-methods research in nursing carried out 
by Bressan et al reported inconsistencies in application and reporting across studies. 
Researchers attempts to articulate how the two distinct research methods related to one 
another often resulted in one or both phases having limitations with methods being 
applied in a less rigorous way (56). Another criticism or weakness of a multi-methods 
approach is that in order to achieve a positive study outcome the researcher requires to 
have a basic knowledge of both quantitative and qualitative methods and importantly have 
an understanding of how to combine these methods appropriately. While conducting this 
study I was fortunate to have a supervisory team which consisted of individuals with 
experience of both research paradigms and how they can successfully interrelate.  
1.5.1. Overall study research questions 
Given that the aims of this study required research data to be generated from different 
perspectives a multi-methods approach was adopted in order to answer the following 
research questions: 
1) What beliefs and attitudes do older heart failure patients and their informal 
caregivers hold about their disease and its treatment? 




3) Which modifiable factors predict non-adherence to medication in older people with 
heart failure? 
1.5.2. Current study methodology 
The study followed a sequential exploratory design as described by Creswell (see Figure 
1.1) (45). Using this approach, an initial phase of in-depth qualitative research sought to 
identify the beliefs held around heart failure and its treatment in a population of older 
people. Following directly on from this exploratory phase quantitative data collection was 
undertaken to facilitate an evaluation of the beliefs held around heart failure and 
medication which consistently predict medication adherence. Using this research 
approach enabled the results of the qualitative findings to be analysed during an 
interpretation phase which assisted in the selection of the outcome measurement tools 







Figure 1.1 Sequential exploratory study design adapted from Creswell (45) 
 
Undertaking a pragmatic approach to science-based healthcare involves using the 
method which appears best suited to the research problem while avoiding becoming 
caught up in philosophical debates. As a pragmatist I believe that every method has its 
limitations and that the different approaches can be complementary. The sequential 
research approach as described by Creswell (45) appeared to offer a natural 
methodological framework for this research. The sequential nature of the methodology, 




















offering the flexibility to conduct both studies independently appeared well suited to both 
the exploratory and descriptive aspect of work contained within this PhD.  
The empirical studies reported within this thesis have been conducted in two sequential 
phases. The first phase has explored the personal experiences relating to the condition 
of HF and its treatment of older HF patients and their informal carers using semi-
structured interviews. Emergent themes from these interviews were examined and used 
to aid the selection of validated questionnaires and tools, which were then used to gather 
quantitative data in the second phase.  The results of both studies have been combined 
with an updated systematic review of interventions to improve medication adherence in 
HF and a rapid review of qualitative studies identifying facilitators and barriers medication 
adherence in HF which were both completed during the period of study. 
1.6. Structure of the Thesis 
This thesis is structured into eight chapters according to the main arguments and 
processes of the research.  
Chapter two reviews the literature relevant to heart failure, medication adherence and 
illness perception thus providing the context for the study.  
Chapter three describes the updated systematic review. It defines the methods and 
provides the results.  
Chapter four reports on the rapid review of qualitative literature. The chapter describes 
the methods used and reports on barriers and facilitators to medication adherence as 
perceived by HF patients themselves. 
Chapter five describes the qualitative study; an overview of the methods is provided along 
with the results of the qualitative interviews and discussion of how the information from 
the semi-structured interviews determined the tools for the observational study. 




Chapter seven integrates the findings of the literature reviews; the qualitative and 
quantitative phases in an overall discussion according to the aims of the study. It 
summarises the conclusions of this thesis, reflecting on its strengths and limitations. 
Chapter eight identifies directions for future research including a description of the 
potential development of the (psychological / psychosocial) intervention.    
Chapter nine concludes the thesis with a short personal reflection on the author’s doctoral 
journey. 
The following chapter details the key concepts of the thesis. Literature pertaining to the 
nature and management of HF, adherence to medication and the role played by illness 
perception and personal beliefs is reviewed and discussed. 
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Chapter 2:  Background 
This chapter begins by defining heart failure, its importance in epidemiological terms, and 
its management with a focus on the older population. The topic of adherence to 
medication will be discussed along with potential factors influencing adherent behaviour. 
This chapter aims to justify the selection of heart failure and adherence as an important 
topic while highlighting the importance of illness perception and treatment beliefs on 
adherent behaviour.  
2.1. Heart Failure 
2.1.1. Defining heart failure 
The Scottish Intercollegiate Guidelines Network (SIGN) guides for the management of 
chronic heart failure describe the condition as: ‟A complex clinical syndrome that can 
result from any structural or functional cardiac or non-cardiac disorder that impairs the 
ability of the heart to respond to physiological demands for increased cardiac output” (1). 
This definition has been adopted in this thesis as it is current, clear and broad enough to 
include different forms of the condition. 
The main terminology used to describe HF is based on the measurement of left ventricular 
ejection fraction (LVEF). The grading of LVEF has been used to predict the severity of 
HF ranging from normal to severe left ventricular systolic dysfunction (LVSD). It is 
important to stress however that patients assessed as having a poor ejection fraction (EF) 
may be asymptomatic while patients with good EF may present with severe symptoms. 
Research into HF initially concentrated on patients with LVSD thus studies assessing 
therapeutic interventions have focused predominantly on this group of patients. Over the 
last 20 years however it has become evident that almost half the patients with HF 
syndrome do not have LVSD. The term HF with preserved ejection fraction (HFpEF) has 
been widely adopted to describe patients with with the clinical syndrome of HF and no 
evidence of LVSD. 
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2.1.1.1. Patient knowledge 
Heart failure is the preferred term in the UK however other terms such as ‟cardiac failure”, 
‟congestive cardiac failure” and ‟left ventricular failure” are common within the literature 
and are commonly used by clinicians. Patients are often uncertain about the term ‟heart 
failure” and what it means for them. Previous studies have estimated that around 20% of 
patients with moderate to severe HF reportedly may not know they have the diagnosis (57) 
while in the study conducted by Artinian et al. low levels of knowledge were reported in 
the areas of medications, self-care, and the ability to recognize the correct definition of 
HF (58). Heart Failure is frequently incorrectly referred to as a disease, while the use of 
the word ‟failure” has a socially constructed meaning that is negative - potentially causing 
unnecessary anxiety for patients and carers fearing that the heart, an organ necessary 
for life, may suddenly cease to work (16).  
2.1.2. Causes and symptoms of heart failure  
For optimal management of HF identifying potential exacerbating factors or other co-
morbid conditions as well establishing the underlying cause of the condition is essential 
(59). HF may develop as a result of a myocardial, valvular, pericardial or endocardial 
disorder or indeed a combination of these. In younger patients HF is frequently a result 
of coronary artery disease (CAD) or a cardiomyopathy of uncertain aetiology, often 
presumed to be viral, with the most common cause of HF among patients under 75 years 
in the UK being myocardial dysfunction secondary to CAD (60). 
Older HF patients differ from their younger counterparts in terms of several biological 
characteristics (61) including the relatively large proportion of HF patients with HFpEF. 
Amongst older patients systolic hypertension and consequent left ventricular hypertrophy 
(LVF) may be more important causes of HF and may be more likely to manifest 
predominantly as abnormalities of diastolic function.  For these older patients the original 
cause of HF can often be difficult to determine as patients may have lived with symptoms 
as well as other co-morbid disease for several years before seeking medical attention. 
Given that the syndrome is characterised by features such as breathlessness on exertion, 
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fatigue and signs of fluid retention and many of these features can be non-specific, a 
diagnosis in the initial stages of the condition often proves difficult. In addition to age the 
aetiology of HF may also depend on ethnic origin, socioeconomic status and geographic 
location.  
The most common type of HF is LVSD with around 50% of patients having reduced left 
ventricular contraction during systole (59). It has been estimated that within the UK 
coronary artery disease accounts for around two thirds of HF cases with many patients 
having experienced a myocardial infarction (MI). A history of non-ischemic 
cardiomyopathy caused by either hypertension, atrial fibrillation, thyroid disease, alcohol 
excess or valvular disease accounts for the majority of the remainder (62). 
2.1.2.1. Risk factors 
Risk factors for HF include lifestyle factors such as obesity, smoking and excessive 
alcohol (63-65) and comorbidities such as hypertension atrial fibrillation, diabetes, renal 
dysfunction and dyslipidaemia (64, 66-68). HF risk increases with age and male gender. Low 
physical activity levels and poorer socioeconomic status are also found to be associated 
with increased risk. Hypertension and CAD are by far the most common risk factors 
conferring a doubling of risk (69). Figures for different ethnic groups are limited, however 
one population-based study carried out by Bahrami et al. in the USA reportedly found 
African Americans to be at significantly higher risk for incident HF compared with other 
ethnic groups. However the results of this study did also specify that higher rates of 
hypertension and diabetes mellitus associated with poverty and other environmental 
factors largely explained the reported ethnic differences (70). 
Key to the diagnosis and on-going management of the condition is recognition of signs 
and symptoms that are specific for HF. When patients present with pronounced 
symptoms diagnosis of the condition may be straightforward. It is acknowledged however 
that many of the symptoms which have prompted the patient to seek medical attention 
are non-specific and may not therefore help distinguish between HF and other possible 
medical problems. Importantly there is no single symptom, sign or combination of both 
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that can be classed as specific for the diagnosis. While previous studies have identified 
the most prevalent symptoms as shortness of breath and ankle oedema (71), the clinical 
diagnosis of HF contains a large amount of subjectivity from both the patient’s and the 
clinician’s perspective (72). Distinguishing the syndrome from other causes of exercise 
intolerance and breathlessness may therefore be more difficult in patients in the early 
stage of the syndrome and when symptoms are mild (73).  
The often-insidious onset of HF means that patients often don’t present until the condition 
is well advanced. Given that symptoms may have been present for several years, 
acceptance of a diagnosis of HF may be difficult for patients resulting in difficulty 
managing the condition and associated symptoms successfully. 
2.1.3. Epidemiology of heart failure 
2.1.3.1. Incidence and Prevalence 
As previously stated, HF has been identified as an epidemic and significant public health 
issue particularly among those aged 65 years and over (74) with the average age at first 
diagnosis reported to be 77years (75). Worldwide, around 26 million are estimated to be 
living with HF (76).  HF incidence and prevalence are highest amongst older people (67). 
with both incidence and prevelance increasing with age, reportedly doubling with every 
decade (16)pp17.   
In the Framingham study, data from the USA, the incidence of HF was estimated to range 
from 2 per 1000 per annum in individuals aged between 45 and 54, increasing to 40 per 
1000 per annum in men aged between 85 and 94 years (77).  Within the UK population 
Cowie et al conducted a study across 31 GP practices in London over a 20-month period 
reporting the incidence of HF to be 1·3 cases per 1000 population per year for those aged 
25 years or over with incidence rising with age to 11.6 in the population of 85 years and 
over, again with incidence higher in the male population (76). More recently, in a 
population-based cohort study which included primary and secondary electronic health 
records of 4 million patients aged ≥16 years, HF incidence was reported as 332 per 
100,000 person years which demonstrated a decrease of 7% between 2002 and 2014. 
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However, it is worth noting that while incidence was decreased, the study reported around 
a 23% increase in people living with HF rising from 750,127 in 2002 to 920,616 in 2014 
(78).  
In relation to prevalence of HF recent estimates report prevalence of HF in Scotland to 
be 8.72% for men and 5.97% for women over 75 years (2).  While both incidence and 
prevalence are lower in woman than in men at all ages the steep increase in incidence 
that occurs with age, along with the proportionally larger number or women in the 
population, results in similar numbers of men and women living with condition (19). 
2.1.3.2. Comorbidity and polypharmacy 
Co-morbidity is common in older patients and has grown increasingly prevalent over 
recent decades. Wong et al analysed data on 1,395 patients with self-reported HF from 
National Health and Nutrition Examination Survey (NHANES) across three different time 
periods. Overall while patients demonstrated overall improvements in blood pressure and 
cholesterol control there was a significant change in complexity in their presentation with 
increase in the percentage of CHF patients who had five or more chronic conditions (42% 
in 1988-1994 to 58% in 2003-2008). Additionally the number of medications prescribed 
to each individual also increased significantly from 4.1 to 6.4 prescriptions during the 
same period (79). 
A cross sectional study carried out by Barnett et al across 314 medical practices in 
Scotland identified multi-morbidity (defined as the presence of two or more conditions) in 
97% of all patients diagnosed with HF while 74% had 3 or more diagnosed conditions (80). 
2.1.3.3. Prognosis 
Despite recent advancements in the pharmacological treatments available for HF 
prognosis for patients with the condition is poor. Following initial diagnosis patients can 
anticipate an average life expectancy of around 3 years, (67) less than is expected for 
many other conditions and similar to some types of cancer (81). A population study carried 
out in Scotland analysing data on 1.75 million patients (82) reported the 5-year survival 
from HF to be around 56% compared to around 68% for prostate cancer and 57% for 
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bladder cancer in men.  In women, 5-year survival for breast cancer was reported as 78% 
however in HF the rate was only 50%. More recently, Mehta et al analysed data from two 
London based population-based studies and reported mortality to be around 14% within 
the first 6 months following a HF diagnosis (19). 
A reduction in mortality from coronary heart disease (CHD) of around 60% has been 
achieved in Scotland over the last decade (83). However, the prevalence of HF continues 
to rise with a 25% five-year survival rates for both sexes (82). A Scotland-wide 
retrospective cohort study undertaken by MacIntyre et al using the Scottish National 
Health Service Linked Patient Database reported prognosis for HF patients as being 
worse than had been previously described in RCT’s with the median survival being only 
1.5 years (84). In this cohort around 50% of all patients admitted to hospital had died within 
one year.  
2.1.4. Healthcare burden of heart failure  
Heart failure is a major and increasing public health problem causing significant costs in 
both economic and personal terms. Current figures estimate that around one million 
inpatient bed days in the UK are currently attributable to the condition. On examination 
these figures relate to 2% of the total NHS inpatient bed days and 5% of all emergency 
medical admissions to hospital (85). Worryingly, due largely to population ageing, hospital 
admissions due to HF are projected to rise by around 50% over the next 25 years; (86, 87) 
this despite a continuing fall at around 1.5% per year of the age adjusted hospitalisation 
rate (88). It is estimated therefore that around 2% of the total NHS budget is attributable to 
HF with the costs of hospitalisation estimated to make up 70% of this total (89).   
Related co-morbidity accounts for a considerable part of prolonged hospital admissions 
of people with a diagnosis of HF (90). The NHS HF survey, a survey of acute HF 
admissions carried out in England, Wales and Northern Ireland, found that while 99% of 
patients with the condition were discharged within 10 days of admission an average 
length of stay of around 7 or 8 days could be expected (91). Readmissions are also 
common. While the Euro Heart Failure survey programme found that within 12 weeks of 
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hospital discharge around 24% of patients had been readmitted (28) within six months of 
discharge Butler estimates readmission rates to be nearer 50% (18).  
In older people readmission may not always be as a result of HF itself but may be due to 
a disproportionate focus being placed on the exacerbation of the condition. Following 
hospital discharge HF patients may experience what Krumholz describes as the ‟ ‘post-
hospital syndrome’ - an acquired transient period of vulnerability post discharge”.  It may 
be that these patients not only have to cope with the ongoing consequences of the 
condition itself but must also try and manage the allostatic and physiological stress 
hospitalised patients typically experience (92).  Conducting an analysis of Medicare claims 
Jencks et al reported that only 37% of the readmissions for recently those previously 
admitted to hospital with HF could be directly attributed to their HF diagnosis. More 
frequently causes of readmission commonly included pneumonia, renal failure or nutrition 
related issues (93).  
2.1.5. Illness trajectory in Heart Failure 
Despite HF being a chronic or long-term condition, those diagnosed with the condition 
may experience recurrent episodes of decompensation which may result in hospital 
admission (94) with early hospitalisation a particular in risk for older patients (95). Figure 2.1 
presents an illness trajectory for a chronic condition such as HF. After each acute episode 
it is common for individuals to experience a decline in their physical, social and 
psychological baseline making it difficult to determine which acute phase will potentially 
end in death.  
Importantly, behavioural factors including non-adherence to medications or self-care may 
contribute to these acute episodes. In a study of 578 hospitalised older adults 14% of all 
medical emergency admissions were reported to be as a consequence of issues with 
medication. Additionally, 7% of these admissions were attributable to non-adherence and 
worryingly 192 (33%) of all patients in the study already had a history of non-adherence 
(97). It is clear therefore that people with HF need to develop and maintain strategies and 





Figure2.1 Trajectories of social, psychological and existential decline in people with heart failure 
(reproduced from Murray et al (96)) 
 
2.1.6. Context of heart failure care 
Treatment for HF usually aims primarily to relieve symptoms, while avoiding preventable 
hospital admission and improving survival rates. Significant involvement from both 
patients and healthcare providers is therefore required in order to achieve optimum 
management of such a complex condition. Generally, medicines have been described as 
being the mainstay of treatment in HF however management of the condition should be 
considered in terms of a range of interventions including both device and pharmacological 
therapies as well as self-care strategies including diet and exercise modification and 
continual monitoring (16).  
2.1.6.1 Pharmacological therapies 
Throughout the literature an extensive evidence base exists to support pharmacological 
management of patients with HFrEF with explicit guidelines regarding prescribing across 
Scotland detailed within Sign Guideline 147: Management of chronic heart failure (1). In 
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parallel with the prescribing of medications such as ACEi (31), ARB’s (98), aldosterone 
antagonists (99) and beta blockers (100) survival rates from HF have improved. Additionally, 
in patients with LVSD these groups of medications have been shown to improve 
hospitalisation rates while the prescribing of ACEi has been associated with 
improvements in quality of life (101,102).  
The current first line treatment in HF is considered to be ACEi and beta-blockers while 
diuretics are prescribed to aid in the removal of excess peripheral and pulmonary fluid. In 
those found to be intolerant of ACEi the prescribing of ARBs is currently recommended. 
More recently medications which combine a neprilysin inhibitor with an angiotensin 
receptor blocker have been found to be superior to ACEi and ARBs for outcomes such 
as hospitalisation and all-cause mortality in patients with  HF (103) increasing the likelihood 
that medications such as Sacubitril will replace these medications in the coming years. 
2.1.6.2 Invasive therapies 
In addition to pharmacological therapy invasive treatments such as cardiac surgery or 
pacemaker insertion can be considered for the management of HF. While cardiac surgery 
can be identified as a curative procedure the lack of available donors makes this an 
unrealistic treatment option for most patients, particularly for the older, co-morbid HF 
patient who would not make a suitable candidate for major cardiac surgery. Given the 
advances in pharmacological and pacemaker therapies few HF patients now require 
cardiac transplantation (1) however those patients with severe HF who are awaiting 
transplantation may have the option to undergo insertion of a mechanical circulatory 
support (MCS) system as an interim measure (104). In patients whose HF has been caused 
by valve disease, surgery to unplace the damaged valve is possible.   
In patients with HF sudden cardiac death occurs at a rate 6-9 times that of the general 
population (105). The insertion of implantable cardiac electronic devices (ICEDs) have 
become increasingly commonplace in the management of patients with HFrEF who are 
already prescribed optimal medical therapy (106). Implantable cardioverter defibrillators 
(ICDs) have proven to be an effective treatment for those who are experiencing life-
threatening ventricular arrythmias (107) while cardiac resynchronisation therapy (CRT), 
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has been demonstrated to significantly reduce morbidity and mortality in HF patients with 
HF and a broad QRS complex on electrocardiography (ECG) (106). 
2.1.6.3 Clinical management 
With the advances in the pharmacological and device management of HF comes 
complexity in the delivery of care to patients (109). According to NICE guidelines a 
multidisciplinary team approach (MDT) is essential in order to achieve individualised care 
which is responsive to the changing needs of the patient and which can be delivered 
seamlessly across both primary and secondary care (75). Central to the delivery of care 
within the MDT are Heart Failure specialist nurses (HFSN) who are ideally placed only to 
promote collaborative working between healthcare professionals across both primary and 
secondary care settings but to deliver evidence-based interventions which aim to address 
the complex health issues faced those with a HF diagnosis (110).   
Ongoing monitoring of patients with HF including assessment of functional ability, 
cognitive and nutritional status, fluid status, cardiac rhythm, review of medications 
including side-effects and renal function is an essential component of clinical 
management, the frequency of which should be dependent on the clinical stability of the 
patient (75).  While monitoring is seen largely as the responsibility of the healthcare 
professional, patient self-management is acknowledged as essential to achieving 
optimum outcomes.  Through supportive relationships with clinical specialists such as 
HFSN patients should be given advice and education regarding their own role in the 
management of the condition and associated treatment in order to achieve clinical stability 
(111). 
2.2. Medication Adherence 
While the prescription of medicines is the most common healthcare care intervention in 
order for pharmacological therapies to be effective, adherence to the prescribed regime 
is key (9). It is well documented that poor adherence to medication results in worsening of 
disease, a higher risk of death, and increased health care costs. 
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2.2.1. Compliance, Adherence and Concordance 
Within the literature three main terms compliance, adherence and concordance are often 
used interchangeably to describe patient’s medicine taking behaviour. Compliance is 
defined in the Oxford Dictionary, as ‟the practice of obeying rules or requests made by 
people in authority” and is commonly defined in healthcare as the degree to which a 
patients behaviour matches the prescribers recommendations (112).  Compliance, a phrase 
also meaning accepting punishment, is a word with negative associations were patients 
are believed to ῾submit’ and follow any given instruction. Inherent to a definition of 
compliance is the assumption that all medical advice is ultimately good for the patient 
therefore rational behaviour necessitates the exact following of the advice. Consequently 
any non-compliant behaviour could be viewed as either patient incompetence or worse 
disobedience. 
Proposed as an alternative term to compliance, the term adherence has been defined as 
the extent to which people follow the instructions for prescribed treatments (8, 113).  In the 
doctor-patient relationship the term adherence attempts to support a collaborative 
relationship between the patient and the healthcare provider removing the balance of 
greater power from the doctor (114). Adherence is seen to be influenced by not only the 
patient and their environment but by the practices of the prescriber and the characteristics 
of the care delivery systems (115). While the term adherence suggests that patients take 
their medication after making an informed choice the term ‘compliance’ implies that the 
patient is submissive and simply complies with instruction (116). The WHO has placed 
great emphasis on the need to differentiate between compliance and adherence stating 
that the patient's agreement to the recommendation is the main difference (35).  
The third term, concordance, is often used incorrectly as a synonym for adherence within 
the literature and was developed by a committee of health care researchers who 
attempted to conceptualise the problem of adherence. Concordance acknowledges that 
clinicians have historically failed to take account of the patient’s perspective and that for 
many non-adherence is a rational choice. Concordance elicits the patient’s wishes and 
considers them to be of paramount importance (117). Overall the term recognises that 
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within any interaction between the healthcare professional and the patient two sets of 
health beliefs are involved and that while these may be different they are equally valid.  
Central to the concordance model is a requirement for patients to be able to make an 
informed regarding any proposed treatment, the potential benefits and possible risks. 
However this type of therapeutic relationship can only be successful if the patient feels 
there is potential benefit from their participation and may run into difficulties should 
patients be unwilling to participate or if they feel participation may be potentially harmful 
(118).  
Finally rather than focusing on the patient's medicine-taking behaviour itself the term 
concordance refers directly to the interaction between the prescriber and the patient (119). 
Given that the term adherence recognises the autonomy of the patient and requires that 
any recommendations given by the healthcare professional are mutually agreeable the 
term adherence has been adopted in this thesis.  
2.2.2. Measuring adherence 
Medication adherence is described as the percentage of prescribed doses which are 
actually taken over a specified period however there is no current consensus for what is 
considered ῾acceptable’ adherence (8). Within the literature medication adherence can be 
reported as either continuous or dichotomous variable data with the latter used most 
frequently. While an eighty percent cutoff point is commonly used to classify patients into 
either adherent or nonadherent groups this varies between 75% and 90% and is not 
based on any empirical evidence (120).   
Importantly there is no evidence to suggest that 100% adherence is needed to achieve 
optimal outcomes in patients with HF (120). In an attempt to determine a cutoff point above 
which a positive relationship between level of medication adherence and event-free 
survival could be established Wu et al conducted a longitudinal study of 135 patients with 
HF. In this study the number of prescribed doses taken or the correct dose required to be 
taken ≥88% of the time to achieve significantly better event-free survival. However, it may 
be that cut-off points for adherence may vary depending on the indication for the drug. 
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The impact of missing or incorrectly administering drugs for conditions such as 
Parkinson’s disease, or epilepsy or omission of medications such as oral contraceptives 
may be great while missing doses of a statin may not have a significant impact on either 
short term or long-term health outcomes. 
The complexity of adherence has resulted in a lack of consensus on measurement of 
adherence with a variety of different methods reported within the area of HF research 
(121). Traditionally, both direct and indirect measures of adherence have been used.  
2.2.2.1.  Direct methods of adherence 
Direct methods may involve ether a direct observation of patient’s medication-taking 
behaviour; measurement of the drug itself or seek to identify a biological effect of the 
medicine within bodily fluid. Additionally where biological effects cannot be directly 
measured the administration of tracer substances, along with the medication, facilitates 
blood or urine levels of the tracer as a direct test to confirm if the medication was ingested. 
However, while considered the most accurate, direct methods may not be appropriate in 
all situations. Measurements are not currently available for all medications, they may may 
require invasive procedures; they may not account for pharmacokinetic variability and 
finally they can be costly to perform (112).  
The ability to obtain a true pattern of adherence may also problematic using direct 
methods. It is possible that given these methods usually require a pre-warning of either 
blood or urine sample collection or a researcher to be physically present to record the 
medication being administered the patient is alerted that adherence is being measured. 
This awareness may result in ‘the toothbrush effect’ were adherent behaviour is altered 
(122). In a similar way that we remember to brush our teeth on the day we are due to see 
the dentist, when people know that they are going to have a blood test or urine test to 
measure adherence, they are more likely to take the medicines on that occasion. 
Consequently, when adherence is measured using direct methods only a simple yes/no 
result is generated without revealing the true pattern of nonadherence or giving the 
researcher insight into their causes. 
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2.2.2.2.  Indirect methods of adherence 
Indirect measurements are more commonly found in adherence research. They include: 
pill counts, patient self-report through questionnaires, interviews and diaries, prescription 
refill history through prescription dispensing data and the use of medication event 
monitoring systems (MEMS) (112, 123).   
Commonly used as a measure of adherence within RCTs are pill counts, data collected 
by simply counting of the number of returned dosage items compared with the number of 
items received. However, pill counts have the potential to overestimate actual adherence 
behaviour (124) as just before the return appointment the patient may discard any 
remaining medication (125,126. In addition, pill counting does not generate a medication-
taking pattern and the removal of the correct number of medicines from the container 
does not necessarily mean the patient has followed the dosing regimen consistently or 
has actually ingested the medication.   
Interviews and self-report are notoriously vulnerable to overestimates of adherence (112). 
Many factors can account for difficulties with accurate reporting of adherence using self-
report measures with social desirability and poor recall being the most common (127). 
Retrospective self-report of medication adherence requires the patients to recall their 
experience of a repeated task over a period. However, the undertaking of a routine and 
recurring task such as the taking of daily medication may lead to the formation of a generic 
memory rather than a memory of each individual event. Additionally, when a task is 
repetitive, confusion may arise between the thought about taking the medication and the 
memory of actual taking it.  
The ability to study adherence within large populations has become increasingly possible 
due to the recent growth in availability of electronic pharmacy data (127). Measures of 
medication adherence based on pharmacy data are usually defined by the number of 
doses dispensed in relation to a dispensing period. While this method can support the 
assessment of multidrug adherence and assists in the identification of patients at risk for 
treatment failure (128) the validity of prescription refills depends on the completeness of 
the pharmacy database (112). 
49 
 
The Medication Events Monitoring System (MEMS) is an electronic device created 
specifically to monitor medication adherence behaviour.  These devices contain a 
microprocessor that records the time and date a dose of medication was taken by 
recording when a medication container is opened. In this way an assessment of 
adherence patterns and timings of dosage can be made while nonadherent episodes can 
be detected (129). Electronic monitoring devices are however not without their 
weaknesses. It has been suggested that use of the MEMS may lead to ‘white coat 
adherence’ where adherence is timed to meet the needs of the consultation with the 
doctor. Additionally, while the system produces evidence that the container has been 
opened there is no assurance that patients have actually taken the medication (130). Apart 
from patients purposefully trying to mislead the system there is potential for them to 
accidentally activate the device out with the medication dosing times (129). 
Overall, direct methods of detection have a higher sensitivity and specificity than the 
indirect methods (131). A study examining the consensus between different measures of 
adherence in patients prescribed daily cholesterol-lowering medication reported that 
electronically monitored doses adherence and pill counting had the highest specificity 
(89.1% each) followed by the self-reported Morisky scale (80%). While all other measures 
assessed in the study had poor sensitivity and specificity three the measures recorded 
high sensitivity, the electronic monitoring interval adherence (84.2%), Haynes self-report 
(84.4%), and the pill count (89.1%) (126). 
In HF, a study looking to predict hospitalisation in HF patients showed medication 
adherence as measured by medication event monitoring system was the best predictor 
of hospitalisation and concluded that it should be added to the previously used variables 
(132). 
2.2.3. Types of non-adherence 
The WHO stress that adherence to any regime may involve many different therapeutic 
behaviours including the seeking out of medical attention, the filling of prescriptions, the 
taking of medication appropriately and self-management (35).  
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Non-adherence has been the topic of many studies over the last 40 years. Despite around 
200 variables such as socioeconomic factors and disease pathology being identified as 
being potentially associated with adherence a consistent link with adherence rates has 
been difficult to demonstrate.  
Nonadherence to medication can be identified in three ways (133): 
1) Non fulfillment adherence: while the health professional provides a written 
prescription it is either not exchanged for the medicines or the medication is not 
commenced. 
2) Non persistence: having commenced treatment, the patient chooses to stop taking 
a medication without seeking the opinion of a health professional. 
3) Nonconforming: while the patient does administer the medication they do not 
adhere to the original prescription. This type of non-adherence may include: the 
skipping of doses, taking incorrect doses or taking dosage at incorrect times, taking 
more medication than prescribed or delaying advice from a healthcare 
professional. 
Adherence may be classified as either non-intentional or intentional. In later life, non-
intentional adherence can be common and may be the result of a number of factors 
including: a failure to remember to take the medication; an inability to swallow or apply 
the medication or an inability to understand the dosage directions due to cognitive 
impairment (134). Intentional non-adherence occurs when, against the advice of their 
health care professional, a patient consciously elects not to take their medication. Central 
to intentional nonadherence is patients’ beliefs about their condition (10).  
Overall barriers to adherence vary widely and may include factors such as concerns about 
efficacy; a fear of potential side effects or safety; inconvenience; poor doctor-patient 
relationship; lack of social support; patient motivation, or incorrect education regarding 
proper use.   
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2.2.4. Scope of the problem 
Very few patients of any age adhere perfectly to their medication regime (135). In the 
general population it is estimated that between 25% and 50% (11, 35) of patients do not 
take their medication as prescribed (8, 11). Even when medications are taken regularly it is 
estimated that as many as one half are taken incorrectly (114).  Adherence to medication 
taken for chronic conditions is worse than for those prescribed for acute conditions and 
deteriorates further after the first 6 months of treatment (8). In the HF population adherence 
to medication is even more unclear with reported adherence rates varying between 10% 
and 98% (43). 
In recent decades the number of medications prescribed for HF has expanded greatly. 
However unlike other conditions these medications, rather than replace existing 
medications have been prescribed in addition to the current regime (136). Poor adherence 
to treatment has been identified as a problem in HF particularly when multiple medications 
are prescribed (25).   
Estimates put rates of non-adherence in HF patients at between 40-60% (123) however 
literature looking specifically at non-adherence in older HF patients report rates ranging 
from 10% in patients newly prescribed digoxin (137) to ≥98% when adherence was self-
reported using structured questionnaires relating to compliance (5). In another study 27% 
of older HF patients were found to be non-adherent one month post hospital discharge 
despite being given written instructions, with the authors attributing much of this non-
adherence due to poor recollection of instructions (138).  Overall establishing an accurate 
non-adherence rate is difficult due in the main to the wide range of adherence recording 
methods used across studies. 
2.2.5. Consequences of non-adherence 
The cost of non-adherence can be significant but may not always be evident to the 
individual patient while the impact non-adherence may have on health care costs may be 
similarly hidden (14, 139). 
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2.2.5.1. Personal consequences of non-adherence 
There is evidence to suggest that patients with poor adherence experience worse clinical 
and economic outcomes than those who adequately adhere to treatment (140). In the older 
population the consequences of non-adherence can be particularly significant (114). A 
study by Col et al attributed 28% of hospital admissions in patients < 65 years to 
medication issues, with 11% of these admissions directly related to non-adherence (141).  
A further study found that 26% of admissions in those over 75 years could be directly 
attributed to non-adherence with medication (142).  
In HF positive clinical outcomes can be achieved when patients adhere to guideline 
recommended treatments. In one third of hospital admissions non-adherence to either 
prescribed medications or lifestyle modifications have been reported as a factor for 
admission (143, 144). In particular, adherence to ACEi and ARB have been associated with 
a significant decrease in mortality and hospitalisations for patients with HF (31, 145, 146). In 
the CHARM trial adherence to study medication was associated with lower all-cause 
mortality (HR 0.65, 95% CI 0.57-0.75, p<0.0001) (147). This association was true for 
participants in both the active and the placebo arms suggesting that patients who adhere 
to prescribed treatment are more likely to adhere to other health-promoting behaviours. 
In HF the aim of treatment is not only to improve prognosis but to relieve symptoms and 
maximise function in order to achieve the highest level of QoL for patients. Nonadherence 
to prescribed treatment may therefore potentially have a detrimental effect on an 
individual’s health-related quality of life (HRQoL) (148, 149) impairment of which has indeed 
been shown to be prevalent within in the HF population (150). In a study comparing HRQoL 
in HF patients with HRQoL in a sample of participants randomly selected from the general 
population those with HF reported more severe physical impairment of QoL than those 
with a history of either arthritis or chronic lung disease (151). Similarly Juenger et al found 
a greater reduction in HRQoL, especially in the areas of physical functioning, social 
functioning and emotional functioning compared to a sample of a healthy population (152).  
Within cardiovascular populations including HF, HRQoL measures have been shown to 
predict mortality and cardiac events (153).  In a study examining the association between 
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HRQoL and antihypertensive medication adherence in older adults low HRQoL scores 
were associated with lower levels of antihypertensive medication adherence (154). In the 
SOLVD study, baseline indicators of QoL including activities of daily living; general health 
and symptoms of heart failure were reported to be predictive of both mortality and 
hospitalisations in both symptomatic and asymptomatic HF patients (155). A systematic 
review and meta-analysis of pharmacological and lifestyle Interventions in patients with 
HF concluded that improved adherence was associated with positive effects on a range 
of outcomes, including quality of life (156).   
While poor adherence to medication is associated with increased personal costs for 
individual patients (140, 147), the financial cost of medication itself has been identified in 
several studies as having negative consequences for adherence to medication in HF. In 
a qualitative study by Horowitz et al decompensation of patients with HF was directly 
attributed to financial difficulties when medical insurance had not covered cost of 
treatment (36).  
2.2.5.2. Wider consequences of non-adherence 
In Scotland the cost of medication prescribing is ever increasing. In 2015/16 total the 
number of dispensed medications in Scotland rose 1% on the previous year to 102 million 
items totalling a net cost to the country of £1.3 billion. Over a ten year period the net cost 
of medication had increased by 28% with the Scottish average sitting at just over £215 
per person in 2014.   
In 2012 the Department of Health reported that 58% of people in England aged 60 years 
and over had been diagnosed as having at least one long‑term condition. Multi-morbidity, 
the presence of two or more long-term conditions now currently affects around 27% of 
the population with numbers expected to continue to grow given the ageing population 
(157). Given that multi-morbidity is a major factor in the prescribing of medicine, the need 
for prescribing will continue to grow with polypharmacy also becoming an increasing 
trend. 
The waste of public resources and increasing cost to public health resulting from non-
adherent behaviour is therefore a significant growing problem for the NHS. It is estimated 
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that medicines returned to pharmacies currently cost the NHS approximately £100 million 
per year while NICE report that the NHS carries an additional financial burden of between 
£36 million to £196 million per year on cost directly related to hospital admission as a 
result of patients not taking their medicines as prescribed. 
Given the size of the problem and the huge financial burden attached to non-adherence, 
the reasons why patients do not take their medicines as prescribed has become a much 
researched area with published articles numbering tens of thousands (158). However a 
lack of consistency exists within the field with no definitive measure of adherence nor a 
coherent picture of the key variables. Consequently, progress in the area of medication 
adherence has been slow (159).  
2.2.6. Factors associated with non-adherence in heart failure 
Non-adherence in HF is clearly a complex problem (136). However in order to develop an 
intervention aiming to support patients in this area a clear understanding around the 
factors which can influence treatment adherence is required (160). The WHO have 
identified five multidimensional factors to be considered when looking to address non-
adherent behaviour: Socio-economic factors; health-care setting; condition related 
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In relation to HF a narrative review undertaken as part of the background planning for this 
thesis found limited high-quality research in relation to the WHO adherence model (See 
table 2.1.). 
2.2.6.1. Socio-economic factors 
WHO have identified factors such as household income, marital and living status, level of 
education and health literacy, social support and household income as having influence 
on adherence (160). 
Socioeconomic Disadvantage 
In general terms, those who are least deprived on average live longer and in better health 
than those with a lower socioeconomic position. Additionally, those classed as most 
deprived tend to access less specialist services than those in higher socioeconomic 
positions but will utilise more general health care services (161). However limited evidence 
currently exists on the possible effect of deprivation on medication adherence. This may 
be due in part from the current knowledge base being drawn largely from results of RCT’s 
which are usually performed on a pre-selected patient population consisting of highly 
motivated individuals drawn from a population of individuals in the higher socio-economic 
groups (161).  
In a cross-sectional population-based study based on data from Sweden, socioeconomic 
disadvantage was associated with medication non-adherence which increased with older 
age, particularly among women (161). In the UK systematic analysis of medication issue 
data from 76 general practitioners associated higher adherence levels with those in less-
deprived areas (162). 
In HF, the relationship between financial status and medication adherence has not been 
examined in detail. In two studies Dunbar-Jacob et al (163) reported that as an individual’s 
income increased medication adherence improved however this is contrary to findings 
reported by Rockwell & Riegel whose study reported no association between 
socioeconomic level and variance in levels of self-care (164). However, it is worth noting 
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that the average household income was lower in the latter study which may have 
somewhat limited the results.  
Impact of Social Support 
Supportive relationships have demonstrated to be not only a factor for improved 
adherence to treatment but may also contribute to improvement in some medical 
outcomes (196) including mortality (197, 198). The exact means by which this occurs however 
remains unclear. 
The involvement of family with medical care is common. A literature review of 122 articles 
reported adherence to medical treatment to be 1.74 times higher when patients reported 
to be from a cohesive family environment than those who reported to be in dispute with 
next of kin. The review also reported that marital status or living with another person were 
also modestly associated with better adherence (199). Family was also found to be 
important in a study involving a cohort of healthy medical outpatients where approximately 
50% of patients reported some family involvement in their medical care including 
medication prompting (196). A review conducted by DiMatteo in general populations 
concluded that presence of practical support had a larger impact on adherence than 
evidence of emotional support however it is unclear how this practical support contributed 
to adherence (11).  
According to Leventhal et al a patient’s ability to adhere to prescribed treatment is strongly 
influenced by the existence of a strong social network, which includes both the receiving 
of support as well as the participation in the social environment. For an individual any 
challenge to this support may result in negative outcomes on adherence (167). The 
influence of social networks was investigated by Simpson et al who conducted focus 
groups with HF patients in order to explore barriers to medication use.  Participants in this 
study believed it was important that family members be involved in HF education in order 
for them to better understand the condition; provide necessary and reinforce medication 
taking (165).  This positive effect was again defined by patients in a later study conducted 
by Simpson et al where patients who reported having a supportive network of friends and 
family described fewer self-reported barriers to taking medication for HF (169). 
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Patients’ perception of the social support they received has been identified as a facilitator 
for adherence in other studies. Wu et al reported that HF patients who felt that they 
received an acceptable level of social support from family members and others were more 
adherent (168) while perceived social support was moderately associated with better self-
reported medication adherence in a study by Sayers et al (166). 
Education 
In HF level of education has been associated with medication adherence (164). Rockwell 
& Riegel’s study reported that after controlling for other variables, education contributed 
4.6% of the variance for self-care (P = 0.009) thus it was deemed likely that those patients 
who were better-educated would engage in self-care more than those who are less 
educated (164). Evangelista et al investigated psychosocial variables relating to adherence. 
In a sample of 82 patients with HF a correlation was reported between higher education 
and overall adherence to treatment (170). Similarly, Chui et al reported level of education 
to be a predictor of diuretic adherence in a study measuring adherence to diuretic therapy 
in patients with HF (200). 
Health literacy has been defined as:  
‟The degree to which individuals have the capacity to obtain, process, and understand 
basic health information and services needed to make appropriate health decisions” (201).  
While currently there is no consensus on the measurement of health literacy (202) reduced 
levels may result in patients having difficulty processing information on how to best 
manage their medical conditions. Previous Studies have shown that inadequate health 
literacy is associated with reduced knowledge of illness (203), poorer physical and mental 
health (204), increased hospitalisation (205), increased mortality (206) and reduced medication 
adherence (207). Overall those with low health literacy are 1.5 – 3 times more likely to 
experience adverse health outcomes (208). While inadequate health literacy can affect 
anyone, it is more common among older people, patients with chronic conditions and 
those who are economically disadvantaged (209).  
59 
 
In HF the prevalence of low health literacy is reported to be 39% (range 17.5% to 97%). 
Consistent with studies in other conditions a recent systematic review found age, 
ethnicity, educational level, and cognition to be independent predictors of health literacy 
among HF patients (207).  
Given that patients with inadequate health literacy are less likely to be able to understand 
or make informed decisions about the information they need to take their prescriptions as 
prescribed researchers have posited that nonadherence to medication may be associated 
with health literacy, particularly functional health literacy. Whilst little has been written 
about health literacy and its relationship to medication adherence in HF two relatively 
recent studies have reported results. Noureldin et al found that participants with adequate 
health literacy demonstrated both higher medication taking adherence and medication 
scheduling adherence than those with inadequate health literacy (209), while a study by 
Mixon et al reported that higher health literacy was associated with lower odds of 
misunderstanding cardiac medication (210).  
2.2.6.2. Healthcare system related factors  
The health care delivery system has the potential to influence the adherent behaviour of 
patients. Reduced access to healthcare, medication supply or medical follow-up, as well 
as poor provider-patient communication and relationships have all been identified as 
healthcare system related factors associated with reduced adherence to treatment (211).   
Healthcare services utilisation 
Recent hospital stay has been associated with enhanced adherence to medication in the 
HF population (43). Monane et al conducted a retrospective follow up study examining over 
7,000 older HF patients commencing digoxin. Using pharmacy prescription data, 
adherence rates were reported to be higher during the 12-month follow up period in those 
who had a reported hospital or nursing home stay prior to the initiation of treatment versus 
those with no admission (137). Following hospitalisation, Rodgers & Ruffin reported that 
every all-cause admission to hospital during the previous year was associated with a 16% 
decrease in the risk of non-adherence in 311 patients with HF prescribed ACEi (171).  
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In contrast a study conducted by Bagchi et al aimed to determine rates of adherence to 
HF medication and examine factors associated with adherence using Medicaid data in a 
sample of over 45,000 HF patents. The authors reported that while patients with co-
morbid conditions such as CAD or diabetes were more likely to adhere to all medications, 
including those prescribed for their HF, when hospitalisation had occurred for health 
conditions other than exacerbation of HF patients were shown to be less adherent (175). It 
may be that while some co-morbidities are likely to necessitate increased healthcare 
contact which increases the potential for HF to be identified and treatments initiated, 
hospitalisation may be as a result of many different medical conditions which are then the 
primary focus for the healthcare team resulting in treatment for HF being overlooked.    
While the above studies report some limited association between inpatient healthcare 
utilisation and adherence to medication there is currently no evidence to support a link 
between adherence and healthcare utilisation in the community setting.  
Patient/Provider Relationship 
As a keystone of healthcare (212) high-quality doctor–patient relationships have the 
potential to improve adherence to treatment plans, enhance self-management of disease, 
improve recall of important treatment information, as well as improve general mental and 
physical health status (213). Over recent years the development of advanced nursing roles, 
specifically nurse prescribing, has enabled nurses to undertake some roles traditionally 
undertaken by medical staff (214).  Given that nurses traditionally have more opportunity 
to deliver holistic care, the development of roles such as HFSN have offered positive 
impacts on patient care in areas such as access to medicines, promotion of self-care and 
increased personal health-related decision making. Patient centered communication 
relating to adherence is an important role of advanced nurses such as HFNS who are 
regularly called upon to educate patients about newly prescribed medications (215). 
Communication between the clinician and the patient as well as between healthcare 
providers have been identified as potential barriers to adherence (158). A lack of 
communication regarding treatment duration, potential side-effects and costs of treatment 
may all have an effect on adherence to medication. Additionally, unclear information 
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regarding correct drug administration may cause confusion around dose and frequency 
of administration, especially during periods of drug titration (216).  
Satisfaction with a medical consultation has been identified as a predictor not only of 
important health outcomes but of adherence to treatment, (217) particularly in those 
diagnosed with chronic conditions (218, 219). In HF specifically, confidence and trust in the 
healthcare provider has been identified as a motivating factor for medication adherence 
in HF patients who stressed the need for healthcare providers to be knowledgeable while 
genuine in their concern for their patients (169). 
A qualitative study aiming to identify misunderstandings associated with medication 
prescribing which occur between doctor and patient was reported by Britten et al. Overall 
those consultations where patients did not voice their expectations and preferences or 
express their opinion to doctors' decisions and treatment plans reportedly resulted in 
misunderstandings. In turn these misunderstandings were associated with potential 
adverse outcomes such as non-adherence to treatment (220).  
A meta-analysis of literature looking at the relationship between doctor’s communication 
and patient adherence to treatment reported that adherence to treatment was significantly 
related to the communication skills of the doctor.  A 19% higher risk of non-adherence 
was reported among patients who experience poor doctor communication than among 
patients who have a doctor who communicates well (221). Data from the European Social 
Survey (ESS) conducted across 24 countries in Europe reported that perceptions about 
the doctor-patient relationship were also strong predictors of non-adherence. In this study 
a reluctance not ask the doctor questions was associated with non-adherence as was the 
belief that doctors do not tell the whole truth. Equally people who believed that their 
doctors treated them as equals and discussed the treatment with them before a plan was 
established were 3% less likely to be non-adherent to the treatment than those who 
believed the opposite (p=0.001) (222).  
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2.2.6.3. Condition related factors 
In the HF population condition related factors such as symptom severity, severity of 
condition, co-morbidities and mood have been hypothesised as being associated with 
adherence (174).  
Presence of Symptoms 
Effective control of symptoms is thought to improve QofL in HF thus posited as a key 
motivational factor for adherence (173). Rockwell and Riegel conducted a study in which 
the typical participant reported moderate symptom severity and limited functional status. 
In this study those patients reporting more severe symptoms reported higher self-care 
scores (164).  In Rodgers & Ruffin’s study a higher NYHA class was associated with 
improved reported adherence to ACEi (171). Similarly, the severity of symptoms 
experienced was reportedly an important factor for patients choosing not to obtain 
medication when they were limited in the number of prescriptions they could acquire per 
month due to cost (172).  
Multimorbidity 
As previously discussed multimorbidity is common in HF. Almost 60% of patients with the 
condition have a diagnosis of five or more additional chronic conditions (76). As a result, 
patients may feel overwhelmed not only by the burden of these co-existing conditions but 
in their management. The potential burden on HF patients has been described by 
Dharmarajan & Dunlay who reported that HF patients may typically spend around two 
hours per day partaking in health-related activities potentially requiring the assistance of 
another with at least one activity of daily living (223). In addition, patients with multimorbidity 
may require to attend an average of fifteen outpatient appointments annually and take ten 
or more medications per day (224).  
The relationship between multimorbidity and medication adherence is inconsistent in the 
HF population (174). Cholowski et al reported an inverse relationship between adherence 
and the number of co-morbidities while also associating multi-morbidity with a reduced 
likelihood that non-adherence to medication was due to forgetfulness (177). Conversely 
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Granger et al have reported an association between enhanced adherence and fewer 
comorbid conditions within the HF population (176).  
Several studies have associated certain co-morbid diseases with the risk of non-
adherence. For HF patients who also had a diagnosis of either hyperlipidaemia or chronic 
obstructive pulmonary disease (COPD) Rodgers & Ruffin reported a reduction in risk of 
nonadherence of around 11% (171). While in the study by Bagchi et al those diagnosed 
with comorbid coronary artery disease (CAD) or diabetes mellitus (DM) were more likely 
to demonstrate higher medication adherence than people without these conditions (175). 
Depression and Anxiety 
While mood disorders are prevalent among patients with HF the association between 
mood and poor outcomes is not completely understood. Ambiguity exists over whether 
anxiety and depression are caused by HF or whether it is the presence of these emotions 
which are a risk factor for HF. Either way, it has been suggested that negative emotions 
may be associated with non-adherent behaviour in HF (225). 
Patients with HF have been shown to experience clinical depression at a rate 2 to 3 times 
higher than those of the general population (226) and while approximately one in five HF 
patients are known to suffer from clinically significant depression the prevalence of minor 
depression may be greater than one in three. Additionally, the risk of depression 
correlates with the severity of the condition with rates increasing further when HF 
advances in stage (227).  
Major depressive disorder in HF is associated with a poorer quality of life (228, 229) and an 
increase in the frequency of adverse clinical events such as hospital readmission (230) and 
increased risk of mortality (197).  Additionally, successful management of the condition may 
be impeded by the presence of depression (227).   
Among the general population patients with depression were found to be three times more 
likely to be non-adherent with prescribed treatment than patients without depression (231).  
In HF a study exploring the association between depression and medication adherence 
found a significant difference in self-reported medication adherence between participants 
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without and those diagnosed with depression (75% vs. 57%, p = 0.008) (179). Similarly in 
a depressed population of older people with CAD Carney et al reported that patients with 
depression adhered to prescribed medication on an average of 45% of days as compared 
to 69% of days in a matched population without depression   (p < 0.02) (180). Finally, an 
improvement in recorded depression scores was found to be positively associated with 
an improvement in adherence in recent study of hospitalised cardiac patients diagnosed 
with a broad range of cardiac conditions (232).  
Anxiety can be defined as “a negative emotional state resulting from an individual's 
perception of threat and characterized by a perceived inability to predict, control, or gain 
the preferred results in given situations” (225) Anxiety is known to negatively impact the 
cardiac output in patients with HF (233) however while much less has been written about 
anxiety in HF than on depression evidence suggests that it is indeed a common 
phenomenon (225) often co-existing with depression especially in older populations (234).  
Overall in the healthy older population anxiety disorders are estimated to have a 
prevalence of around 4%. However, 18% of a study population of older outpatients with 
HF were reported to have at least one anxiety disorder (235). A study of cardiac patients 
compared the anxiety scores of patients diagnosed with HF, MI of CABG a cohort of 
healthy older people. While the healthy older people expressed a mean anxiety score 
40% lower than the normative threshold for anxiety all 3 cardiac-patient groups reported 
significantly higher levels of anxiety (236). Worryingly if anxiety is persistent it may impact 
negatively on the health of patients with cardiac disease in the long term (225).  
To date only a limited number of studies have explored the role of anxiety in HF prognosis 
and while results around the impact of anxiety are inconclusive a study by Clarke et al 
reviewing data collected as part of the SOLVD study found anxiety it to be among several 
psychosocial factors which could be identified as predictors of risk for severe functional 
limitations in patients with LVSD (237). Finally, while no studies have reported a direct 
association between increased anxiety and adverse clinical outcomes in HF several 
studies have demonstrated an association between increased anxiety and subsequent 
CHD events in patients with existing coronary heart disease (238, 239).  
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2.2.6.4. Treatment related factors  
As previously stated alongside the burden of managing multimorbidity the burden from 
medicines specifically prescribed for HF is ever increasing. When following National 
Clinical Guidelines for the treatment of advanced HF clinicians may be directed to 
prescribe in excess of six medications specifically for that condition alone (240). For 
patients with HF therefore treatment often requires a lifelong commitment to follow an 
ever increasingly complex medical regime which may cause unpleasant side-effects and 
require frequent modification (188).  
Complexity of Regime 
The complexity of a patient’s medication regime is influenced by several factors including 
the number of prescribed medications, the dosage frequency and form, as well as the 
instructions given for administration. Despite a number of studies reporting an association 
between number of prescribed medications and adherence in HF evidence in this area is 
inconsistent. An overly complex regime and inadequate instructions were cited as the 
main reasons for non-adherence in an observational study conducted by Toh et al with 
47/66 (71%) of patients reporting difficulties in this area (185). Two studies conducted by 
Muzzarelli et al and Gislason et al reported a positive association between an increased 
number of prescribed medicines and enhanced adherence (145, 186). Conversely Roe et al 
described poor adherence to ACE-inhibitors as being associated a higher complexity of 
the medical treatment (211).  
Frequency of dosing has been shown to be a contributory factor to non-adherence in 
populations with chronic conditions (241) including those with chronic cardiovascular 
disease (242). In the HF population Riegel et al assessed adherence using MEMS and 
reported that those patients who required to administer medication ≥2 times per day (OR 
= 2.59, p=0.016) were more likely to experience a decline in adherence rather than 
demonstrate continued adherence (183). Similarly, adherence to ACEi has been found to 
be around 90% in patients with HF prescribed daily prescriptions compared to around 
68% in those where their medication was prescribed three times per day (184). However, 
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in contrast, Udelson et al found that drug regimen simplification did not improve 
adherence to carvedilol (243). 
Side-effects of treatment  
Despite not taking their medication as prescribed it is possible that patients may view 
themselves as adherent (5). Perceived side-effects of medication have been identified as 
a factor for non-adherence causing patients to either delay or miss dose administration. 
Van der Wal et al reported that the most important barriers to medication adherence 
among the HF patients interviewed in their study were nocturia and other difficulties 
related to diuretic therapy (5).  
Several studies have described how patients choose to alter their use of diuretic therapy 
because of the drugs’ effect on social activities (187) including a qualitative investigation by 
Simpson et al who reported that adverse events (actual or perceived) altered a willingness 
to continue therapy in patients with HF (165).  
2.2.5.5. Patient related factors 
The majority of literature reviewing medication adherence has focused on patient related 
factors (160). In studies age, gender and cognitive function are frequently identified as a 
potential determinant of adherence however, a patient’s knowledge of their condition and 
treatment as well as the beliefs they hold about the condition may also play a key role in 
medication adherence. 
Age and Gender  
While numerous studies investigating adherence have focused on patient characteristics, 
they have not demonstrated a consistency to predict adherence (244). Given that older 
patients are often receiving treatment for multiple chronic health conditions while 
experiencing memory difficulties exacerbated by medications or early dementia, age has 
been identified by WHO as a determinant of adherence (35).  
The relationship between age and medication adherence is inconsistent within the HF 
population. While some studies have reported a higher risk of non-adherence among a 
younger population (144, 171, 175, 188) others have reported no significant relationship 
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between age and adherence (176, 186, 189).  A systematic review analysing the evidence for 
age as a determinant of medication adherence in patients with HF was carried out by 
Krueger et al (245). It concluded that while older age was not related to medication 
adherence, older patients may receive a higher level of support with medication than 
younger populations.  
For gender, literature has identified that different patterns of adherence behaviour for men 
and woman who may also differ in views and beliefs regarding their amount of medication 
use, their adherence to medications, and their likelihood of receiving ongoing medication 
monitoring (246). In HF however, as with age, association of gender and adherence are 
inconsistent. While several studies have not found a significant relationship between 
gender and adherence, (164, 168, 171, 189) nonadherence has been reported to be higher in 
males (144, 175, 247, 248) with Dunlay et al reporting that while men had lower ACEi/ARB 
adherence than women sex was not associated with adherence to other medications (188).  
Cognition  
Mild cognitive impairment (MCI) refers to a condition in which there are subtle cognitive 
deficits which do not meet the criteria for dementia. Although people with MCI may 
continue to perform basic activities of living reduced adherence to therapeutic advice 
given for chronic conditions such as diabetes has been reported in this population (249). 
Additionally decreased ability to carry out essential self-care activities in HF patients with 
cognitive impairment has been reported (250).   
There has been increasing evidence to suggest that low cardiac output is independently 
associated with cognitive impairment (CI) with the prevalence of MCI ranging from 53% 
to 58% in older people with mild to moderate HF (251). Compared to the general population, 
patients with HF have been found to have up to a 4-fold higher risk of developing CI (190).  
Independent of other factors, MCI has been shown to predict 30-day hospital readmission 
and death in patients with HF (252). An association between medication adherence, 
cognition and HF was previously reported by Hawkins et al (190). In this study medication 
adherence was significantly worse (78% to 70%, P=0.017) for patients with evidence of 
MCI compared to those without.  
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Inadequate knowledge in disease management 
Adherence to prescribed treatments requires an understanding of both condition and 
treatment (160) however knowledge alone cannot guarantee adherence (182). Lack of 
knowledge and misunderstanding about HF have been reported in several studies (138, 182, 
182, 253, 254). From a HF patient’s perspective, the minimum information required to achieve 
adherence relates to the purpose, the potential benefits and the possible adverse 
reactions of prescribed medications as well as an understanding of all drug specific 
instructions (165).  
To date, evidence around the influence of knowledge on HF treatment adherence is 
inconclusive. In patients admitted to hospital with decompensated HF Michalsen et al 
reported that knowledge about drug treatment was not associated with enhanced 
adherence (191); conversely 25% of HF patients who presented at hospital as an 
emergency reported lack of knowledge as a barrier to medication adherence (193).  Overall, 
low levels of knowledge, especially in the area of HF medications is reported in the 
literature (58). 
While patients can be furnished with information regarding a health condition or 
associated treatment, this act alone does not necessarily translate into knowledge. In a 
study carried out among 117 new patients visiting a HF clinic, Ni et al reported a significant 
correlation between adherence to self-care and knowledge (r=0.33, p<.001). However, 
despite 80/113 (71%) of the patients self-reporting that HF educational materials had 
been supplied to them, only 11/80 (14%) said they knew "a lot" about HF. Similarly Cline 
et al reviewed patients who had all received standardised written and verbal information 
regarding their medication and reported that only 12/22 (55%) of patients with HF could 
correctly name their prescribed medication while only 11/22 (50%) were able to describe 
the prescribed dosage. Worryingly, one month after hospital discharge 6 of the 22 
participants previously admitted to hospital due to HF were found to be non-adherent to 
medication (138).  
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Beliefs and attitudes 
Personal beliefs are known to form the foundation of any decision making (173) with beliefs 
held by patients regarding their illness playing an important role in decisions made 
regarding adherence (187, 255). Individually held beliefs about medication have been shown 
to affect both intentional and unintentional adherence to medication in older people (256).  
As previously stated, poor adherence to medication may result in worse outcomes in the 
HF population. Albert et al conducted a study of 195 HF patient attending the accident 
and emergency department for decompensated HF. Inaccurate HF beliefs and poor self-
care adherence where reported in this group of patients reflecting a need for improved 
HF education (184).  
Percival et al (195) explored the beliefs of 43 HF patients towards their HF medicines and 
self-care activities. Using the Beliefs about Medication Questionnaire (BMQ) the authors 
reported that those who believed their prescribed treatment to be necessary had 
significantly higher adherence scores than patients who reported high levels of concern 
around the treatment. In particular, adherent behaviour was related to the perception that 
HF medication was helping the heart and was related to their health. 
Several studies have investigated the role of beliefs and attitudes relating to barriers to 
medication adherence, as perceived by patients with HF. Wu et al (168) conducted a study 
on 134 patients with mainly advanced HF reporting that the most consistent predictor of 
adherence was patient perception of barriers to medication adherence. Similarly, 
Cholowski & Cantwell reported that a belief in the need for medication adherence was 
negatively related to being careless about taking medication (177) in a population of older 
patients with HF. In a cross-sectional study of 58 older patients with HF Molloy et al 
examined whether beliefs about HF were associated with adherence to ACI. Using the 
illness perception questionnaire (IPQ-R) those who thought their HF to have a more 
chronic timeline or perceived their condition to have more consequences where found to 
be less likely to adherence to their medication than those who believed otherwise (44). 
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2.2.7. Interventions to improve adherence 
Historically interventional approaches to improving medication adherence have been 
based mainly around a biomedical model with the provision of information regarding the 
medication or treatment being the main focus (116). As previously stated however 
adherence is multifaceted and may include cognitive, motivational, behavioural and social 
factors. In order to fully address the issue of non-adherence in older HF patients a greater 
understanding of the perceptions and agendas of this population are thus essential (257). 
Indeed before the development and evaluation of any intervention aimed at improving 
adherence in this population can be undertaken a better understanding of the barriers 
older adults face must be obtained.  
Interventions looking to improve adherence have been conducted across many different 
health conditions. The first review of adherence interventions was conducted around thirty 
years ago with many systematic reviews, meta-analyses and narrative reviews having 
been taken place since (258). In a recent Cochrane review of Interventions for enhancing 
adherence to prescribed medications several interventions were found to modestly 
increase adherence (259). However, while some interventions improved patients’ 
outcomes in the short-term, less than half of the studies showed any benefits at all with 
effects inconsistent across studies. The review concluded that existing methods of 
improving adherence for chronic health problems are mostly complex and ineffective 
resulting in the full benefits of treatment not being realised for patients.  
On a positive note however it has been demonstrated that improvement in adherence to 
medication is possible. Identifying strengths and weakness of previously evaluated 
interventions offers potential for the development of an adherence enhancing intervention 
tailored to meet the needs of older HF patients. A full review of previously evaluated 
interventions aimed at improving medication adherence in the HF population is described 
later in this thesis.   
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2.3 Theoretical approaches 
In order to improve both the likelihood of success and to aid its generalisation to different 
populations or health systems any intervention aiming to change health behaviours 
should all be based on a theoretical model which provides an explanation of that 
behaviour (260).   
When trying to understand adherence Leventhal et al states that previous studies have 
been guided by five major theories of adherence: the biomedical model; operant 
behaviour and social learning; the rational belief theory; a communication approach and 
the self-regulative systems theory (261). To varying degrees each theory concentrates on 
an individual’s understanding of their illness; their perception of risk; their motivation to 
comply and the selection of coping behaviours. 
Originating in the study of human anatomy and physiology the most common of these 
models throughout western society has been the biomedical model. Considering the 
patient to be the recipient of instructions provided by a healthcare provider the theory 
ascribes only limited consideration to the patient’s actual understanding of the treatment. 
However previous research utilising this approach has contributed greatly to both the 
knowledge and understanding around the measurement of adherence as well as making 
valuable contributions to various scientific advances including controlled release 
medication, combination drugs and monitored dosage systems (131).  
The biomedical model, while focusing on the transmission of information from the clinician 
to the patient, fails to consider the effect of underlying psychological processes on 
adherent behaviour. Additionally the model does not make considerations for how the 
healthcare professionals own behaviour may impact on the patient’s adherence. It is 
desirable therefore to underpin the design of an intervention aiming to improve medication 
adherence with the use of a model of behaviour which aims to address these specific 
issues (134).  With this in mind Leventhal’s common sense model (CSM) has been chosen 
as the model for the work within this thesis and the rationale for this is explained below. 
However, there are a number of alternative theoretical models and a brief overview of 
these is given first below. 
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2.3.1. The Health Belief Model 
The Health Belief Model (HBM) was developed in the 1950’s by Hochbaum, Rosenstock 
and Kegels, a group of social psychologists working in the United States of America who 
looked to explain why people failed to take up public health prevention measures before 
the onset of clinical symptoms. Following its development the theory has since been 
applied to treatment adherence regimens (262).  
The HBM was first presented with main concepts: Perceived Susceptibility, Perceived 
Severity, Perceived Benefits, and Perceived Barriers. The concept of Cues for Action was 
added later to "stimulate behaviour." Finally, in 1988, the concept of Self-efficacy was 
added to address the challenges of habitual unhealthy behaviors such as smoking and 
overeating resulting in six key concepts (263) (see table 2.2).  
The model is based on the understanding that a person will undertake a health-related 
action if they: 
1. Feel that the adverse health condition can be avoided. 
2. Anticipate that by taking a suggested action the adverse health condition will be 
avoided. 
3. Believe that they can carry out the recommended health action. 
In addition to personal beliefs individual factors such as age, culture, education level and 
past experience are now also accepted as having an indirect effect on individual 
perceptions and the likelihood of taking positive action and thus component parts of the 
model (see figure 2.3). 
2.3.1.1. Studies using the HBM 
The HBM has been previously utilised in the development of behaviour change 
interventions investigating medication adherence across a range of treatments and 
illnesses (264) including hypertension (265), asthma (266) and diabetes (267). However in HF, 
while the HBM has been used to compare health behaviours in self-care (268)(5) and to 
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identify predictors of non-adherence (269) there is a lack of evidence to support application 
of the model to interventions to improve medication adherence in HF populations (270).  
 





An individual’s evaluation of how likely it is that they 
will get the condition. 
The greater the perceived risk the more likely the 





An individual’s evaluation of how serious a 
condition and its consequences may be. While 
individual perceptions may be based on some 
medical understanding it also encompass an 
individuals around the impact of the condition on 
their life in general. 
Perceived 
Benefits 
An individual’s perception of how effective the 
proposed action may be. 
Perceived Barriers 
 
An individual’s perception of both the physical and 
psychological costs of the proposed action 
 
Cues to Action 
 





An individual’s confidence or belief in their capacity 
to carry out the proposed action 





Figure 2.3 component parts of the Health belief model adapted from Janz et al 2002 (263) 
 
2.3.1.2. Strengths and weaknesses of HBM 
While the HBM has been used successfully across previous adherence enhancing 
intervention studies (264) it has several limitations. Firstly the model does not acknowledge 
the effect of personal beliefs on behaviour. It assumes that for all individuals’ engagement 
with the behaviour is solely for health-related reasons disregarding the role played by 
other potential determinants (262). Additionally the model makes the assumption that 
everyone has equal access to health-based information.  
Criticised by Janz et al who noted that the key constructs of the model have often been 
utlilised inconsistently and inadequately assessed the HBM could be described more as 
a descriptive than explanatory model in that it does not advise on an appropriate approach 
for changing health-related behaviours (262). 
The use of the model to successfully improve adherent behaviour is therefore unclear.  A 
recent systematic review aimed at evaluating the effectiveness of HBM based 
interventions in improving adherence reported on 18 studies. While the majority of the 
studies reported an overall improvement in adherence 15/18 (83%) only six of the studies 
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had in fact used the HBM in its entirety calling in to question whether the improvements 
reported where indeed due to the application of model constructs (264). 
2.3.2. Theory of Planned Behaviour  
The Theory of Planned Behaviour (TPB) developed by Fishbein & Ajzen, is an extension 
of the Theory of Reasoned action (TRA) developed by due to limitations noted with the 
original model (271). Comprising of six constructs (see table 2.3) the model focuses on an 
individual’s intention to perform a specific behaviour (see figure 2.4). The key component, 
intention reflects the individual perception to the model that intentions capture the 
motivational factors that influence behaviour; they are indications of how hard people are 
willing to try, of how much of an effort they are planning to exert, in order to perform the 
behaviour. According to TPB, perceived behavioural control, together with behavioural 
intention, can be used directly to predict behavioural achievement. As a general rule, the 
stronger the intention to engage in a behaviour, the more likely should be its performance. 
 
Concept  Definition 
Intention 
 
The motivating factors influencing the behaviour.  
The behaviour is more likely to be undertaken if the 
intention is strong. 
Attitude An individual’s appraisal of the behaviour and the degree 
to which it is considered beneficial or detrimental.  
Subjective norms Individual beliefs held regarding the opinions of peers and 




The codes of behaviour considered customary within a 
specific group. 
Perceived power The perceived factors available to the individual which 
may support or obstruct the undertaking of the behaviour. 
Perceived 
behavioral control 
The Individual's perception of how problematic 
undertaking the behaviour may be. Received control may 
change depending on circumstances.  
















Figure2.4: Theory of Planned Behaviour reproduced from Ajzen 1991 (271) 
 
2.3.2.1. Studies using TPB 
Across a range of health conditions including diabetes (273), stroke (274) and HIV (275) the 
TPB has been used as a theoretical framework to both understand predictors of 
adherence and to guide the development of interventions (272). In HF Wu et al recently 
conducted an observational study which aimed to evaluate which factors of the TPB 
predicted sodium intake in patients with HF. In total 244 HF patients, of which 163/244 
(77%) were male, completed a sodium restriction questionnaire which comprised of 
subscales relating to 3 components of the TPB namely: attitude, subjective nom and 
perceived behavioural control towards following a low-sodium diet. The only concept 
found to be a predictor being subjective norm supporting the hypothesis that support from 
both health care providers and significant others for adhering to a low-sodium diet from 
can have a positive outcome (276).  
Additionally, the TPB has been used as the theoretical underpinning for several 










again by Wu et al aimed to encourage positive behavioural beliefs relating to medication 
adherence. The intervention aimed to educate both patient and their significant others in 
symptom control and management via 4 educational and counselling sessions with the 
addition of personal feedback relating to actual levels of medication adherence for a 
subgroup of participants receiving the intervention.  While initial results from this study 
are positive in that those who undertook the intervention where more adherent at follow 
up than those in the control group it is worth noting that the study was a sample of 
relatively young HF patients (mean age 60 years), had a relatively small sample size of 
82 participants and a limited follow-up time of only 9 months (277).  
In a similar vein, Welsh et al used the TPB to develop a 6-week educational intervention 
which was specifically aimed at reducing the dietary sodium intake of patients with HF. In 
this study daily sodium intake was assessed using food diary data for 52 HF patients. 
While there was no significant difference in sodium intake between groups at baseline, 
sodium levels in those receiving the intervention decreased at 6-month follow-up while an 
increase in sodium intake was reported in the control group while attitudes towards 
following a low sodium diet also improved in the intervention group. While initial results 
for use of the TPB seem positive the results of this study are limited by the small sample 
size and the possibility that participants completed the food diaries inaccurately simply to 
meet the social norm (278).  
2.3.2.2. Strengths & weaknesses of TPB 
The TPB has been widely used and has found to be successful in predicting a range of 
health intentions (272). However it is not without criticism. A review of the TPB conducted 
by McEachan et al found that when studies were longitudinal in nature or when outcomes 
were measured objectively rather subjectively the TPB appeared to be less successful in 
predicting behaviour (279). Additionally, the model assumes that individuals looking to 
undertake a specific health related behaviour will have both the means and the 
opportunity available to them. It does not account for other variables such as 
psychological, environmental or economic factors or an individual’s past experiences (280).  
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2.3.3. The experience of illness  
Overall the majority of people can expect to enjoy a reasonable level of health with ill 
health usually confined to the final few years of life (281). As previously stated one major 
challenge facing healthcare systems today is the rising prevalence of long term conditions 
such as HF. When chronic illness is diagnosed increased involvement with healthcare 
professionals usually follows (281). Despite their importance however patient’s opinions 
are seldom sought during medical consultations where patients traditionally did not 
discuss their illness beliefs with their doctor (282). Despite this lack of disclosure it is clear 
that in order maintain a reasonable QoL patients must have the ability to integrate their 
long term condition into their daily life by finding a way to make sense of the condition 
and its symptoms.  
Self-regulation, as defined by Zeidner et al, ‟is a systematic process involving conscious 
efforts to modulate thoughts, emotions and behaviours in order to achieve goals within a 
changing environment” (283). “Survival and coherence” according to Carver and Scheier 
are the two natural goals possessed by humans and form the basis on which all other 
goals are produced (284). Given that an experience of illness has the potential to threaten 
both survival and coherence presenting significant challenges to self-regulation it is 
necessary to consider both of these goals when attempting to understand how 
behavioural patterns develop over the course of a health threat experience.   
2.3.3.1. The Common Sense Model (CSM)  
As previously stated the guiding theoretical framework for this study is the Common 
Sense Model (CSM) of illness cognitions and behaviour (261). The model provides a 
theoretical framework to help understand how an individual’s conceptualisation of their 
condition can impact both their coping behaviour and ultimately their health outcomes. It 
describes a process of self-regulation which involves the setting of personal goals; the 
development and enacting of approaches to realise these personal goals and an 
evaluation of progress with potential for modification of both goals and approaches (285). 
In this way self-regulation can be viewed as a structure which is not only functional and 
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motivational but encompasses the individual’s emotional response to ill health linking it 
directly to the cognitive processes (160). 
CSM is an extension of the parallel processing model (39) which evolved from an early 
study investigating the influence of fear on smoking behaviour. While Leventhal and 
colleagues demonstrated some positive short-term effects any change in smoking 
behaviour did not continue over time thus demonstrating that the processing of the health 
threat and the processing of the fear emotion were in fact two separate pathways (286). 
The CSM suggests that when an individual receives a diagnosis or is challenged with the 
management of ill health they will inevitably develop their own individual beliefs about the 
condition which may or may not be related to the clinical features of the condition (282). 
Based on the individual’s understanding or experience of the condition these beliefs or 
“illness representations” run in parallel to emotional responses shaping the individuals 
coping strategies and action plans this providing what Leventhal et al call a “framework 
for action” (287). Given that these representations are formed in the minds of individuals 
the CSM identifies what the authors believe are individual, ‟common sense” beliefs about 
illness. 
A three-stage structure (see figure 2.5), the CSM hypothesises that when an individual 
recognises that they are faced with a health threat (stimuli) they will respond to it. 
Dependant on personal symptoms, understanding of the condition and any pre-existing 
beliefs the individual will form their own representation of the illness (stage one) which in 
turn will direct the selection of coping responses (stage two) which are in turn evaluated 
in terms of how they have removed or managed the health threat (stage three). The 
coping strategy (stage two) will be dependent on how the threat has been viewed by the 
individual (stage one) and may include strategies including the seeking out of medical 
attention, emotional expression emotion or denial of the stimuli (134).  
In addition to the formulation of illness representations the challenge of a health treat also 
provokes an emotional response. In an attempt to control these emotions the individual 





Figure2.5 Leventhal’s Common-Sense Model reproduced from (39) 
 
Once an individual has acknowledged the health threat the next step is for this threat to 
be conceptualised as an illness. Lau and Hartman classify Illness representations into 
five main domains: identity, timeline, consequences, cause and control (288). Formed from 
a range of both social and cultural influences these five domains are not independent but 
inter-related and have been incorporated into the CSM (see table 2.4) (289). 
A clear and significant strength of the CSM model is that it is a dynamic process requiring 
the individual to undertake ongoing appraisal not only of the effectiveness of their coping 
strategies and health behaviours but of the illness itself. A meta-analysis of 45 studies 
conducted by Hagger and Orbel has provided support for Leventhal’s CSM. Across the 
included studies the authors found a strong negative association between the control 
dimension of the model and illness identity, consequences and timeline while a positive 
correlation could consistently be found between the three dimensions of timeline, 
consequences and illness identity. In terms of coping behaviours expressing emotions 
and avoidance or denial were positively associated with serious consequences and a 
strong illness identity across the included studies while the ability to seek support and 
problem-focused coping was associated positively with the control dimension of the CSM. 
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Importantly a high level of perceived control over the illness or condition consistently 
correlated with psychological well-being across the included studies (290).  
The model does however make a number of assumptions. Firstly, it presumes that 
individuals are self-motivated and able to utilise both current knowledge and past 
experiences to manage the health threat. Secondly the process of forming an illness 
representation is both time and situation specific and finally because the model assumes 
that cognitive processes are not directly visible observers are required to undertake their 





Identity  The label a person gives to their illness. It is based on 
an individual’s knowledge about the symptoms 
associated with the condition. 
Timeline  Specifies the length of time an individual expects their 
illness to last and the timescale of their symptoms. 
Consequences  Encompasses an individual’s beliefs about the 
seriousness of their illness and its likely impact on their 
overall well-being. 
Causes  Describes the factors an individual considers to be the 
cause for the illness. 
Control Specifies the extent to which an individual believes they 
have control over their illness. Related to beliefs around 
efficacy of treatment. 
Table2.4: Domains of Illness Representation in Leventhal’s Common-Sense Model  
 
2.3.3.2.  CSM and heart failure 
A number of studies have explored illness representations in HF. In a qualitative study of 
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12 older HF patients, interviewed using a schedule based on CSM, MacInnes investigated 
illness representations and treatment beliefs and concluded that HF lacked a clear illness 
identity despite patients having been told they had HF (291). The illness was commonly 
attributed to external factors such as family history, other illnesses, medication and stress. 
Patients in the study were unable to make connections between previous CAD and their 
current condition however they did have an accurate view of the condition in terms of 
timeline and the seriousness of the condition, and they held consistent beliefs about the 
importance of medication in controlling symptoms and the necessity of this medication 
(291).  
Similarly illness representations were investigated by Horowitz et al who also reported a 
poor association between symptoms and HF with symptoms frequently attributed to other 
conditions. In this study however patients described HF as an acute condition and did not 
recognise that symptoms worsened over time resulting in poor symptom management 
and acute exacerbations (36).  
Quantitative studies have also studied illness representation in HF. The revised Illness 
Perception Questionnaire (IPQ-R) was used by Voelmeck in a sample of 98 patients with 
HF. In this study no correlation was found between illness representations and self-care 
(292). Similarly MacInnes conducted a cross-sectional survey in 169 HF patients aiming to 
determine relationships between illness representations, beliefs about treatment and self-
care. In this study along with perceived medication knowledge and beliefs about 
medication necessity illness coherence was found to be moderately correlated with self-
care. Additionally three factors were found to be significant predictors of self-care: 
knowledge of medication; a belief that the illness may have serious consequences and 
the impact of medication on lifestyle (293). 
Cherrington studied 22 patients with HF and concluded that while participants believed 
their HF to be a chronic disease, serious outcomes could be controlled through treatment. 
Additionally, participants in this study believed that they had a good understanding of their 
condition and did not have a negative affective response to their HF (294). In contrast 
however, Albert and Zeller used the Survey of illness beliefs in heart failure tool (SIBHFT) 
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concluding that patients actually held inaccurate beliefs and perceived little control over 
their HF ( 295). 
In a cross-sectional study Albert et al looked at the accuracy of illness beliefs around HF 
and self-care in patients admitted to A&E with decompensated HF. Using the SIBHFT 
accuracy and certainty of patients’ HF illness beliefs related to the five CSM illness 
representation domains were measured. Patients were found to hold inaccurate HF 
illness beliefs in certain areas including a belief that their HF could be cured with 
medication and other therapies; a belief that HF was a condition which was only present 
when symptoms were present and a belief that HF medicines are most effective when 
symptoms are present (194). 
2.3.3.3. CSM and medication adherence  
The use of various social cognition models has provided evidence to suggest that an 
individual’s decision regarding treatment can be significantly influenced by their belief 
about the need for treatment and their thoughts on the benefits and risks associated with 
commencing that treatment (134). As the CSM looks to address factors underlying health 
related behaviour, it has been suggested that it provides a solid framework for predicting 
adherence to treatments (296). A recent review of literature on the topic of patient illness 
perceptions and medication adherence which included a total of 11 studies spanning 
different patient populations including asthma, hypertension, diabetes and HF concluded 
that with the exception of illness coherence each of the illness perception factors were 
shown to have a positive impact in medication on medication adherence however this 
was not consistent for all patient populations across all perception factors  (134).  
A strong belief that medication would improve symptoms was positively associated with 
medication adherence in a group of patients randomised in the carvedilol or metoprolol 
European trial (COMET) (297). While studies such as this have demonstrated that beliefs 
about medication can influence an individual’s initial treatment preferences ongoing 
adherence is determined not just by ones beliefs about medication but is also determined 
by what concerns they hold regarding the treatment.  
Expanding on the CSM work Horne developed the Necessity-Concern framework. 
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According to Horne, while non-intentional non-adherence can be viewed in terms of an 
individual’s inability to adhere to treatment intentional non-adherence must be understood 
in terms of the individuals personal motivation to commence and continue with treatment 
The Necessity-Concern framework describes medication adherence as a function of an 
individual’s beliefs which may lead them to question the actual necessity of the 
medication. If an individual believes medicines to be harmful or unnatural this questioning 
may lead to intentional non-adherence (298). 
In order to ensure that patients with HF capitalise on pharmacological therapeutic benefits 
healthcare professionals need to improve their understanding of what influences HF 
patients to make decisions regarding their health (299). In an attempt to understand illness 
and treatment beliefs in HF a number of previous studies have measured illness 
representation and as such the CSM has been selected to underpin the design of both 
the qualitative and quantitative explorative studies aiming to identify predictors of non-
adherence in older HF patients contained within this thesis.  
2.3.4. Self-Efficacy 
As previously stated the CSM can be utilised to help understand the illness perceptions 
of HF patients and the beliefs which may underpin adherent behaviour however a deeper 
understanding of how an individual manages complex treatment plans is also necessary.  
Self-efficacy, a modifiable factor, is the belief in one’s own ability to successfully complete 
a task has been recognised as a key component in a number of theoretical models. 
Rather than focusing on an individual’s skills and physical ability to perform a task self-
efficacy concentrates on the individuals opinion of what can be done with those skills. 
According to Albert Bandura’s Social Cognitive Theory (SCT) individuals, rather than 
simply being responsive, are actually “self-organising; proactive; reflective and self-
regulating” in nature (300). From a SCT perspective an individual’s functioning is shaped 
by the dynamic interaction between personal, behavioral, and environmental 
determinates, all of which are possible target areas when considering interventions aimed 
at improving health outcomes. 
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Identified as an important predictor of behaviour (301), an individual’s self-efficacy beliefs 
are said to be shaped by four sources: personal previous achievements; experience of 
observing others successfully perform the task; social persuasions and the individual’s 
emotional state (see table 2.5). The theory proposes that the level of confidence one has 
in their ability to undertake a health behaviour will ultimately determine the amount of 
effort and commitment they will afford to those behaviours (302). Additionally, self-efficacy 
not only influences the goals an individual will set but will also determine an individual’s 
expectations of the outcome and what they believe may be facilitators and barriers to 
undertaking the behaviour (see figure 2.6) (303). Failure to persevere with the behaviour is 
less likely if a commitment to the setting and maintaining has been made and the 
individual has been able to face challenges with an increased and continued effort (304).  
 
Sources of self -efficacy Definition 
Mastery of past 
performance 
An individual’s previous experience of overcoming 
difficulties. Once an individual believes they are able to 
overcome difficulties they will be more likely to persist. 
Observed experience of 
others  
Observing others undertake similar behaviours 
facilitates knowledge transfer and the teaching of self-
care skills.  
Social persuasion Verbal encouragement reassures individuals that they 




Stress levels are a way for individuals to assess their 
own abilities. However it is not the stress reaction itself 
but the individual’s perception and understanding of it 
which is important. 
 








Figure2.6: impact of self-efficacy on behaviour adapted from Bandura (303) 
 
2.3.4.1. Self-Efficacy and heart failure 
Belief in self-efficacy therefore has the potential to affect an individual’s QofL, particularly 
in a chronic often cyclical condition such as HF. For patients who require to adhere to 
complex treatment regimes a belief in personal ability is necessary in order for the 
behaviour to be completed successfully long term.  
Previous literature has demonstrated a link between improved self-efficacy and self-care 
(304, 305). In a study looking at the determinants of self-care in 65 patients with HF self-
efficacy, as measured by level of self-confidence, was shown to significantly influence 
self-care behaviour (306). Patients who believed in their ability to recognise and manage 
their symptoms were much more likely to engage in self-care activities such as medication 
adherence. Additionally, patients who had not reported a hospital admission within the 
previous six months reported higher self-confidence rates than those who had. 
Similarly Schweitzer et al reported self-efficacy as measured by self-confidence in 
maintaining health to be a strong predictor for self-care in patients with HF (189). Self-
efficacy was found to predict adherent behaviour for all self-care behaviours including 
sodium restrictions; smoking and alcohol avoidance and exercise adherence except for 
adherence to medication and fluid restriction. However given the modifiable nature of self-
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efficacy in that it can be tailored to either the task (adherence to medication) of the 
condition interventions looking to improve adherence should insure that it is targeted for 
improvement through improved knowledge and patient motivation (305).  
2.4 Summary 
In this chapter three main areas of literature have been examined: the nature and 
management of heart failure has been described mainly from a biomedical perspective; 
medication adherence and potential factors influencing adherent behaviour in HF have 
been discussed and finally the importance of illness perception and treatment beliefs on 
adherence has been highlighted. 
In summary HF, a prevalent clinical syndrome, is a major cause of disability, 
hospitalisation and death, particularly amongst older people. For some patients defining 
what HF is can be problematic, not only due to the various terms used by their clinicians 
but due to the lack of a definitive diagnosis. The often-insidious onset of HF may result in 
a lengthy delay in diagnosis causing difficulty in its acceptance and association to ongoing 
symptoms. This, coupled with the presence of multi-morbidity, may result in suboptimal 
symptom management and consequentially recurrent episodes of decompensation 
causing significant costs in both economic and personal terms. 
Medication adherence, the extent to which people follow instructions to prescribed 
treatment, is strongly influenced by the individual, their environment as well as the 
practices of associated health care professional and the care delivery system. While 
adherence can be measured in several different ways each method is not without 
limitation and currently there is no agreement on a ‘gold standard’ method of assessment. 
Importantly there is no evidence to suggest that 100% of adherence is needed to achieve 
optimal outcomes in HF.  
Recent improvements which have been achieved in symptoms and mortality with the HF 
population can in part be attributed to the prescribing of effective medications such as 
ACEi, beta-blockers and spironolactone. While there is evidence to suggest that these 
medications can improve outcomes, there is also evidence to suggest that adherence to 
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medication is sub-optimal in these patients, especially amongst the older population.  
Results from the CHARM study where an improvement was found in all-cause mortality 
even in the placebo group suggests that adherent behaviour itself is associated with 
clinical outcome and highlights the requirement to find ways to improve medication 
adherence.  
Beliefs around illness have influenced several theoretical models which aim to both 
explain and predict adherent behaviour. Leventhal et al’s CSM is a widely used theoretical 
framework which recognises emotional influence on behaviour. The interaction between 
beliefs and behaviour is seen as a dynamic process which involves an appraisal of 
outcomes influencing beliefs. In an attempt to understand illness and treatment beliefs in 
HF illness representation has been measured in a limited number of qualitative and 
quantitative studies the later utilising both the IPQ-R and BMQ tools.  
The aim of the work contained within this thesis is to establish a basis on which to develop 
an intervention aimed at improving adherence within the HF population. Any intervention 
aiming to understand and ultimately improve nonadherent behaviour must be founded on 
an understanding of the complexity of the problem. A narrative review undertaken based 
around the WHO multidimensional adherence model found limited high-quality evidence 
to support socio-economic; health care setting; condition related; treatment related and 
patient related factors as potentially influencing medication adherence in HF. Further 
research around the impact of these potential factors for adherence therefore requires 
further investigation in the older HF population.   
Despite this lack of evidence previous studies have attempted to develop and evaluate 
interventions to improve both self-care and medication adherence within the HF 
population. The following chapter describes the methodology and results of a systematic 




Chapter 3: Systematic Review of Interventions to 
Improve Medication Adherence in Heart Failure. 
3.1. Background 
The previous chapter highlighted that whilst achieving optimal control in chronic 
conditions medication adherence is vital, as many as half of all medications prescribed 
for long-term conditions are not taken as proposed (35). With increasing numbers of 
effective self-administered treatments available, there is a clear need for better 
understanding and management of non-adherence within the HF population (307). 
The problem of non-adherence is often multifactorial, thus programs aiming to improve 
medication adherence need to adopt comprehensive approaches. These interventions 
may include: improving patients understanding, ensuring access to adherence tools and 
strategies to enhance adherence and self-monitoring as well as counselling in order to be 
effective (306).  A literature review investigating interventions to enhance medication 
adherence in CHF was completed by Molloy et al in 2010 (42). It concluded that while 
improvement in adherence to medication may be possible in this patient population there 
was a lack of clarity around the specification of effective techniques and called for further 
research in this area. Given that available evidence is dynamic and evolving, and that 
systematic reviews are most useful when they are up to date (309) this chapter continues 
with a description of a systematic review carried out reviewing medication adherence 
enhancing interventions in the HF population. 
3.2. Study Design 
The best research evidence available should inform decisions for health care. Systematic 
reviews aim to identify, evaluate and summarise the findings of all high-quality relevant 
studies, combining the results of several studies to obtain a more reliable and precise 
estimate of an intervention’s effectiveness than one study alone (310).  
Systematic reviews adhere to a strict scientific design based on explicit, pre-specified and 
reproducible methods. This systematic review was conducted using the method 
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described by Khan (311) to identify all relevant literature relating to interventions used to 
improve medication adherence in HF patients. Firstly, a clear research question was 
formulated before the undertaking of an extensive search using multiple resources was 
conducted. An assessment of for methodological quality for each included study was 
completed along with a summary and interpretation of the findings.  
3.3. Methods 
The methods described in the next section of this chapter outline the process used 
when searching for and evaluating the relevant literature.  
3.3.1. Framing the Question 
The first step in systematic reviewing is defining the research question as part of the 
research protocol (310). The undertaking of an initial scoping exercise helped identify the 
characteristics of the question in terms of  
• Who – the specific population to be studied  
• What – the content of any intervention carried out as part of an RCT were a 
comparator was clearly identified and the  
• How – what affect the intervention had in terms of outcomes 
Following the initial scoping exercise the following research question was established: 
“Which interventions to enhance medication adherence in patients with chronic heart 
failure have been tested and which, if any, have been effective?”  
3.3.2. Protocol Development 
Following the formulation of the research question the second step in the process is the 
development of the protocol. This was written to ensure the methods for literature 
searching, screening, data extraction, and analysis were all established within a written 
document to minimise bias prior to commencing the literature search. Appendix A shows 
the Protocol used for this systematic review. 
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The systematic review was registered on the PROPERO database, an international 
database of prospectively registered systematic reviews in health and social care and 
public health, registration number CRD42015019092.  
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015019092 
3.3.3. Inclusion Criteria 
3.3.3.1. Types of studies 
Given the focus of the question was to identify which therapies were available randomised 
controlled trials (RCT’s) were selected in order to include research studies yielding the 
highest level of evidence. RCTs where an intervention was compared to usual care or a 
clearly justified comparison group and where the intervention strategy clearly had a 
primary or secondary aim of increasing adherence to HF medication were eligible. In 
order to assess efficacy of the intervention included trials also required to have used a 
measurement of medication adherence as an outcome. Adherence reported by pill count, 
electronic monitoring, refill or prescription records, self-report, or biochemical measures 
of drug ingestion specific to heart failure medications were all eligible for inclusion.  
3.3.3.2. Types of participants 
The review included trials enrolling patients’ ≥ 18 years of age, with a clinical diagnosis 
of HF, who did not have their daily medication administered by a healthcare professional. 
Children were excluded as not only do causes and presentation of HF in this population 
usually differ from adults, children are not normally responsible for adhering to their 
medication regime without supervision.  
3.3.3.3. Types of interventions 
All interventions aimed at enhancing adherence to heart failure medication compared to 
usual care were included. Any interventions to enhance medication adherence in other 
chronic diseases or those not directed at patients (e.g. trials aimed at improving the 
education of healthcare professionals about the importance of adherence) were excluded. 
For the purpose of the review studies were grouped by intervention type and categorised 
into one of four groups previously used elsewhere (42, 313). 
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1) Patient Education and Information: Interventions designed primarily to educate 
patients using methods such as face to face oral, written material, visual aids or 
mailed instructional materials. This method is based on the premise that patients 
who possess greater knowledge of their illness and treatment will be more 
informed and therefore more likely to adhere to prescribed therapies. Interventions 
are usually designed primarily to educate patients using methods such as face-to-
face oral, written material, visual aids or mailed instructional materials. 
2)  Intensified Patient Care: Interventions designed to increase the contact between 
participant and health care professional either by direct patient contact or by 
telephone / tele-monitoring programs. 
3) Complex Behavioural Approaches: These interventions usually include several 
components and aim to bring about changes in an individual’s behaviour through 
changes in cognitions. They may involve processes for planning and implementing 
a comprehensive, strategic set of interventions and activities to change behaviours 
at many levels and are usually theory based. 
4) Simplification of the Drug regimen: These interventions enhance adherence by 
amending dosage schedules in order to simplify the regime. This can be by either 
reducing the number of pills taken and/or the number of doses taken daily. This 
approach aims to reduce the burden associated with pill taking. 
3.3.4. Exclusion criteria 
The following set of exclusion criteria were applied to the reviewed studies: 
1. Interventions were not aimed at enhancing adherence to heart failure medication. 
2. Interventions aimed to enhance medication adherence in other chronic diseases. 
3. Interventions not directed at the heart failure patients themselves. While the role 
health care professionals play may be an important facilitator in adherence the 
focus of the work in this thesis is aimed at developing an intervention that could be 
applied to individual HF patients. Interventions focused on the education of 
healthcare professionals about the importance of adherence were thus excluded. 
93 
 
4. Studies that did not report the results in full (e.g. conference abstracts) or studies 
where further information (sufficient to make a fair appraisal of the methodological 
quality and results of the study) were not available from the authors. 
5. Non-randomised studies. 
3.3.5. Electronic Search Methods  
To identify and retrieve all relevant RCTs of medication adherence in HF the electronic 
databases of Medline, CINAHL, Embase, PsycINFO and Cochrane Central Register of 
Controlled Trials were searched from date of inception to end of March 2015. 
For completeness, a search was made of Controlled Clinical Trials.com and National 
Health Service Scotland e-library (The Knowledge Network) while grey literature was 
identified from Google. A supplementary hand search of bibliographies of extracted 
articles and reviews to acquire records not identified electronically was also conducted. 
No limits on either language or publication status were imposed. 
3.3.6. Search Terms 
Before conducting the search the key words and search strings used by the author of the 
previous review and of authors of related articles were reviewed. The terms ‘randomized 
controlled trial’ or ‘controlled clinical trial’ were combined with keywords relating to non-
adherence: ‘patient compliance’, ‘treatment refusal’, ‘patient dropouts ’, ‘attitude to health, 
‘patient satisfaction’ ‘adherence OR non-adherence’, ‘compliance OR noncompliance or 
non-compliance’, ‘’ refuse’, ‘dropout’ as well as ‘heart failure’ or ‘cardiac failure’. To make 
the search strategy more comprehensive key terms were mapped to database specific 
subject headings (MeSH) then ‘exploded’ to include all relevant sub-categories. 
Truncations and Boolean operators (e.g. ‘AND’, ‘OR’) were used where necessary to 
broaden the search window.  
3.3.7. Selection of studies 
All identified records were imported into RefWorks 2.0 reference manager (ProQuest, 
Michigan, USA), and all duplicated items were removed. The files containing all the 
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selected titles were then exported to the second reviewer who independently pre-
screened all search results (titles) for possible inclusion at the same time as I reviewed 
each title. Each reviewer indicated whether: 
• A citation was relevant (i.e. appeared to meet the inclusion criteria)  
• A citation was clearly not relevant   
• A citation gave insufficient information to make a judgement.  
All discrepancies were resolved by discussion and consensus, overseen by a third review 
author, with abstracts for all potentially relevant titles subsequently obtained and the 
process repeated. 
Full text articles were obtained either where abstracts appeared relevant or when 
insufficient information was provided from which an adequate assessment of relevance 
could be made from the abstract alone.  
3.3.8. Data extraction 
The standardised data extraction form (see Appendix B) was developed using guidelines 
in the Cochrane Collaboration Handbook (314) and then piloted on a random sample of two 
studies. The following data were collected:  
a) Study characteristics: including the study design, inclusion/exclusion criteria; 
recruitment procedures used (e.g. details of randomisation, blinding). 
b) Patient characteristics: including age, gender, ethnicity, severity of illness, co-
morbidities; current medication, as well as number of participants in each 
characteristic category for intervention and control group. 
c) Intervention and setting: including the setting in which the intervention is delivered; 
method of delivery; description of the intervention and control; duration of treatment 
period; sample size and description of co-interventions if relevant. 
d) Outcome data/results: including outcome names; measurement tool or method 
used for outcome measures; length of follow-up number and/or times of follow-up 
95 
 
measurements; number of withdrawals, exclusions, deaths or recorded 
hospitalisation and results of study analysis. 
3.3.9. Assessment of Risk of Bias 
An overall risk of bias assessment was conducted on all included studies based on 
checklists recommended by the Cochrane collaboration (315). For each study a summary 
assessment was made for the primary outcome (high, low or unclear risk of bias). Each 
study was assessed for adequate sequence generation and allocation concealment 
(selection bias), the presence of blinding in outcome assessment (performance and 
detection bias), and whether reporting of losses to follow-up and intention-to-treat 
analysis were specified (attrition bias) using a standardised quality checklist developed 
from the Cochrane Collaboration quality assessment tool (See table 3.1 for classification 
scheme). 
Type of Bias Description Relevant domain in 




Systematic differences between 
baseline characteristics of the 





Systematic differences between 
groups in the care that is provided, 
or in exposure to factors other than 
the interventions of interest. 




Systematic differences between 
groups in how outcomes are 
determined. 
Blinding of outcome 
assessment 




Systematic differences between 
groups in withdrawals from a study. 
Incomplete outcome data 
Reporting 
bias 
Systematic differences between 
reported and unreported findings. 
Selective outcome 
reporting 
Table3.1: Classification scheme for Bias adapted from Cochrane Handbook (315) 
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3.3.10. Data Synthesis 
Clinical and methodological heterogeneity across the included studies was evaluated by 
comparing the characteristics of participants, interventions and study designs. Where 
data were missing or insufficient or missing additional information was sought from the 
study authors. Meta-analysis, the process of pooling collected data quantitatively and re-
analysed using established statistical methods (316) was considered, but included studies 
were found to be insufficiently homogeneous in terms of design and measurement of 
adherence to allow meta-analysis of results. 
3.4. Results 
The five main databases searched yielded a total of 3279 records as shown in Table 3.2 
Database 













Table3.2: Records identified by database searches 
 
The Knowledge Network library identified 178 studies while clinical trials.gov identified 24 
giving a total of 3,481 records. A review of literature in Google did not produce any 
previously unidentified records. After combining the search results into one library using 
RefWorks 2.0 and removing 1,680 duplicated records 1,801 records remained. Figure 3.1 
shows the PRISMA diagram depicting the flow of information through the different phases 




Figure3.1 PRISMA flow diagram for systematic review (reproduced from Fulton, 2017 (317) 
 
After reviewing the titles and abstracts of all 1,801 records 56 articles were considered 
suitable for full text appraisal. Almost half of the records were excluded following a review 
of the full text for the following reasons:  
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1)  The majority of the records (19/35) excluded from the narrative review were excluded 
because the aims of the interventions did not include improving medication adherence 
(316-334) 
2) Two records were identified as conference abstracts. Several attempts were made to 
contact the authors of the first (337) however non-response meant this article was excluded 
as the abstract contained insufficient data from which an inadequate assessment of risk 
of bias could be made. The second conference abstract record was not included as this 
was found to be related to another title which contained all the data required to make a 
judgement on possible inclusion (338) 
3) Five records on closer inspection were found to be in fact duplicates of four 
independent trials which had been selected for inclusion in the narrative review (339-343).  
4) Two records (344, 345) were abstracts for theses. Attempts were made to locate and 
contact authors; one was unobtainable, while an email was sent to the other. No response 
was received thus both were excluded.   
5) Two studies (346, 347) were excluded as the intervention being trialled was directed at 
the healthcare professional rather than the heart failure patient. 
6) Three records were found to be non-randomised controlled trials and thus did not meet 
the inclusion criteria (348-350). 
7) On closer inspection another two articles were subsequently excluded for inclusion in 
the narrative synthesis. The trial by Goldstein et al (351), although looking to improve 
medication adherence, focused the use of the adherence aids themselves while the trial 
conducted by Bocchi et al focused on improving self-care not medication adherence (352). 
Therefore the evaluation of the 56 full texts yielded 21 studies that met the inclusion 
criteria for the systematic review. No further studies were identified following hand 
searching of the reference lists of the 21 studies. Characteristics of the included studies 
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Measurement 
Follow up in 
months 
Key Study Findings Relating to 
Adherence 
Intervention group 






United States(368)  
 
117(69%) 
C: 56 (10.3) 
 
I1: 57 (11.1) 
 
I2: 55 (10.2) 
C: 68% 






(MEMS) for 2 










MEMS - I1 -91% at baseline – 
90% at 8 mo follow-up 
 
I2 -87% at baseline – 83% at   
8 mo follow-up 
 
 
MMAS for I1 – 85% at 
baseline 
77% at 3 mo follow-up 
MMAS for I2 – 89% at 
baseline – 81% at 3 mo follow- 
up 
MEMS – 8 0 %  at baseline – 







MMAS – 82% at baseline - 86% at 3 
mo follow- up 
  Mussi 
  (2013) 







C: 63 (12.1) C: 64% Self-reported 
measure of 
medication 
taking on a 5- 
point scale: 1 – 
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100% at follow-up 
 







C: 60 (11.5) 
 











≥ 80% pills taken in 55% at 3 m 
follow-up 70% at 12 m follow-up 
MMAS - 5.03 at baseline 7.04 at 
12 mo.  
 
 




≥ 80% pills taken in 28% at 3 m 
follow-up 30% at 12 m follow-up  
 
MMAS - 4.80 at baseline 




Table3.3: Characteristics of included studies (Adapted from Fulton, 2017 (315).  
C, Control group; I, Intervention group; 11, Intervention group 1; 12, Intervention group 2; MMES, Medication event monitoring system; MMAS, Morisky 





3.4.1. Assessment of Risk of Bias 
The reporting quality of the 21 included studies was sufficient to adequately 
assess the potential risk of bias. Judgements regarding the risk of bias for each 
study were categorised as: “Low risk of bias”, High risk of bias” or “Unclear risk 
of bias”. Table 3.4 shows the risk of bias assessment for each of the included 
studies. 
Sixteen trials provided information about adequate sequence generation, 
however allocation concealment was unclear in 10 of the 21 studies. Although 
masking participants to intervention allocation is difficult in most behavioural 
studies, two of the included studies did make an attempt to do this by offering 
an educational intervention to both groups (342, 343). Information regarding the 
blinding of adherence assessors that was sufficient to make a judgement was 
available in only 13 of the 21 studies, with clear blinding of outcome data 
evident in only eleven of the of the included studies. Seventeen studies 
reported details for participants lost to follow up but only twelve studies 
specified intention to treat analysis. None of the trials met all the criteria. 
3.4.2. Characteristics of Included Studies 
Twenty-one randomised controlled trials were identified containing a total 
sample of 4,346 patients. The median sample size was 148 patients with a 
range from 50-902. 
More than half the studies (11/21) were carried out in United States with 6/21 
carried out within Europe. The average age of the participants ranged from 56 
to 85 years with male participation ranging from 27% to 92%. The median 
follow-up time was 9 months, ranging from 2 weeks to 12 months, with 10 
of 21 (48%) of studies having follow-up times of ≤6 months. The mean 
percentage of patients included at follow-up was 80.7% in the 17/21studies 
that provided these data with a range of 28 –100%. Adherence to medication 
was measured in several different ways across the included studies. 
Participant self-report was used as an outcome measure in 8 studies, the 


































































































































































































Goodyer (1995) L U H L L L 
Rich (1996) L L H L L L 
Fulmer (1999) L L H H H L 
Varma (1999) L U H U L L 
Bouvy (2003) L L H U L L 
Laramee (2003) U U H H L L 
Ross (2004) L L H U L L 
Tsuyuki (2004) L L H U L L 
Gwadry-Sridhar (2005) L L L L L L 
Sadik (2005) L U H L L L 
Lopez-Cabezas (2006) L L H L H L 
Murray (2007) L L H L H L 
Udelson (2009) L U H U L L 
Wakefield (2009) L L H U L L 
Antonicelli (2010) U U U L H H 
Powell (2010) L L L L L L 
Wu (2012) U U H U L L 
Dunbar (2013) U U H L H L 
Mussi (2013) L L H L L L 
Boyne (2014) L U H U L L 
Granger (2015) U U H H L U 
L= Low risk of bias         H= High risk of bias       U= Unclear risk of bias 
Table3.4: Risk of bias assessment for each of the included studies reproduced from 




and medication refill records in 2 studies. Two studies using other methods 
also measured Morisky Medication Adherence Score (MMAS). 
Adherence rates across the studies ranged from 28% to 93% however across 
the 21 studies the 21 studies the heterogeneity of measurement of adherence 
and limitations in reporting make it difficult to carry out a meta-analysis of rates 
of adherence or results for the reviewed studies. 
3.4.3. Reported Intervention Techniques 
Intervention techniques varied widely across the studies. While the reviewed 
trials were classified into four categories it is important to highlight that several 
of the trials contained multicomponent interventions that could have been 
included in more than one of these categories. A clear alternative 
categorization of strategies did not emerge. 
3.4.3.1. Patient Education and Information 
Three trial interventions were classified as patient education (354, 364, 368) offered 
as individual sessions except for Dunbar and colleagues (368) who offered 
group education. Written and verbal Information was delivered in all of the 
studies while family education was included in 2/3 studies (364,368). The study 
described by Lopez-Cabezas (364) found that initial improvements to adherence 
noted between groups had disappeared by 12-month follow-up while neither 
of the other two trials found evidence that this class of intervention led to 
enhanced adherence. All studies did however report adherence rates of ≥ 74% 
at follow-up.  Two of the three studies were carried out on patients post hospital 
discharge with only Dunbar et al targeting outpatients while two of the three 
trials were delivered by a pharmacist (368,354). It is important to note that this 
intervention also incorporated intensified patient care and simplification or 
optimisation of medication regimens.  
3.4.3.2. Intensified Patient Care 
The majority of trials (14/21) were categorized as intensified patient care and 
could be further subdivided into (a) nine direct patient contact interventions 
(355, 356, 358-360, 362, 363, 365, 369) and (b) five telephone or tele monitoring programs 
(341, 357, 361, 366, 367). Five of the nine direct patient contact interventions led to 
107 
 
enhanced medication adherence (355, 356, 358, 359, 363), whereas only 1 of the 
telephone or tele monitoring programs led to enhanced adherence (367). Of the 
5 telemonitoring studies 3/5 involved contact with a healthcare professional 
via a telephone or video phone (357, 366,367) with the others increasing contact 
with patients online (369) or by other electronic devices (341). Only 1/5 trials 
categorized as telephone/tele monitoring carried out by Antonicelli and 
colleagues reported enhanced medication adherence. The intervention 
involved contact with the patient or next of kin by telephone call at least weekly, 
to obtain information on adherence and clinical symptoms in order to evaluate 
and modify therapeutic regimes. However, the sample size was small, follow 
up was not reported and no detail was given regarding the outcome method 
other than self-report. Unfortunately several of the other telemonitoring studies 
reported consistently high adherence levels throughout reducing the potential 
for significant findings relating to the intervention itself.  Five of the eight direct 
patient contact interventions were pharmacist-led.  
3.4.3.3. Complex Behavioural Approaches 
Three studies examining complex multicomponent interventions to enhance 
medication adherence in HF were identified in this review (276, 352, 370). The 
study carried out by Powell and colleagues in over 900 HF patients found no 
evidence that a complex multicomponent intervention that included a range of 
behavior change techniques led to enhanced medication adherence. A smaller 
study by Granger et al which also used a complex intervention (in-depth 
interviewing to determine beliefs, concerns and perceived necessity for 
medication in order to develop a symptom response plan) did however report 
a significant between-group difference in adherence (70% vs. 30%) in favour 
of intervention group at 12 month follow-up (370).  
Wu et al also recorded a significant between-group difference in their study 
which evaluated an intervention based on the TPB (276). Eighty-two participants 
were randomised to one of three groups: a) education and behaviour change 
counselling, b) education, behaviour change counselling and feedback from 
medication taking using MEMS or c) usual care. Enhanced medication 
adherence was reported in both the intervention groups at 9-month follow-up.     
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3.4.3.4. Simplification of the Drug Regimen 
Only one study solely targeted simplification (243). This study attempted to 
evaluate medication simplification to a simpler controlled release regime but 
did not find evidence of enhanced adherence. Attempts to simplify medication 
regimens did occur in some of the other studies included in this review (356, 363) 
although not necessarily directly by the research team. A full description of the 
interventions used in each study is detailed in Table 3.5. 
3.4.4. Studies showing positive results 
Of the 21 studies included in the review only 8 showed significant 
improvements in medication adherence compared to the control group. More 
than half of these (6/8) used intensified patient care and the other two complex 
behavioural approaches.  
3.4.4.1. Intensified patient contact trials: 
I. Bouvy et al (359) evaluated a pharmacist led intervention aiming to 
enhance compliance to diuretic therapy in heart failure patients. 
Structured interviews using medication history facilitated discussion of 
drug use, reasons for non-adherence, possible side effects and the 
integration of medicines into daily life. Those participants allocated to the 
intervention group received monthly interviews for the six-month follow 
up period. Medication event monitoring system (MEMS) data were 
collected on loop diuretic medication only. Total adherence was recorded 
as total possible days without diuretic: intervention group 140/7656 
possible days versus control group 337/6196 (relative risk 0.32 [95%CI 
0.19-0.55]). 
II. Goodyer et al (355) carried out a counselling-based intervention delivered 
to outpatients with heart failure aged 70 years and over. Each participant 
received three episodes of counselling over a 3-month period by a 
pharmacist who incorporated individual verbal counselling, medication 
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outcome measurement was the mean adherence scores, expressed as 
a percentage of the maximum medication that should have been taken. 
While there was no significant between-group difference at baseline:  
control group 49% (SD 33%) versus intervention group 61% (SD 31%), 
by three months adherence was reported as 51% (SD 32%) in the control 
group versus 93% (SD 11.7%) in the intervention group (p<0.001). 
III. Rich et al (356) targeted inpatients with heart failure aged 70 years and 
over. Using a prepared teaching guide those participants receiving the 
intervention received daily visits until hospital discharge from the study 
nurse who repeatedly emphasised the need for medication adherence. 
Members of the wider multidisciplinary team including a dietitian, social 
services representative and a geriatrician who carried out a medication 
review also visited as part of the intervention. Following discharge, 
participants in the intervention group received regular contact from the 
study nurse until the 30 day follow up appointment as well as a visit from 
the homecare team. Outcome measurement was by pill count at 30-day 
follow-up. Overall adherence was measured in two ways: firstly, the 
percentage of pills taken correctly for each medication was calculated 
then values averaged, and secondly the total number of pills taken was 
divided by the total number which should have been taken. For method 
1, adherence was 88% ± 12% in the treatment group verses 81% ± 17% 
in the control group (p=0.003) while adherence rates using the second 
method were 88 ± 13% versus 81 ± 17% (p=0.004). 
IV. Another pharmacy led trial reported by Sadik et al (363) involved a 
pharmacist who identified possible areas for drug simplification with the 
physician of participants in the intervention group; each participant then 
received an information booklet and advice on self-monitoring. Self-
monitoring diaries were issued to participants in the intervention group 
and used to facilitate discussion about their condition at any subsequent 
appointments with their physicians. In addition completed diary cards 
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where returned to the research pharmacist each time medication was re-
issued with the pharmacist reviewing and offering guidance as required. 
Outcome measurement was adherence by self-report which was 
measured at 3 monthly intervals until the trial was complete at 12 months. 
The number of intervention group patients versus control who exhibited 
self-reported medication as demonstrated by completed entries in the 
self-monitoring diary was reported as 85 versus 35 at 12 months (p 
<0.05). 
V. Varma et al (358) conducted a trial in 83 older HF patients. Participants in 
the intervention group received a pharmacist led education programme 
focusing on the condition, its treatment and symptom control along with 
simplification of their medication regime. Outcome measurement relating 
to medication adherence was collected by self-report and knowledge of 
HF medication with additional analysis of pharmacy drug use profiles 
(DUP) available in 26/83 (31%) of participants. At 12-month follow-up the 
intervention group demonstrated an increased knowledge of medication 
compared to the control group (p=<0.05) and while DUP reported a 
statistically significant difference in adherence between groups (p=0.039) 
no significant difference was noted using the self-report data. 
VI. Antonicelli et al (367) conducted the only successful intensified contact trial 
that investigated the impact of telemonitoring systems on medication 
adherence in heart failure. During the 12 month follow up period a 
member of the telemonitoring team contacted each participant in the 
intervention group at least weekly by telephone to obtain information on 
heart rate, blood pressure and other clinical signs, which were evaluated 
by the team, and the therapeutic regime modified as necessary. All 
participants, regardless of group allocation, were seen by their hospital 
clinician every 4 months. The outcome measure was self-report however 
no other information on this outcome was provided. Adherence was 
reported as 90% in the intervention group versus 36% in the control 
group (P<0.03). Several unsuccessful attempts were made to contact the 
authors for further information thus it is difficult to determine the true 
effect of this intervention given those in the intervention group had 
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significant changes made to their medication regime by the study team 
in direct response to the ongoing clinical information being gathered 
which may have had more of an impact on their adherence behaviour 
than the intervention itself. 
  3.4.4.2. Complex Behavioural Approach Trials 
VII.Granger et al (370) conducted a trial exploring the theoretical linkage 
between symptom experiences and medicines with the aim of improving 
adherence to medication. A symptom response plan was developed 
following an in-depth interview where participants and carers were 
encouraged to establish meaningful associations between adherence 
and symptom onset. Skill-based learning was used to facilitate learning 
of the medication regime. Adherence was measure by both nurse 
assisted pill counts and by using the Morisky Medication Adherence 
Scale (MMAS). Using an adherence cut off of 80%, results pooled over 
all time points reported that participants in the intervention group were 4 
times more likely to be adherent to medications than those in the control 
group (odds ratio 3.92, p=0.0007). Participant reporting using the MMAS 
mean score also indicated higher adherence: intervention group 7.04 
(SD 1.55) versus control 6.12 (SD 1.33; p=0.005). 
VIII.Wu et al (276) trialled an intervention based on the theory of planned 
behaviour, which included personalised feedback of medication-taking 
behaviour by a nurse to enhance medication adherence in a younger 
population with heart failure (mean age 60 years). Two intervention 
groups were established, one which received four sessions of 
counselling and teaching (Lite) and another (Plus) which received 
feedback in addition to the teaching and counselling to encourage 
positive behaviours. The intervention groups both participated in two face 
to face teaching/counselling sessions delivered during months one and 
two with telephone follow up sessions conducted two weeks after each 
face to face session. All participants, including those in the control group, 
received a monthly telephone call to collect outcome data between 
months 3 and 9. MEMs was again used to assess adherence at 1, 2 and 
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9-month time points with 88% of medications taken chosen by the study 
team as the cut-off point for adherence. The trial reported that both 
intervention groups were more adherent to medications at 9-month 
follow-up:  Plus group 74%; Lite group 65% versus control group 36% 
(p=0.015). 
3.4.5. Components of interventions  
3.4.5.1. Personnel 
Across the 21 included studies interventions were carried out by a variety of 
qualified people including specialist cardiac nurses and medics and other 
professional disciplines with a cardiac background. A multidisciplinary team 
approach was employed in one study (356) however a number of interventions 
were delivered by staff who did not have obvious clinical experience of heart 
failure (352, 357, 360, 362, 366, 368). In the main pharmacist input appeared to be 
utilised more often than others in successful direct patient contact 
interventions (358, 359, 363).  
3.4.5.2. Education 
Education on condition or treatment was identified as the most commonly 
utilised component and reported as an element in the majority of studies 
15/21(71%) (276,353-356,358-364,368-370). Within these studies participants received 
educational information on a one to one basis, except for those undertaking 
the study by Dunbar et al where group educational sessions were delivered 
(366). All included studies provided participants with increased information in 
varying forms with the exception of the study by Udelson which focused on 
simplification of medication regime (243) and two studies focusing on telehealth 
(364,365). For those eight studies reporting positive results (276,355,356,358,359,363,367, 
370) all except one (367) provided participants with either written or verbal 
information as part of the intervention.  
3.4.5.3. Self-monitoring 
A self-monitoring component was identified in 9/21(43%) studies with 
participants engaging in activities such as the monitoring of shortness of 
breath and tiredness as well as the recording of daily weights and oedema. 
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However less than half of these included structured guidance if symptoms 
deteriorated (358, 360, 363, 370). Overall self-monitoring was included in 3 of the 8 
studies reporting positive results (358, 363, 370). 
3.4.5.4. Prompts/restructuring 
Several of the studies identified a need for review or restructuring of the 
treatment regime. Several studies addressed burden of treatment by looking 
to simplify prescribed treatments (243, 356, 363) while prompts and adherence aids 
were utilised in several others (355, 357, 360, 362, 365, 370). Overall 4/8(50%) 
interventions which reported positive results included this component in their 
design. 
3.4.5.5. Beliefs around medication 
Finally while only two studies focused on the role of individual beliefs around 
medication both reported positive outcomes (276,3708). Granger et al utilised a 
framework which encouraged HF patients to identify personal beliefs and 
concerns around prescribed treatment in order to develop meaningful 
association between symptoms and treatment (370). The intervention by Wu et 
al looked to encourage positive beliefs about medication again by establishing 
an association between the condition, symptoms and treatment (276).  
3.5. Discussion 
In common with previous reviews of the literature, the proportion of patients 
adhering to their medication varied greatly between studies (11, 112). However 
the overall estimate of approximately one third of patients not taking 
medications as prescribed underlines the importance of being able to identify 
and offer appropriate interventions to this large group of patients. 
Successful management of HF is complex, requiring significant input from 
patients, carers and healthcare providers to achieve optimal control. 
Treatment for the condition usually encompasses pharmacological therapies, 
behaviour modification and ongoing monitoring (371) and the multifactorial 
nature of non-adherence requires programs aiming to improve medication 
adherence to adopt comprehensive approaches. In this systematic review of 
interventions to enhance medication adherence in patients with CHF 
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medication adherence was reported to be significantly higher in the 
intervention group compared to control group by the end of follow-up in 8 
studies. Evidence of effective interventions using various different techniques 
was found however a set of clearly efficacious intervention strategies did not 
emerge. The most commonly used intervention was the provision of education 
to enhance knowledge of heart failure and drug therapy, however the evidence 
suggests that simply supplying information without enhanced contact from 
professionals within the healthcare team does not appear to be a successful 
way to help patients optimise the use of their medication. Five of the eight 
direct patient contact interventions were pharmacist-led which may go some 
way to explain why the use of aids to adherence such as medication calendars, 
pillboxes or simplification of drug regimens interventions (355, 356, 360, 362, 363, 365). 
As with the previous systematic review in this area, there was evidence to 
support pharmacist-led interventions, especially when such initiatives were 
underpinned by engagement with other healthcare professionals (358, 359, 363). 
Two of the three trials adopting a complex behavioural approach reported 
enhanced adherence. Both were much smaller than the third trial which did 
not show a benefit. Interestingly though, both of these smaller trials adopted 
an educational component and telephone follow-up as part of their intervention 
(276, 370). Given that adherence has multidimensional contributory factors it may 
be that a complex behavioural intervention, underpinned by a clear theoretical 
framework and combining components of knowledge, self-monitoring and 
enhanced communication between health care providers may achieve better 
results. 
Although the average age for first diagnosis of heart failure is 76 years (83) the 
majority of trials included in the review enrolled participants with a lower mean 
age and are thus not representative of the typical heart failure patient seen in 
clinical practice. This limits the generalisability of the findings and calls into 
question how transferrable some of the interventions may be to older, frailer 
heart failure patients.  It is also well documented that the average rates of 
adherence in clinical trials can be remarkably high, owing to the attention study 
patients receive and to selection biases operating in recruitment. With no 
general consensus around what is an acceptable level of adherence it is 
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difficult to compare results even in trials that claim to report positive results but 
where no definition of what is meant by ‘adherent’ is given. 
Given that lack of adherence is an issue common across populations with 
chronic disease and not specific to patients with heart failure, interventions 
may be better targeted towards high risk groups that cut across disease silos, 
for example those with a low level of health literacy, sensory impairment or 
linguistic and cultural differences, rather than targeting the intervention at one 
particular disease. 
3.6. Limitations 
As with any systematic review it is possible that some trials may have been 
missed despite a detailed search of databases, grey literature and thorough 
hand searching of reference lists. The quality of the review results is limited by 
the methodological choices and the quality of reporting of the primary study 
researchers, which resulted in research methodology and intervention 
techniques varying widely.  
Heterogeneity in intervention techniques, limitations in intervention reporting 
and measurement methodology left an inability to conduct a meta-analysis or 
provide a coherent method of categorising the identified studies, while lack of 
response from authors of original papers and abstracts resulted in the 
exclusion of several trials due to inadequate reporting of intervention methods 
and outcome data. Tallying positive studies has well-recognised limitations 
and therefore the results should be interpreted with caution.  
The categorisation method chosen also deserves comment; the grouping was 
chosen on pragmatic grounds based on the emergent features of the included 
studies, however the four categories were not necessarily mutually exclusive 
nor systematically developed. 
The difficulty in measuring adherence accurately is a significant limitation for 
any systematic review seeking to assess the effectiveness of different 
adherence enhancing strategies. Currently there is no ‘gold standard’ for 
measuring adherence to medication with no agreed method of measurement 
(8). It is also worth noting that the high levels of adherence at baseline found in 
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many of the trials included in this review might reduce the efficacy of 
interventions (the ‘ceiling effect’) and may thus lead to under-estimation of the 
intervention effect in less adherent populations.  
3.7. Conclusions 
This review sought to broaden understanding of interventions on adherence in 
patients with chronic heart failure. A review of the literature concluded that the 
reasons for non-adherence to medication in patients with HF are complex and 
multi-factorial with health behaviours and outcomes influenced at several 
levels, starting with the individual and continuing with the family and the 
community, the health care system, and ending at the environmental level. 
RCTs in this area however are still limited in both number and quality.  
Heterogeneity in both intervention techniques and measurement methodology 
resulted in an inability to establish a reliable and effective intervention 
approach. Importantly the lack of a mutual agreement on valid methods for 
measuring adherence as well a lack of representative inclusion of older 
patients with chronic heart failure failed to give a realistic picture on which 
interventions are successful in patients routinely seen within clinical practice. 
Few studies included in this review failed to include long term follow-up, of 12 
months and more, which may have provided a more realistic picture of 
adherence to life-long treatment and allowed for the evaluation of morbidity 
and costs. 
While this review provided evidence to suggest adherence to medication can 
be improved in patients with chronic heart failure a clear picture of specific 
effective interventions did not emerge. The results highlight the need for future 
research focusing on multi-component interventions, acknowledging patients’ 
beliefs and preferences and incorporating them into adherence-enhancing 
interventions which combine a number of strategies including information 
provision, reminding and reinforcement.  
In order therefore to develop an effective complex intervention aimed at 
improving adherence in HF patient’s perceptions and experiences of this group 
of patients in relation to medicines and self-care activities requires further 
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exploration. The following chapter describes the methods and results of a rapid 




Chapter 4: Rapid Review of Qualitative 
Literature 
As noted in previous chapters, an understanding of barriers and drivers to 
adherence is essential in when considering the design of an intervention to 
enhance medication adherence. As discussed in chapter two, intentional non-
adherence occurs when the patient consciously chooses not to take their 
medication against the advice of their health care professional with patients’ 
beliefs about their disease being central to adherence (10). Examining the 
personal experiences of people with HF in relation to medicines and self-care 
activities may help inform the development of interventions which aim to 
change perceptions which in turn could improve adherence. This chapter 
commences with a summary of the methods used to conduct a review of such 
literature and continues with results and discussion identifying current gaps in 
knowledge which will shape the design and conduct of the qualitative work 
presented in this thesis. 
4.1. Design 
While systematic reviews are considered to be the gold standard in knowledge 
synthesis they are not without their limitations. Systematic reviews usually 
require between 6 months and 2 years to complete and often focus on a 
narrow clinical question. Rapid review is an emerging methodology which can 
be viewed as part of a “continuum of methodologies in assessing evidence” 
(372).  
In the rapid review elements such as proficient searching and the use of 
extended search techniques are utilised within shorter timeframes than for 
other evidence-based summaries however, while rapid reviewing offers the 
opportunity to provide a timely and valid view of evidence rigor may be 
compromised (373). Given that the rationale behind the qualitative review was 
not to seek decisive answers but to obtain an overview of existing work in order 
to guide the work detailed in subsequent chapters, rapid review methodology 
chosen purely on pragmatic grounds for this piece of work. 
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The purpose of this of a rapid review was to systematically assess qualitative 
evidence answer the following research question:  
“What are the barriers and facilitators to medication adherence in heart 
failure patients based on patient’s perceptions and experiences?” 
4.2. Methods 




4.2.1. Search strategy  
A comprehensive search was conducted using Medline; CINAHL and Embase 
to retrieve all relevant articles for studies published up to end April 2016. No 
restrictions were placed on language or publication status. Guided by the study 
inclusion/exclusion criteria (see figure 4.1) all titles and abstracts were 
screened to determine eligibility followed by a review of the reference lists of 
all retrieved articles to identify any additional publications. 
4.2.2. Data extraction 
Details including aims, participant demographics, methodology, and methods 
of data collection and analysis were collected. Participant quotes and 
observations (first-order constructs) and authors’ themes, concepts and 
interpretations (second-order constructs) were also extracted. All included 
papers were entered in and managed with QSR’s NVivo 10 software. All text 
under the sections of “results” and “findings” were considered as data.  
4.2.3. Data synthesis 
To aggregate the findings a thematic synthesis approach as described by 
Thomas et al (374) was adapted and used to synthesise the data from the 
selected articles. Firstly, the data were coded line by line before being 
organised into related areas to create descriptive themes. Descriptive 
summaries of data extracted from each study were created enabling a table of 
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barriers and facilitators associated with medication adherence to be 
presented. 
Figure4.1: Rapid Review inclusion & exclusion criteria 
4.2.4. Quality assessment of studies 
For qualitative studies, the Centre for Reviews and Dissemination (CRD) 
emphasises the importance of using a structured approach to quality 
assessment when assessing inclusion in reviews. The CRD does however 
acknowledge the lack of consensus around the definition of poor quality (310). 
While a selection of appraisal tools are available there is currently no 
consensus on how to assess qualitative evidence. Given that quality 
assessment can be a useful way to gain an understanding of the relative 
strengths and weaknesses of studies the methodological quality of the studies 
which were included was in this review were assessed using a tool from the 
Critical Appraisal Skills Programme (CASP) (375) criteria for qualitative studies. 
Inclusion criteria 
Types of studies: Qualitative studies using interviews or focus groups, mixed methods 
studies reporting qualitative findings were also included. 
Participants/population: Adult participants (>18 years of age) with a clinical diagnosis 
of heart failure 
Intervention/exposure: Phenomenon of interest: in order to be included studies required 
to directly explore 
• Factors and barriers that correspond to adherence to medications 
• Any aspect of the patients experience or perceptions regarding medication 
taking 
Exclusion criteria 
• Studies using structured questionnaires as the sole method for data collection 
•  Quantitative studies reporting quantitative assessments of quality of life or 
reporting only quantitative data not elicited from the patients themselves.  
• Observational epidemiological studies, editorials, reviews, non-research articles 




No studies were however excluded on the basis of quality. Three domains 
were assessed: adequate reporting of the research, appropriateness of 
research design, and research conduct. 
4.3. Results 
When duplicates were removed the database search yielded 309 citations. 
Based on information in the title seventy-three articles were assessed as 
relevant and abstracts were obtained. A further a further 50 articles were 
excluded following screening of the abstract resulting in a total of 23 empirical 
papers being selected for full text review. Of these only 10 studies were 
included in the final analysis with others excluded because they focused purely 
on self-care. The majority of studies were conducted in either the United 
Kingdom (4) or the United States of America (4), with single studies conducted 
in Malaysia and the Netherlands. More than half of the studies did not specify 
a particular qualitative methodology. The 10 included studies incorporated 
data from 228 patients. Table 4.1 lists a summary of included studies. The 
results of the quality assessment indicated that the majority of studies were of 
medium to high quality. 
4.3.1 Demographic Characteristics 
Across the included studies information such as demographics, comorbid 
disease, prescribed medication and level of HF were described however 
reporting was consistent across the studies. The sample in the included 
studies comprised participants ranging in age from 27-94 years. Of the 9 
studies reporting gender 124/191 (65%) of the participants were male, while 7 
studies provided demographic characteristics such as ethnicity, education 
level and home living circumstances. Five studies reported length of time with 
a chronic HF diagnosis which ranged from 1 – 16 years. 
Across studies convenience, purposive and maximum variation sampling 
strategies were employed from various recruitment sources including 
outpatient clinics, inpatient wards and utilisation of computer records.  Eight of 
the included studies reported approval by an institutional review board with the 












Main Strengths (+) and Weaknesses (-) 









To explore how HF patients 
adapt to life with HF and what 
facilitated or impedes self-
care 
M +Basic descriptive design and approach to analysis reported in an 
easy to read manner. Interview guidelines supplied  
-Lack of clarity around rigour of qualitative design; Participants 
enrolled had previously been involved with studies. While Themes 
were reported the results lacked adequate representation from the 
participants.  








To explore patients 
understanding of their 
symptoms and treatment 
M +Clear description of methods used in both collection and analysis of 
data. 
- Theoretical background unclear. Limited reference back to 
participants despite relatively large sample size. Emergent themes 
unclear 












To identify the lived 
experiences of  H/F patients in 
relation to adherence 
H +Theoretical approach clearly identified. Methodological approach 
clearly reported. Participants’ views clearly represented throughout.  
- None identified 
 
Table4.1: Summary of Studies included in Rapid Review (n=10) 
Quality Appraisal Quality Rank Key: H = High; M = Moderate; L = Low 
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Field et al (378)  










sampling - guided 
by an expert 
advisory panel 
(n=37) 
To investigate how awareness 
of medicines equips patients 
to participate in informed 
discussion 
M +Clear description of research methodology. Good use of supporting 
quotes from participants 
- Emergent themes not identified 






not identified  
(n=50) 
To explore patients views of 
the management of 
medication of CHF 
H +Rigorous methodology described. Interview guide supplied. Large 
sample size with patients well represented in the data. 
-Patients recruited from outpatient HF clinics with access to a 
cardiologist thus may have received increased support for medication 
management 








To explore factors influencing 
adherence to prescribed 
medication 
 
M +. Participants are clearly represented throughout supporting themes.  
-No linkage between methods chosen and research question. 
Sampling criteria not fully described. Themes appear a little basic 
while interview guide appears directive.   










To explore patients’ reasons 
and motivations for 
compliance 
M +Theoretical approach clearly used as basis for interview questions. 
Clear description of methods. Recommendations for daily practice 
useful.  
-Selected to use the term ‘compliance’ which is outdated and may 
have influenced methods used. Themes appear broad and overlap. 
Participants had recently completed a trial, content of which was not 
discussed. Lack of data from participants 
Table4.1 cont.: Summary of Studies included in Rapid Review (n=10) 












To identify factors influencing 
adherence to medications in 
readmitted HF patients  
M 
+Good description of data analysis and list of identified themes 
supplied; Patients well represented via use of supporting quotes. 
-Exclusion of discussion on theoretical basis.  The interview guide 
was not provided 











To explore the theoretical 
linkages between symptom 
experiences and meaning 
associated with medication 
adherence 
M 
+Clear use of theoretical framework to structure the interview guide 
and conduct analysis; Mixed methods approach with qualitative the 
dominant paradigm. 
-There is a lack of patient data to support results 









To explore the beliefs patients 
with heart failure hold about 




+Use of theoretical framework to structure the interview guide. Good 
use of supporting quotes from participants linking back to theory 
throughout.  
-Interview guide not supplied; population currently managed by H/F 
nurses (these patients may already be receiving support for 
medication management) 
Table4.1 cont.: Summary of Studies included in Rapid Review (n=10)  
Quality Appraisal Quality Rank Key: H = High; M = Moderate; L = Low
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4.3.2. Aims of Included Studies 
Although the aims of the included studies differed, some commonalities were 
evident. Six of the ten studies focused fully on medication (167, 376, 378, 379, 381, 382) 
while four studies discussed medication adherence as part of self-care in HF 
(182, 219, 377, 380). The main aims of included studies ranged from gaining a deeper 
understanding of personal beliefs and knowledge held around HF, symptoms 
and medications to identifying which factors influence both medication 
adherence and the management of the condition. While not addressing 
medication adherence directly one study sought to explore the beliefs that 
patients with HF held about the condition and its treatment (219) while another 
looked at participants’ level of awareness regarding their heart failure and 
treatment in order to determine how equipped individuals were to make 
informed decisions regarding their treatment (378). 
4.3.3. Emergent Themes 
In Table 4.2 articles are organized chronologically. The table summarises the 
main findings relating to the facilitators and barriers to medication adherence 
in patients with HF which emerged from the 10 studies. Within the table 
barriers to adherence are highlighted in red text while facilitators are 
highlighted in green text. These can be grouped into three categories: factors 
related to the condition of HF; factors related to beliefs and experiences of 
medicines; and factors related to the role of significant others. 
Several of the studies (6/10) reported main motivating factors for adherent 
behavior. These factors are recorded within the last column of the table. Across 
the ten studies, a lack of knowledge around HF itself as well as a poor 
understanding of the role of medications, medication side-effects or the need 
for long term medication were identified as barriers to optimal medication 
adherence. Studies identified individual patient beliefs as both barriers and 
facilitators. Holding the belief that a medicine could be stopped in the absence 
of symptoms or the belief that an absence of symptoms could be a contributing 




 Knowledge and beliefs around 
condition and medications Difficulties regarding medications Communication with significant others Main motivating 
factor for 
adherence 
 Barrier Facilitator Barrier Facilitator Barrier Facilitator 
Riegel & Carlson  
(2002) 




books to educate 





Memory aids to assist 
Adapting regime if 
going out 
Lack of emotional 
support –  





To stay out of 
hospital 






































becomes part of 
normal life 






Wish to remain 
at home 
Field et al  
(2006)  




need for long 
term medication 
  






Not reported  
Table 4.2: Facilitators and barriers to medication adherence in HF taken from included studies.  
Red text =barriers to adherence.   Green text = facilitators for adherence 
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Reid et al 
(2006) 
UK (379) 





out at different 
times 
 
Development of a 
routine  
Visual and verbal 
cues 
Medications being 
part of everyday life 
 
Receiving support 
and help from 
family Trust in 
prescriber 














Frequency of meds 
& Polypharmacy, 
Side-effects, Cost & 
Forgetfulness 
 
Developing a habit  











Help from family 
Be as well as 
possible 
To stay out of 
hospital 
Preserve a good 
quality of life 









Use of medication 
aids Establishment of 


































Lack of information 
Regime complexity 
Dislike of taking 
medicines 
 
Pill boxes  











Desire to stay 
alive and be 
healthy 
Table 4.2 cont.: Facilitators and barriers to medication adherence in HF taken from included studies.  
Red text =barriers to adherence, Green text = facilitators for adherence 
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part of life 
Feeling that carers 
have insufficient 
time 

















Use of various 




 Not reported 
Table 4.2 cont: Facilitators and barriers to medication adherence in HF taken from included studies.  
Red text =barriers to adherence   Green text = facilitators for adherence  
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Having a belief in the potential for medicines to cure the condition or believing 
that prescribed medicines were indeed necessary were reported as potential 
facilitators.  
Practical difficulties including coping with complex drug regimes, 
polypharmacy and the availability of medications were cited throughout the ten 
studies as barriers to adherence. Aids to assist memory, adapting drug 
regimens if going out, the development of a routine, use of visual and verbal 
cues, and making medication taking part of everyday life were all identified as 
facilitators.  
The roles of significant others including healthcare providers, family as well as 
social care providers were also identified as being important to adherence. 
Having trust and a positive relationship with healthcare providers as well as 
the availability of emotional and physical support of others was identified 
across several of the studies.  
4.3.3.1. Factors related to the condition of heart failure  
Across the studies knowledge of HF was generally poor. Field et al reported 
that HF patients regularly identified themselves as having a ‘heart problem’ 
with participants having difficulty differentiating HF from other kinds of heart 
disease (378). This issue with illness identity was also reported by MacInnes (219) 
who found that differentiating HF from other conditions as well as the various 
different terminology used by different healthcare professionals led to 
difficulties for patients. In both these studies (291, 378) patients displayed a lack 
of understanding despite input from the Heart Failure Nursing Service.  
Although a lack of understanding around HF was reported, participants in both 
the studies by Riegel and Carlson (182) and Field (378) felt they had been well 
informed about their condition. Field also reported that along with poor 
knowledge a gradual deterioration in their condition had left some patients 
downhearted, feeling nothing more could be done for them. In this instance 
patients wished to limit the amount of information they were given, preferring 
to leave decisions regarding treatment to healthcare professionals. Reid et al 
(379) identified a lack of communication as an issue, commencing at diagnosis 
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with patients reporting that none of their healthcare professionals had actually 
given them an exact diagnosis. 
Patients in the MacInnes study identified HF as a chronic condition, and 
attributed the condition in to external factors such as family history and other 
conditions. HF in these patients was reported to have major consequences on 
their lives (291). In only one study, conducted by Rogers et al, did patients 
appear to have a good understanding of their condition; however participants 
in this study still lacked knowledge around medications prescribed for the 
condition (376).  
Co-morbidities appeared to complicate participants understanding of HF (279, 
376) with ageing noted as an influencing factor (291). Nonspecific symptoms 
could also complicate matters for patients who reportedly had difficultly 
determining whether symptoms were related to the HF itself or occurred as a 
negative consequence of prescribed medication (281,366). Where 
misunderstanding about the condition occurs there is potential that patients 
will be unable to monitor their symptoms of the side-effects of medication 
effectively (378).  
4.3.3.2. Factors related to beliefs and experiences of medicines 
Association between medication taking and positive symptom outcomes was 
identified in two studies (167, 382). Granger et al reported a link between 
medication adherence and meaningful associations with medications. In this 
study participants who could identify a direct association between symptom 
control and medication taking were more likely to be adherent (382). Granger 
also highlighted that adherence may not always be associated with positive 
sentiments. The study identified participants who reported negative 
associations related to intention with one viewing medication adherence as the 
way to avoid death and other who felt that medicines were simply part of life. 
Wu et al (167) also reported a link between knowledge of condition, individual 
symptoms and the effectiveness of medications to decrease these symptoms. 
Reported facilitators for adherence included an individual’s ability to make 
these connections, as well as their ability to assimilate medicine taking into 
their daily routine, and the use of environmental cues.   
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Field et al (378) found that participants who were described as being the least 
aware of their medication regime had difficulty accepting that medicine was 
the only available treatment for them. These participants did not understand 
the long-term nature of the treatment and were unable to directly link side-
effects of the medicines with symptoms.  The necessity for medication was 
identified as a factor for adherence identified by MacInnes (291). In this study 
participants reportedly held the belief that control of symptoms had been 
gained as a result of medication regimes. Drug information sheets and 
potential side-effects however caused concern among these participants (291).  
Medication adherence is not necessarily dependent on a person’s 
understanding of the condition or the role prescribed medicines play in 
reducing symptoms. Reid et al (379) identified a lack of knowledge around most 
medications except for diuretics which were frequently mentioned as their side-
effects were easily demonstrable and understood. Poor understanding of 
medications was also reported in two further studies. Rogers et al (376) found 
participants were concerned about the dosage of medications they were 
prescribed as well as the combination of drugs they were taking. Van der Wal 
(380) also reported misconceptions about medication linking it directly to 
adherence in one participant. 
4.3.3.3. Factors related to the role of significant others 
Supportive environments created by family, healthcare providers or carers 
facilitated adherence (167, 182, 377, 379, 381). The role of healthcare professionals 
was cited in several studies as being a positive experience. The study by 
Scotto (377) however identified a lack of understanding and perceived lack of 
support from health care professionals as being a deterrent to maintaining 
positive self-care practices which included medication adherence. Two of the 
studies, those carried out by Ming et al (381) and Wu et al (167), described respect 
for health care providers and a trust in them to provide the best treatment. 
While participants in the studies by both Reid et al (379) and Riegel and Carlson 
(182) described generally positive relationships between healthcare providers 
and patients this was not always the case for all patients.  
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Family support was identified as a key facilitator for adherence in studies by 
Ming et al (371) and Riegel and Carlson (171). In the study by Ming et al 85% of 
participants lived with family members who appeared to have active roles in 
maintaining adherence while Riegel and Carlson describe emotional support 
as being offered from a variety of sources.  
4.3.4. Limitations of included studies 
While the focus of the studies included in this review was the HF population 
the results have a number of limitations. Firstly, despite a number of studies 
being identified within this review the overwhelming literature has attempted to 
identify facilitators and barriers to self-care in HF with limited focus on 
medication adherence specifically. The evidence therefore remains 
inconsistent due to the relatively small number of studies looking at barriers 
and facilitators to medication adherence. Additionally, while the included 
studies reported an age range from 27-94 years very little work has conducted 
specifically in older HF patients who also have the added burden of co-morbid 
disease. It is unclear therefore from the literature how much of an impact the 
presence of other conditions has on the management of HF medication.  
When considering how the results of this review can be applied to the 
development of an intervention to be delivered within the local area it is 
important to consider what potential the impact of culture and national health 
policy may have on adherent behaviour. None of the reported studies have 
been conducted in Scotland where the health and social care system is 
different not only from the rest of the UK but significantly different form the 
health care systems present in Europe and North America where the majority 
of the reported studies were conducted. 
4.4. Conclusion 
This review has once again highlighted the multi-factorial and complex nature 
of non-adherent behaviour in patients with HF. Individual beliefs and level of 
knowledge have the potential to influence medication adherence in both a 
positive and negative way. Environmental factors such as memory aids have 
potential to facilitate adherence while experience of polypharmacy and 
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complex drug regimens can potentially pose serious barriers for patients who 
may be struggling to understand and manage multi-morbidity. Importantly the 
key role played by significant others as both barrier and facilitator to adherence 
should be acknowledged.  
It clear then that any future interventions aimed at improving adherence to 
medication in patients with HF must consider potential factors relating to the 
beliefs held about the condition itself, the medication prescribed as well as the 
role played by significant others. However, while this review has identified 
potential barriers and facilitators to adherence in HF it is still unclear what 
illness beliefs older HF patients and their informal caregivers hold about both 
the condition and its treatment. The following chapter describes the explorative 
qualitative study undertaken to identify illness and treatment beliefs held by 
older HF patients and their informal carers with the local population.    
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Chapter 5: Qualitative Study Phase  
As reported in chapter four the majority of the literature identified in the 
qualitative rapid review focuses on the theme of adherence to self-care in HF. 
In order to ensure that any future intervention aiming to improve adherence to 
medication in older HF patients is underpinned by a suitable behaviour change 
intervention gaps in current knowledge relating to the experiences and 
perceptions of this population require to be addressed. While potential barriers 
and facilitators to medication adherence have been reported in previous 
studies the beliefs older HF patients and their informal caregivers hold about 
both the condition and its treatment remain unclear. The aim of this phase was 
to undertake an exploratory qualitative study in order to answer the following 
research questions: 
I. What are experiences of older patients with heart failure and their 
informal caregivers around their disease and its treatment? 
II. What are the barriers and drivers to medication adherence for older 
patients with heart failure? 
Following completion of this phase results were to be used to guide the 
selection of outcome measures indicative of local patient experiences and 
assist in the adaption and modification of validated measurement instruments 
to assess medication adherence in a similar population to be undertaken in 
phase two, a prospective observational study 
5. 1. Qualitative Study Methods 
As discussed in chapter one, the work contained within this thesis was 
undertaken using a sequential exploratory multi-method research design as 
described by Creswell (45). While quantitative research can test theories, look 
at cause and effect or make predictions qualitative research, which shares 
its philosophical foundation with the interpretive paradigm, supports the view 
that reality is multiple and subjective (383). With this is mind, and given the aims 
of this phase of the research, the author considered an exploratory 
qualitative research design to be the best approach when undertaking a 
study exploring the phenomenon of beliefs and behaviour. The methods 
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undertaken to complete this exploratory qualitative study, were data was 
collected via semi-structured one to one interviews and analysed using 
Framework Analysis based on initial themes taken from the CSM are described 
below and can be found in the study protocol (see Appendix C). (Figure 5.1 
details a summary of qualitative procedures) 
5.1.1. Study Approval  
The study was conducted at a single site (NHS Tayside) and was approved by 
Tayside committee on Medical Research Ethics (ref number 14/ES/0066) on 
22nd May 2014.  The study was conducted in accordance with the principles of 
the good clinical practice. Based on the principles of the Declaration of 
Helsinki, written informed consent was obtained from each participant prior to 
the interview (see appendix D).  
Fieldwork for this study was undertaken over 8 months in 2014 - 2015. Data 
were collected using semi-structured interviews which were audiotaped. All 
audio-taped interviews were transcribed verbatim by RF. All transcribed 
interviews, field notes, reports, and other records were identified in a manner 
designed to maintain participant confidentiality will all records kept in the 
allocated secure storage area within Department of Ageing & Health, 
Ninewells Hospital, Dundee. 
5.1.2. Study Population 
Participants were all community dwelling people ages 70 and over with a 
diagnosis of CHF according to the European Society of Cardiology (ESC) 
guidelines see figure 5.2 for inclusion/exclusion criteria.  
Given that the aim of the study was to explore barriers and drivers to 
adherence from the patient’s perspective, those currently residing in a nursing 
or residential home and those currently receiving daily visits from district 
nursing service to administer medications were also excluded on the grounds 
that responsibility for medication in this group lies in the main with a healthcare 






































Sampling and recruitment 
(A) 
Participants in HF clinic or 
MFE clinic identified by 
purposive sampling. 
Information Sheet, reply slip 
and stamped address 
envelope supplied by clinic 
Data collection (A) 
Semi-structured interviews conducted in 
participants own home. Field notes written. HADs 




transcribed and reviewed in 
tandem with data collection  
Data analysed thematically 
using Framework analysis 





reviewed and coding 
verified by 
supervisor 
Data collection (B) 
Semi-structured interviews with informal 
carers conducted in participants own home. 
Field notes written.  
Sampling and recruitment 
(B) 
Informal carers nominated by 
participants supplied 
Information Sheet, reply slip 
and stamped address 
envelope either via HF patient 
or researcher as agreed 
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All participants were recruited from secondary care via HF and Medicine for 
the Elderly outpatient clinics, or from medical wards in Ninewells Hospital, 
Dundee. The range of recruitment sites aimed to ensure that the study 
population included recently hospitalised patients whose HF may not be 
optimally controlled, as well as those patients who were being managed 
successfully within the community. Given the use of a purposive sampling 
strategy recruitment from primary care was deemed to be more problematic 




Figure5.2: qualitative study inclusion and exclusion criteria 
 
5.1.3. Sampling Strategy  
Eligible participants were recruited to participate in the study using a purposive 
sampling strategy as described by Patton (384). A non-probability method of 
sampling, purposive sampling (also known as subjective, judgement or 
selective sampling) is where the researcher relies on his or her own judgement 
INCLUSION CRITERIA 
• Community dwelling people aged 70 years and over with a diagnosis of 
chronic heart failure according to the European Society of Cardiology 
(ESC) guidelines 
• Patients with New York Heart Association (NYHA) class II to IV 
symptoms 
• Nominated informal carers of the participants described above 
 
EXCLUSION CRITERIA 
• Unable to give written informed consent 
• Residing in Nursing home or Residential Home Environment 
• Currently receiving daily visits from district nursing service to administer 
medications 





when choosing members of a population to participate in a study. In short, the 
researcher actively selects who they consider will be the most productive 
sample in order to answer the research question. According to Marshall, while 
utilising a random sampling method may facilitate the generalisation of results 
to an entire population it is not the most effective way to gain an understanding 
of complex issues relating to human behaviour (385). Given that the purpose of 
the study was to provide a detailed picture of living with HF, a purposive 
sample of eligible participants was chosen using a framework of variables 
which might affect an individual's contribution.  
Based on personal practical knowledge of the research area along with 
information gleaned from the reading of current literature, the following two key 
variables were chosen as selection criteria and entered into a sampling matrix: 
a) Gender  
b) Recent hospital admission (admission ≤ 12 months) following an episode of 
decompensated heart failure.  
While ensuring that the two key a priori variables were used as essential 
selection criteria the sample was monitored to ensure variability in other factors 
– e.g. age, presence of a spouse and comorbid disease. 
5.1.4. Sample Size 
Recommendations for sample size vary widely with many researchers 
reluctant to suggest what constitutes a sufficient sample size (386).  Given that 
qualitative research is concerned with exploring different representations of a 
topic sampling depends on the methods used, time constraints, the quality of 
data obtained and the nature of the phenomena being studied (387). 
When determining sample size, the concept of data saturation - the point in 
data collection when no new or relevant information emerges has been 
identified an important factor (388).  Prior to data collection however saturation, 
while helpful at the conceptual level, provides the researcher with little practical 
guidance for estimating sample sizes. Guest et al carried out a review of a 
previous study involving 56 interviews concluding that data saturation had 
actually occurred after the first twelve interviews with the basic elements for 
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meta-themes present even earlier (389).  In a similar field to this current study 
Scotto (377) explored the experiences of patients living with HF and their 
adherence to prescribed regimens interviewing a total of 14 participants while 
Ming et al (381) conducted 20 interviews when exploring the factors influencing 
adherence in HF patients.  
While sampling in qualitative research is concerned with the richness of the 
data collected O’Reilly et al propose “appropriateness and adequacy” as the 
two key elements necessary to guide sampling and suggest that qualitative 
research should be undertaken using an approach which is both pragmatic 
and flexible (387). Based on the nature of the topic a sample size of 
approximately 12 HF patients and 12 informal carers was initially estimated, 
however the final number would be determined when it was deemed that the 
research question had been sufficiently answered.  
5.1.5. Participant Enrolment  
Potential participants were identified within the relevant clinic or inpatient areas 
by members of the medical and nursing team who supplied a copy of the 
Participant information Sheet (PIS) (see appendix E), a reply slip and a 
stamped addressed envelope. After reading the PIS only those individuals who 
wished to know more about the study were asked to respond by returning the 
reply slip. All respondents expressing interest were then contacted by 
telephone. During these initial contacts potential participants were given a brief 
outline of the purpose of the study and were encouraged to ask questions at 
any point during the phone call. Referring to the sampling matrix, personal 
details were obtained to establish if the individual met the sampling selection 
criteria. All participants meeting the inclusion criteria were asked to nominate 
an informal carer to participate in the carer’s interview. Those patients unable 
to nominate a carer were still eligible to participate in the individual interview if 
they met the selection criteria as directed by the sampling matrix (see table 
5.1).  
Participants who were selected were invited to participate in the individual 
interview. All interviews were conducted primarily in the participants own home 
in order to reduce any inconvenience, however all were given the opportunity 
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to nominate an alternative setting should they wish. Nominated carers were 
contacted separately and asked if they would agree to participate in a 
separate, individual interview at the location of their choice (see appendix F for 
the Carers Participant Information Sheet & appendix G for the Carers Informed 
consent sheet). 
 
 Target sample number 
Male Female 
Record of Hospital admission due to 
decompensated HF within last 6 months 
3 3 
No record of Hospital admission due to 
decompensated HF within last 6 months 
3 3 
Table 5.1 Qualitative sampling matrix 
 
5.1.6. Ethical Considerations 
According to Beauchamp and Childress four principles underpin medical 
ethics: autonomy, justice, non-maleficence and beneficence (390). Autonomy 
considers study participants to be independent individuals who can make their 
own choices and who should be able to make an informed choice to engage 
in studies without coercion.  According to Polit and Beck, ‘informed consent 
means that participants have adequate information about the study, 
comprehend the information, and have the power of free choice, enabling them 
to consent to or decline participation in the research voluntarily” (383). 
Within this study all participant information was supplied to the patient in written 
form, at least one full week prior to them agreeing to participate in the study 
visit. This period was deemed to be sufficient to allow patients to consider the 
information, discuss the content with significant others if they wished and make 
an informed choice regarding participation. For this study no formal cognitive 
assessment was conducted in order to assess the individual’s ability to 
comprehend the information supplied. All participants had been supplied the 
PIS by either medical or nursing staff within an outpatient clinic setting and 
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thus it was assumed that the information had only been supplied to those 
individuals who were suitable to receive it. Despite being reassured that refusal 
to take part would not in any way effect the healthcare they received it could 
be argued that by adopting an approach were initial contact was via a 
healthcare professional with whom the participant had a patient-clinician 
relationship some individuals may have agreed to consent to please their 
clinician.   
Within the PIS, content relating to: the nature and purpose of the research; 
how the individual came to be selected; the procedure involved along with how 
their personal information would be stored, utilised and disseminated was 
included. In addition, contact details for the researchers were included to 
facilitate any queries. At the being of the study visit the research was 
introduced with a copy of the PIS used as a prompt for discussions, 
confidentiality was explained before the consent document was read through 
with the participant ensuring the content was understood before written 
informed consent was taken.  A signed copy of the completed consent form 
was given to the participant for personal reference with another copy placed in 
the trial master file. All participants were reassured that they could withdraw at 
any point during the study and that no monetary award was offered. 
According to the ethical principle of justice all individuals, regardless of age, 
gender, ethnic origin, disability or other criteria should have equal opportunity 
to take part in research studies (390). Within this the target population was aged 
≥ 70 years, a population frequently underrepresented in research studies while 
study visits were carried out within the participants own home to avoid 
potentially difficult travel.   
Two of the most fundamental ethical principles applicable to research are non-
maleficence and beneficence. Researchers have a responsibility to balance 
potential benefits of the research against potential risks, protecting and 
safeguarding participants from harm (391). For this study all clinical staff were 
asked to exclude any patient deemed too unwell to take participate thus 
minimising the potential for both physical and psychological discomfort. Given 
that there was potential for some participants to become upset during the 
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interview all participants were informed that they could invite a significant other 
to attend the interview and should they become fatigued or upset the interview 
could be concluded early. Regarding the principle of beneficence, given that 
taking part in this study was unlikely to directly benefit the participant this was 
explained in the PIS. It was suggested however that some participants may 
value the opportunity to walk about their health. 
Relating directly to the four underpinning principles are the concepts of 
confidentiality and privacy. To ensure the anonymity of participants all 
identifying data relating to the individuals, their families and the organisations 
they discussed such as local hospitals and healthcare professionals were 
changed. Additionally, within the PIS participants were informed that 
anonymity would be maintained during any future write up or publication of this 
research.  Given that the interviews were conducted out with the healthcare 
setting and to protect the safety of the researcher information regarding the 
scheduled interviews such as date and time of appointment and the address 
of each visit was given to the study CI prior to each appointment and destroyed 
by the researcher on return to the department. 
Given that confidentiality prohibits the sharing of any personal data without an 
individual’s consent all tapes, transcripts and any other documents which could 
potentially identify an individual were stored securely within a locked cabinet 
within the department of Ageing and Health, University of Dundee. All data 
which required to be stored electronically, including transcripts, were stored on 
an encrypted file on the University of Dundee’s secure drive. At the conclusion 
of the study all audio-tape recordings were destroyed.  
Finally, when conducting qualitative research, the relationship between the 
researcher and the participant is an important consideration. When the aim of 
the study is to encourage participants to speak openly it is unrealistic to expect 
the researcher to remain an objective outsider. The researcher in this study 
was aware that the existence of prior knowledge of HF coupled with pervious 
nursing experience with older people meant that interviews had the potential 
to be approached with preconceived ideas and expectations. According to 
Holloway & Wheeler a health professional’s own assumptions may result in a 
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loss of focus on the patient’s own concerns during interviews offering potential 
for the discussion to be driven along a different path (392). Conscious that 
should participants be made aware of the researcher’s clinical background 
they may view the interview more as a clinical consultation the researcher 
introduced themselves as a research student and avoided divulging any more 
personal information than was necessary. 
5.1.7. Data Trustworthiness 
While methodological rigour can be described in terms of internal validity, 
reliability, objectivity and external validity within quantitative research, in 
qualitative research these criteria can be replaced credibility, dependability, 
confirmability and transferability (393). Within qualitative research credibility, the 
confidence which can be placed in the plausibility of the research findings, can 
be demonstrated through the use of strategies such as triangulation of data 
and member checking. Within this study the decision was taken not to use 
member checks, the practice of returning transcripts of interviews back to 
participants for feedback (394), on a purely pragmatic basis.  
Given the use of a purposive sampling strategy within this study transferability 
of the findings of this study was not a major consideration however the 
researcher collected background data, detailed within this thesis, which aimed 
to assist with the transferability judgement of others. Additionally the concepts 
of dependability and confirmability were considered. To ensure inter-
subjectivity throughout the coding process the researcher met regularly with 
her supervisory team to discuss the coding data with verification of coding was 
undertaken by one supervisor.  
5.1.8. Data Collection 
While various qualitative data collection methods such as observations, focus 
groups or individual interviews exist, the emphasis of this phase of the study 
was on the experiences of individuals rather than a collective response. With 
this is mind in-depth interviews were deemed to be most appropriate. While 
interviews can potentially be carried out either face-to-face, on the telephone 
or online, the age group under study advocated the adoption of a face-to-face 
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approach. This method was adopted to avoid potential difficulties with 
communication deficits and to ensure that non-verbal cues could be detected 
in order to assist with both running the interviews and interpreting the 
discussion. A semi-structured format enabled the phenomenon to be studied 
in detail but remain focused. 
An interview topic guide (appendix H) was developed and theoretically 
informed but not confined to, elements of the CSM as well as adherence and 
self-efficacy literature. In order to explore each participants adherent behaviour 
the topic guide aimed to outline key themes and areas of questioning thus 
enabling the interviewer to probe individual beliefs about HF before seeking 
out individual coping practices and motivating factors for adherent behaviour. 
Additionally, while it ensured a degree of constancy in the data collection 
process the topic guide offered the interviewer a degree of flexibility in order 
that details relevant to each individual could be explored.  
Field notes, a mechanism to remember and record the behaviours, activities, 
events, and other features of an interview were collected immediately following 
each interview. Each record contained both descriptive and reflective 
information and was used primarily as a reflective tool.  Field notes, along with 
the transcripts of previous interviews were reviewed by the researcher 
between each interview in an attempt to identify missed questions or emerging 
themes not covered in the interview guide. Using an iterative approach to data 
generation the researcher repeatedly reviewed the data between each 
interview using this evolving understanding to guide the next data collection. 
This process continued until the data collection was complete. 
5.1.8.1. Interviews 
According to Richie et al (395) in-depth interviewing consists of six component 
parts: stage one: the arrival and introduction; stage two: introducing the 
research; stage three: beginning the interview; stage four: during the interview; 
stage five: ending the interview and stage six: after the interview.  
The researcher allocated either a full morning or afternoon to undertake the 
study visit. Each participant was advised that the study visit would last around 
90 minutes to 2 hours which would which would give enough to conduct an 
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interview of around one hour’s duration without making the participant feel 
rushed. At the beginning of each interview and following the brief personal 
introduction and informed consent permission to tape record the interview for 
transcribing at a later date was obtained. In order to collect important 
contextual information all interviews commenced with some introductory 
questions such as ‘can you tell me how old you are?’ These easy to answer 
factual questions aimed to place the participant at ease and establish a 
rapport. Information on other demographics including home circumstances 
and formal help at home were also collected at this time, along with a list of 
the patient’s current medication.  
Key themes of illness representation, self–efficacy and beliefs about 
medication where explored using open questions such as ‟Can you tell me a 
little bit about any medical conditions you have?” and ‟Are you able to describe 
to me any symptoms you may have which you feel are related to your heart 
condition”.  In general, the topic guide was used to guide the order in which 
topics were discussed. If however a topic was discussed by the participant at 
an earlier stage of the interview they were encouraged to continue to ensure 
the interview flowed like a conversation.  
The review of the literature had highlighted depression as a common variable 
in medication adherence thus mood was formally assessed in all participants 
with their permission using a commonly used assessment tool - the Hospital 
Anxiety and Depressions Scale (HADS) (396). While ideally this scale would 
have been conducted before the start of the in-depth interview the researcher 
was keen to avoid the asking of formal, potentially upsetting questions at the 
beginning of the interview. Before ending the interview, permission was sought 
for the HADS to be completed once the interview had been concluded.  
After the conclusion of the interview time was allocated to explain what was to 
happen next with the information that had been collected. Occasionally this 
elicited some new information. Permission was sought to use this ‘doorstep 
data’ however, rather than restarting the recorder, this extra data was added 
to the field notes immediately following the interview. Conducting in-depth 
research interviews requires skill and experience to develop good techniques. 
147 
 
However due to time constraints pilot interviews were not undertaken instead 
refining of the interview technique developed over the duration of the study. 
Interviews with participants continued alongside data analysis with the 
recruitment of participants continuing until it was considered that the research 
questions had been answered.  
5.1.8.2. Carers Interviews. 
While all participants were asked to nominate an informal carer only 6/8 (75%) 
of those enrolled in the study felt they could do so. Approach was therefore 
made to these six carers with subsequent interviews conducted with four.  All 
interviews with nominated informal carers were carried out at their home 
address. Two of the carers requested that their interviews be carried out on 
the same day as their spouse. One carer requested that the participant and 
carer interview be conducted at the same time while the other was conducted 
immediately following the interview with the HF patient. Carer’s interviews all 
followed the same format at those carried out with the participants themselves 
except that a formal assessment of mood was not carried out. 
5.1.9. Data Analysis 
All data was anonymised and allocated a unique identifier for the study. 
Following transcription all data was uploaded and stored in an encrypted file 
on the University of Dundee’s secure drive. Analysis of all the data was 
conducted using a computer-assisted qualitative data software package 
(NVivo 10, QSR International Pty Ltd). This was chosen on practical grounds 
as it was a software package currently licensed for use by the University and 
therefore easily accessible. Formal training in the use of NVivo was undertaken 
prior to any data being collected. In order to enhance familiarisation of the data 
the researcher transcribed all taped interviews following the interview as soon 
as was practicably possible. Transcripts along with all accompanying field 
notes were uploaded into NVivo 10 in preparation for data analysis. 
Identifying and refining important concepts is a key part of the iterative process 
of qualitative research. Unlike quantitative analysis however there are currently 
no clear guidelines for analysing qualitative data (397). While many different 
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approaches to qualitative analysis exist, most are tied to a particular theoretical 
or epistemological position. One analytic approach, thematic analysis, is a 
method independent of theory and epistemology which can be applied across 
a range of theoretical or epistemological approaches (397). In thematic analysis 
the process of identifying, analysing and reporting patterns within the data 
enables the researcher to identify which themes are important in the 
description of the phenomenon under study. 
5.1.9.1. Framework Analysis 
Data analysis followed the framework approach based on work developed at 
the National Centre for Social Research by Ritchie and Lewis (395). In order to 
assist the researcher attain a deeper understanding of the patient experience 
this approach draws on features of the scientific model adapting them to suit 
the nature of qualitative data (398). Described by Ritchie et al (395) as both a 
deductive and inductive form of thematic analysis the approach directly 
contrasts other entirely inductive approaches such as grounded theory and is 
underpinned by the principle of balancing interpretivism and reflexivity with 
pragmatism and transparency (399).  
Widely used in healthcare research, the framework approach acknowledges 
that neutrality and objectivity can never be totally achieved in qualitative 
research. In order to reduce the degree of authority the researcher has on each 
participant and to enhance the rigour of the analytical processes the framework 
approach charges the researcher to remain as objective and unbiased as 
possible during the collection, interpretation and presentation of the data (398).  
In this study the use of the framework approach provided a structure to 
undertake the process of qualitative data analysis systematically thus enabling 
the exploration of the data in depth, while simultaneously maintaining an 
effective and transparent audit trail. Using this approach initial themes are pre-
set based on the research questions while further themes develop from the 
interviews with participants. The five key stages of framework analysis as 
described by Pope are as follows (400): 
• Familiarisation with the interview: The researcher reads and re-reads 
the transcripts and contextual or reflective notes and listens to the audio 
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recordings of the interviews formulating a list of key ideas and recurrent 
themes. 
• Identifying a thematic framework: Deductively and inductively a-priori 
themes and recurring themes emerging from the data are identified an 
index of key themes is formulated. 
• Indexing: The thematic framework is systematically applied to all the 
data.  
• Charting: A chart of each theme is created including summaries of the 
views and experiences of participants under each theme heading. 
• Mapping and interpretation: The range and nature of the phenomena 
are mapped. This stage is influenced by both the research questions 
and the themes which emerged from the interviews.   
The thematic framework used in this study was initially based on illness and 
treatment representations and health behaviour. During the various stages of 
the analysis however other issues emerged which were incorporated into the 
thematic framework, which was refined as more data were collected. During 
indexing the thematic framework was manually applied to the data. The text 
relevant to each theme was highlighted in each transcript before charting the 
data by theme. The final stage of the analysis, the mapping and interpretation 
stage was guided by Rabiee’s criteria for interpreting coded data (401).  The 
following criteria were used to assist not only in the interpretation of individual 
quotes but in the linking of the data as a whole:  
1.  Consideration of the actual words used and their meaning 
2.  The context of the comments made by participants 
3.  The frequency and extensiveness of the comments 
4.  The intensity of the comments 
5.  The checking of internal consistency of comments between 
participants  
6. The specificity of responses. 
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5.2. Qualitative Study Results 
5.2.1. Recruitment  
Fieldwork for this study was undertaken over 8 months in 2014 - 2015. An 
initial approach was made to 31 HF patients of which 22 agreed to read the 
patient information sheet. In total eight older patients with HF participated in a 
semi- structured interview, as did four nominated carers. Six of the eight 
participants were recruited from the Heart Failure clinic at Ninewells Hospital 
and two from Medicine for the Elderly Clinic at Royal Victoria Hospital Dundee. 
All interviews were conducted in the participants’ own homes except for one 
which was conducted in a palliative care day hospital setting during the 
participant’s routine weekly visit. The average interview produced just under 
one hour of audio recording with the shortest interview taking 38 minutes and 
the longest around 1 hour 15 minutes.  Table 5.2 details recruitment according 
to the key variables of gender and recent hospital stay. 
Given that 75% of recruitment came from the heart failure clinic it is perhaps 
unsurprising that the recruitment of female participants who had no recent 
record of hospital admission proved difficult. Given that women with HF tend 
to be older than men and their HF aetiology is more likely to be attributable to 
hypertension (in contrast with ischaemic heart disease in men), it may be that 
the majority of female patients with HF are being managed in the community 
by their GP.  
 
 Male Female 
Record of Hospital admission due to decompensated 





No record of Hospital admission due to decompensated 









The recruitment of informal carers also proved difficult. In total six of the eight 
participants identified an informal carer. One participant stated that they did 
not require ‘care’ from their family and thus did not feel it appropriate to 
nominate someone while another stated that a recent marital separation left 
them with no-one suitable to nominate. Additionally, two people who had been 
nominated as an informal carer did not feel it was their place to discuss the 
health or treatment of their loved one. In one case a nominated carer declined 
as they felt inadequately knowledgeable about their relative’s health.  
5.2.2. Characteristics of sample 
Participants had a mean age of 77 years (range 71-85 years). All three female 
participants lived alone at home while three of the five male participants lived 
at home with their wife / partner. The median number of multi-morbidities 
recorded was 8.5 (range 4-11) while the median number of medications 
prescribed was 9 (range 4-18). Seven of the eight participants were of White, 
British ethnic origin with one drawn from a South Asian ethic group. Of the 
eight participants only two did not use a medication aid to assist with 
medication adherence. None of the participants had received a formal 
diagnosis of cognitive impairment. 
Assessment at interview indicated that seven of the participants were in NYHA 
class II with one in NYHA class III. Six of the eight participants agreed to 
complete a HADS at the end of the interview. Of these, two of the male 
participants reported high scores in both the anxiety and depression domains 
neither of which were in receipt of antidepressant medication. However, during 
subsequent discussion with these two participants the first described a strong 
relationship with their GP who was fully aware of their long-standing issues 
with mood while the second and their spouse agreed that while there was a 
reluctance to add to an already extensive list of prescribed medications they 
would discuss the matter with the GP at a future appointment. HADS scores 
for all others fell within normal range. All participants described symptoms 
relating to their HF diagnosis. 
Of the four carers who agreed to take part in the study all were female; two 
carers were the daughters of participants with the other two being partners of 
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participants. Of these one partner did not live at home with the participant. The 
age range of the carers was 52-64 years. Of the participants who nominated 
their partners both were older in age by around 22 years than their respective 
partners. This age gap was as a result of being in second relationships 
following the deaths of a previous spouse.  
5.2.3. Themes 
Table 5.3 shows the a priori themes which were sought in the data based on 
the research questions, and other themes which emerged during the analysis 
process. 
5.2.3.1 Identity  
The identity domain is composed of the label or name given to the condition 
and associated symptoms (402). The following describes the theme of identity 
in terms of knowledge transfer and retention; confusion with other cardiac 
conditions; emotional representations and the recognition of related 
symptoms. 
Knowledge Transfer and Retention 
Nearly all participants had a poor understanding of HF and struggled to 
describe the condition.  The label ‘heart failure’ was not a term routinely used 
by the participants in this study who seemed to prefer the use of the label “the 
heart” when describing heart failure. Although some participants denied any 
previous consultation regarding a diagnosis most could recall being given 
some kind of explanation as to the nature of the condition: 
‟Someone told me about a chamber that is not working is that it? I 
forget, I do forget a lot but that’s it vaguely, is that it?” [P01]. 







Table5.3: a priori themes 
 
While several participants could relate their HF to difficulties occurring within 
the chambers of the heart and could recall being given a diagnosis by their 
doctor, participants had difficulty retaining this information:  
‟The right side of, I can’t remember if it’s the right or the left side, one 
side of my heart is no working” [P07] 
 Theme Summary of theme 
A Priori 
Themes 
Identity  The label a person gives to their heart 
failure identity and reflects their 
knowledge about symptoms 
associated with the condition 
Cause Reflects factors or conditions believed 
to be cause for their heart failure 
Timeline Indicates how long the person expects 
their heart failure will last and the 
timescale of symptoms 
Consequences Comprises of a person’s beliefs about 
the severity of their heart failure and 
likely impact of illness on physical, 
psychological and social well-being 
Control The extent to which an individual 
believes that he/she has personal 
control over their heart failure and 
beliefs related to efficacy of treatment 




Doctor - Patient 
Relationship  
Patients account of the interaction with 






‟I only know the word heart failure I don’t know what it is” [P02] 
‟I think I have probably been told that in the past but it never sunk in” 
[P08] 
One participant had actually attended a specialised heart failure clinic the week 
before interview but was unable to recall a single discussion regarding their 
diagnosis or related symptoms.  
Participants were not alone in having difficulty retaining information. One carer 
tried to recall whether a healthcare professional had offered either her mother 
or the family a full explanation regarding the condition: 
‟I can’t think that anyone sat down and actually explained it, they may 
have done and I am maybe just not remembering it properly” 
[C01daughter] 
Acute or chronic? Confusion with other cardiac conditions: 
By using the term “my heart” rather than HF most of the participants in this 
study were unable to separate previous or potential future acute cardiac events 
with having a chronic condition like HF: 
‟I died for a couple of minutes on the table he said you left us and that 
lady and gentleman brought you back” [P06] 
‟If it comes it happens, it gets sorted out by all these kind professionals, 
experts and I’m saved for another while” [P01]  
In these examples participants are describing HF as an acute event which has 
the potential to reoccur in the future. Participants would frequently refer back 
to these acute episodes when asked to talk about their experience of heart 
failure. Only one participant, who was receiving palliative care, appeared to be 
able to make a direct distinction between heart failure and an acute cardiac 
episode: 
‟Well heart failure is usually there for keeps and the heart attack you 
can take it and come out of it in minutes” [P04] 
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For most other participants however there did not appear to be any difference: 
 ‟Much the same… it’s still a heart problem isn’t it?” [P05] 
For carers the nature of HF was also difficult to understand. Two of the carers 
interviewed also confused their relative’s HF diagnosis with an acute cardiac 
episode:  
 ‟So straight away the mind goes heart failure oh, heart attack, what 
will happen now?” [P02] 
However both of the carers who were children to the participants appeared to 
understand that the condition was a chronic and progressive condition: 
‟I am not waiting for her to have another big heart attack or anything I 
just see that progressive decline, that’s what I see I just see that 
progressive decline getting worse” [C01daughter] 
Confusion around cardiac conditions was not limited to heart attacks. One 
participant appeared to be describing their diagnosis of arrhythmia when 
talking about their HF diagnosis: 
“They say this pulse beat (and) the heartbeat, the two are different, they 
should be the same. That is heart failure” [P02] 
Emotional representations 
Emotional representations’ such as anxiety or depression are the feelings that 
may arise following diagnosis of a condition. When recollecting their HF 
diagnosis some participants recalled feeling afraid and uncertain as to what 
heart failure meant, particularly if they could not identify anyone they knew as 
having the condition: 
‟And I took the book home and read it and then I knew I had heart 
failure… its worrying, disconcerting” [P04] 
‟The doctors told me there and I got a bit frightened cause I thought oh 
I have no got long then…but at that time I didna know anyone with heart 
failure” [P07] 
The label ‘heart failure’ itself also caused concern for one participant who 
recalled the doctor having to give the diagnosis: 
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‟She said it’s a terrible heading heart failure, I wish I could think of 
something different” [P04] 
Anxiety regarding their relative’s diagnosis was described by all of the carers. 
One daughter described feeling stressed about her mother at the thought her 
mother may collapse at any time while another carer was clearly upset about 
the lack of explanation or support they had been given post diagnosis: 
‟Oh it scared the, it scared the bejesus out of me I tell you, I don’t know 
how he felt but it scared me… It’s the fact that they tell you that you 
have got heart failure and then you are just left to your own devices, I 
mean, you don’t know how bad that heart failure is. Well it could come 
up at any time” [C03] 
This carer described how, while symptoms of the condition had been present 
for some time, her partner had been recently given the diagnosis by a heart 
failure consultant and advised that a HFSN would contact in due course to 
offer further advice regarding medication. Unfortunately the HFSN allocated 
was on annual leave resulting in a delay in the post diagnostic visit. The carer 
had attempted to speed up the visit by telephoning another member of the HF 
liaison team but was left with feelings of anger and frustration that other nurses 
within the team had not appeared to understand the urgency for the support 
requested.   
Recognising associated symptoms 
While the majority of participants were able to identify typical HF symptoms 
such as breathlessness, tiredness and ankle swelling these were infrequently 
related directly to having heart failure. More often symptoms were labelled as 
a consequence of ageing or explained away as consequences of other medical 
conditions: 
‟Well it’s hard to say how much of that is getting older and how much is 
to do with actual symptoms of your heart not working as well” [P08] 
‟My whole leg was swollen up, I think that was because of the diabetes” 
[P05] 
‟Is that (leg swelling) vascular or is that your heart as well?” [P01] 
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However one carer in particular made accurate associations between 
symptoms and the condition. When discussing the symptoms associated with 
their mother’s HF diagnosis one daughter was able to draw on past 
experiences as her father had been diagnosed with the condition before his 
death: 
‟The reason why I can see that is because my dad went through the 
same thing” [C01] 
In summary identifying the nature of HF was difficult for most participants. This 
could be attributed to several factors. Transfer and retention of knowledge 
around the condition appeared poor. Few participants used the term ‘heart 
failure’ throughout the interviews. The explanations of HF given by participants 
in this sample contained language such as ‟ventricle” and ‟enlarged heart”. 
This language had been clearly used at some point previously by healthcare 
professionals to describe the condition however it is clear that the full 
explanations had not retained by the participants.  
A lack of purposeful information from healthcare professionals and an inability 
to identify significant others as having heart failure may have caused difficulty 
for individuals trying to establish a clear picture of the condition. Finally the lack 
of a clear condition identity alongside the existence of multi-morbidities may 
have attributed to participants failure to associate related symptoms to their 
HF diagnosis.   
5.2.3.2. Cause 
Causative factors can usually be grouped into external and internal factors and 
behaviours. However, beliefs about causation around heart failure were 
difficult to assess in this sample due in large part to the difficulty with identity.  
Internal and external factors 
Given that the majority of participants in the study failed to identify HF as a 
condition the only causal internal factor identified was advancing years. Age 
was used to explain away the reason for symptoms, not the condition itself: 
 “I think maybe its just old age you know” [P08] 
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Several participants talked about stress as an external factor. Again however 
again, this stress was mainly viewed as a cause of general ill health or a 
contributing factor to a previous acute cardiac episode rather than a direct 
causal factor for heart failure. One participant described running his own 
business involving frequent travel. The stress caused by this situation was 
cited as being a contributory factor in the negative life style choices he made. 
Another participant recalled a conversion he had had many years back when 
starting a new job in social work: 
‟The guy told us, in this job you are heading for haemorrhoids, heart 
failure and diabetes and different things. He says it runs throughout the 
profession and he was dead right cause of the stress” [P04] 
The carers in this sample also described poor understanding on causation. 
One carer attributed a recent exacerbation of the condition to an extreme drop 
in weather temperature while abroad: 
‟And slowly and gradually his legs swoll up and we don’t know what is 
happening to him and we thought it was because the weather is very 
cold” [C02] 
Instead of identifying external factors participants referred directly back to 
other cardiac conditions causation for their HF: 
“I had a bypass and probably the valve or whatever they have put in is 
no working well as it should work and that’s that” [P07] 
In one instance causation was described by a carer as the permanent damage 
caused to her mother’s heart following a previous heart attack: 
‟When you have a heart attack there is although you may recover from 
the heart attack … there is em irreparable damage made and the whole 
functioning of the heart is impaired” [C01] 
However, while two of the carers did appear to have a basic understanding of 
causation they described a lack of explanation from healthcare professionals, 
similar to what had been identified by the participants: 
‟Heart failure to me would be that the hearts not functioning at the 




Several participants in the study cited lifestyle factors as causation:  
‟Heart eh failure primarily is putting too much strain on the heart for a 
variety of reasons one of which may be running too fast, I don’t mean 
in a physical way but mentally you know running too fast and I always 
did that, I was always on the go always a hard worker” [P03] 
 “Just bad living I think, eating the wrong things and smoking. Smoking 
didn’t help, I blame the smoking for it actually, cause we all like things 
which are supposed to be no good for you” [P05] 
In both of these examples participants appear to be identifying lifestyle choices 
as factors for ill health relating their heart in general. Identifying HF as a 
condition was difficult for these two participants who both had a history of 
myocardial infarction and angina. 
In summary the cause of HF was attributed to external factors and behaviours 
such as lifestyle choices and stress. As previously stated, participants had 
difficulty in differentiating the condition from other cardiac and non-cardiac 
disorders with several participants referring to previous acute events or cardiac 
surgery such as coronary artery bypass grafting (CABG) identifying them as 
contributary factors for the condition and their current HF symptoms. Several 
participants referred to a family history of heart problems but did not expand 
as to whether they considered this to be a factor in their own diagnosis. One 
participant cited advancing age as a cause. 
5.2.3.3 Timeline 
The timeline domain refers to the predictive belief about how long the condition 
might last. It describes the expected illness trajectory including symptoms and 
timeline to recovery. Timeline beliefs may be acute or chronic. 
Uncertainty around Acuteness or Chronicity of condition 
Participants had difficulty identifying HF as a chronic condition and while they 




‟I don’t think it (my heart) will change for the better but It will change for 
the worse and it’s just a case of what sort of rate it will change” [P03] 
‟I think it will get worse I don’t think it’s gonna get any better, well no its 
no gonna get any better” [P08] 
Participants frequently related their HF back to having an acute event, which 
in the future could potentially prove fatal: 
‟I think someday I am going to go out the door and just drop down dead” 
[P05] 
This sudden end to life was seen by some to be more preferable than 
progressively becoming sicker and more dependent on others:  
‟I know we have all got to die and I would rather just go like that, boom 
(laughs), I signed it, I don’t want resuscitated cause look what I am 
suffering now. What would I be doing then?” [P04] 
‟I wouldn’t like to be a burden on someone, better out of way” [P05] 
Unfortunately healthcare practitioners did not appear to have clarified the 
question of prognosis for participants:  
‟I asked him the prognosis and he laughed and he just telt me well I can 
say you have ten years but it’s no like cancer where you can say you 
have only got so long you, can go any time really he has no got a crystal 
ball….the doctor did explain that heart failure was nothing to worry 
about, you can go on for ten years or you can just get knocked down by 
a bus. That is the way he explained it” [P07] 
Carers’ beliefs around illness trajectory: 
On a similar theme the illness trajectory of their relatives’ HF was unclear for 
the nominated carers within this sample. While the condition was described as 
progressive by both of the daughters interviewed, the partners considered 




‟Yeah I don’t know how much damage there is to the heart so that is 
obviously irrecoverable and how quickly that could go downhill I don’t 
know” [C04daughter] 
‟When I see my mums ankles getting bad and her breathlessness and 
I think oh god so it does make me a bit more kind off pessimistic… Oh 
yeah its gonna get worse, I mean I don’t see that improving at all” 
[C01daughter] 
‟You don’t know how bad that heart failure is, well it could come up at 
any time. He could be on his own in here” [C03partner] 
Despite acknowledging that treatment had been initiated, one carer remained 
unclear as to the treatment plan or the prognosis: 
“I don’t really know what will happen what with the medication, again 
that wasn’t explained to me… but now-one has actually said this is what 
to look out for” 
Finally the ability to draw on past experiences had enabled one carer to 
recognise similarities and the possible long-term outcome. This they 
acknowledged had enabled them to support and inform other family members 
who were also caring for their mum: 
‟I can see my dad and we got to the stage where my dad was doing all 
these different things, he was going for that treatment and he was going 
for that treatment and really in the long term it wasn’t having any impact 
and I kinda see that with my mum” [C01daughter] 
In summary HF was seen by some participants and their carers in terms of a 
previous acute event or other cardiac condition which had the potential to 
reoccur at any point, potentially bringing their life to an abrupt end. For 
participants who identified their HF as chronic, it was viewed as a condition 
which would not improve and likely to worsen over time. While carers were 
also uncertain of prognosis, having previous experience of the condition 
enabled one carer to recognise the condition as one where a gradual 




The consequences domain describes the beliefs an individual holds about the 
effects of the condition and how this will impact on them physically, 
psychologically, financially and socially. These representations may or may not 
develop into more realistic beliefs over time.  
Overall participants felt their health had deteriorated as a result of their 
condition: 
‟My health is not so good now” [P02] 
‟Well it’s put the brakes on me in many ways” [P03]  
‟Heart failure stops you from doing a lot of things” [P07] 
Only one participant who described an extensive cardiac history including MI 
and CABG was able to discuss how the diagnosis of HF they had received 2 
years earlier had affected them physiologically: 
‟Well, I know that if the fluid starts there or the build up there I will end 
up with fluid on the lungs and I will be short of breath but … Four or five 
times I have been in and out of hospital, six monthly, three monthly all 
with shortage of breath” [P04] 
Identifying the consequences of having the condition was difficult for the 
majority of these participants due in large part to not having a clear picture of 
what HF is and being unable to relate directly to it.  
Physical Consequences 
Physical consequences of HF were most frequently described in terms of 
symptoms including shortness of breath, swollen ankles, and tiredness. One 
participant described loss of appetite. Four participants described depression, 
which could be categorised as either a symptom or a consequence of the 
condition. 
Seven of the eight participants described breathlessness: 
‟Definitely short of breath yeah, as you can hear my voice keeps going” 
[P05] 
‟I get breathlessness and I’m much slower” [P01] 
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Increasing breathlessness led to consequences such as limiting how active 
participants could be:  
‟I’ve seen me walking out the step there and up the road there.. Now 
it’s only a small hill and when I get to the top I can hardly breathe” [P01]  
Six of the eight participants described leg or ankle swelling: 
‟Well my ankles swell up” [P05] 
‟My legs were swollen and my ankles really swell up” [P07] 
While fatigue or tiredness was described by half the participants: 
‟Oh yeah I get tired easy… more than fifty yards and I’m beat” [P05]  
And this resulted in periods of inactivity: 
‟In the morning I will not do anything, I just sit” [P06] 
A concern for most participants was a reduction in mobility limiting their ability 
to participate in everyday activities:   
‟My movement, my walking is slow, slower than before” [P02] 
‟No I used to take the dog out quite regular, I used to go away up the 
hills and now I don’t take him out at all” [P05] 
This reduction in physical ability resulted in a home move for one participant: 
‟I moved here because it’s all on the flat, I had stairs, I had to wash the 
stair and the close so I moved here four years ago” [P07] 
Psychologically participants could not describe any direct consequences of 
their heart failure with several participants not viewing themselves as being ‟ill” 
‟There are some people that love being ill and I don’t and I dinna feel 
ill, I know I don’t look ill you know” [P01] 
Instead they talked with concern about having a future heart attack with some 
admitting to altering their daily activities to try and prevent having another acute 
cardiac episode” 
‟I am frightened I strain my heart” [P01] 
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When thinking of how their HF may impact them in the future one participant 
thought: 
‟I think I will be housebound I won’t be able to get out anywhere” [P05] 
Psychological Consequences 
While undue anxiety was not identified as a feature for the participants within 
this study five of the eight participants described psychological symptoms of 
depression, which could be categorised as either a symptom or a 
consequence of HF. 
For two participants, depression had been diagnosed in the past with one 
participant still in receipt of ongoing prescriptions of anti-depressant 
medication: 
‟Aww yeah, you get affy depressed, I was suffering from depression. I 
had to take tablets” [P06] 
HADS scores collected on six of the eight participants reported scores below 
the recognised cut off point for anxiety (8/21) for all those who completed the 
questionnaire (further discussion of HADS measurement tool can be found in 
chapter 6). Regarding depression however two participants who were currently 
prescribed treatment for a mood disorder, reported scores above the cut-off 
point of 8/21.  
Social consequences 
The social consequences of living with HF were again difficult to assess. While 
examples of how life had changed where given, participants often did not 
attribute these changes to their condition but rather to advancing age or other 
medical conditions. Participants indicated that while they had had to make 
changes they tried to maintain their activities as much as possible: 
‟Normally we would leave about three and we would have a wander 
around... but he knows I canna go and walk about, I would be tired and 
not be able to enjoy the show, the music so eh that’s the way it is now, 
I try not do things to make myself worse” [P01] 
‟There is a pub I used to go into, I don’t go now because it is too far for 
me to go” [P03] 
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While help from family members assisted some to manage at home 
successfully:  
‟I can’t do housework which gets me but my family do it” [P01] 
‟She sees to me as well and she looks after me and sometimes I say to 
her I’m ok, I’m fine, you dinna want to put pressure on them, they have 
enough to do when they are working” [P07] 
Consequences described by carers  
For carers the consequences of HF were described in terms of the effect on 
their relative and on themselves. When discussing the effect the condtion had 
on the patient themselves carers described symptoms of the condition and 
how they felt they had affected them on a day-to-day basis both physically and 
mentally: 
‟Well certainly her levels of energy, em breathlessness em I look at her 
ankles and seems to have got, her ankles are getting worse over the 
past months” [C01daughter] 
‟ I don’t think she had realised it that she was so out of breath that she 
wasn’t seeing it like we were seeing it from outside, I don’t think that she 
realised that she was so out of breath and puggled (a)…She really was 
down and not eating you know” [C04daughter] 
Carers focused on what the condition had stopped their relative doing. All felt 
that their relative had deteriorated physically and that independence had 
suffered because of heart failure. As a result of this carers felt their relative had 
suffered social consequences: 
‟ But now the key thing that is missing from mums life now is the ability 
to go out independently, go into the town. When she gets into town she 
doesn’t have the energy and that’s the thing that has limited that 
element of her life and for her that is a big thing, it’s a big big thing” 
[C01daughter] 
                                            
a “puggled” - a word often used by older people residing in Dundee meaning exhausted  
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‟ It got her out and got her socializing but she has given that up now and 
she used to occasionally go into town on her own you know but now 
that has stopped. She used to come with me every week for the 
shopping and em every time we went round she was puggled, 
struggling for breath and eh hanging on to the shelves” [C04daughter] 
Three of the four carers described having their own ongoing medical 
conditions.  One carer diagnosed with COPD described how she worried that 
her relative’s HF would result in an acute event that she would be unable to 
manage. Another carer described her own feelings of increased stress caused 
by witnessing her mum’s symptoms: 
‟It (heart failure) doesn’t seem to worry him but to me I couldn’t lift him 
or anything, I mean I carry my phone and I would just have to phone the 
hospital. I panic and then end up taking a COPD attack or a panic attack 
and then I wouldna be any use to him” [C03partner] 
‟she was breathless and she was dizzy I was quite worried…. 
I thought you know she was going to collapse right away… I used to get 
all stressed because I thought she was gonna collapse one day” 
[C04daughter] 
All carers felt a responsibility for the mental welfare of their relative that 
impacted on them in a practical way. Both of the daughters described times 
when they had to either stay with their relative or bring their relative to live with 
them during a period of ill health: 
‟I saw that she wasn’t coping mentally and I went up and said mum why 
don’t you pack a bag and come down stay with us for the weekend and 
I felt she needed a little bit of company, social support. She didn’t take 
any persuasion she just did it and she stayed here two weeks until she 
was ready to go” [C01daughter] 
‟I said to my husband you know if she just had someone there who was 
running back and forward making cups of tea…so I just go and 
mollycoddle her a bit, so I stayed for must have been about five days. I 
stayed with her but she really did pick up” [C04daughter] 
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In summary the majority of participants did not appear to have a clear 
understanding of the condition and thus had difficulty in identifying how heart 
failure was impacting on their life. Most people did not feel their physical health 
would improve but indeed worsen over time. It is unclear if the participants 
contributed this outcome directly to heart failure or to ageing and other co-
morbid conditions.  
All eight participants described physical symptoms that in some instances 
were contributed to their “heart”. Reducing physical activity and the worry of a 
potential acute cardiac event in the future caused concern for the majority of 
participants. In order to maintain independence and participate in social 
activities several participants discussed changes they had made to their life. 
However, they did not directly attribute these changes to having HF choosing 
to refer more frequently to their advancing age. None of the participants 
discussed financial consequences although one person had the expense of 
moving to a more manageable home. 
For carers, the condition had consequences for both the patient and 
themselves. The daughters of two of the participants could relate HF 
symptoms to physical limitations, mental wellbeing and social isolation. All 
carers expressed a feeling of responsibility to ensure their relative was well 
cared for despite having their own health concerns or family commitments. 
5.2.3.5 Control and curability 
The domain of cure and controllability describes beliefs about whether the 
condition can be cured or kept under control and the degree to which the 
individual plays a part in achieving this. The majority of participants discussed 
control with only one participant discussing the possibility of a potential cure 
for the condition in the future: 
Potential for cure 
One participant expressed a belief that while they understood HF to be a 




‟I don’t think it will be cured but what they are doing now in, what do 
they call it gene therapy, growing muscles and all the rest of it who 
knows?” [P04] 
This particular participant however was aware of the seriousness of the 
advanced stage of their own HF. The following example indicates that they 
were conscious that the treatment they were currently receiving was not a cure: 
‟The cardiologist had given up on me and sent me home and according 
to my own doctor he thought he had done all he could so sent me home 
to die” [P04] 
Perceived control: 
All participants discussed their strategies for dealing with ill health. For some 
participants the condition had potential to deteriorate however there was a 
perceived lack of ability to influence this: 
‟Well my heart may get worse but then you have no control over that” 
[P01] 
While not always referring specifically to their heart failure however some of 
the participants felt that they had potential to maintain their health or at least 
find appropriate treatment: 
‟I mean I am doing my best to be healthy” [P08] 
‟Whatever you have got there seems to be a treatment for it you know” 
[P01] 
When discussing control participants often referred to their symptoms and the 
actions they took to control these: 
‟I have a heart that is half working. I have got a pacemaker that is 
assisting and if I don’t do too much I am ok” [P04] 
‟I do get a bit breathless but I just walk slower to cope with that” [P04] 
‟I stop there and take a spray it is ok then and I can carry on” [P02] 
For some participants however while they could identify actions they could take 
to improve their condition they had not always managed to do so: 
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‟Well I know what I should be doing, stopping smoking, just take life at 
a gentler pace” [P03] 
Like the participants the carers in this sample did not discuss cure for heart 
failure. Control was described in terms of how their relative managed on a day-
to-day basis as well as the taking of medicines. One participant described how 
their mother tried to mask the condition from her family:  
‟Mum was showing off that week, she was trying to create a difference 
between somebody she perceived to be always ill (and herself), 
because she doesn’t like being ill my mum, I thought that was so 
interesting, she put on a face, and she did it so successfully but behind 
the scenes you know, she will hide it, she will hide it but she can’t hide 
it all the time with us because we see her at different times” 
All carers discussed things what they did in order to maintain social contact 
and maintain independence, both seen as important in order to ensure health 
was managed: 
‟ We try at least once a week like today we go at least a Wednesday 
and maybe a Saturday we go out and spend a while out, ok we don’t do 
much we just go to the market or whatever but it is better than just sitting 
staring at the walls in the house” [C03partner] 
‟We are trying to get her to do kind of conversions in the house, she 
wants to stay. We are trying to say you know the house is not really 
suitable for her, it’s a great family house you know but the bathroom, 
she is on diuretics, the bathroom is halfway up the stairs‟ [C04daughter] 
Avoidance coping 
Within this sample the most regularly discussed control mechanism was 
refusing to focus on the condition or in ill health: 
‟Oh I just say oh I am not gonna let it bother me” [P06] 
‟I was inclined to think oh I have got heart failure I might no live a long 
time, I dinna want to die yet and it just gets worse and worse so you are 
better no thinking oh it, that works for me. I think the more you know the 
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more you worry... I dinna want to worry about what is gonna happen” 
[P07] 
This coping strategy was also identified by carer who felt that their relative 
coped better with the condition by not questioning health care professionals 
about prognosis or management of their health conditions: 
‟I think she would rather it was unknown, unknown definitely” 
[C04daughter] 
In summary while the majority of participants did not discuss cure, there 
appeared to be an acceptance that their condition would deteriorate over time, 
something they felt they had little control over. Control of HF symptoms 
appeared possible through lifestyle modifications however, refusing to focus 
on the condition appeared to be a common coping strategy employed by the 
participants. Support from carers (both practically and emotionally) was 
identified as important elements to enable participants to maintain control and 
live independently.  
5.2.3.6. Treatment Beliefs 
Treatment beliefs is an extension of the CSM and refers to the beliefs held 
about the necessity and concerns about treatment. In terms of this sample 
group treatment for HF revolved around taking prescribed medicines. One 
participant referred to having a pacemaker inserted which had helped their HF, 
while several discussed how a previous heart bypass had improved their 
heath. 
Beliefs about treatment necessity:  
Among the participants there was a general belief that effective treatment is 
available: 
‟Whatever you have got there seems to be a treatment for it you know” 
[P01] 
The belief that medication works is an important facilitator for adherence. Most 
participants in this study held the view that medicines were necessary: 
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‟There is no alternative, there is nothing else you can do….. I depend 
on them (medicines)” [P02] 
‟It’s stopping it getting worse really I mean that’s why I am taking them” 
[P08] 
However as far as HF medication was concerned, only the diuretic medication 
was identified as having a direct physical effect: 
‟He gave me a tablet to stop my, to stop water building up on my heart 
and that helped” [07] 
Carers also expressed the belief that medication was necessary when 
discussing both medication required by themselves as well as the HF 
participants: 
‟ Well I personally I take my (medicines), well of course I have been told 
to take them but also I don’t want to ever regress, to ever you know, my 
condition to get worse and go back to where I was before” 
[C04daughter] 
However, this belief in the necessity of their medicines was not held by 
everyone: 
‟I sometimes wonder if I need to take these tablets or am I just wasting 
my time and everybody else’s time taking them” [P03] 
‟What stop taking them for good? I don’t think it would matter, I don’t 
think there would be any difference. I don’t think so” [P06] 
While most participants held positive beliefs about treatment necessity they 
appeared unquestioning about how medicines worked and simply accepted 
that they did: 
 ‟I think they are good, they are good and that is it” [P02] 
‟Regarding tablets, I take what I am given” [P04] 
Participants and cares both described the role of significant others including 
family and healthcare professionals in their decision making around the 
necessity of the medicines: 
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‟I say to my oldest daughter I’m taking all these tablets and she says 
mum, they are keeping you alive” [P01] 
‟I keep taking them just because I was told this is what you need to keep 
your heart going…. Just because the doctor told me” [P05] 
‟The doctor has told her, he has prescribed them he has told her to take 
them that’s it you just take them that’s it” [C04 daughter] 
Concerns about treatment: 
Apart from the inconvenience of urinary frequency due to furosemide no one 
identified any current unsatisfactory side effects related to their current 
treatment: 
‟The only thing that annoys me really is taking the frusemide, I am on 
80 in the morning and 40 at teatime and some days I am never away 
from the toilet” [P05] 
‟I do nothing but run to the toilet, you have a drink, you have to go to 
the toilet” [P07] 
Two participants did however recall previous unpleasant experiences when 
prescribed ACE inhibitor medication:  
‟I had one and I got dizzy, the room was spinning around so I said oh I 
am not taking that new tablet you gave me, he says that’s alright so the 
doctor changed it” [P06] 
‟That one (Ramipril) has been put down because I was feeling dizzy 
with the higher one and I actually fell once with it” [P07] 
While one participant was concerned about the side-effects caused by their 
statin and asked their doctor to have a trial without them: 
“One of them wasn’t agreeing with me, I mean if you touched me I was 
sore you know, really sore and then one woman that I know she said I 
bet you are on statins” [P08] 
This one participant was the only one to express concerns that medication did 
have the potential to do harm: 
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“The less medication I take the better I like it cause I think everything 
that you put in your body has some good or bad effects on you” [P08] 
Adherence Beliefs 
When discussing their beliefs around the need for medications several 
participants could identify a consequence of poor medication adherence in 
other medical conditions they had or they had witnessed in other family 
members: 
‟ I am remembering he said if he missed it or he was late with it he used 
to get a splitting headache you know and he knew then that he needed 
to take the medication” [P08] 
However with regard to their HF, participants did not perceive any negative 
consequence for medication non-adherence. While participants appeared 
happy to take the medication they did not associate poor adherence with 
changes in health condition for HF. While most participants did not see any 
negative consequences for missing the medications now and again, most felt 
they were needed for long-term control: 
‟If I missed them for a day I don’t suppose it would make a difference, 
if I missed them for a week probably, if I stopped them longer than that 
then yes (negative consequences) [P04] 
‟I have been on them tablets for that long it’s in my system I don’t think 
taking them, forgetting to take them that once would do any harm.” [P05] 
One participant recalled a time when they had forgotten to take their medicines 
describing the belief that there had been no consequence for this accidental 
non-adherence: 
 ‟Yeah and I didn’t feel any different for not taking them” [P04] 
Finally one carer who had spent several years receiving kidney dialysis before 
receiving a kidney transplant described how missing her antirejection 
medication would result in significant negative consequences for her health. 
This carer felt her mother could not place the same importance on her own 




‟I don’t want to ever regress to ever you know my condition to get worse 
and go back to where I was before so but mum has never really gone 
through a sort of a mean I know a heart attack is critical illness but a 
really critical illness like the situation I was in” [C04daughter] 
In summary, this sample of patients with HF perceived treatment for the 
condition mainly as the taking prescribed medications. Participants believed 
that the mediation was doing them some good, however not everyone believed 
in the efficacy of their drug regime. Significant others played a part in 
reinforcing beliefs with trust in the doctors prescribing and family support both 
being important. Concern around side-effects focused mainly on urinary 
frequency, a consequence of diuretic therapy, however some participants were 
able to discuss examples of medicines they had previously been prescribed 
and how they had dealt with perceived side-effects. 
5.2.3.7. Medication knowledge 
When describing their current drug regime there was a lack of knowledge or 
understanding regarding their medication among participants, with little 
understanding about why it had been prescribed.  
‟No I wouldn’t remember what half of them are for I just keep taking 
them.” [P05] 
‟I can’t even remember the names of them now” [P03] 
‟I dinna look at the name I just look at the colour and the boxes” [P07] 
Sources of information: 
Some participants claimed they made an attempt to read information sheets 
enclosed with the medicines: 
“I am still reading them because I forget what they are about and I look 
at them and I think what am I taking that for? What’s a Beta Blocker 
anyway? So I have got to read it again because it doesn’t sink in” [P08] 
Only one carer discussed what she thought was the importance of reading the 
information leaflets: 
‟she is not taking them (medicines) blindly, just because someone tells 
you. She reads all the information for you know the side-effects, so she 
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is not taking them without questioning but I think that is a good thing” 
[C01daughter] 
Although patient information leaflets attempt to inform patients about their 
prescribed medication, the information supplied appeared in some instances 
to add to concerns: 
‟When I opened this this thing I went in the name of God… it was like 
terrible things could happen to you, you could bleed from your eyes, 
bleed here, bleed there. Yeah and some of it is quite scary stuff I 
pictured blood spurting all over the place [P01] 
‟I come home and read them and sometimes they frighten you. It says 
don’t take if you have got heart problems” [P07] 
For one carer the lack of clear information passed from the prescriber to her 
mother had been frustrating and she had thus made attempts to educate her 
mother herself: 
‟this is a beta-blocker” but it wasn’t made clear why it was needed you 
know, to a lay person, I mean I knew what a beta-blocker was but I don’t 
think, I think medical people tend to talk in medical language so then 
when I was filling up mums box I made her you know, we read the script 
and I said you know this is your  know to regulate your heartbeat from 
going too fast that is what has been making you tired and puggled” 
[C04daughter] 
Health Literacy 
When asked about names of medications on their current prescription list 
nearly all participants were unable to state either the name or the correct 
dosage without prompting. Participants often attempted the names with 
varying success: 
‟Well in the morning I take me, oh god, what old folk used to call the 
water tablets, ben or bendofluazide or something like that… I take a 
zoda something this tiny wee one, when I start taking I take that and eh 
Primazole or something Brisa it begins with a B” [P01] 
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Understanding around the role of each medication and the associated 
condition was also limited. Where participants could identify medications 
limited understanding led them to be simply described them as being “for the 
heart” or “the diabetes”. 
Knowledge on side-effects of particular medications was extremely limited. For 
one participant the urinary frequency was such an inconvenience he has 
attributed it to all of his medicines: 
“That is for water, yeah cause there is water on the heart. That’s for to 
make us go to the toilet to pee…they are all for that” [P06] 
In summary knowledge of medical reasoning around medication prescribing 
was poorly understood by this sample of patients with HF. The majority of 
participants could not easily say the names of their HF medications or describe 
in any great detail the reason they had been prescribed the medications.  While 
several of the participants could associate certain medicines with their related 
medical conditions they could not however expand on the necessity for each 
medication. This lack of knowledge around reasons for prescribing led to a lack 
of association with medication side-effects. That the doctors had felt the 
medicines were required was deemed sufficient reason for adherence.  
No one in this sample of HF patients expressed any desire to be given any 
more knowledge than they currently held. Several participants stated that they 
had in the past read the supplementary patient information sheets to improve 
their understanding of their medications, but this had caused alarm for one 
particular person.   
5.2.3.8. Medication Adherence 
All participants in this sample of older HF patients felt they managed their 
medication well. The carers in this sample also held this belief: 
‟She deals with them quite well em because she stayed here so I can 
see here whole daily routine and she has explained to me how she 
works her system…. She seems to be on top of what’s what, what each 




However while the majority of people claimed to adhere to their medications 
there were admissions that full adherence was not always achieved: 
“Regarding tablets, I take what I am given” [P04] 
“The majority of the time I take them but I haven’t taken todays” [P03] 
Facilitators to adherence: 
When discussing how medications where taken the majority of participants 
explained how they each organised their drug regime. While some participants 
used pill-dispensing boxes, others choose to store the medicines in a visible 
place.  
Taking medicines at the same time daily as part of a routine appeared 
important in facilitating adherence: 
‟I put them beside my bed sitting for the morning so as soon as I step 
out of bed I take them… I have it down to a fine art, you just need a 
system” [P01] 
‟I put them in the middle of my kitchen table and when I am sitting at my 
breakfast I am looking at it” [P07] 
Even if it meant not directly following the specific instructions given for each 
medicine: 
“The medicines are already there - in the morning before breakfast, 
afternoon and all that. I don’t care about all that, I take them all at once. 
If I take it when they said and I am not at home I won’t take it, they are 
left out. This way I use the tablets every day” [P02] 
This belief that the taking of medications at the specifically prescribed time was 
not important was repeated by this participant’s carer during their own 
interview: 
‟Anytime he can take it. So if he is not taking it in the morning he can 
take it at night-time” [C02partner] 
While all participants stated they were responsible for their own medication 
taking, support from significant others was described as a facilitator for 
adherence by some participants: 
178 
 
“Sometimes she tells me have you taken your lunchtime tablets? Eh, 
she knows fine I haven’t. That’s her way of telling me I haven’t taken 
them” [P04] 
Access to repeat prescriptions was discussed by several participants. While 
the close proximity of the doctor’s surgery and pharmacy ensured medication 
was always available for one participant, the inconvenience of repeat 
medication running out at different times in the month was cited as a barrier to 
adherence for another:  
‟I am very good at picking them up, well it’s just across the road so it is 
convenient….just drop the prescription of at the doctor, they forward it 
to the chemist for me and I go to the chemist and pick it up” [P08] 
‟I would forget to take them if I haven’t ordered them quick enough 
because they dinna all run out at the same time…that’s the only thing, 
you just don’t get them all at the same time” [P07] 
Facilitating the ordering and collection of prescriptions was therefore identified 
by carers as something they had to assist with to ensure adherence to 
medications continued: 
‟Occasionally she will say oh I have only got one of, oh I have run out 
of that so you say oh mum why didn’t you say and we will rush off and 
try and get her tablets from the doctors” [C01daughter] 
‟I am still keeping an eye on that, I don’t let her order. I am doing the 
checking and the ordering” [C04daughter] 
Barriers to adherence 
Forgetfulness was a reason given for non-intentional non-adherence by 
several participants: 
“I don’t know how old folk manage, you forget… Other times the 
lunchtime ones are still there at teatime” [P04] 
“Invariably it’s because I have forgotten and the day has gone by and 
suddenly it’s a bit late to start taking them now you know, I have seen 
me actually at the stage of taking my morning tablets in the middle of 
the afternoon” [P03] 
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“Well Sunday morning I forgot to take them, they are still there…Just 
stupidity on my part because it’s a thing I take on a regular basis, twice 
a day I take tablets” [P05] 
Intentional non-adherence was described by several participants and carers. 
This usually related to the taking of diuretics in order to avoid unwanted side-
effects: 
‟ A couple of times she hasn’t taken them, like on a Wednesday when 
we go up to the clinic” [C04daughter] 
 One participate however described previous occasions when he deliberately 
withheld his medication to assess their necessity: 
“Sometimes I would try to stop them one or two and I felt something 
wrong with me. I start them again it is ok. To me then I need that.” [P02] 
While this example shows the participant identified a negative consequence of 
non-adherence, others reported no consequences of non-adherence to 
medication: 
“And I don’t feel any different for not taking them” [P04]  
While participants in this sample all described a daily routine which facilitated 
adherence this custom did not always guarantee medications were taken as 
prescribed: 
“You just forget because you are taking them day in day out. You would 
think it would become a habit but it doesn’t” [P04] 
“I can afford to relax with them because I take them regular as I rule so 
I think if you miss one day it wouldn’t bother you” [P06] 
The potential for physical limitations to affect medication adherence was 
discussed by one participant who stated that they had difficulty removing the 
medications from the packets: 
‟Sometimes it is hard to get them out of the packets…..I have got 
arthritis in my hands you see, if I dinna manage I need to get my 
daughter to come up and do it” [P07] 
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In summary self-reported adherence to medication in this sample of HF 
patients was good. All participants described the routine for medication taking 
they had adopted in order to assist in adherence. Despite the adoption of habit-
forming behaviour adherence was not always achieved.  
Forgetfulness was the main reason given for non-adherence. This may have 
been as a result of the lack of direct association of medications with physical 
symptoms or due to an absence of any meaningful consequence of non-
adherence. Intentional non-adherence occurred infrequently and was mainly 
related to the withholding of diuretics in order to facilitate a trip out of the home. 
5.2.3.9. Doctor / Patient relationships: 
While the initial themes of this study were based around the CSM the 
relationship between patients and health care professionals, particularly 
doctors, emerged as a highly important theme running through all of the 
interviews.  
In the main participants talked positively about their experiences with medical 
staff. Trust in decision making and a good therapeutic relationship both 
appeared to have influence on motivation for adherence to medicines. The 
transfer of knowledge around both condition and medications was also 
discussed by both participants and carers.  
Trust in doctors’ decision making and knowledge: 
Participants appeared to have a high level of trust them to make decisions 
regarding health and medication prescribing: 
“I got all that treatment you know, I’m so grateful and I do trust them all” 
[P01] 
“Oh no I put a lot of stock into the doctor I think he knows what he is on 
about oh I would trust him completely” [P06] 
“Well if he gives you a tablet, well it must be right” [P07] 
One participant described how this trust in doctors was reinforced by family: 
“My daughter, she says if the doctor tells you to take it take it, he 
wouldna be telling you to take it if you didna need it” [P07] 
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Carers also described trust in GP’s however one suggested this might be a 
generational theme: 
‟she is of the era that would never question the GP quite a lot of them 
are like that, what the GP says is gospel, especially her GP, she thinks 
he is wonderful” [C04daughter] 
Some participants held the belief that doctors have greater knowledge and 
therefore in a better position to make decisions regarding health:  
“You have to understand that they have all this education... They 
haven’t gone and studied all these years for nothing… [P08] 
“I just tell him I have a problem, I can’t discuss anything, I don’t know 
much about it” [P02] 
This trust in the doctors’ knowledge resulted in participants taking prescribed 
medications even if you didn’t agree initially with their recommendations: 
“You have to give it a chance, even if you think what a load of tosh” 
[P08] 
However not everyone was willing to follow all of their doctor’s 
recommendations: 
“I don’t have to take any insulin I am happy with the tablets. He (the 
doctor) asked me for eight years to take insulin and I have said no” [P02] 
There was an unwillingness to question doctors about healthcare decisions or 
to burden them unnecessarily. Participants in general could see no reason why 
anyone would question the actions of the doctor: 
“I would be happy to say I don’t agree with that but I haven’t ever needed 
to” [P05] 
Therapeutic relationship: 
Patients described the importance of having a relationship with their healthcare 
professionals - particularly their GP’s and hospital doctors - valuing their input, 
especially when they had been acutely unwell: 
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“It’s important that some-one sits down and explains what has 
happened to you and what that means for you. To answer any 
questions, you may have” [P04] 
Being made to feel they were part of the decision making regarding their health 
was important for some: 
“I think I am very lucky with the doctors along there, no they really are 
good you know they do explain what they are doing…. he would actually 
say oh I am not sure about that and would look it up, and he would 
actually turn the screen and you know… let you see what was on the 
screen as well you know, taking time to share that if you like with you, 
that’s important because it makes you feel as if you are a wee bit in 
charge of your own health” [P08] 
However not all participants felt that doctors always engaged positively: 
“The last time I saw a young doctor she did (listen), others, I think they 
had made their decision before they come to the bed” [P04] 
While on carer expressed the belief that the treatment being offered may not 
always be appropriate: 
‟They don’t want to do anything for him because they are watching his 
age” [C02partner] 
Participants expressed positive feelings regarding their GP. Accessibility and 
approachability were themes describes by participants:  
“He was always good to me, always attentive to his patients…he treats 
you as if you really matter” [P01] 
While one participant recalled the therapeutic effect of a recent visit from the 
heart failure specialist nurse they could not recall the content of what had been 
discussed within the consultation: 
“She reassured me because I felt better when she came…I canna 





Transfer of knowledge 
As previously stated causation and illness identity were poorly understood by 
most of the participants who found difficulty in recalling who had informed them 
of their diagnosis.  
“She says he is the heart failure (doctor) and you are now under his 
care, you have got heart failure, which was news to me and I don’t even 
know what that entails to be honest with you” [P01] 
This problem with being able to recall important information regarding health 
and treatment plans was also highlighted by a carer who described their own 
feelings with regards to accompanying her mum to the doctor: 
‟she definitely didn’t say now its really important, you must take this 
every day... There was nothing as definitive as that. I mean even if they 
give them a leaflet to take away and read you know afterwards because 
I think well certainly people of my mums age, well even I do it in front of 
a doctor, I always you know if it was something serious I always took 
my husband, I would never challenge the consultant you know but my 
husband would ask the questions” [C04daughter] 
In this example the daughter felt that information relating to the treatment had 
not been communicated effectively by the doctor. This reluctance to ask 
questions or challenge the doctor was expressed by the majority of participants 
and may account for the overall lack of understanding around the condition. 
Limited knowledge, the use of terminology and being under the care of different 
specialist doctors caused confusion for one carer and their relative: 
‟ I am not sure of the exact differences but he said no I am not a heart 
failure consultant. He is a cardiologist and I think for my mum and for 
Joe Blogs it is quite hard to know the difference between the two” 
[C04daughter] 
However when information regarding health was communicated effectively it 
could make a positive difference to understanding the condition. The following 
example describes one carer’s positive experience of information being 
transferred successfully.   
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‟just before he died he was in ward 15 and this very very fantastic staff 
nurse em explained to us what was happening… so he explained how 
the heart not working affected the kidney and I remembered that so I 
now I know the swelling blah blah blah is related to your heart not 
functioning properly.. That was the first time that someone had actually 
explained it and explained it very visually and very simply” 
In summary trust in doctors’ decision-making regarding treatment of the 
condition was high among the participants in this sample. These patients with 
heart failure valued their relationship with their healthcare professionals, 
particularly their doctors, and trusted them to make the correct health 
management choices on their behalf. Feeling included in the decisions made 
some participants feel they had some control over their life however not all 
participants chose to follow the health or treatment advice given to them and 
information given regarding their heart failure was not always retained.  
5.3. Discussion 
The aim of this qualitative study was to explore what beliefs are commonly 
held around HF and its management by older patients with HF and their 
nominated carers and to examine how these beliefs might interrelate with 
medication adherence. In this study the CSM of illness representation was 
used to conceptualise medication adherence.  
Illness perceptions are influenced by knowledge, beliefs and attitudes. Within 
this sample of older HF patients most participants could be identified as having 
a knowledge deficit, this despite interaction from doctors and in some cases 
from HF nurse specialists.  In the main participants in this study lacked a clear 
understanding of what HF was, why they had developed the condition and 
what implications this had for them. Participants rarely used the label “heart 
failure” throughout their individual interviews and failed to connect symptoms 
to the condition.  
Overall, patients with HF in this sample did not demonstrate a clear 
understanding of the timeline, causes or consequences of heart failure. While 
participants were vague about the progressive nature of the condition itself the 
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majority expected their health to worsen over time. This expected deterioration 
was described in terms of overall general health and was attributed to 
advancing age or co-morbid disease.   
This difficulty with identity is consistent with results reported by other studies 
in this area (371). Problems in differentiating HF from other cardiac conditions 
was described by Field et al with participants in this study referring to the 
condition in terms of having a “heart problem” (378).  Difficulty with identity was 
similarly reported by Horowitz et al (36) who found inadequate knowledge of the 
causes, symptoms and consequences of HF among their sample. The 
challenge of determining if symptoms are a consequence of co-morbidities or 
age appears to be a common thread across all studies and appears to 
complicate participants’ understanding of HF. Where deficits in knowledge 
around identity of condition and associated symptom control are poor 
motivation to adhere to medication may be reduced. 
Only one participant in this current study appeared to have a good 
understanding of the condition. This participant, the only one to routinely use 
the term heart failure throughout the interview, had advanced heart failure and 
was receiving palliative care input to manage their symptoms. Several recent 
hospital admissions with exacerbation of HF and ongoing support from a Heart 
Failure Liaison Nurse may have contributed to this improved level of 
knowledge. While recent hospitalisation has been associated with increased 
adherence to medication in patients with HF (43) there is no conclusive 
evidence that increased contact with healthcare professionals’ leads to 
increased knowledge in this patient group. Unlike others in the study this 
participant made associations between medication and symptom control and 
could describe how medication had been previously changed in order to 
manage their HF successfully. In addition this participant stated they had 
themselves, on occasion, made medication changing suggestions to the HF 
nurse. In a study by Chen et al (403) health literacy, was directly linked to 
knowledge of HF. 
Where participants identified HF they were unclear about it being a chronic 
progressive condition although overall they expressed an accurate illness 
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trajectory indicating that they expected their health to deteriorate over time. 
Similar difficulties identifying HF as a chronic condition have been reported 
elsewhere (291). 
Failed communication and knowledge transfer between healthcare 
professionals and patients which contributed to a poor level of understanding 
of HF was another common theme in this study. A previous study by Reid et 
al (379) found similar issues including a lack of communication commencing at 
diagnosis with patients unable to recall healthcare professionals actually giving 
them an exact diagnosis. This scenario appears to have been mirrored in this 
current study with participants having difficultly recollecting who had given 
them their initial diagnosis. Indeed, one participant recalled being advised they 
must have HF while declaring their current medication regime when applying 
for travel health insurance. Another participant claimed they had simply 
received an unannounced appointment in the post for an outpatient 
appointment at the HF clinic.  
Where participants did recall being consulted about the condition retention of 
information was limited. A previous study by Blackman & Sahebjalal (404) 
concluded that explanations for cardiac conditions offered by doctors were 
considered inadequate by 40% of patients who also identified excessive use 
of terminology. In the main doctors’ overestimated patients understanding of 
terms such as echo, leaky heart valve and the term heart failure itself. Similarly 
while several participants in this current study used terminology such as 
“ventricle” or “valves” or “chambers of the heart” it was clear these terms were 
simply being recalled but had not been clearly understood. 
Most participants in this sample lacked a clear understanding of why they had 
developed heart failure. Given that the majority of heart failure diagnosis can 
be attributed to coronary heart disease only one participant related their 
condition back to their angina and previous CABG. While all eight participants 
in this sample referred back to previous heart attacks, coronary bypass 
surgery, hypertension, angina or implantable cardioverter defibrillators the 
majority did not explicitly identify these as cause for their condition. While 
several participants expressed concern that they may suffer a future sudden 
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life-threating episode most did not view their heart failure as a life threating 
condition. This belief that HF is non-life threatening has been identified 
previously and associated with the similar intermittent, non-adherent behaviour 
demonstrated by participants in this current sample (298). 
Stress, particularly due to employment was identified as causation for HF by 
several participants and was cited as reason for partaking in previous risky 
behaviours known to increase the risk of heart disease. Stress has been 
identified as a perceived cause in other cardiac conditions, some of which were 
cited as co-morbid conditions by the participants in this current study. While 
stress can be both cause and consequence of HF it was found to be attributed 
to symptoms of the condition in the study by Horowitz e al (36). 
All participants in this study reported classical symptoms of HF including 
fatigue, dyspnoea and oedema however these were not always interpreted as 
symptoms relating to the condition. This deficit in association between the 
condition, symptoms and medication has been reported elsewhere (183, 376, 379). 
Many participants isolated symptoms and attributed them to other illnesses 
such as COPD, diabetes or peripheral vascular disease, unaware they were 
also related to their heart. When discussing other medical conditions however 
participants seemed to have a greater depth of understanding readily 
connecting symptoms to other illnesses, such as relating chest pain to angina 
and heart disease. 
Several of the participants in this current study referred to depressive illness, 
either currently or at some time in recent history. A previous meta-analysis on 
medication compliance concluded that depressed patients were at significantly 
higher risk of treatment non-adherence than those without depression (231). 
While it is difficult to determine if depression is causative or consequential in 
heart failure a relationship between depression in heart failure and negative 
beliefs on compliance has been previously identified (405). 
Living with HF requires the patients to face multiple challenges including 
symptom control, complex medication regimes and reduced functional ability.  
Participants in this study described several different coping mechanisms. For 
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dealing with physical and functional limitations all described the adjustments 
they had made in order to maintain independence.  
Several participants described feelings of fear and anxiety when discussing 
their HF with avoidance described by some as a coping mechanism.  Choosing 
not to focus on the condition could be seen as an attempt to cope with the 
situation and maintain ‘normal’ life. While this strategy has previously been 
identified as one of four coping strategies by Buetow et al (406) a review of self-
care in HF concluded that avoidance or denial of the condition resulted in 
reduced self-care capabilities (407). 
In this study the participants described the management of HF mainly in terms 
of medication taking. Here participants expressed beliefs that effective 
treatments were available and necessary. Participants routinely believed that 
the medication was doing them some good however there was a commonly 
held belief that absolute adherence to their regime was not crucial. It may be 
that this belief stemmed from an absence of meaningful consequence of non-
adherence. Perception of risk (408) and belief in necessity of treatment (195) are 
directly associated with medication adherence. Overall participants in the 
study held the belief that no direct harm would be caused as result of their 
medications being omitted occasionally. Given this belief and the absence of 
a direct link direct between medication adherence and positive symptom 
control the admission of occasional non-adherence in this sample is 
unsurprising. While participants in this study could not directly link symptom 
control to medication taking direct association between medication adherence 
and positive symptom control is however possible in HF populations as 
evidenced by studies carried out by Wu and Granger (167, 382).  
Dowell & Hudson (409) identifies three groups of medication users: passive; 
active and rejecters, two of which could be used to describe the participants in 
this current study. The majority of the participants could be described as 
passive. They took their medication regularly despite not having a full 
understanding of their condition or indeed of the medications themselves. 
Belief in prescribed medications in this sample of patients often stemmed from 
a trust in the knowledge of the prescriber rather than any personal knowledge. 
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Several participants indeed cited motivation for adherence as stemming from 
the desire to follow the directions of the doctor. In this passive group of 
medication users control of the individual’s condition had been handed, in the 
main to the prescribing healthcare professional.  
Two participants in the study could be described as “active” medication users. 
Both of these participants, while having trust in their medical prescriber were 
able to draw from past experiences in order to either make suggestions 
regarding medication changes to their healthcare provider or adapt their 
medication regime to accommodate themselves and their symptoms. No-one 
in this current study could be identified as rejecters.  
All participants denied persistent non-adherence. Where previous concerns 
regarding medications had occurred all had been addressed successfully with 
their doctor. Current concerns around side-effects focused mainly on urinary 
frequency, a consequence of diuretic therapy however some participants were 
able to discuss examples of medicines they had previously been prescribed 
and how they had dealt with perceived side-effects. This dissatisfaction with 
diuretic therapy is not a new finding. Van der Wal et al (405) sampled over 950 
HF patients of which 57% cited the consequence of taking of water pills as the 
biggest barrier to adherence. 
While not one of the initial a priori themes the doctor patient relationship was 
a significant theme running through all the interviews. Participants valued 
highly their doctors and trusted them with decisions regarding their health. In 
the main participants gleaned their knowledge from their GP and used terms 
such as ‟attentive”, ‟good rapport”, ‟taking time”, ‟trust” and “educated” when 
referring to their doctor. These traits have been previously identified as 
facilitators to adherence by Simpson et al (169) who emphasized the need for 
healthcare providers to display genuine concern for patients’ well-being while 
being knowledgeable and able to answer questions. 
 A “blind faith” in the decision making of doctors within the HF population has 
been documented elsewhere (410). In a study by Stromberg et al (187) 
participants described similar beliefs to those in this current study in that 
patients stated that they took their medications as prescribed because that was 
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what the doctor had instructed. While several participants indicated they would 
question the doctors reasoning none had felt the need to do so in relation to 
their heart failure. One participant responded that they would not question their 
doctor because they did not feel they had the appropriate level of knowledge 
about the condition to do so. There was only one example in this study of 
someone who had refused to follow the doctor’s advice. This was however in 
relation to diabetes and not their HF. In this instance the participant believed 
they had sufficient knowledge about their health and condition and believed 
that the self-care practises they had adopted were sufficient to control the 
diabetes. 
Holt et al highlighted the importance of communication with healthcare 
providers with 64% of their sample group of older adults reporting that positive 
relationships can contribute to better adherence (245). While doctors have one 
to one opportunities to discuss medication adherence during initial diagnosis, 
review consultations and when prescribing medications it was clear from the 
majority of the participants in this current study information had not been 
transferred successfully to the patient.  
In some instances participants described how significant others played a part 
in their lives. Family had the ability to facilitate adherence to medication by 
offering both practical help and by reinforcing beliefs in the necessity of 
medication. The desire to maintain independence and not become a burden 
on family or doctor appeared to effect behaviour in a positive manner.  
It is clear that while the majority of participants in this study certainly lacked 
knowledge about their condition in the main they held positive beliefs about 
prescribed medication. When considering the design of an intervention aiming 
to improve adherence to medication in this population it may be that the timing 
of transfer of knowledge requires greater consideration. Emphasis should be 
on delivering knowledge at the appropriate level at an appropriate time while 
focusing on an individual’s personal motivating factors.  
Carer’ is a professional term and may not resonate with a husband or wife or 
daughter or son. Informal care is simply ‘happening’ and not identified as a 
particular set of tasks Additionally people who had been nominated as an 
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informal carer did not feel it was their place to discuss the health or treatment 
of their loved one. In one case a nominated carer declined as they felt 
inadequately knowledgeable about their relative’s health. 
5.4. Limitations of the study 
This explorative qualitative study has a number of noticeable limitations: 
• Overall the majority of participants who volunteered for this study were 
relatively stable with limited input from specialist healthcare 
professionals. While several patients demonstrated an inability to recall 
being given a clear diagnosis of their condition it is impossible to 
determine the accuracy of this claim.  Given the methods employed 
within this study it is not possible to know whether clinicians had 
previously discussed a new diagnosis of HF with patients or their 
informal carers at either initial or subsequent follow up consultations.  
• While the original aim of the study was to recruit an informal carer along 
with each HF patient enrolled in the study this proved extremely difficult. 
In total only four carers agreed to participate in the study. The lack of 
carer participation therefore limits the voice of family and informal carers 
within the study.   
• The decision to conduct a formal assessment of mood using the HADS, 
a quantitative measure, was taken as it was deemed important to 
identify formally any evidence of mood disorder given the link between 
HF and depression. It is acknowledged that while the HADS is 
successfully used as a screening tool at an individual level in clinical 
practice the usefulness of the data collected in this study is extremely 
limited due to the very small sample size and number of participants 
who agreed to complete. Additionally its inclusion at the end of the 
interview may have some impact on the scores given that participants 
had been engaged in discussions which may have evoked upsetting 
thoughts.  
• Given the age group and frailty of the participants enrolled in the study 
member checking was not performed on any of the participant 
transcripts potentially placing some limitations on the overall 
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trustworthiness of the results. During the data collection phase several 
compromise suggestions regarding the best approach to participant 
validation of the data were considered. Firstly while it would have been 
possible to send out a partial section of the transcript to participants for 
review the researcher felt this may have caused confusion for the 
participants regarding where the text fitted into the broader interview 
discussion. Secondly while it would have been possible for the 
researcher to physically return to each participant and review the text in 
a more interactive way this was not possible due to time restraints.  
• Thematic analysis was conducted on all transcripts without 
disaggregating the data into those who had a nominated a carer 
enrolled in the study and those who did not. The decision to analysis 
the data in this way means it is impossible to determine the possible 
impact of informal carers on an individual’s experience of living with HF 
or their management of the condition. 
5.5. Conclusion 
This chapter has described the methodology and results of a qualitative study 
undertaken to explore beliefs around HF and its management with an aim to 
identifying which commonly held beliefs predict medication adherence. This 
study concluded that knowledge of both condition and medication was poor 
amongst this sample of older HF patients. In the main health literacy was low 
and while participants felt that overall medication was beneficial association 
between treatment and symptom control was poor.   
Participants described both non-conforming non-intentional and intentional 
non-adherence. A wish to remain independent and a belief in the healthcare 
professionals’ ability to manage their condition and prescribe appropriate 
treatment were the main reasons given for adherence.  
Previous randomised controlled studies in HF populations have attempted to 
improve adherence to medication by purely focusing on improving the 
knowledge of their patients (341, 352, 356). These studies reported no positive 
effect from the intervention. As discussed in previous chapters improved 
adherence has been shown to be possible in studies which contained multi-
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component interventions. The results from this current study highlight the need 
for healthcare practitioners to use language which can be easily understood at 
a time when information is likely to be retained by this population.  
While increased knowledge has been shown to improve self-care skills 
generally, the importance of patients’ beliefs and preferences should not be 
underestimated. By focusing on the individual rather than the population 
personal motivational factors can be incorporated into adherence-enhancing 
interventions which should combine a number of strategies including 
information, reminding and reinforcement.   
Following the analysis of the results of this qualitative study emergent themes 
were used to guide the outcome measurement tools used in the quantitative 
observational study. This thesis continues with a description of how the themes 
of condition identity and its impact on day-to-day life; health literacy; beliefs 
about medications; quality of life, and doctor patient relationship were 




Chapter 6. Quantitative Study Phase 
The previous chapter described the exploratory phase of this PhD undertaken 
to explore HF and adherence to prescribed treatment from the patient and 
informal carers’ perspective. The results were used in the design of an 
observational study that aimed to quantify the association of a broad range of 
factors (including attitudes, opinions and behaviours of older HF patients) with 
medication adherence. Such an approach complements the findings from the 
qualitative work. 
This chapter contains the study design, methodology and results of this 
observational study, concluding with the discussion of these findings. Given 
that this quantitative phase of the PhD was designed to measure which 
modifiable risk factors where most closely linked to adherence to medication 
the two main aims of the study were: 
1. To assess adherence to ACE inhibitor and Furosemide medication in a 
sample older patients with heart failure. 
2. To establish which factors are associated with non-adherence to 
medication in older patients with heart failure. 
6.1. Observational Study Design   
The study was a prospective observational study approved by East of Scotland 
Research Ethics Service (EoSRES) committee (Ref Number ES/15/0200) on 
22nd December 2015. It comprised a single visit either within Tayside Institute 
Cardiovascular Research (TICR) research facility at Ninewells Hospital, or at 
the participants own home if this was preferred by the participant. Participants 
were asked to nominate one informal carer who was asked to complete and 
return a questionnaire. 
6.1.1. Training and Preparation 
Background research was undertaken on quantitative questionnaire design 
and delivery. In an attempt to reduce the burden on the participants, eight of 
the nine questionnaires were compiled into one easy to follow booklet with the 
exception of the Montreal Cognitive Assessment (MoCA) which was to be 
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administered separately. The questionnaire order was carefully considered to 
ensure there were natural break points during the study visit when the 
participants could take a rest and restart when able. Font size was maximised 
to make the questionnaires as easy to read as possible without excessively 
increasing the number of pages.   
In order to gain an understanding of the time it would take to complete the 
questionnaire, respondent fatigue and identify other potential other constraints 
the booklet was piloted with three older people. Following the pilot stage the 
booklet was fine-tuned with some minor adjustments (see appendix I for 
questionnaire booklet).   
6.1.2. Study Population 
Community dwelling people aged 70 and over resident in the NHS Tayside 
health board area with a history of HF (see figure 6.1 for inclusion and 
exclusion criteria) were recruited from the community via the Scottish Primary 
Care Research Network (SPCRN) or via the Scottish Health Research 
Register (SHARE). 
 
Figure6.1: Observational Study inclusion and exclusion criteria 
INCLUSION CRITERIA 
• Community dwelling people aged 70 years and over with a diagnosis of 
chronic heart failure according to the European Society of Cardiology 
(ESC) guidelines 
• Patients with New York Heart Association (NYHA) class II to IV 
symptoms 
• Patients currently prescribed both ACE inhibitor and oral Furosemide.  
• Nominated informal carers of the participants described above 
EXCLUSION CRITERIA 
• Unable to give written informed consent 
• Residing in Nursing home or Residential Home Environment 
• Currently receiving daily visits from district nursing service to administer 
medications 




6.1.3. Participant Selection and Enrolment 
Initial recruitment of study participants was conducted through SPCRN. 
However, following slower than expected recruitment from primary care it was 
decided to open recruitment to potentially suitable participants currently 
registered on the SHARE database. Following an amendment to the study 
protocol a submission to the EoSRES committee was made and approved on 
8th September 2016. 
6.1.3.1.SPCRN 
The SPCRN, a network funded by the Chief Scientist Office of the Scottish 
Government, aims to act as a framework to co-ordinate national research 
activity in primary care. The network is operationally managed at a regional 
level by five nodes based in Aberdeen, Inverness, Edinburgh, Glasgow and 
Dundee. 
Research active general practices were invited to join the study by staff 
employed within the Dundee node. Using the practice IT system and the study 
inclusion / exclusion criteria a SPCRN research officer produced a list of 
participants who were potentially eligible for the study. The list was reviewed 
by one of the practice GP’s to exclude any patients who they deemed 
unsuitable to enter the study because, for example, they had recently been 
diagnosed with a serious illness, or had been recently bereaved.  
An invitation letter and reply slip (appendix J) along with a Participant 
Information Sheet (PIS) (appendix K) and a stamped addressed envelope 
were sent from the GP practice to all the patients who were potentially eligible. 
After reading the PIS, those individuals who wished to know more about the 
study were asked to respond by returning the reply slip. 
Reply slips were collected by the SPCRN team and forwarded to the principal 
investigator (PI) on the study who subsequently contacted all respondents by 
telephone. During this initial contact a brief outline was given of the purpose of 
the study and details of what involvement in the study would entail. Eligibility 
was also checked and potential participants were encouraged to ask questions 
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at any point during the phone call. If happy to participate in the study a mutually 
agreed date was arranged to carry out the study visit. 
6.1.3.2. SHARE 
SHARE is a NHS Research Scotland initiative created to establish a register 
of people interested in participating in health research. Since inception in 2011 
SHARE has recruited over 200,000 people across Scotland who have agreed 
to allow SHARE to use the coded data stored in NHS computer records to 
check whether they might be suitable for health research studies (411).  
Following ethical approval the completion of an online application a search for 
potentially suitable participants was carried out by the SHARE team. Potential 
participants were identified, and provided with details of the study by 
telephone, email or letter by members of the SHARE team. Those who 
expressed a wish to know more about the study gave consent to have their 
contact details passed to the research team for further information. 
At this point the study PI contacted potential participants by telephone. During 
this initial call a brief summary was given of the purpose of the study and details 
of what participation in the study would involve. Eligibility was also checked 
and potential participants were encouraged to ask questions at any point 
during the phone call. If appropriate, a PIS was sent by either post or email 
and details of further contact arranged. Once sufficient time had lapsed contact 
was made again to discuss any queries and arrange the study visit if 
applicable.  
6.1. Informed Consent  
Regardless of recruitment site, all those who agreed to participate in the study 
and attend the study visit gave verbal consent during the initial telephone 
contact for the study PI to review their hospital notes in order to further assess 
eligibility and document past medical history. Written informed consent was 
obtained from each participant at the beginning of their study visit (see 
appendix L for observational study consent form) 
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6.1.5. Observational Study Outcome Measurements 
All visits for the study were carried out either in the participants own home or 
within the study rooms at TICR, Ninewells Hospital. Taxi transport was 
provided if required. (See table 6.1 for the study matrix of visit activities). 
During the pre-visit phone call all participants were instructed to take all their 
medications as normal on the day of the visit and to bring along an up to date 
record of all current medications.  
Inclusion / exclusion criteria were re-examined at the beginning of the study 
visit to confirm suitability for study entry.  
6.1.5.1. Demographic information  
In order to assess their possible effect on HF medication, social support and 
demographic information were collected during the initial stage of the study 
visit. For each participant, characteristics such as ethnicity, gender, age, home 
circumstances and marital status were recorded in the case report form (CRF).  
As previously discussed there is currently no conclusive evidence to support 
either age or gender as factors for non-adherence in this population while living 
alone has been associated with an increased risk of non-adherence to 
medication.  
A meta-analysis of literature looking at the effect of social support on 
adherence to medical treatment reported a modest increase in adherence 
levels amongst those who were married or and living with another person (188). 
Lack of social support has also been cited as a factor for non-adherence. 
Several studies have examined the role played by family and significant others 
concluding that support from family and friends was important for taking 
medicines and following medical advice in HF. With this in mind those carers 
nominated by participants were given invited to participate. An invitation letter 
(appendix M); a Carers Participant Information Sheet (appendix N) and a 
Carers Consent Form (appendix O) was given to the HF patient to pass on to 













Inclusion/Exclusion Criteria  
   
Verbal Consent      
Informed Consent     
Demographics     
Medical History 
 
    
Measurement of Adherence to Medication: 
Direct adherence assessment: Blood sample 






Adherence self-report assessment: Morisky 





Retrospective prescription filling data:  
Assessed by dividing the total number of HF 
medication dispensed by the total number of 
days the medication was prescribed in the 
previous 12 month period 
 





Predictors of Adherence: 





Medication burden: list of current medication     
Symptoms of condition: NYHA class     
Record of Recent Hospitalisations     
Comorbidity: Charlson comorbidity index     






Beliefs about Medication Questionnaire (BMQ)     
Illness Perception questionnaire (IPQ-R)     
Cardiac Self-efficiency Scale     
Cognition: Montreal Cognitive Assessment     
Mood: Hospital Anxiety and Depression Scale 
(HADS) 
    
Health Literacy Assessment     
Carers beliefs: Carers Questionnaire     
Quality of Life: Kansas City Cardiomyopathy 
questionnaire (KCCQ) 
    
Satisfaction with doctors’ communication: 






Table6.1: Observational Study matrix 
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6.1.5.2: Measurement of Adherence to Medication 
According to Lam et al (129) any medication adherence measure should be both 
reliable and flexible whilst remaining low cost and practical. Given that there is 
no one ‘gold standard’ tool to determine medication adherence levels, the use 
of a multi measure approach may help compensate for recognised 
weaknesses of individual measures (129). While objective measurements 
usually involve the detection of a marker in a body fluid such as blood or urine, 
indirect measures may include prescription filling dates, tablet counts, 
interviews or diaries as well as therapeutic and preventive outcome measures 
(112). In order to accurately assess measurement of adherence to medication, 
the following adherence measures were used: 
a)  Direct methods for assessing medication adherence: 
Adherence to ACEi  
According to current SIGN guidelines all patients diagnosed with HFrEF should 
be prescribed ACEi medication (1) which are now an accepted part of the 
routine management of patients with HF and commonly prescribed amongst 
this group of patients. 
One direct method of assessing that a particular medicine has been taken 
involves the detection of the drug or its metabolite in a biologic fluid (122). Serum 
ACE (SACE) is already commonly measured in hospital laboratories as a way 
of assisting with the diagnosis of sarcoidosis, a disease in which SACE activity 
is elevated. ACEi suppress the activity of SACE – in most cases to 
undetectable levels. SACE activity has therefore been used in HF patients to 
identify non-adherence with ACEi therapy (412). In previous research conducted 
by Struthers et al, SACE activity <6.5u/l was reported to give a predictive 
accuracy of 81% that adherence to ACE I treatment was > 85% (412).  
While the measurement of SACE may provide high predictive accuracy for 
identifying poor treatment adherence trace presence of a particular drug simply 
confirms that the patient has taken a dose recently (122).  As previously 
discussed it cannot however quantify the way the medicine has been taken or 
assess adherence over a period of time. A 5ml sample of venous blood was 
collected from each participant in a gold vacutainer. Following collection all 
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samples were delivered to the Core Laboratory at Ninewells Hospital, Dundee 
for analysis. SACE was measured by monitoring the alteration in absorbance 
at 340nm of the hydrolysis of furylacrylolylphenylalanylglycylglycine (FAPGG) 
to FAP and GG on the automated Advia 2400 chemistry system (Siemens, 
UK). All results were returned within 24 hours with a cut of <6.5u/l taken as 
adherent to medication. 
Adherence to Furosemide 
Despite the advances in treatment of HF over the for 20 years with the 
introduction of drugs such as ACEI, angiotensin receptor blockers (ARBs) and 
beta-blockers diuretic therapy remains part of routine management in the 
majority of patients with HF (413). Diuretics inhibit the reabsorption of sodium or 
chloride at specific sites in the renal tubules and have been shown to show 
diuretics improve both mortality in patients with HF (414) as well as relieve 
congestive symptoms and fluid retention (415). 
Due to their potency and ability to maintain their diuretic effect loop diuretics 
such as furosemide and bumetanide are the most commonly used class of 
diuretic therapy in HF (416). Following oral administration of furosemide the 
onset of diuresis usually occurs within 30 minutes to 1 hour with optimum effect 
after around 1–2 hours. In patients with HF however pharmacokinetics of loop 
diuretics are altered resulting in a prolonged time to peak concentration (417).   
Given that furosemide is much more commonly prescribed than other loop 
diuretics, and that approximately 50% of the oral dose of furosemide is 
excreted unchanged in the urine, furosemide was selected as a suitable HF 
drug suitable to assess adherence.  
All participants were asked to provide a sample of urine obtained within six 
hours of taking their morning medication which was transferred into two 1ml 
urine aliquots before being stored in a locked laboratory in a -20oC freezer. 
Following the last participant visit all samples were analysed in the Biomarker 
and Immunoassay Biomarker Core Laboratory, University of Dundee using the 
assay Neogen Furosemide ELISA kit Product# 104219-1 [Lexington, KY, USA]  
which is designed for the screening of trace quantities of Furosemide and /or 
other metabolites in human urine, blood or oral fluid. The intra assay variation 
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of optical density of duplicate samples was found to be 7.1% on the first plate 
and 11.8% on the second with intra assay variation on quality control (n=6) 
5.2%.  
Indirect methods for assessing medication adherence  
While adherence monitoring methods which asses the level of medicine or 
metabolite in blood or urine are considered to be more robust than indirect 
methods, variations in metabolism mean that there are also limitations to these 
direct methods of adherence assessment (127). While assessment of both 
SACE and urinary furosemide levels offer an indication of adherence to HF 
medication on the day of the study visit it is important to highlight that these 
direct methods may indeed result in a biased measure of patient’s medication 
taking behaviour as results refer only to the days of sample collection (418).  
As previously stated in this thesis indirect methods to assess adherence to 
medication are commonly utilised and can be either objective, such as pill 
counting, or subjective, such as participant self-report.  
Self-Reported Adherence 
Self-report measures have the benefit of being inexpensive acceptable to 
patients and easy to administer. However, methods such as structured 
interviews and patient diaries are open to the potential for inaccurate patient 
recall or the reporting of an overly high estimation of adherence in order to 
please healthcare providers (419). Factors such as the relationship between the 
healthcare professional and the patient, the time frame used to recall 
behaviour and the wording of questions have been identified as having a 
potential effect on both accuracy and validity of self-report measures (124). 
In order to minimize the limitations of self-report methods and to standardise 
the measurement of adherence to specific medication regimes, structured self-
report questionnaires have been designed and validated against other 
subjective and objective measures (129). While several questionnaires exist no 
one tool has however been identified as being “gold standard” or deemed 
appropriate for every setting (420). Prior to the selection of a self-report measure 
for use within the study several questionnaires were considered: 
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The Brief Medication Questionnaire (BMQ) is a questionnaire consisting of 
three sections designed to detect repeat and sporadic non-adherence; assess 
beliefs about medication and identify difficulties in remembering medication-
taking behaviour (421).  One notable limitation of the BMQ is that it requires the 
production of a comprehensive list of medication regimens the completeness 
of which may pose difficult for those patients with recall deficits if the 
medications are not to hand (422). 
The Medication Adherence Questionnaire (MAQ) is a structured, 4-item self-
report questionnaire originally developed to measure medication adherence to 
antihypertensive treatment by Morisky et al. In the original study researchers 
reported that participants scoring high on the MAQ were significantly more 
likely to have their blood pressure controlled compared to those who scored 
low on the scale (r=0.58; P<0.01) (423). Additionally the MAQ is noted to be 
adaptable, quick to administer and validated in a broad range of conditions 
(424). 
The Morisky Medication Adherence Scale (MMAS-8) is an 8-item 
questionnaire based on the MAQ with the addition of items focusing on 
medication-taking behaviours. The questionnaire has been specifically 
designed to avoid the ‘yes saying’ bias where patients only offer positive 
answers to a series of questions regardless of their content (425).  The new scale 
has been determined to have higher reliability compared to the 4-item MAQ 
scale (Cronbach’s α= 0.83 vs 0.61) (423, 425).  
The MMAS-8 has been validated in patients with a range of chronic diseases. 
In HF it has been used to assess medication adherence in several studies (368, 
370) where the term “antihypertensive medication” had been substituted for 
“heart failure medication”. In a previous cross-sectional study conducted 
among an older hypertensive population, the MMAS-8 was reported to be 
significantly associated with non-adherence determined by pharmacy fill 
adherence, correctly classifying ≥ 75% of patients as being adherent or not 
(426).  
Each item on the questionnaire measures a specific medication taking 
behaviour, not a determinant of adherence behaviour. A dichotomous 
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response choice of  “yes” or “no” is  requested for the first seven items while 
the last item adopts a 5-point Likert response (“never”, “rarely”, “sometimes”, 
“often” or “always”). Following scoring guidelines reported elsewhere (420, 425), 
each no response was scored as “1” and each yes response scored as “0” with 
the exception of question 5 where the scoring is reversed.  For item 8, the 
Likert score was rated from “0” to “4” with the number divided by four before 
the value of the eight responses is summed. Unlike other scales which have 
recommended cut off values for adherence the MMAS-8 ranks the the degree 
of adherence as low, medium or high instead of defining an absolute cut off. 
Given its previous validation within the HF population the MMAS-8 was chosen 
as a measure of medication adherence self-report for the purposes of this 
thesis.  
While self-report questionnaires should be completed by patients themselves 
this may pose difficulties for some older patients and those with low levels of 
literacy. While all participants were asked to complete the questionnaire 
themselves, the questions were also read out to the participants if they 
requested this in order to clarify what was being asked. The degree of 
adherence was determined according to the score resulting from the sum of 
all the correct answers: high adherence (eight points), moderate adherence (6 
or 7 points) and poor adherence (< 6 points) previously used in other studies 
(427, 428) 
Despite the use of a validated questionnaire designed specifically to reduce 
bias it is important to view the results of the self-report measure in relation to 
the other primary outcome measures. In a study reporting on self-report 
adherence verses MEMS, Nieuwenhuis et al assessed adherence to ACEi/ 
ARB medication in HF patients where medication adherence measured by the 
MEMS was reported to be significantly lower than self-reported adherence 
(76% v 100%) (121). 
Computerised Pharmacy Records 
Computerised prescribing records and computerised pharmacy dispensing 
records can be used to provide an indirect assessment of medication 
adherence. First developed in the 1980s these measures have become more 
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widely available with the greater availability of electronically recorded, routinely 
collected clinical data, and have been shown to correlate with a broad range 
of patient outcomes in patients with CAD (429). In a longitudinal study assessing 
the accuracy of computer pharmacy records in patients with HF who were 
prescribed beta-blockers dispensing records reported adherence as 97.8% ± 
11.8% (range 58.1-128.6%) compared to MEMS adherence which was 
reported as 97.1 ± 7.3% (range 58.1-103.9%) (430).  
While both computerised prescribing records and computerised pharmacy 
dispensing records have previously been used to assess medication 
adherence the disadvantage of computerised prescribing records is that they 
only report the prescribing of a medication, not whether that the patient has 
taken it to a pharmacist to be dispensed. For the purposes of this thesis 
prescription refill records taken from computerised pharmacy databases were 
used to obtain estimates of adherence, thus overcoming this limitation of 
prescribing records.  
Computerised pharmacy data containing all medications issued for each 
participant during the 24 months preceding enrollment into the study were 
obtained from the Health Informatics Centre (HIC) at University of Dundee.  
HIC hosts various linkable health data for the population of Tayside and Fife 
including community dispended prescribing, laboratory tests, hospital stays 
and deaths. To protect confidentiality, data can only be accessed through a 
restricted, secure IT environment, where the data handler is given secure 
remote access to carry out their analysis. 
Medication adherence to HF specific medication was calculated as the 
proportion of days covered (PDC), based on the total number of days supplied 
for each class of medication divided by the observation time interval. Patients 
were classified as “nonadherent” based on a PDC <0.80. 
6.1.5.3. Predictors of adherence 
As many as 200 factors have been hypothesized to influence adherence and 
these factors can be classified as either intentional or unintentional (431). Such 
a high number of factors could not be included in one observational study, 
especially where numbers of participants are limited. The results from both the 
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systematic review and the qualitative study were examined to identify the 
following determinants as possible factors to adherence in this population 
warranting further assessment. 
1. Comorbidity and medication burden  
In order to assess the burden of co-morbid disease and medication on 
adherence the following information was collected: 
I. Past medical history, obtained from the medical case notes and patient 
self-report. This included dates of diagnosis (if known) and whether the 
condition was currently an on-going problem.  
II. A list of concomitant medications to assess medication burden. 
Participants were asked the following:  
a. Their understanding of each medication currently prescribed  
b. To identify the reason they believe it had been prescribed,  
c. To describe any associated side-effects experienced and  
d. Their understanding of the likely duration of prescribing.  
e. To describe their usual routine for medication taking identifying 
any visual cue or prompts or medications used to aid adherence 
III. To access the effect of multi-morbidity on adherence, The Charlson 
Comorbidity Index (CCI) was calculated for each participant. The CCI 
was originally developed as a prognostic indicator for patients with a 
variety of medical conditions and is currently the most extensively 
validated measure used to assess the prognostic impact of multiple 
chronic illnesses (432). The CCI score was calculated for each participant 
using the assigned weighting score for each of the 19 categories of 
comorbidity. Each condition is assigned with a score of one, two, three 
or six depending on the risk of dying associated with this condition. The 
final CCI score was calculated simply as the sum of weighted values 
ranging from 1 (only HF present) to 30 (extensive comorbidity) and 
recorded in the CRF. Given that all participants were aged 70 years or 
over no score was attributed to age. 
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2. Symptoms of condition 
As determined by the literature several studies have shown a relationship 
between presence of symptoms and adherence to medication (164, 1710, 172) thus 
worthy as consideration as a factor for adherence in this population. While 
dyspnoea is identified as a classic symptom of HF it is important to highlight 
that it is also a symptom commonly found in the general population. Not all 
patients with HF experience dyspnoea, while this symptom may be present for 
a host of other cardiac and non-cardiac reasons (433).  
Another symptom commonly associated with HF is fluid retention occurring as 
a compensatory response to poor cardiac output. An excess of fluid leaks out 
of tissue space as a result of hydrostatic pressure and the osmotic process 
usually ending up in the ankles due to gravity. If this fluid continues to build up 
it may be forced higher into the sacrum and abdomen (ascites). Ankle oedema 
in HF is bilateral and described as ‘pitting’ to pressure (16).  
The most commonly used classification system for HF is the New York Heart 
Association (NHYA) functional classification system which provides a four 
stage classification of symptoms relating to everyday activities and quality of 
life.  This classification system has been in use since 1902 and provided a 
common language for clinician communication before objective measurements 
of cardiac function were available. It is a simple practical method to assess if 
someone has improved or worsened and has been widely used in both clinical 
practice and clinical trials. It is not however without its problems. The lack of 
standardized criteria in assigning an NYHA class has been criticised - the scale 
is highly subjective relying as it does on patient self-reported information 
leaving it open to bias. Overall there is little evidence for the reliability, or 
reproducibility, of the NYHA classes, leaving a serious gap in the literature (434).  
Importantly, the NYHA classification may be difficult to assess in patients with 
some co-morbid conditions such as respiratory disorders or in people with 
physical function limited by other conditions.  It may be difficult to determine if 
people with severe arthritis, or with conditions such as Parkinson’s disease, 
are limited by these or by the HF. This can be a particular problem in older 
people, who often don’t complain of being breathless but choose to limit their 
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activity before they become breathless. 
All patients were examined for evidence of ankle oedema. Where oedema was 
not present at the time of the study visit participants were asked to report on 
any history of leg swelling as well as describe any activities which may result 
in episodes of shortness of breath. NYHA class was reviewed at the study visit 
and recorded in the CRF. 
3. Record of recent hospitalisations and contact with health care professionals 
Healthcare utilisation has been identified as a possible factor for adherence to 
medication in patients with HF.  A systematic review carried out by Oosterom-
Calo et al reported on a limited number of studies assessing adherence across 
different aspects of healthcare utilisation. While a positive association between 
adherence and institutionalisation was reported the evidence regarding 
outpatient visits and number of healthcare professionals seen was found to be 
inconsistent (43). 
All participants were asked to recall hospital stays of 24 hours or more within 
the previous 12-month period as well as all contact made with healthcare 
professionals.  Hospital case notes were checked to validate this self-report 
and establish any stays or appointments which the participant had forgotten. 
A record detailing all hospital stays along with relevant healthcare related 
contact was detailed in the participants CRF. 
4. Deprivation Level 
As previous stated, while those who are least deprived on average live longer 
and are more likely to access specialist medical services such as a HF 
consultant run clinic there is limited evidence to support the possible effect of 
deprivation on medication adherence (1610). Quick and easily accessible, the 
Scottish Index of Multiple Deprivation (SIMD) (435) provides a relative measure 
of deprivation based on the methodology developed by the Social 
Disadvantage Research Centre at the University of Oxford. The index 
identifies multiple deprivations for 6505 small areas (data zones) across 
Scotland. They are a combination of 38 indicators across seven domains, 
namely: income, employment, health, education, skills and training, housing, 
geographic access and crime. The term ‘deprivation decile’ is used to 
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represent 10% of a population with a particular level of deprivation therefore, 
the most deprived decile equates to the most deprived 10% within a 
population, while the least deprived decile represents the 10% of a population 
living in the least deprived circumstances.  
The Scottish Government Website contains a database of all Scottish 
postcode areas. Within the database users can enter a postcode for any local 
authority. Each SIMD decile was identified using the postcode from the 
participant’s home address and recorded on the CRF. 
5. Cognition: 
In HF, evidence suggests that the presence of cognitive impairment may have 
a negative effect on adherence (190). Given the lower age limit for recruitment 
to this study was 70 years assessment of cognitive function was assessed as 
a factor for adherence. A review of available screening tests for cognitive 
impairment identified 39 available tests, 13 of which were deemed suitable for 
brief assessment in the doctor’s surgery or outpatient environment (436). Of 
these the Folstein Mini-mental Status Examination (MMSE) was the most 
widely used. Developed over 40 years ago the MMSE is a 30-point 
questionnaire focusing primarily on language and short-term memory, while 
briefly touching on other cognitive domains such as aphasia, apraxia and 
agnosia (437). The MMSE has however not only proven to be insensitive to early 
changes in these domains it does not examine executive function and has 
been found to be insensitive to the detection of mild CI (438). Furthermore, the 
MMSE is copyrighted causing alternatives assessments to be sought. 
The Montreal Cognitive Assessment (MoCA) is a single page 30-point 
screening tool which is available to use free without permission. The test has 
been validated for use in both the community and academic setting.  Detecting 
a broader range of cognitive deficits that MMSE (which is heavily weighted to 
orientation), the MoCA has been reported to be better at identifying executive 
dysfunction, particularly important in those with vascular disease. A 
longitudinal study comparing the effectiveness of the MMSE and MoCA in 50 
older patients found poor correlation between the mean test score for MMSE 
and the MoCA (26.5 vs. 22.2) with a Pearson’s correlation co-efficient between 
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scores of 0.695 (p<0.003) The study authors concluded that the MMSE lacked 
sensitivity to milder cognitive deficits, was influenced by age, gender, 
educational level and socio-economic status and thus did not perform well as 
a screening tool for mild cognitive impairment. 
Commencing with an assessment of executive function, the test can be 
completed in around 10 minutes and comprises of assessment of the following 
eight cognitive domains: orientation to time and place; short term memory 
recall; visuospatial ability; working memory, attention and concentration; 
executive functioning and language (439). In the initial study establishing the 
MoCA, the control group had an average score of 27.4 out of a possible 30 
compared with 22.1 in those with mild cognitive impairment. Those diagnosed 
with Alzheimer disease recorded an average score of 16.2. For this current 
study the following cut off ranges were used to grade severity: 18-26 = mild 
cognitive impairment, 10-17= moderate cognitive impairment and less than 
10= severe cognitive impairment.  
For the purposes of this thesis the MoCA was chosen as a measure of 
cognition. All participants where guided through the assessment following 
collection of the demographic and background data with the overall score out 
of 30 calculated and reported in the participants CRF. 
6. Illness Perception:  
When faced with a new diagnosis of a condition individuals develop a pattern 
of beliefs in order to manage that illness. The majority of published studies 
focusing on patients perceptions of illness are based on the self-regulatory 
model of Leventhal et al (440) which proposes that representations both 
cognitive and emotional are generated and that these illness perceptions 
directly influence both an individual’s emotional response to the illness and 
their coping behaviours such as medication adherence (441).  
Identifying and modifying an individual’s perception of illness has been shown 
to improve outcomes in patients following MI as well as other conditions such 
as diabetes. The Illness Perception Questionnaire (IPQ) was developed to 
provide a quantitative assessment of the five components of illness 
representation (442). The Revised Illness Perception Questionnaire (IPQ-R) 
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extended the original scale by increasing the number of domains to seven (443). 
The control dimension was split into personal control and treatment control 
while a cyclical timeline dimension and an overall comprehension of illness 
dimension were incorporated.  
The IPQR and the IPQ-R have both been used with a wide variety of patient 
groups including those with asthma (444), post myocardial infarction (445) in atrial 
fibrillation (446) and hypertension (447). Overall it has demonstrated good internal 
reliability and predictive validity (448).  In HF the IPQ-R has been used to assess 
the relationship between illness representations, treatment beliefs and self-
care (2931). In this study the questionnaire was adapted to make the questions 
specific to the HF population and reported internal reliability of α=0.74. In 
relation to medication adherence, the IPQ-R was utilised by Molloy et al who 
reported beliefs about HF to be directly associated with adherence to ACEi 
medication (44).  
For this current study perceived identity of HF was assessed using a list of 15 
possible symptoms detailed on the initial part of the IPQ-R. Each participant 
was asked if they had experienced any of the listed symptoms and whether 
they perceived each of the symptoms as being as a result of having HF. Each 
symptom is rated using a yes (1) no (0) scale, thus the higher the score, the 
greater the number of symptoms experienced or perceived to be related to HF.   
For each of the remaining questionnaire domains participants were asked to 
rate their response to a number of statements on a 5-point Likert scale. In 
addition to the domains discussed above, the questionnaire also examines the 
patient’s perception of the causes of their illness. The questionnaire lists 
possible causes, with the opportunity for the participant to identify any other 
cause not listed.   
Personal understanding about the illness and positive beliefs about the 
controllability of the illness are indicated by the recording of high scores on the 
personal control, treatment control and coherence dimensions. However high 
scores recorded on the identity, timeline, consequences, and cyclical 
dimensions represent strongly held beliefs about the number of symptoms 
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attributed to the illness, the chronicity of the condition, the negative 
consequences of the illness, and the cyclical nature of the condition. 
For the purpose of this thesis the IPQ-R was adopted to assess beliefs around 
the condition of HF. All participants were guided through the questionnaire and 
encouraged to complete all parts if possible. Reponses where transferred into 
an Excel spreadsheet to enable the calculation of individual scores for each of 
the seven domains. 
7. Self-Efficacy: 
As stated earlier in this thesis the belief in one’s ability to carry out a task and 
achieve the desired result has been identified as a predictor of behaviour.  
According to Bandura because self-efficacy is concerned with perceived 
capability any measurement tool looking to assess the construct should adopt 
questions phrased in terms of ‘can do’ (judgment of capability) rather than ‘will 
do’ (a statement of intention) (448). Additionally assessment of self-efficacy can 
only relate to behavioural factors over which people can apply some element 
of control. Bandura himself developed a standardised measurement tool used 
to rate confidence in performing a task which included a 100-point scale, 
divided into 10-unit intervals however this format was not based on any 
empirical evidence. Alternative formats of the initial measurement tool have 
been used subsequently including a rating scale that consists of choices from 
1 to 5 or 1 to 4, or a simple yes / no format (449).  
Historically, studies of self-efficacy in patients with cardiovascular disease 
have focused mainly on its role in cardiac rehabilitation however several 
systematic reviews having been published addressing self-efficacy strategies 
to improve exercise in patients with HF (301) and self-efficacy and educational 
Interventions in HF (304). The Cardiac Self-Efficacy Scale (CSES) is a self-
report inventory developed to examine the role of self-efficacy in patients with 
coronary disease. In completing the questionnaire respondents are asked to 
rate their confidence with knowing or acting on statements using a 5-point 
Likert-type scale ranging from not at all confident, to completely confident (450).  
Each item can also be rated as not applicable. A score is acquired by summing 
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the responses to each element before dividing the total by the number of rated 
items. Items rated as not applicable are not included in the averages (451).  
The CSES has been shown to be a reliable measurement of self-efficacy in 
patients with a history of CHD. The original authors divided the CSES into two 
subscales - controlling Symptoms (SE-CS 8 items) and maintaining functioning 
(SE-MF 5 items). On initial testing both sub scales demonstrated excellent 
internal consistency reliability Cronbach's alpha =0.90 for SE-CS and 0.87 for 
SE-MF. Controlling for a selection of baseline variables, the CSES also 
demonstrated good convergent and discriminant validity significantly 
predicting physical function, social function, and family function (452).  
Despite the CSES being developed initially for use in patients with CAD where 
day-to-day symptoms do not usually fluctuate as they may do within the HF 
population, the initial evaluation study by Sullivan et al  comprised of a sample 
of whom 30% of the participants presented with LVEF <50%.  Since inception 
the tool has since been successfully used to measure self-efficacy within the 
HF population (452-455). For the purposes of this thesis the CSES has been 
adopted as the measurement of self-efficacy. 
8. Medication beliefs:  
As previously discussed non-adherence behaviours can be categorised as 
either non-intentional or intentional, the latter arising when a patient makes a 
deliberate decision not to take their treatment as instructed. While theoretical 
models such as the HBM and the TRA have previously demonstrated a 
relationship between adherence and perceived barriers, they do not consider 
health-related decisions to be a dynamic process (40).   
Research conducted with patients with a variety of long-term conditions 
suggests that the key beliefs influencing patients’ common-sense evaluations 
of prescribed medicines can be grouped under two categories: perceptions of 
personal need for treatment (necessity beliefs) and concerns about a range of 
potential adverse consequences (456).  
Over the past decade, a number of studies have been conducted using the the 
Beliefs about Medicines Questionnaire (BMQ), a validated tool developed by 
Horne and Weinman to measure medication beliefs related to taking 
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medications for chronic conditions (457). Comprising of two sections, the 
questionnaire examines firstly the beliefs about medications specific to the 
individual themselves (BMQ-specific) followed by a section relating to beliefs 
around medication in general (BMQ-general). The questionnaire has been 
devised to enable one section to be used either in conjunction with or 
independently of the other.  
The BMQ-specific is a 10-item scale comprising of two 5-item subscales 
assessing firstly an individual’s beliefs about the necessity of prescribed 
medication (Specific-Necessity) followed by their concerns about any negative 
effects resulting from taking their medications (Specific-Concerns). 
Participants are asked to rate each item on a 5-point Likert scale ranging from 
1 – strongly agree to 5 – strongly disagree. Each subsection is then summed 
giving each a score ranging from 5 to 25. A higher score on the specific-
necessity subscale indicates a stronger belief in the necessity of the 
medication while a higher score on the specific-concerns subscale indicate 
stronger concerns around the taking of medications (458). 
The BMQ-General comprises two 4-item sub-scales assessing beliefs that 
medicines are harmful (General-Harm) and that medicines are overused by 
doctors (General-Overuse). Items are again scored using a 5-point Likert scale 
before being summed resulting in possible score of 4 to 20. Higher scores 
indicate stronger beliefs about the corresponding concepts in each sub-scale, 
i.e. the higher the score the more negative beliefs about medicines held.  
In the original questionnaire development the researchers carried out 
replication of the tool across different illness samples and demonstrated an 
acceptable degree of stability. It is therefore suggested that each individual 
aspect of the tool represents a ‘core theme’ underpinning common 
representations of both specific and general medications thus suitable to be 
used across different disease specific populations (457). 
A recent meta-analysis reported on studies using the BMQ to examine 
perceptions of medication in patients with long term conditions (456). Across 94 
studies, stronger perceptions of necessity of treatment was associated with 
higher adherence, OR=1.74, [95% CI 1.57 to 1.93], p=0.0001, and fewer 
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concerns about treatment, OR=0.50, [95% CI 0.45 to 0.56], p<0.001. The 
association between necessity and adherence as measured by MMAS was 
OR=1.84, [95% CI 1.31 to 1.86], p<0.001 while association between concerns 
and adherence as measured by MMAS was OR=0.59, [95%CI 0.43 to 0.82], 
p=0.002.   
In patients with HF, Percival et al utilised the BMQ to identify beliefs held about 
medication and how these beliefs related to adherence. The authors reported 
a significantly higher median necessity score in the adherent group v non-
adherent group (22.0 vs.19.5, p=0.03). Patients with a strong necessity score 
also had significantly higher self-reported adherence compared to patients with 
a strong concerns score (21.5 vs. 18.0, p=0.006) (195).  
Importantly, beliefs about medicines have been shown to remain stable over 
time. As part of a study about non-prescribed analgesics Porteous et al used 
the BMQ-General to compare beliefs about medicines at two time points, four 
years apart, in 3,000 individuals selected randomly from the Scottish electoral 
roll. Participants reported beliefs about medication which remained stable over 
time, irrespective of changes in health status (459). 
For the purposes of this thesis the BMQ–specific and the BMQ–general have 
been adopted to assess the beliefs held about medications in this sample of 
HF patients. All participants were asked to complete both parts of the 
questionnaire. All sub-scale scores were calculated as described above and 
entered into the CRF. 
9. Measures of Physical Function: 
Impaired physical function and impaired exercise capacity are a major source 
of disability in older people (1532). Measures of physical function have been 
shown to be accurate indicators of current health status, be predictive of future 
health and disability, and are useful tools to predict the likelihood of health and 
social care use in the future (154). As a predictor for adherent behaviour, it is 
unclear if poor physical function, perhaps as a consequence of symptomatic 
HF, increases adherent behaviour in an attempt to improve symptoms or 
conversely whether having to take medication is simply too much of a burden 
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when physical function is reduced. Function may be assessed by either self-
reported questionnaires or by tests of physical performance. 
Standardised physical performance tests are commonly used in ageing 
research and have been found to be positively associated with health status 
as well as being predictive of outcomes such as hip fracture, nursing home 
admission and death (155).  Evidence also exists that these tests are suitable 
for use in non-disabled adults (156) as well as being able to identify those who 
are at increased risk for the onset of functional dependence (157;158). 
The Short Physical Performance Battery (SPPB) is an objective assessment 
tool for evaluating lower extremity functioning in older persons and has been 
designed to measure physical performance and decline over time. It was 
developed by the National Institute on Aging and is freely available for use 
without permission or the payment of royalty fees. The SPPB predicts long 
term disability and future institutionalisation (159). A 4 year prospective cohort 
study of older, non-disabled older adults found that those with the poorest 
lower extremity performance at baseline spent significantly more days in 
hospital (17.7 v 9.7 days) when compared to those who had recorded a high 
performance even after adjustment for baseline chronic conditions (160). In a 
recent study comparing the predictive value for mortality of several different 
performance measures, the SPPB score emerged as the strongest predictor 
of mortality in older community dwelling participants with the chair stand 
subtask showing highest predictive value (161). The test is easily administered, 
takes around 10 minutes to complete and can be easily reproduced.  
The three-part test was explained fully to each participant and commenced 
only after they had had the opportunity to rest for 5 minutes.  Each part of the 
test was demonstrated by the researcher before scores were obtained by the 
participant for each of the three parts: balance testing; gait speed testing and 
chair speed testing and entered into the CRF under the relevant section. The 
test focuses on lower limb function using tasks that mimic daily activities and 
includes balance stands with the feet held in 3 different positions for 10 
seconds each; one chair stand followed (if completed successfully) by 5 timed 
chair stands, ; and finally a timed 4 metre walk to measure gait speed. 
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 Any part of the test either not attempted or not completed by the participant 
automatically scored a zero and was entered into the CRF while standardised 
encouragement was offered at various points during the test. 
10. Mood 
In HF, evidence suggests that negative emotions, particularly depression, may 
be associated with non-adherent behaviour (225). The Hospital Anxiety and 
Depression Scale (HADS) is a self-report scaling system consisting of fourteen 
items on a 4-point scale (range 0-3). The questionnaire comprises of seven 
questions for each of the domains of anxiety (HADS-A) and depression 
(HADS-D) interspersed within the questionnaire. It has been suggested that a 
sub-score of ≥11 indicates probable presence requiring further management 
with scores falling between 8 and 10 suggestive of the presence of the stated 
and further assessment should be carried out (460). 
The HADS was initially developed as a screening tool for identifying and 
quantifying anxiety and depression in patients with physical health conditions. 
Unlike other scales such as the Beck Anxiety Inventory (461) or Generalized 
Anxiety Disorder-7 the HADS does not contain somatic symptoms such as 
headaches, insomnia and fatigue which could be attributed to the participant’s 
physical ill-health (462). Additionally the HADS correlates well with other 
measurement tools for anxiety and depression (463).  
The HADS, while not a diagnostic tool, has been shown to be a valid and 
reliable tool used to identify medical patients who may have depression and 
anxiety (464). In a systematic review of 71 papers the sensitivity and specificity 
of HADS-A and HADS-D with a threshold of each subscale of ≥ 8 ranged from 
0.7 to 0.9. In a study examining the validity of both the GDS-15 and the HADS 
within the older HF population the HADS was identified as a valid tool for 
detecting anxiety and depression symptoms in older HF patients within an 
outpatient setting.  
For the purposes of this thesis the HADS has been adopted to assess mood 
in the study population.  Each participant was instructed to choose one of four 
possible answers rated on the 4-point scale in relation to their general mood 
over the preceding month. Once all fourteen questions had been completed 
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the total score was calculated for each domain by totalling the scores from the 
respective seven questions. The total scores for each domain (range 0-21) 
were recorded in the CRF. 
11. Carers Beliefs  
According to Leventhal et al self-regulation process ‟does not take place in a 
social vacuum; rather, it is interpersonal as well as intrapersonal” (286). The 
formation of beliefs about illness is therefore strongly influenced by information 
gathered from peoples’ social environment, including of course family 
members. When presented with a diagnosis of HF therefore patients will begin 
to develop subjective interpretations of the condition in order to develop an 
understanding (465).   
Research shows that having the support of significant others plays an 
important part in how an individual manages their illness. In order therefore to 
be able to fully understand adherent behaviours an awareness of how 
significant others view the condition and its treatment is important (465).  In a 
study looking at the degree of similarity between patients post MI and their 
partner’s perceptions of MI, those patients and partners who reported similar 
positive cure/control beliefs greater change in behaviour related to dietary 
intake were reported (466).  
In this thesis carers beliefs regarding their relatives HF were assessed using 
the previously described IPQ-R while the BMQ assessed whether the beliefs 
that carers held around medication had an impact on the adherence 
behaviours of the participants.  
At the end of the participants’ study visit, time was allocated to discuss the 
possible nomination of an informal carer. Those participants who felt able to 
do so were supplied a carer’s pack containing the following: a carers invitation 
letter (appendix M); a carers PIS (appendix N); an informed consent from 
(appendix O), both questionnaires and a self-addressed envelope for return of 
completed documentation. Name and contact details for the study team were 




12. Health Literacy 
As previous stated, health literacy has been associated with reduced 
knowledge of disease, poorer health outcomes and reduced adherence to 
medication (203-207). In HF, higher levels of health literacy have been associated 
with higher levels of adherence (209). Several screening tools for health literacy 
currently exist focusing on an individual’s ability to read, and in some cases 
use, numbers. One such test is the Short-Form Test of Functional Health 
Literacy (S-TOFHLA), which consists of a 36 item reading comprehension test 
required to be completed within a 7-minute time frame. The S-TOFHLA entails 
the reading of a health related passage from which words have been omitted. 
The participant is required to select each appropriate missing word from the 
multiple-choice list supplied.  Scores are categorized as: inadequate (0–16 
points), marginal (17–22 points), and adequate (23-36 points).  
While the S-TOFHLA has been identified as a reliable and valid measure of 
health literacy (467) an evaluation of the measurement tool within a population 
of HF patients reported that a 15 percent correct score improvement was noted 
when the 7-minute time limit was not enforced.  This would mean 25% of 
participants improving at least one literacy level (468). The study authors 
concluded that use of the S-TOFHLA might result in patients with HF being 
inaccurately categorized as having low or marginal health literacy when the S-
TOFHLA time limits are enforced. For these reasons the tool was not deemed 
a valid measure of health literacy for this study. 
Worryingly, given that the only ongoing reinforcement of correct medication 
taking instructions HF patients may receive is contained on the label of their 
daily medication one in three older adults are unable to understand the basic 
usage instructions written on a medicine label (469). With this in mind functional 
health literacy was assessed in this study using a brief four item 
comprehension test based on the instructions given on an over the counter 
purchased medication. This assessment method has been used and reported 
on elsewhere including the International Adult Literacy Survey (470).   
Participants were invited to read a fictitious medicine label enlarged to A4 size 
before being asked four questions developed by Bostock et al (469) based on 
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the conceptual framework that defines literacy as an ability to fulfil goal directed 
tasks (455). Each correct answer scored 1 point resulting in a health literacy 
score of 0-4. Level of literacy was then categorised into high (no errors), 
medium (one error) or low (more than one error). While neither validation nor 
performance metrics for the tool are not available, this scoring method has 
been used previously in a longitudinal cohort study of older adults who reported 
medium or low functional literacy levels in 32.8% of the 7857 participants 
sampled. Similarly von Wagner et al classified functional health literacy as 
being either marginal or inadequate in 30% participants aged >65 years in a 
population survey carried out in the UK using the TOFHLA (471). 
13. Quality of life 
HRQoL is an important indicator for assessing the burden of disease or illness 
on an individual and it is widely believed that patients who adhere to their 
treatment regimes should experience an improvement in their HRQoL (472). 
HRQoL assessment measurement tools may be either generic or disease-
specific.  
A systematic review of currently available HRQoL tools for CHF, identified 
seven questionnaires (473). Of these seven, three disease-specific instruments 
were recommended above the others: The Minnesota Living Heart Failure 
Questionnaire (MLHFQ); The Chronic Heart Failure Questionnaire (CHFQ) 
and the Kansas City Cardiomyopathy questionnaire (KCCQ). While reliability 
and validity is well documented for both the MLHFQ and the CHFQ some 
studies have questioned the MLHFQs responsiveness to interventions (474) 
while the CHFQ has been criticised for being overly complex to administer (475). 
The Kansas City Cardiomyopathy questionnaire (KCCQ) is a 23-item, (15 
question) disease-specific measurement of HRQoL. The most recently 
developed of the HF specific HRQoL instruments designed when advantages 
and disadvantages of the other tools had been identified. The questionnaire 
has five individual subscales: physical limitation; symptoms; quality of life; 
social interference and self-efficacy. All items are measured on a Likert scale 
with 5–7 response options with missing values assigned a score based on an 
average of the answered items within that domain. Scale scores are 
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transformed to a 0 to 100 range by subtracting the lowest possible scale score, 
dividing by the range of the scale and multiplying by 100. An overall higher 
scores indicates better health status, fewer symptoms, and greater disease-
specific HRQoL. 
Two summary scores are included to aid interpretability (476). Firstly the 
combining of the physical limitation and symptom domains (excluding 
symptom stability) forms a functional status score. A clinical summary score 
can be calculated by combining the functional status with the quality of life and 
social limitation domains with higher scores indicating better symptoms and 
physical functioning. The original authors reported Cronbach’s alphas of 0.93 
for the functional status score and 0.95 for the clinical summary score with self-
efficacy the only subscale which failed to reach high internal consistency at 
0.62.  
The KCCQ has demonstrated good overall construct validity. A significant 
correlation (r=0.45, p<0.001) has been reported with the health perception 
scale of the generic 36 item Short form Health Survey (SF-36) while correlation 
with NYHA class, mortality and hospitalisation has also been reported (476). A 
change of 5 points on the scale scores is regarded as clinically important (477).  
In a recent prospective cohort study adherence to medication conducted by 
Marti et al those with good adherence had reportedly higher KCCQ functional 
status (70.1 ± 24.6 vs. 63.8 ± 22.8; p=0.011) and clinical summary (75.3 ± 22.8 
vs. 68.6 ± 21.6; p=0.003) scores. The authors also reported significantly better 
scores in several KCCQ domains among patients with good adherence 
including, physical limitation, symptom frequency, symptom burden, total 
symptom, self-efficacy, and quality of life scores (478). Similarly Morgan et al 
reported significantly worse HF–related health status among patients who self-
reported difficulty taking their medications than patients medication difficulty 
taking medications, independent of other demographic and clinical 
characteristics (8.0 ± 3.2 lower mean KCCQ summary scores; P=0.01) (178).  





14. Patient – Provider Relationship 
A significant theme running through all the qualitative interviews carried out as 
part of this multi-methods study was the relationship between patient and the 
healthcare provider.  Satisfaction with care is widely evaluated as an outcome 
measure for medical consultations. However, many questionnaires have been 
developed for use in single studies thus limiting the information on external 
validity for most measures (479). Support for two measurement tools: the 
Consultation Satisfaction Scale (CSQ) and the Medical Interview Satisfaction 
Scale (MISS-21) is however documented in the literature (479). 
The 18-item CSQ questionnaire is divided into four subscales: general 
satisfaction (3 items), professional care (7 items), depth of relationship (5 
items) and perceived length of consultation (3 items). Respondents are asked 
to rate each statement using a 5 point Likert scale resulting in an overall 
satisfaction score ranging from 18-90, with higher scores relating to a greater 
level of satisfaction. The CSQ was found to be a reliable measure of patient 
satisfaction with the original author reporting Cronbach’s alpha 0.91 for the 
overall questionnaire with subscales ranging from 0.67 for general satisfaction 
to 0.87 for professional care (480). 
The Medical Interview Satisfaction Scale Medical Interview Satisfaction Scale 
(MISS-21) was developed in USA as a specific tool focusing on doctor-patient 
interaction rather than on a general evaluation of doctors or healthcare facility. 
Originally a 26-item questionnaire with three subscales (cognitive, affective 
and behavioral) it has evolved firstly into a 29 point MISS before being 
developed into a simpler Miss-21 item scale adapted for use in British general 
practice (219). The assessment comprises of four subscales: distress relief (6 
items), communication comfort (4 items), rapport (8 items) and compliance 
intent (3 items) and respondents are asked to indicate their level of agreement 
to each statement on a 7-point Likert scale. The MISS-21 has been found to 
have satisfactory internal reliability (Cronbach’s alpha values cited as between 
0.67 and 0.92 for subscales) and scores have been found positively to 
correlate with satisfaction with previous appointments. 
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A comparison of the MISS and the CQS questionnaires was conducted in 
nearly 200 patients across eight GP surgeries in Wales. The study authors 
could not identify one scale as being superior in terms of psychometric terms. 
The individual scales appeared to be equally acceptable to respondents and 
although the CSQ produced a slightly wider range of scores than the MISS the 
distribution of scores was similar with high correlation between total scores for 
each questionnaire and the subscales within them.  For the purposes of this 
thesis the MISS-21 was adopted as the measurement tool for patient 
satisfaction with their doctor.  
6.1.6. Data Handling  
The researcher recorded data for each participant on the CRF during each 
study visit. CRFs were kept securely within the department of Ageing and 
Health, University of Dundee.  
All data were entered into an Excel spread sheet by the researcher at regular 
intervals during the study in preparation for data analysis. Data missing from 
questionnaires were dealt with according to the individual questionnaire 
instructions and excluded from the analysis of outcome measures. 
6.1.7. Data Analysis  
All data were analysed using SPSS statistical package (Version 21.0). For 
each individual test a two-sided p value of <0.05 was taken to be significant 
for all analyses. Bonferroni correction was used to correct for multiple 
comparison. Initial analysis of the data confirmed that most were not normally 
distributed. Patient characteristics and all possible adherence related factors 
were compared between adherent and non-adherent participants as 
determined by the primary outcome using Mann Whitney test for non-normally 
distributed data. Categorical variables were compared using Pearson’s Chi-
squared test. 
6.1.8. Sample Size 
Initial sample size calculations, carried out as part of the original doctoral 
fellowship application, had proposed recruitment of 90 participants to the 
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study. This preliminary target number of participants was reviewed after 
discussion with the funder due to limitations in available funding.  
To detect effect sizes (Cohen’s F2) of 0.20 in a multivariable linear regression 
model (equivalent to a moderate effect size), and assuming there are 10 
variables in the model, it was estimated that 60 patients would be required to 
detect this magnitude of effect with 80% power assuming alpha = 0.05.  
6.2. Observational Study Results 
6.2.1. Recruitment  
Recruitment took place between 1st July 2016 and 28th March 2017. The initial 
criterion for inclusion into the study was current prescription for both ACEi and 
oral Furosemide medications. The screening of three initial primary care sites 
indicated that numbers of patients prescribed both medications appeared 
lower than expected and the potential to recruit 60 participants from the 
selected locality was low. Following revision of the inclusion/exclusion criteria, 
permission was obtained from the local Research Ethics Committee to open 
recruitment to patients who were prescribed at least one of the two medications 
(rather than both) thus increasing the potential for recruitment.  
In total 64 patients agreed to participate and attended the study visit. Following 
discussion to establish informed consent 4 of the 64 patients decided they did 
not wish to consent and proceed. These participants were thanked for their 
time and their study visit was terminated. For those happy to proceed 
assessment of suitability for study entry was reviewed. Inclusion / exclusion 
criteria were re-examined prior to all participants undertaking informed 
consent. 
The initial target number of 60 people were recruited and consented and 
completed the study visit (see Figure 6.2 for CONSORT diagram and 
participant flow through the study). A total of 44/60 (73%) participants elected 
to have their study visit within their own home while 16/60 (27%) of participants 
elected to travel to the study visits all of which were carried out in the TICR 
study rooms, Ninewells Hospital, Dundee. 
225 
 
6.2.1.1. Recruitment via GP surgeries 
Ten of the GP practices approached by the SPCRN agreed to participate with 
a search of their databases identifying 232 potential participants. All those 
identified as potentially suitable were contacted by letter and of the 232 letters 
sent 62 (27%) responded indicating their interest in the study. A breakdown of 
responses by individual practice is given in Table 6.2.   
 












Reason for non-entry into 
study 
Practice 1 13 3 (23) 3 (23) 
 
Practice 2 49 11 (22) 10 (20) Asymptomatic HF (n=1) 
Practice 3 43 8 (19) 5 (12) Asymptomatic HF (n=1) 
Declined to consent (n=1) 
Wished to consult with 
cardiologist (n=1) 
Practice 4 18 5 (28) 5 (28) 
 
Practice 5 11 2 (18) 1 (9) Episode of acute HF not  
chronic HF (n=1) 
Practice 6 6 4 (67) 2 (33) Refused to consent (n=1) 
HF not diagnosed (n=1) 
Practice 7 18 6 (33) 2 (11) Declined to consent (n=3)  
Currently participant on a 
RCT (n=1)  
Practice 8 19 6 (32) 5 (26) HF not diagnosed (n=1) 
Practice 9 15 7 (47) 4 (27) HF not diagnosed (n=2) 
Refused to consent (n=1) 
Practice 10 40 10 (25) 4 (10) Currently participant on a 
RCT (n=1)  
Unable to contact (n=1)  
Asymptomatic HF (n=1) 
HF not diagnosed (n=3) 
Total  232 62 (27) 41(18)  
 




















Figure6.2: Participant recruitment to study 
SPCRN  
Potentially eligible on GP searches across 10 GP surgeries 




Total number consented (n=60) 
No reply (n=168) 
SHARE  
Agreed to be contacted by research team  
(n=36) 




Patient information sheet sent  
(n=23) 




Declined to participate n=2 
No clinical signs of HF n=5 
Not on inclusion medication n=2 
Already participating in current 
study n=1 
 
Not consented to study 
(n=4) 
Admitted to hospital n=1 
Chose not to participate n=3 
Ineligible (n=17) 
Refused to participate n=3 
Asymptomatic n=3 
No diagnosis of H/F n=8 
Currently in RCT n=2 
Unable to contact n=1 
Did not consent 
(n=4) 
Unable to contact (n=3) 






 6.2.1.2. SHARE recruitment 
Permission was granted from 36 potential participants identified from a search 
of the SHARE register to have their details to be forwarded to the current study 
team. Despite contact having telephone numbers or email addresses supplied 
3 (8%) patients could not be contacted. Of the 33 patients contacted by 
telephone 23 (70%) agreed to receive a participant information sheet in the 
post and consider the study further. For the ten who were not sent further 
information two had declined participation; five had no clinical signs of HF; two 
were not prescribed inclusion medication while one patient was found to have 
already participated in the current study. After reading the PIS 19/23 patients 
agreed to participate, 3/23 declined while one person was admitted to hospital. 
6.2.2. Participant characteristics 
Participant characteristics were collected on all 60 participants and are shown 
in table 6.3. Overall participants had a mean (SD) ages of 79 years (5) with 
45/0 (70%) being male. While in the main characteristics was found to be 
similar across both sites of recruitment, those recruited via SPCRN were older, 
more likely to live alone, less likely to be prescribed a loop diuretic, had lower 
anxiety scores and had fewer concerns about their prescribed medication. 
6.2.3. Adherence to medication 
a) Self-Reported Adherence.  
59/60 participants completed the MMAS-8 (see table 6.4) with one participant 
declining to complete the questionnaire. Adherence to HF medication was 
reported as either high (scores of 8/8); medium (scores of 6 or 7/8) or low (less 
than 6/8).  In total 21/59 (36%) of participants reported that they had forgotten 
to take their HF medication on occasion, however only 6/59 (10%) reported 
deliberated non-adherence to HF medications in the two-week period prior to 











p (SPCRN vs 
SHARE) 
Mean age (years) (SD)  79.4 (4.7) 80.2 (4.5) 77.7 (4.7) 0.05 
Male sex (%) 45 (75) 30 (73) 15 (79) 0.63 
Past Medical History     
Angina / CABG (%) 16 (27) 8 (20) 8 (42) 0.07 
MI (%) 22(37) 12 (29) 10 (53) 0.08 
Hypertension (%) 33(55) 21 (51) 11 (61) 0.48 
Valvular Disease (%) 12(20) 8 (20) 4 (21) 0.89 
Medication Data     
On ACEi (%) 36 (60) 28 (68) 8 (42) 0.05 
On ACEi or ARB (%) 46(77) 31 (76) 15 (79) 0.78 
On beta blocker (%) 44(73) 29 (71) 15 (79) 0.50 
On loop diuretic (%) 44(73) 26 (63) 18 (95) 0.01 
Median diuretic dose (mg) (IQR)* 40(40-80) 40 (40-80) 40 (40-80) 0.95 
Median medications prescribed (IQR) (range 3-19)* 8 (6-10) 6.5 (6-10) 8 (5.4-10.5) 0.10 
Medication Adherence aid (%) 27 (45) 17 (42) 10 (53) 0.48 
Social History     
Walking aid (%) 19(32) 14 (34) 5 (26) 0.09 
Home help (%) 8 (13) 7 (17) 1 (5) 0.21 
Lived alone (%) 30 (33) 19 (46) 1 (5) 0.002 
Median SIMD score (IQR)* 8 (3) 8 (3) 7 (6) 0.51 
Table 6.3: Observational Study Participant Characteristics 
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p (SPCRN vs 
SHARE) 
Adherence Determinants     
NYHA status ( II / III) 49/11 34/7 15/4 0.71 
Record of recent Hospital admission (%) 13 (22) 9 (22) 4 (21) 0.94 








Median SPPB (IQR) * 6.8 (3-9) 7.0 (2.25-9) 8 (3-8.5) 0.19 
Mean BMQ Specific - Necessity Total (SD) (range 13-25) 
* 
20 (4) 20 (4) 21 (3) 0.31 
Mean BMQ Specific – Concern Total (SD) (range 5-18) * 11 (3) 11 (3) 12 (3) 0.02 
Mean BMQ General - Overuse Total (SD) (range 4-16) * 12 (3) 11 (3) 12 (3) 0.35 
Mean BMQ General – Harm Total (SD) (range 4-15) * 9 (2) 9 (2) 9 (2) 0.63 
Median HADS Anxiety (IQR) * 3 (1-6) 2 (1-4.75) 5 (4-6) 0.01 
Median HADS Depression (IQR) * 3.5 (2-5) 3 (2-5) 4 (2.5-6) 0.35 
     
Table 6.3: Observational Study Participant Characteristics cont. 
Threshold for significance for this table is p= >0.002 
* Comparison using Mann-Whitney test.  CABG, coronary artery bypass graft; MI, myocardial infarction; ACEi, Angiotensin converting enzyme inhibitor; NYHA, New York Health 







Measure Threshold Total (%) 
MMAS-8 (n=59) 
High adherence  
Medium adherence  
Low adherence  





SACE (n=34) SACE ≤6.5 U/L 
25 (74) 
Urinary furosemide (n=38) Urinary Furosemide present  
38 (100) 
ACEi prescription data (n=36) ≥80% adherence  
 
34 (94) 






Table6.4: Medication Adherence Measures 
 
MMAS-8 Morisky Medication Adherence Scale; SACE, Serum Angiotensin converting enzyme; ACEi, Angiotensin 
converting enzyme inhibitor 
 
When asked to complete the final question detailing how often participants felt 
they had difficulty remembering to take all their medication 35/59 (59%) 
reported they never had difficulty while 17/59 (29%) reported occasional 
difficulty and 7/59 (12%) stated they sometimes forgot to take all their 
medication. All participants reported that they had taken their heart failure 
medication the day prior to the study visit and no-one stated they had ever 
stopped medication or reduced the dose because they felt well. Only 5/59 (9%) 
of participants reported difficulty in adhering to their treatment plan. 
b) Computerised Pharmacy Records 
Prescribing data were available on all participants. Participants were assessed 
as adherent if dispensed prescriptions covered ≥80% of the days the 
medication had been prescribed. Of 36 participants prescribed ACEi 34/36 
(94%) had acquired medication to cover the number of days prescribed while 




medication to ensure adherent behaviour ≥80% of the days the medication had 
been prescribed. See figure 6.3 for Adherence to ACEi medication reported 
across measures and figure 6.4 for adherence to furosemide medication 
reported across measures. 
 
 








Comparison of Adherence Methods 
All methods of adherence where compared using Cohen’s kappa. Using 
Landis guidelines for interpretation of kappa (481) agreement between self-
reported adherence (were adherence was reported as high, medium or low) 
and adherence to ACEi was found to be poor, k=0.02, p=0.8. Similar results 
were reported between adherence to ACEi and self-reported adherence 
following the introduction of a single adherence cut-off point of six to indicate 
non-adherent behaviour, k=-0.01, p=0.94. 
For prescription data agreement was found to be poor between prescription 
data relating to furosemide adherence and self-report using both the rating 
scale (k=-0.002, p=0.96) and the single adherence cut-off point of six to 
indicate non-adherent behaviour (k=-0.07, p=0.67). For ACE i prescribing data 
slight to moderate agreement was noted between the prescription data and 
self-report using the single adherence cut-off point of six (k=0.36, p=0.28) 
however this agreement was not evident when compared to the initial rating 
scale (k=-0.01, p=0.61) (Figure 6.5 agreement of adherence to ACE inhibitor 
& Figure 6.6 agreement of adherence to Furosemide) 
Given the similarity in results using both the MMAS-8 adherence rate and the 
cut off rate of 6, further analyses of the MMAS-8 were conducted using a cut 










Figure6.6: Agreement of adherence to Furosemide  
 
6.2.4. Predictors of Adherence 
Results of univariate analysis of factors associated with adherence can be 
found in Tables 6.5 and 6.6. None of these participant demographics where 
found to have a significant relationship with adherence to HF medication.  
1. Comorbidity and medication burden 
There was no significant relationship between multi-morbidity or number of 
medications and medication adherence using any of the adherence methods 
used. 
2. Symptoms of condition 
NYHA was not a significant factor for adherence to HF medication. 
3. Record of recent hospitalisations  
Record of hospital stay was not identified as a significant factor for 
adherence to HF medication. 
4. Deprivation 
Deprivation was not identified as a significant factor for adherence to HF 
medication. 
5. Cognition  
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Table6.5: Univariate analysis of factors associated with adherence (a) 
Data * analysed using Mann-Whitney tests for non-parametric tests. Threshold for significance for this table is p= >0.002 
MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety Depression Scale; SMID, Scottish Index of Multiple 
Deprivation; SPPB, Short Physical Performance Battery; BMQ, Beliefs about Medication Questionnaire; KCCQ, Kansas City 
Cardiomyopathy Questionnaire; IPQ-R, Illness Perception Questionnaire-Revised; MISS, Medical Interview Satisfaction 
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Table6.6: Univariate analysis of factors associated with adherence (b) 
Data * analysed using Mann-Whitney tests for non-parametric tests. Threshold for significance for this table is p= >0.002 
MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety Depression Scale; SMID, Scottish Index of Multiple 
Deprivation; SPPB, Short Physical Performance Battery; BMQ, Beliefs about Medication Questionnaire; KCCQ, Kansas City 







6. Illness Perception:  
A total of 57/60 (95%) of participants completed the IPQ-R. A reliability analysis 
was carried out on the overall questionnaire as well as the individual 
subdomains. Cronbach’s alpha showed the overall questionnaire reached 
acceptable reliability, α = 0.81 while all subdomains with the exception of 
consequences demonstrated good internal consistency.  Results for each 
subdomain can be found in table 6.7.  
 






Timeline acute/chronic 6 16-30 23 (21-26) 0.81 
Timeline cyclical 4 4-18 8 (8-10) 0.86 
Consequences 6 12-27 18 (15-20) 0.63 
Personal control 6 12-30 22 (18-24) 0.85 
Treatment control 5 5-25 16 (15-19) 0.72 
Illness coherence 5 8-25 18 (14-20) 0.81 
Emotional representations 6 8-23 13(12-14) 0.80 
Table6.7: IPQ-R subdomains 
 
The most common symptoms experienced by the participants where pain 
48/60 (84%); breathlessness 48/60 (84%); fatigue 43/60 (77%) and loss of 
strength 40/60 (70%). Overall the median number of symptoms experienced 
by participants was 7 (IQR 0-13). Participants attributed only 2 (IQR 0-8) of 
these symptoms to their HF which was considered by most to be a chronic 
condition with little variation, and which did not have an overly negative impact 
on the lives of participants.   
While participants reported a relatively good level of personal control over their 




participants felt they had a reasonable level of understanding around their HF 
it did not evoke strong emotional representations.  
The presence of symptoms was found to have a significant association with 
adherence to medication when assessed using the SACE levels. This effect 
was found to be significant even when the symptoms were not directly 
attributed to HF. However, this association was not consistent across the other 
adherence outcome measures. Of the other IPQ-R domains only 
consequences of condition was found to have a significant association with 
adherence. As with symptoms however this significant result was only reported 
when adherence was measured using SACE and was not consistent across 
the other measures. 
7. Self-Efficacy   
All 60 participants completed the cardiac self-efficacy questionnaire. The 
median control score was 4 (IQR 1). A total of 21/60 (35%) of participants did 
not however relate their HF medication to episodes of SOB and thus ticked the 
N/A box. However, the majority of participants (56/60 (93%) reported being 
either ‘very’ or ‘completely’ confident in their ability to take their heart failure 
medication.  
The median maintain score was 3 (IQR 2). When asked about social activities 
21/60 (35%) did not feel confident that they would be able to maintain their 
usual social activities, however 44/60 (73%) were confident they could 
maintain their social interaction with their family at home.  
There was no significant relationship between self-efficacy and adherence to 
HF medication. 
8. Medication beliefs   
All 60 participants completed the BMQ. Participants held strong beliefs in the 
necessity for the medications they had been prescribed while not showing 
undue concern for these medications. Participants did not report negative 
beliefs regarding medication in general. The median overuse score was 
12.0/20.0 (IQR10-14) (range 4-16) while the general harm score was 9.0/20.00 




There was no significant relationship between beliefs in medication either 
specifically or generally prescribed and adherence to heart failure medication. 
9. Functional Status 
Almost one third of participants (19/60) required the use of a walking aid to 
mobilise. The overall median SPPB score was low at 7 out of a possible 
12. While the median score for balance was high: 4 out of a possible 4 
(IQR 3), the reported median score for chair stands was much lower: 1 out 
of a possible 4 (IQR 3). On individual testing, worse physical function was 
found to have significant associations with adherence to medication 
(p=0.01) using the furosemide specific prescribing data. This association 
however was not significant following correction for multiple comparison and 
was absent when adherence was assessed using the other outcome 
measures. 
10. Mood 
All participants completed the HADS questionnaire. Median HADS scores for 
both anxiety and depression were within normal range with only 3/60 (5%) of 
participants recording scores ≥ 11 suggesting the presence of anxiety or 
depression. Ongoing pharmacological treatment for depression was 
prescribed for 3/60 (5%) of the participants. No association between 
depression and adherence to medication was identified across any of the 
adherence measures used.  Using the furosemide specific prescribing data 
higher anxiety scores were found to have significant associations with 
adherence to medication in individual testing (p=0.01). However, this 
association was not significant following correction for multiple comparison 
and absent when adherence was assessed using the other outcome 
measures. 
11. Carers Beliefs about medication and heart failure 
In total 21/60 (35%) carers returned completed consent forms and 
questionnaires. Of these 20/21 (95%) were female with 18/21 (86%) 
describing themselves as married or partners of the patient with HF. Three 




carers responses could be linked to furosemide prescription data, all of 
which demonstrated positive adherence. Linkage of the ACEi prescription 
data demonstrated similar results with 13/14 demonstrating positive 
medication adherence. Further analysis was therefore not appropriate as 
there was no poor adherence category with which to compare those with 
good adherence. 
Univariate analysis of carers beliefs associated with the self-report data 
and SACE can be found in table 6.8. There was no significant relationship 
between carers’ beliefs in medication and adherence to HF medication as 
assessed by the BMQ. Similarly, carers’ perceptions of HF did not play a 
significant factor to medication adherence in this sample.  
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Table6.8: Univariate analysis of carers’ beliefs associated with adherence 
*Data analysed using Mann-Whitney tests for non-parametric tests. Threshold for significance for this table is 
p=>0.005 
BMQ, Beliefs about Medication Questionnaire; IPQ-R, Illness Perception Questionnaire-Revised; ACE I, Angiotensin 






Subsequent assessment of both the BMQ and the IPQ-R questionnaires 
showed the overall questionnaires reached acceptable reliability, α = 0.81 
α = 0.88 respectively. However, several of the subdomains of both 
questionnaires demonstrated questionable internal consistency. 
12. Health Literacy   
57/60 (95%) of participants completed the health literacy questionnaire. Of 
those 22/57 (39%) were assessed as low level of health literacy, 17/57 
(30%) were assessed as medium while only 18/57 (32%) answered all 
questions correctly and were thus assessed as having a high level of health 
literacy. While the majority of participants 55/57 (96%) could correctly 
identify the maximum number of days the medication could be taken only 
32/57 (56%) could identify when they should consult a doctor while 40/57 
(70%) could not identify any of the specified conditions for which the 
described medication should be taken. Similarly 36/57 (61%) participants 
could not identify conditions of contra-indication.  
There was no significant relationship between health literacy and adherence 
to HF medication. 
13. HRQoL   
A total of 58 participants completed the KCCQ which demonstrated a high 
level of internal consistency (Cronbach’s α = 0.91). Analysis of data 
reported no significant relationship between HRQoL as assessed by the 
KCCQ, and adherence to HF medication. 
14. Patient – Provider Relationship  
53/60 participants completed the MISS Questionnaire however three of these 
participants felt unable to complete the compliance intent section as they had 
not been given treatment at their last consultation. For the 7 participants who 
chose not to complete the questionnaire five felt they could not recall 
sufficiently the details of their last medical consultation while two expressed a 
wish not to discuss their relationship with their doctor. Overall the median 
overall satisfaction score relating to the last consultation the participant had 




The MISS score demonstrated high internal consistency (Cronbach’s α = 0.93) 
in this sample. There was no significant relationship between satisfaction with 
the doctors’ consultation and adherence to HF medication.  
6.2.5. Additional analysis 
Disappointingly no predictor for adherence was shown to significantly 
determine adherence to medication when assessed by self-report. Further 
analysis was conducted using the self-report adherence data as continuous 
rather than dichotomous data. Results from this supplementary analysis are 
reported in tables 6.9 and 6.10. 
 
 Correlation between 
variables 
 
Carer BMQ Specific– Necessity score (n=20) rs= 0.10, p=0.69 
 
Carer BMQ Specific – Concern score (n=20) rs= 0.13, p=0.58 
 
Carer BMQ General – Overuse score (n=20) rs= 0.15, p=0.53 
 
Carer BMQ General – Harm score (n=20) rs= 0.15, p=0.53 
 
Carer IPQ-R identity (n=20) rs= 0.20, p=0.40 
 
Carer IPQ-R consequences (n=20) rs= 0.07, p=0.79 
 
Carer IPQ-R personal control (n=20) rs= 0.37, p=0.11 
 
Carer IPQ-R treatment control (n=20) rs= -0.05, p=0.82 
 
Carer IPQ-R illness coherence (n=20) rs= -0.07, p=0.78 
 
Carer IPQ-R timeline cyclinical (n=20) rs= 0.15, p=0.52 
 
Carer IPQ-R emotional representation (n=20) rs= 0.17, p=0.49 
 
Table6.9: Correlation of MMAS-8 as a continuous variable and beliefs held by carers  
* Data analysed using Spearman’s rank correlation coefficient.Threshold for significance for this table after Bonferroni 
correction p=0.005.  










Age (n=59) rs=-0.00, p=0.98 
Gender (n=59) rs= -0.14, p=0.30 
Formal Help at home (n=59) rs= 0.14, p=0.28 
Living alone at home (n=59) rs= 0.01, p=0.96 
Number of medications (n=59) rs= -0.15, p=0.27 
MoCA score (n=56) rs= 0.21, p=0.13 
HADS Anxiety (n=59) rs= -0.41, p=0.001* 
HADS Depression (n=59) rs= -0.21, p=0.12 
SMID rank (n=59) rs= 0.05, p=0.73 
SPPB score (n=56) rs= -0.01, p=0.95 
Charlson Score (n=59) rs= -0.27, p=0.04 
BMQ Specific– Necessity score (n=59) rs= -0.07, p=0.63 
BMQ Specific – Concern score (n=59) rs= -0.34, p=0.01 
BMQ General – Overuse score (n=59) rs= 0.05, p=0.70 
BMQ General – Harm score (n=59) rs= -0.24, p=0.06 
Cardiac Self-efficacy Questionnaire - control  rs= -0.14, p=0.30 
Cardiac Self-efficacy Questionnaire - maintain rs= -0.01, p=0.92 
Health literacy Score (n=57) rs= 0.17, p=0.22 
KCCQ Functional Status score (n=58) rs= 0.16, p=0.22 
KCCQ Clinical summary score (n=58) rs= 0.21, p=0.12 
IPQ-R identity (n=52) rs= -0.12, p=0.38 
IPQ-R consequences (n=52) rs= -0.09, p=0.52 
IPQ-R personal control (n=52) rs= 0.13, p=0.36 
IPQ-R treatment control (n=52) rs= 0.00, p=0.10 
IPQ-R illness coherence (n=52)  rs= 0.15, p=0.30 
IPQ-R timeline cyclinical (n=52) rs= 0.14, p=0.31 
IPQ-R emotional representation (n=52) rs= -0.31, p=0.03 
IPQ-R total symptoms (n=57) rs= -0.23, p=0.09 
IPQ-R total symptoms due to H/F (n=57) rs= -0.20, p=0.14 
MISS – Overall Satisfaction score (n=50) rs= 0.14, p=0.35 
Table6.10: Correlation of MMAS-8 as a continuous variable and factors associated with 
adherence 
* Data analysed using Spearman’s rank correlation coefficient. Threshold for significance for this table after Bonferroni 
correction p=0.002.  
MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety Depression Scale; SMID, Scottish Index of Multiple 
Deprivation; SPPB, Short Physical Performance Battery; BMQ, Beliefs about Medication Questionnaire; KCCQ, 





6.3. DISCUSSION  
6.3.1. Summary of Main Findings 
The aim of this prospective observational study was to assess adherence to 
ACEi and Furosemide medication in older patients diagnosed with HF and to 
identify the key determinants of primary non-adherence in patients with HF. 
Using multiple, complementary measures, adherence to medication was found 
to be optimal in this sample of patients; however discrepancies existed 
between the methods used.  
No single determinant was found to consistently predict adherence across the 
different adherence measures used. For those participants prescribed 
furosemide, anxiety and overall physical functioning where identified as 
significant factors for adherence when reviewed against prescribing data. 
Disappointingly however this association was not significant following 
correction for multiple comparison or when adherence was measured using 
the dichotomous self-report adherence data. Similarly, while consequences of 
condition and evidence of symptoms was found to be a significant factor for 
adherence to ACEi when assessed using direct methods again this was not 
consistent with the other adherence measures or following correction for 
multiple comparison. Interestingly however, when self-report data was 
analysed as a continuous rather than dichotomous variable, a significant 
correlation was found with self-reported anxiety. While research within the 
heart failure population has not previously identified any link between anxiety 
and adherence to medication, in patients with LVSD, functional ability has 
been shown to be limited by the presence of anxiety (237) which may have the 
potential to negatively impact on adherence within this population. Further 
investigation in this area is therefore warranted. 
6.3.2. Recruitment  
While the study originally aimed to recruit patients who were prescribed both 




protocol was necessary to enable the study to meet its aim to recruit 60 older 
people with a diagnosis of HF. Several factors were likely to have contributed 
to this difficultly with initial recruitment when both medication required to be 
prescribed. 
Firstly, the participants in this study had a mean age of 79 years and a 
diagnosis of varying other medical conditions including chronic kidney disease, 
stroke, postural hypotension, diabetes and chronic obstructive pulmonary 
disease. The existence of co-morbidities may complicate the management of 
HF caused in part by the lack of guidance on polypharmacotherapy or due to 
additional complications of drug interactions and adverse effects (482). While 
drugs such as ACEi may be considered first line treatment in patients with 
HFrEF it may be that these medications are withheld in particular cases 
because of interactions and side effects, particularly in older patients.  
The decision to include patients who had a diagnosis of HFpEF in the study 
meant recruitment was extended to a group of patients for whom prescribed 
medication may not have necessarily included the medication detailed in the 
study protocol. While treatment with ACEi is recommended in all symptomatic 
and non-symptomatic patients with HFrEF there is inconsistent evidence for 
an improvement in symptoms, morbidity or mortality in those patients 
diagnosed with HFpEF (483).  
Diuretic therapy is indicated in all patients with symptomatic HF. While 44/60 
(73%) of study patients were prescribed ongoing treatment 5/44 (11%) of these 
participants were taking bumetanide as an alternative to furosemide which was 
not measureable with the assay techniques available.  For patients who have 
intolerable side effects with ACEi, ARBs are prescribed an alternative in 
patients with HFrEF (484). In this study while 46/60 (77%) of patients were 
prescribed either ARB or ACEi, 11/60 (18%) were in fact prescribed an ARB 
which would have excluded them if the initial protocol had been retained. In 
total just over 50% (31/60) of our study participants were prescribed both the 
medications required by the initial study protocol. Poor potential for recruitment 




therefore of this pattern of prescribing, thus a decision was made to open 
recruitment to those prescribed either ACEi or furosemide medication.  
The low numbers of participants with poor adherence limited the ability of the 
study to find significant associations on univariate analysis. This fact, 
combined with the relatively small size of the study, led to the decision not to 
conduct multivariable analyses. Such analyses would be unlikely to be robust, 
and would add little to the univariate analyses. 
Difficulties with recruitment to research studies, particularly among the older 
population, are well documented (485).  Despite widening the inclusion criteria, 
recruitment via GP surgeries continued to prove lower than expected. While 
response to the GP invitation letters yielded a good (27%) response rate the 
number of participants suitable for initial approach fell short of expectation. The 
addition of recruitment from the SHARE register which retains a register of 
patients’ comorbidity and pharmacological treatment enabled a more targeted 
approach to recruitment which resulted in the recruitment of the target study 
number. While minimal differences existed between the participants recruited 
from the two sources these may have had a more significant impact on 
adherence with a larger sample size.  
6.3.3. Adherence to medication 
The results from this observational study report ACEi levels comparable with 
those reported elsewhere. A previous study conducted by Molloy et al 
assessing adherence to ACEi using similar methods to ours reported serum 
reported adherence to be 72% compared to the 74% adherence rate in this 
current study  (44).  
Results with prescription data are not as consistent. Butler et al (486) reported 
adherence to ACEi as assessed by prescription data dropping from 77% at 30 
days post hospital discharge to 63% at 1 year while prescription data in this 
current study reported adherence to be markedly higher at 94%. Unlike the 
participants in our study participants in Butler’s study were recruited post 




part of a serious acute event and did not understand the necessity for long 
term use of these HF drugs.  
While it might be expected that participants may have made a conscious effort 
to take all of their prescribed medication on the day of the study visit (the 
“toothbrush effect”) this was not the case. While all participants were found to 
be adherent to their diuretic therapy (a drug known to be selectively withheld 
by patients due to adverse side effects) on the day of the study visit, lower 
adherence to ACEi treatment was reported.  
One explanation for this may be that patients usually have some 
understanding that diuretic therapy is associated with their heart condition - 
both the beneficial effects and side-effects of administration of this treatment 
are clearly visible. When describing their current drug regime patients 
frequently identified the need to pass urine as an unwelcome side-effect of 
their diuretic while many were unable to attribute any notable side-effects to 
other medications.  Participants may have considered that omitting this 
medication on the day of the study visit may have given the researcher the 
impression that non-adherence was a regular occurrence effecting the opinion 
the researcher may have had of them.   
Another explanation for the higher than expected adherence to diuretic 
treatment may have been that the majority of study visits 47/60 (88%) were 
conducted within the participants own home.  Patients often describe delaying 
or missing doses of their diuretics when they have to leave the house (183).  All 
participants who elected to travel to the study visit were provided with the 
option to select a time convenient to them enabling a later appointment time to 
be set when increased diuresis had subsided but presence of furosemide 
would still be detectable in the urine. 
6.3.4. Predictors of adherence 
With over 200 possible factors for non-adherence previously identified this 
study preselected the determinants identified from both current literature and 




Overall none of the preselected determinant factors proved significant across 
the adherence measures. Several reasons may account for this. Firstly with 
such a wide range of determinants being studied it may that the sample size 
of 60 was insufficient to detect any significant effect played by the determinants 
measured. Our initial sample size calculation demonstrated an initial 
estimation of 90 participants however this was revised due to budget 
constraints. identified  
Common across this sample of HF patients was an intention to comply with 
the advice given at the time of medical consultation. Overall the included 
participants demonstrated greater adherence to HF medication than had been 
reported previously with the results from the urinary furosemide measures 
excluded from the analysis. As a result the low percentage of non-adherent 
participants may not have been sufficient to detect effect on some of the 
individual factors for adherence shown to have been significant in other 
studies.  
Despite looking to recruit a sample typical of the HF population some of the 
preselected factors where difficult to assess. Results from the systematic 
review had identified hospitalisation as a factor however only 13/60 (22%) of 
the study population had been in hospital due to an exacerbation of the HF. 
Overall this was a sample of HF patients whose condition was stable, perhaps 
as a direct consequence of the high adherence rates reported. Similarly, rates 
of depression in this sample were less than the 1:5 suggested as 
representative of the population while participants’ socio-economic status was 
typically higher than the average. It may be that any association between these 
and non-adherence to medication may have been difficult to identify without a 
larger, more representative sample size. 
Another explanation may be that Scotland has a unique healthcare system. As 
previously highlighted by the qualitative review no reported studies have been 
conducted here in Scotland. It may be that the factors for adherence in the 
locality may differ to those reported in other populations. While factors such as 
the financial implications of continual long-term access to healthcare providers 




may well be that socio-economic; healthcare system and treatment factors are 
also different from those in other populations.  
6.4. Strengths and Weaknesses 
6.4.1. Strengths  
This observational study has a number of noticeable strengths: 
• The study focused its recruitment strategy around community-based HF 
patients rather than those hospitalised with HF related conditions. 
Previous to this the majority of studies assessing adherence to 
medication in older HF populations had been conducted in patients 
recruited to studies following a hospital admission. The intention of this 
study was to assess determinants of adherence in a population of stable 
HF patients who were responsible for their own treatment regime and 
may have had limited input from specialist services. The vast majority 
of patients in this study had never required a hospital admission for an 
exacerbation of their HF. Medication was in the main prescribed by the 
participants GP or doctor in an outpatient hospital setting where 
presenting symptoms did not warrant acute hospital admission. As 
such, the population studied was arguably much more representative of 
the vast majority of older patients with HF and hence the results should 
be more generalizable than studies focussing on a smaller, selected 
population of patients with recent hospitalisation. Understanding and 
improving adherent behaviour in this large group of patients may go 
some way to optimising treatment, slowing the progression of the 
condition and reducing the large number of avoidable hospital 
admissions experienced by this population of older HF patients every 
year (138). 
• Despite the average age for first diagnosis being 76 years previous 
studies in this area have focused on HF patients with a lower mean age. 
This study recruited participants over the age of 70 years, a highly 
relevant group as HF is more prevalent in later life along with multi-




• Many of the study visits were undertaken in the participants own home 
which facilitated a more relaxed atmosphere and importantly avoided 
potentially lengthy travel to the research centre. It is well documented 
that many patients can be selective with particular medications 
including diuretic treatment when having to leave their home. In 
eliminating the need for travel it is likely that the participants adherence 
recorded on the day was more reflective of their normal routine.  
• In order to addresses the well documented limitations associated to 
adherence assessment methods a triangulated approach was taken. 
Previous studies within the HF population have demonstrated 
substantial differences across the different measures of adherence. 
Smith et al demonstrated a lack of consistent agreement across the 
different measures of adherence when measuring adherence in a 
population of HF patients with a mean age similar to that in the current 
study (487). Self-report was found to have overestimated adherence 
when compared to other objective measures. Overall, the variation in 
results, while suggesting that overall adherence was better than 
previously reported demonstrated poor agreement between the 
different methods therefore supporting the chosen approach. 
6.4.2. Weaknesses 
• The candidate determinants were selected based on evidence gleaned 
from the qualitative study and a comprehensive review of the literature 
a decision. However, it may be that other determinants play a greater 
role in adherence to medication for patients with HF than those 
examined in this study.  
• It was not possible to assess the effect of hospitalisation in this study. 
Data were collected on hospital stays and while 13/60 (22%) of the 
participants did report an overnight stay in hospital within the preceding 
12 months only three of these were directly related to their diagnosis of 




hospital discharge may have demonstrated a link between 
hospitalisation and non-adherent behaviour. 
• Participants who volunteered were relatively stable and appeared to be 
managing their condition successfully. In general people who respond 
to observational studies may be more motivated to understand their 
condition and listen to health care provider’s advice. Participants who 
responded from the SHARE database had previously demonstrated an 
interest in participating in research studies and may not be 
representative of the general HF population. In order to fully understand 
which beliefs which may have an impact on adherence, participation 
studies require the participation of patients who may have difficulties in 
managing their medication and are less motivated  
• The population recruited to the study was self-selecting, they 
volunteered to participate in a study which was clear in its objective to 
assess medication taking. It is more likely therefore that while 
participants across both the qualitative and observational studies 
described episodes of both non-conforming non-intentional and 
intentional non-adherence consent into the study itself may have been 
less likely in a population for whom intentional non-adherence was an 
issue. A particular theme emerging from the study was the importance 
of the patient – doctor relationship.  Those with a greater tendency to 
omit medication may have avoided recruitment concerned that their 
doctor may look less favourably on them during future contact thus 
biasing the results in favour of adherent behaviour. 
• With such a range of factors being assessed the choice of suitable 
measurement tools proved difficult. Assessment of validity was 
conducted for all questionnaires during the selection phase and while 
some of the included questionnaires used had demonstrated good 
construct validity when used in other settings it may be that they were 
less suitable for this population of older patients with HF. While overall 




internal consistency, scores for some of the subdomains were less 
robust.   
6.5. Conclusion  
In conclusion this chapter has described the methods and results of the 
quantitative study. Adherence to ACEi and furosemide medication in 60 older 
patients with a diagnosis of HF has been reported using a range of different 
methods for assessing adherence. Possible determinants for non-adherence 
were assessed. Overall adherence to both HF medications was found to be 
high however adherence rates differed across the measures used. Surprisingly 
adherence on the day of the study to diuretic therapy, a drug known to be 
routinely withheld by patients, was 100%.  
As expected with this population the majority of participants were prescribed 
multiple medications. While participants demonstrated a lack of knowledge 
around their prescribed medication and their related side-effects many 
demonstrated a keenness to adhere to their regime and describing the use of 
pill boxes and reminder stimuli to promote adherence.  
Finally no single determinant consistently predicted non-adherence. While 
several of the determined factors proved significant using one of the 
adherence measurements this was not consistent across the measures of 
adherence. A lack of validated tools for measuring factors for medication 




Chapter 7: Discussion of Overall Results  
The purpose of this chapter is to bring together all of the findings from the 
studies reported in this PhD thesis and to discuss these results in the context 
of the existing literature.  
7.1. Context of the Study 
As set out at the beginning of this thesis HF is an important clinical issue for 
many older people. A diagnosis of HF can have huge implications for both the 
patient and their family as well as society as a whole. With an estimated half a 
million people currently living with the condition in the UK the cost to an already 
burdened healthcare system is set to increase with more people living into old 
age and developing long-term conditions such as HF. While there is significant 
evidence to support the use of medication in the treatment and management 
of HF, any failure to adhere to prescribed treatment may result in suboptimal 
benefits producing an exacerbation of these costs on both a personal and 
economic level. 
The original aim of this PhD was to improve understanding around the issue 
of non-adherence to medication in older people with HF in order to inform the 
development of an appropriate adherence promoting intervention. While an 
accurate picture of the level of non-adherence in this population was difficult 
to establish previous work in the area had concluded that interventions which 
aimed to improve medication adherence among HF patients had the potential 
to have significant effects on reducing readmissions and decreasing mortality 
in this population. 
This PhD employed a multi-methods approach conducted in three phases. 
Phase one involved the undertaking of a systematic review evaluating 
previously reported interventions aiming to enhance medication adherence in 
the HF population. The review was followed by a rapid review of qualitative 
literature exploring potential facilitators and barriers to medication adherence 
within the same population. Phase two entailed the collection and analysis of 




literature.  In total 8 HF patients and their informal carers participated in semi-
structured interviews aiming to explore beliefs and understanding around the 
condition and its treatment. Finally, data from the first two phases was collated 
and used to select which possible determinants of adherence were to be 
assessed in a population of 60 older HF patients who were recruited to the 
observational study conducted in phase three. The key findings from the 
programme of work are summarised below: 
7.2. Main findings  
7.2.1 Phase one findings 
In order identify which component parts have previously proved successful at 
improving improve adherence in patients with HF this PhD commenced with 
the undertaking of a systematic review of current literature. Across the 21 
studies included in the review heterogeneity in both the intervention techniques 
as well as the adherence measurement methodology meant the identification 
of a reliable and effective intervention was not possible. In addition a number 
of other notable limitations across the literature were identified including: a lack 
of representation of older HF patients in research studies; limited long term 
follow up studies demonstrating positive results and importantly a lack of 
agreement on either a valid measure of adherence in this population or what 
constitutes an acceptable level of adherence.  
Qualitative literature exploring perceptions and experiences of people with HF 
in relation to their condition and its management also demonstrated a number 
of limitations. While individual beliefs and level of personal knowledge were 
identified as potential factors for adherence in HF patients the exact detail of 
these beliefs remained uncertain. Again this is even more unclear given the 
lack of studies focusing on older HF patients who have the added burden of 
co-morbidity  
Despite the study limitations a number of important results were established. 
Firstly despite literature consistently reporting that adherence is suboptimal not 
only in HF patients (488) but also among the older population (489) across the 




previously documented that adherence levels in research study patients may 
be uncharacteristically high compared to those seen routinely in clinical 
practice (490) these results suggest that additional work to establish an accurate 
level of adherence in this population requires to be undertaken.  
Importantly the work contained within the systematic reviews demonstrated 
that improvement in adherence to medication was indeed possible within the 
HF population. Improvement in adherence following the delivery of an 
intervention was noted across 8 of the 21 included RCT’s. These results are 
encouraging offering potential for the future development of a complex 
intervention drawing on some of the component parts which showed positive 
results. 
7.2.2. Phase Two findings 
Following the inconclusive but encouraging results obtained in phase one a 
qualitative study was undertaken to explore the beliefs held by older HF 
patients in relation to the condition and its management. In-depth semi-
structured interviews with eight older HF patients and their nominated informal 
carers were conducted with several themes emerging. While health literacy 
relating to both condition and treatment was found to be low, participants spoke 
about adherence to treatment in a positive manner with desire to remain as 
independent emerging as a strong motivating factor for adherence.  
For the older HF patients included in the study another important motivator for 
adherence was the relationship they felt they had with their healthcare 
professional. Overall participants had a strong belief in the doctor’s ability to 
prescribe appropriate treatment and make appropriate decisions regarding the 
management of the condition. Participants were in the main identified as 
“passive” medication users who appeared to have a strong belief in the need 
to adhere to prescribed treatment plans, this despite an obvious lack of 
knowledge and understanding.  
Adherence was therefore facilitated by having a positive relationship and a 
high level of trust in the doctor’s decision making along with a strong belief in 




themes of maintaining independent functioning and not become burdensome 
on informal carers’ where key themes in relation to adherent behaviour taken 
forward to explore further in phase three.  
7.2.3. Phase Three findings 
In the final phase, an observational study reporting on 60 older patients with 
HF, adherence to medication was evaluated using a multi-method approach 
while a wide range of potential facilitators for adherence informed by the 
worked conducted in two previous stages of this PhD were explored. 
Adherence to medication ranged from 74% as measured using serum ACE to 
100% when adherence was measured using urinary furosemide levels.  Given 
that there is currently no gold standard for measurement for adherence it was 
important that adherence was measured using a multi-method approach. This 
study reported serum ACE rates to be similar to those found using this 
collection method previously in a similar population (44). Importantly 
triangulation of adherence outcomes identified consistently high adherence 
rates not only for the day of the study visit but over the year preceding study 
consent.  
While previous studies have found highly variable levels of adherence the work 
contained within this PhD was based on the hypothesis that adherence to 
medication was suboptimal within the HF population (149). Given that the 
observational study demonstrated a good level of adherence, with results 
similar to those previously reported locally, (44) it may be that the significance 
of poor adherence for older HF patients might not be as great as previously 
suspected and that non-adherence therefore is not a major problem in this 
population. It is important to view this assumption with some degree of caution 
however given that it is based on the results of two local studies both with 
relatively small sample sizes.  
Additionally it is important to remember that these results reflect adherent 
behaviour in a population of older patients who volunteered to participate in a 
research study aiming to investigate adherent behaviour. As previously stated 




in research, therefore the high adherence rates reported here may not be fully 
representative of the patients found in general populations. While the high 
levels of adherence are encouraging it is important not to disregard adherence 
as a problem as it may still remain a problem for a minority of older people.  
Factors gleaned from the literature which seemed most relevant along with 
those emerging from the qualitative interviews were examined further within 
the observational study. Disappointingly none proved to be a significant factor 
for adherence in the population of older patients with HF recruited to the study. 
This finding has significance for future research in this area in that it makes 
clear that the selection of participants for future studies aiming to improve 
adherence should not be based purely on these suggested possible factors. 
Instead the results of this PhD suggest that any future intervention should 
focus on an individual’s personal motivating factors, which may play a more 
significant part in addressing non-adherence. 
7.2.4 Overall context for older HF patients  
In order to optimise adherence to prescribed treatments in older HF patients 
the above results make clear that the traditional view targeting the individual 
factors thought to influence adherence has potential for only limited success. 
Before designing an intervention it is important to contextualise how the issue 
is viewed from the perspective of those living with the condition and managing 
the treatment. During both the qualitative interviews and the observational 
study the majority of participants did not feel that HF was having a major impact 
on their daily life. HF, although correctly identified by most as a chronic 
condition, was judged by patients to be stable and importantly the majority of 
patients felt they had a good personal level of control over the condition.  
As previously stated, having a high level of self-efficacy has the potential to 
impact greatly on one’s ability to manage self-care tasks like adherence to 
medication. Older people who feel they have a good level of personal control 
and confidence in their ability to continue with prescribed treatment may be 
more likely to follow increasingly complex treatment plans. An acceptance by 




is due to them having a good understanding of the condition or simply 
attributing deteriorating health to the ageing process along with the desire 
commonly expressed by older people to remain independent and avoid being 
a burden may potentially aid healthcare professionals to engage patients in 
accepting these treatment plans.    
For older patients with HF it is important to recognise that the condition is not 
managed in isolation. Indeed for patients over the age of 75 years a diagnosis 
of HF without co-morbidity is extremely rare (491) with the majority of HF 
patient’s requiring to manage a minimum of 5 co-morbid conditions unrelated 
to a cardiac diagnosis (492). Particularly when compounded by physical and 
psycho-social deficits co-morbid conditions commonly found in older people 
such as diabetes mellitus, depression, cognitive impairment, thyroid disorders 
and skeletal myopathy have been shown to complicate the management of HF 
in older people. Acknowledgment of the role played by other conditions, in both 
the development of progression and the successful management of HF is 
therefore essential to optimise treatment adherence (493). Rather than looking 
at HF in insolation, a model of care which encompasses concurrent diagnoses 
has the potential to improve not only outcomes related to HF but other co-
morbid conditions and therefore the individual’s overall health.  
HF is known to encompass a number of nonspecific symptoms which may 
have emerged over time. For many HF patients other co-morbid conditions 
such as COPD or arthritis may be perceived to have more of an impact on their 
daily lives with causal factors for the presence of typical symptoms of HF 
explained by age or being related to other co-morbid conditions (291). Given that 
patient knowledge around both HF and treatment is found to be consistently 
poor but relatively high levels of adherence have been reported (44) it may well 
be that for older people factors other than causation may be important in 
relation to adherence. Previous research has demonstrated that for some older 
people there is a practical acceptance that medication is required to allow them 
to continue “ticking over” (494).  Simply put, it may be that a combination of an 
acceptance of the potential consequences of advancing age along with a belief 




providers may be more important in enhancing adherence in older patients 
than developing an understanding of how a specific drug effects symptoms of 
a specific condition.  
Currently around one in three older people live alone (495).  For older people 
with HF maintaining independence and avoiding becoming burden on others 
appears to be an important motivating factor for adherence to treatment. Many 
of the older HF patients recruited to the empirical studies contained within this 
thesis accepted that while their usual social activities would not be maintained 
indefinitely social interaction with family would be. Rather than focusing on 
educating patients using motivational factors such as maintaining 
independence while establishing positive believes in the need for treatment 
and improving confidence in being able to manage their own health with 
appropriate support from significant others may encourage older people with 
HF to participate in self-care.  
7.2.5. Burden of Heart Failure  
Modern healthcare increasingly requires patients to take on more responsibility 
for the management of their conditions which in HF requires ongoing 
monitoring of symptoms while routinely participating in self-care and complex 
polypharmacy regimes (496). For older people this means the burden of living 
with multiple conditions is likely to increase.  Despite the view that conditions 
other than HF have more limiting factors on daily functioning than HF, living 
with the condition impacts on an individual’s physical, psychological and social 
well-being with potential consequences for quality of life (497). Any improvement 
which can be achieved in the management of symptom burden has the 
potential to improve overall function in patients with HF positively impacting on 
levels of independence a factor identified for adherence. 
However the burden of illness is not the only consequence of living with a long-
term condition. As previously described within this thesis there has been a 
significant increase in the number of treatment options available for long-term 
conditions such as HF in recent years. While clinical guidelines such as SIGN 




outcomes for patients living with long-term conditions they focus on single 
disease. Given that older patients with HF have an average of three comorbid 
conditions clinical guideline recommendations offer potential for the number of 
prescribed treatments to rise without consideration of other comorbidities or 
how best to prioritise guideline recommendations. (498).   
Consequently following disease-centred care not only increases potential for 
adverse reactions it may also result in complex treatment plans which are 
uncoordinated and do not consider the individual, their personal preferences 
or any limitations they may have in regard to their capacity to understand and 
participate in the management of their conditions (499). Given that 
multimorbidity is the norm in older people with HF all treatment associated with 
the management of HF must be considered in context of patient-centered 
rather than disease-centered care (500).  
Burden of treatment refers to the additional workload placed on patients in 
order to adhere to healthcare recommendations and to the resources available 
to patients in order to respond to increase in workload demands (495). In HF 
patients require to commit to the undertaking of a life-time of routine tasks such 
as regular medication taking, symptom monitoring and lifestyle changes. It has 
been estimated that patients with chronic conditions such as HF have been 
estimated to spend around 86 minutes per day managing a single condition 
exclusive of any time allocated to undertake recommended exercise programs 
(501).  Additionally the extent of this burden can be intensified due to factors 
including the subsequent prescribing of additional medications and the need 
to attend regular medical appointments as well as a lack of continuity and poor 
communication between health professionals (500). 
For older patients with HF the presence of co-morbidities may mean that 
balancing workload and individual ability can be particularly difficult. When 
considering medication adherence therefore rather than simply focusing on 
health at a condition specific level it may be more useful to look an individual’s 
interaction with health and how well their treatment plan for all co-morbid 




approach which looks impose the minimum treatment burden possible in order 
to achieve the goals an individual has set for their health (503).  
In order to enable patients to undertake an increased personal role in their 
health the MDM model proposes that two strategies are necessary: firstly, the 
right care needs to be identified and secondly we need to enable that care to 
happen. While it is clear that specialist medicine plays an important role in the 
prescribing of treatment for older people with HF the complexity of regimes 
prescribable for all co-morbid conditions undoubtedly has potential for high 
levels of treatment burden in this population. An alternate model of care which 
is designed around a team of co-ordinating healthcare professionals who sees 
the patient on a regular basis may be better placed to manage care reducing 
the potential for repetitive outpatient appointments while overseeing and 
rationing the prescribing of treatments. 
In order for burden of treatment to be reduced healthcare professionals require 
not only an overview of the treatments necessary for each diagnosed condition 
but a clear understanding of the work involved in managing treatment regimes. 
Importantly treatment needs to be holistic and viewed firmly from the patient 
context for older people. A constant theme running through the work contained 
within this thesis is the importance placed on the relationship between the 
healthcare professional and the patient. For older people with HF developing 
this relationship has potential to improve treatment adherence not only through 
the development of trust but through the ability to improve knowledge and 
understanding of treatment while ensuring that treatment regimes remain 
appropriate and within the patient’s capabilities.  
7.3. Conclusion 
The work contained within this PhD has gone some way to advance the 
understanding of adherence to medication in older people with HF. It sought 
to establish a better understanding of which factors play a role in determining 
adherent behaviour with a view to establishing which components would make 
the make the greatest contribution towards improving adherence and health 




Despite the increasing availability of new medications available for the 
treatment of HF it is clear that an improvement in health may be gained from 
improving adherent behaviour to current medical treatments rather than adding 
to the overall burden of treatment. However, research looking to address 
medication adherence in older patients with HF is still limited in both quantity 
and quality. There remains no consensus on what would be classed as the 
minimum acceptable level of adherence in this population. While many studies 
have evaluated the effect on health-related outcomes for many of the drugs 
currently prescribed for patients with HF it may well be that 100% adherence 
is not required to achieve acceptable treatment results.   
It is the recommendation of the author of this thesis that any future research 
should attempt to explore multi-component interventions, acknowledging 
patients’ beliefs and preferences and incorporating them into adherence-
enhancing interventions which combine a number of strategies including: the 
adoption of a holistic rather than condition specific approach; the transfer and 
reinforcement of appropriate knowledge at an appropriate time and addressing 
patient capability issues. However, by focusing on optimal strategies for the 
comprehensive management of the patient with HF rather than the isolated 
effects of single drugs or on the individual factors deemed responsible for non-
adherence interventions can be developed which ensure that the already 
heavy burden of living with HF is not increased. 
Finally, by empowering patients healthcare professionals must also accept that 
patients ultimately have the choice in whether they adhere to the healthcare 
advice they are given. While interventions have the potential to improve 
adherence outcomes they will not work for everyone therefore it is important 
that individuals are empowered to adhere in order that they are in a position to 
make an informed personal choice and not just because we want to achieve 






Chapter 8: Implications for Future Research 
The impetus for this PhD was to gain an understanding of adherence in older 
patients with HF in order to establish the framework for a future intervention 
aiming to improve adherence medication in this population. This chapter 
concludes the thesis by summarising the implications that the results from this 
study have for future work. An overview of the proposed content of a future 
intervention aimed at improving medication adherence in older people living 
with HF will be discussed.  
8.1. Proposed content of a future intervention 
No single, simple intervention has consistently proven effective in improving 
adherence to medication in the HF population. Further research therefore 
needs to focus on exploration of a multi-component intervention. However, in 
designing an intervention containing several interacting component parts, 
consideration should be given to the level of complexity which may have an 
impact on the feasibility and cost-effectiveness of implementing such a solution 
in clinical practice. 
The intervention proposed in this chapter uses the guidance developed by the 
Medical Research Council (MRC) for the development and evaluation of 
complex interventions as an underlying framework (504). The framework 
describes four main stages: development; feasibility; evaluation and finally 
implementation (see figure 8.1). The work contained within this thesis has 
gone some way to address the ‘development’ stage of the MRC framework; 
the next step is the establishment of a working group to complete the design 
of a theoretically-based intervention prior to preliminary testing in a pilot study.   
In the initial stages of intervention development, a working group made up of 
a range of stakeholders will review the knowledge gleaned from this PhD to 
establish a working protocol detailing a full description of the intervention and 
its component parts. The stakeholder group will need to include multi-
professional representatives with specialist knowledge of HF, of behaviour 
















Figure8.1: Elements of the MRC framework adapted from Craig et al 2006 (504) 
 
8.1.1 Theoretical grounding of the intervention 
When considering the development and evaluation of a complex intervention 
theory is considered a central component by the MRC framework (505). The use 
of theory is likely to improve the success and generalisability of interventions 
(506), and underutilisation of theory in many of the previous studies in the field 
of adherence has resulted in guidance of limited usefulness.  
Previous adherence interventions in the HF population have focused primarily 
on specifics such as the relationship between healthcare provider and patient 
(360, 362, 365) or on improving knowledge around self-care and treatment of 
disease (354, 368), and these interventions have in the long-term been mostly 
unsuccessful. More recent studies have increasingly utilised self-regulatory 
and social cognition models including the Common-Sense Model utilised 
within this thesis. However, while these models focus on the beliefs held by 
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individuals as well as their ability to follow advice and may offer valuable insight 
into what might underpin non-adherence they may be rather limited in their 
usefulness to guide any change in the nonadherent behaviour itself (507).  
The numerous techniques used to bring about behaviour change have been 
classified and incorporated into a taxonomy of behaviour change (508). 
Following a synthesis of 19 pre-existing frameworks Michie et al developed the 
Behaviour Change Wheel (BCW), a single interface which provides a 
framework for intervention development incorporating a theory of behaviour, 
intervention functions and categories of policy. At the heart of the BCW sit the 
three components Michie et al propose are required in order to bring about a 
change in behaviour:  
1) (C) the physical and psychological capability to perform the behaviour 
including necessary knowledge and cognition 
2) (O) the social and physical opportunity to perform the behaviour which 
include all the factors which lie outside the individual and 
3)  (M) motivation or the cognitive processes such as decision making as 
well as habit and emotion responses.  
Known as the COM-B model of behaviour change the model proposes that 
while each of these three components have the ability to effect behaviour 
directly behaviour is part of an interacting system involving all three. 
Importantly the interaction between these three components may explain why 
a recommended behaviour (such as adherence to medication) is not employed 
(see figure 8.2). Interventions therefore must aim to change one or more 
components in such a way the result is a new system minimising the risk of 
the behaviours reverting back. 
Given that the COM-B model sits at the centre of the BCW, once barriers and 
facilitators to these components have been established the BCW includes a 
selection of nine intervention functions which can be selected. Recently, the 
COM-B model has been used to identify factors associated with self-care 














Figure8.2: application of COM-B model to adherence adapted from (492) 
 
As a starting point to guiding the selection of the specific effective interventions 
required to implement this proposed complex intervention the COM-B model 
developed by Michie et all will form the basis for development (493). Within this 
thesis the use of the Common-Sense Model has enabled factors underlying 
adherence to medication in older HF patients to be defined. These factors, 
alongside the facilitators and barriers to adherence described by HF patients 
within both the qualitative study and qualitative review reported in this thesis 
can be easily mapped to the COM-B model (see table 8.1).  
In a recent article Jackson et al suggested that the COM-B could be applied to 
medication adherence emphasising its inclusion of automatic processes, 
system level factors and the specificity of its components as offering a positive 
basis on which appropriate interventions could be developed (492). Using the 
findings of this period of PhD study, the following section proposes the likely 
















8.2. Essential components of the intervention 
8.2.1. Study Population 
While the results from this thesis suggest that the majority of people may in 
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Identity – Comprehension of condition 
and understanding of management 
Cues/control – beliefs about physical 
ability to undertake management of 
conditions. Ability to organise and 
execute management plan 
• Ability to use memory aids 
and adapt regime when 
necessary 
• Forgetfulness / cognitive 
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• Assistance from others 
Opportunity  
 
 • Availability of medication  
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Identity – Perception of condition and 
associated treatment 
Cause - Perception of cause of illness  
Timeline – Perception of chronic/acute 
nature of condition 
Consequences – Beliefs about the 
condition, symptoms, associated 
management and potential outcomes  
Cues/control – Beliefs about self-
efficacy and efficacy of treatment  
 
• Maintaining independence 
and avoiding hospitalisation 
• Avoidance of being a burden 
on others 
• Belief and trust in healthcare 
professionals  
 
Table8.1: Mapping of CSM and identified facilitators and barriers to adherence to the 
COM-B Model 
 
patients who may gain most benefit from any planned intervention. The aim of 
such an intervention would be change the health trajectory for HF patients who 
have poor understanding of HF and its management or HF patients whose 
adherence is known to be low and therefore are potentially at high risk of 




scope to change the underlying behaviours and motivations that underpin 
adherence. The intervention would aim to target patients newly diagnosed with 
the condition in order to help establish a good level of understanding around 
the condition and its management at the earliest stage possible. In addition the 
intervention could also target those with a recent hospitalisation for HF where 
adherence has been identified as suboptimal thus providing a ‘teachable 
moment’ for behaviour change.  
8.2.2. Core components 
It is clear from the results of this study that any proposed intervention requires 
to be tailored to the needs of each individual while not creating additional 
treatment burden for those already managing multiple disease. During the 
initial stages the working group will utilise the BCW to complete the design of 
the intervention, but based on the work contained in this thesis several core 
components are suggested (see figure 8.3 for proposed components). 
 
Figure8.3: Essential components of proposed intervention 
 
• Educational component delivered at first contact and continued 
throughout intervention delivery.   
• Participation in a series of home based person centred interviews 
enabling the development of a personal action plan incorporating: 
o Linking personal motivating factors with symptoms and 
treatment of all ongoing medical conditions. 
o Identification and proposed management of social, physical 
and psychological barriers to adherence 
• Involvement of significant others for the individual including family 





As discussed in chapter three of this thesis interventions which are focused 
purely around an educational component do not have the ability to improve 
adherence to medication. However, improving knowledge around both 
condition and prescribed treatment has been an integral part of those 
interventions which successfully improved adherence to medication within the 
HF population. 
During the empirical studies conducted as part of this PhD study most older 
patients with HF chose to have the researcher conduct their study visits within 
their own home. Conducting interviews within the home environment has 
obvious benefits. Not only is it important that patients feel at home in order that 
a full assessment of social, physical and psychological barriers to adherence 
can be undertaken and a management plan proposed but the patient’s own 
home environment may be more conducive to promoting discussion around all 
co-morbid conditions rather than the focus being primarily on the management 
of  HF which, as previously stated, is often not felt to be of great importance to 
patients. 
As identified during the qualitative interviews while older people with HF live 
with symptoms of the condition these are often related to other conditions. 
When discussing how health effects daily lives other conditions were often 
seen as more problematic having a greater impact on daily living. Development 
of a personal action plan will enable a holistic approach and enable the 
intervention to be tailored to the specific needs of the individual pulling on the 
motivational factors unique to each individual. 
Finally, the important role played by carers and family is central to the success 
of the intervention. While factors such as living status or carers beliefs did not 
have a significant effect on adherence during the observational study during 
the qualitative interviews the patients desire to avoid becoming burdensome 
on loved ones was clear. This desire to remain functionally independent 
coupled with a desire to avoid burdening either relatives or medical practitioner 




8.2.3. Intervention Delivery  
The qualitative and observational studies described earlier in this thesis 
reported that many patients are unclear about when they received a diagnosis 
or who told them of the diagnosis. Therefore early engagement and 
reinforcement of the diagnosis at the time of initial diagnosis has the potential 
to help overcome this lack of understanding. Consulting with potential 
participants at their first clinic appointment and engaging them in the 
intervention by giving them the educational pack with follow-up shortly after 
the first visit may go some way to establish a memory of diagnosis, while 
regular follow-up in the one year period following this diagnosis would 
potentially reinforce existence of the condition particularly when symptoms 
may have been initially been contributed to other conditions or ageing.  
While it has been highlighted that several trials looking to improve adherence 
in the HF population have been undertaken by pharmacists it may be more 
practical to consider that this role may be undertaken by a specialist nurse or 
Advanced Nurse Practitioner who has the necessary knowledge and skills. A 
significant finding of the study was the importance placed on the relationship 
participants had with their doctor. Establishing a positive link between the 
study and the participants’ doctor may help with reinforcement of adherence. 
The supply of an education pack focusing specifically on the new HF diagnosis 
would be issued at the first clinic appointment which could further aid 
reinforcement of both diagnosis but also the link with medical staff.   
Currently it is already routine practice across many HF services information to 
supply information regarding the condition. Modifying this information could by 
including material around adherence could help both increase knowledge but 
help open discussion around adherence. In addition while information may be 
supplied to those attending specialist clinics there is a need to deliver this 
information to people who are not currently seen by HF services. This is 
particularly important for older people, who may receive the diagnosis from 
geriatricians, general medical services, or GPs, and are not always involved 




Finally, while the intervention looks to address specific factors within each of 
the three components of the COM-B model an important element of the 
intervention will be enabling the individual to establish a feedback loop 
between capability, opportunity and motivation positively influencing 
adherence to medication. 
8.2.3.1. Addressing Capability 
In order to take into consideration both the psychological and physical 
capabilities of the study participants an important consideration for the delivery 
of this intervention is the “right time, right place” question. Delivering the 
intervention in the participants own home may enable an accurate assessment 
of the current barriers and facilitators to adherence however, a degree of 
flexibility is required to enable patients wish to engage with the intervention 
elsewhere to do so.  A review of the patient’s current medication taking regime 
will potentially allow simplification of the regime but will also facilitate an 
assessment of health literacy and the development of an individualised plan 
on how to overcome barriers to adherence such as reduced cognitive function.  
Education alone is not sufficient to improve adherence. Nevertheless, 
sufficient knowledge of HF and the purpose of the medications is likely to be a 
necessary component of an intervention. An educational element within this 
proposed intervention would focus on supplying information based not only on 
HF but tailored to include the other medical conditions experienced by the 
patient. By encompassing all the conditions which are important to the patient, 
the education component may go some way to enabling the patient to manage 
often complex regimes with competing effects and harms. This improved all-
round health knowledge may also allow an increased understanding of the 
specific signs and symptoms of deterioration in their HF which may previously 
been wrongly associated to other conditions potentially enabling patients to 
seek medical guidance before the condition deteriorates significantly. 
Towards the end of the intervention the inclusion of a personal reflection on 
each individual’s health trajectory since initial diagnosis may help place the 




patients place the condition in context but may once again reinforce the 
diagnosis and need for ongoing management. 
8.2.3.2. Addressing Motivation 
Studies which have shown some effectiveness in improving self-care and 
adherence in patients with HF have included the a positive relationship with 
health care providers, promoting self-efficacy; identification of a link between 
HF and symptoms; family or carer giver involvement and are individualised 
and responsive.  A focus on personal motivating factors will be an essential 
component of the intervention with interviewing tailored to avoid extra burden 
of treatment.  
During the home visits, person-centred interviewing will seek to establish the 
individual’s perception of the condition, their prognosis and the beliefs they 
hold about the medications they have been prescribed. During the one-to-one 
interviews, participants will be encouraged to explore their own motivation for 
medication adherence. These motivational interviews will enable the patient to 
establish a meaningful association between symptoms, their condition and 
medication, over time, this focus on personal motivational factors alongside 
positive reinforcement will allow the patient to develop realistic expectations of 
their own health trajectory and adopt increased responsibility for their own 
health and treatment. The option for inclusion of family and informal carers in 
the person-centred interviews will be actively encouraged given their 
importance as highlighted by the findings in this thesis.   
8.2.3.3. Addressing Opportunity   
The proposed intervention will also focus on factors which offer the individual 
both physical and social opportunities to improve adherence to medication. 
Interlinking with the other domains of the COM-B model, the intervention will 
include assessment of the external factors which may impact on adherence. 
Conducting the interviews in the participants own home will enable an 
assessment of individual’s physical environment identifying facilitators and 
barriers and planning ways to maximise the value of facilitators whilst planning 




diaries, use of prescription services shown to be of value in other studies (156) 
can be added as part of the individual action plan at this stage. 
Finally, linking with the motivational domain, the intervention will include family 
and significant others including members of the healthcare team. This will aid 
in the identification of relationship factors such as the influence of family, 
friends and importantly the patient’s own doctor which have been shown to be 
important in influencing how patients with HF think about both their condition 
and its management. 
8.3. Pathway to future testing and study 
Finally, when considering the development of a complex intervention it is 
important to consider the interplay between: development, piloting, evaluation 
and implementation of interventions as described by the MRC framework (489). 
In order to facilitate the examination of the proposed intervention within a full 
RCT the author proposes the following iterative pathway as the route to future 
testing and study (see figure 8.4). 
 
 




Firstly the intervention development will be undertaken as described above. 
Once the component parts have been agreed by all stakeholders and 
manualisation has occurred a non-randomised study, conducted on a series of 
HF patients, is proposed. This feasibility study will involve the collection of both 
qualitative and quantitative feedback which will allow adherence to the 
intervention to be evaluated and inform refinement of the intervention design. 
Following any necessary modification the intervention will be trailed in a small 
pilot RCT. This study will aim to test the intervention in the same way as would 
be done for the main trial with adherence to the intervention as the main 
outcome. Again process outcomes would be collected to further refine the 
intervention.  
Finally the intervention will be examined as part of a multi-centre RCT. At this 
stage likely outcomes would be adherence to medication, symptom 
management, QoL, and hospitalisations. Additionally, process outcomes to 
determine if that the intervention was actually used by participants would also 
be conducted. 
This chapter has described the proposed content of a future intervention aimed 
at improving medication adherence in older people living with HF. Following 
the MRC framework for complex interventions the COM-B model has been 
selected as the theoretical underpinning for the intervention development.  The 
specific targeting of newly diagnosed HF patients, those with poor 
understanding of the condition as well and those whose adherence is known 
to be low would aim to help establish a good level of understanding around the 
condition and its management.  
The following concluding chapter contains a brief personal reflection on my 





 9. Personal Reflection 
The motivation for the development of this PhD was a desire to investigate 
which modifiable factors were associated with poor adherence to medication 
in older patients with HF with a view to developing a theory-based intervention. 
This experience has taken me in a surprising direction. While my previous 
experience undertaking RCT’s in older people had equipped me with basic 
quantitative research skills this period of study has enabled me to explore 
adherence using multi-methods.  
Over the last five years I have developed a grounding in the principles of 
systematic reviewing, developing my skills not only around literature searching 
but also in critical appraisal and the synthesising and disseminating of results. 
My knowledge and skills within this area continue to develop and are used 
daily as part of my new teaching role. 
The inclusion of a qualitative study helped fill in many of the gaps that had 
been missing in previous research I had conducted. The experience has 
enabled me to challenge my own perceptions and develop a reflexivity 
previously missing from my research. Overall, I have developed a confidence 
and belief in my abilities previously missing.  
The undertaking of a study looking to understand something as complex as 
adherence has been extremely rewarding. My journey has brought me into 
contact with older HF patients who despite having limited knowledge or 
understanding of their condition or treatment are managing to live with multi-
morbidity and polypharmacy. It has been a privilege to meet with both patients 
and carers who were all most generous in the sharing of their personal stories. 
It is clear that a desire to remain as independent as possible and not become 
a burden on those around them was an important factor motivating most the 
people I came in contact with. Despite not finding any conclusive results 
around which modifiable factors are associated with poor adherence in HF I 
remain convinced that there is a need to develop and test a theory-based 
intervention within this population. My work over the next few years will 





1. Scottish Intercollegiate Guidelines Network (SIGN). Management of Chronic 
Heart Failure: A national clinical guideline. Edinburgh; 2016. 
2. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M. 
Cardiovascular Disease Statistics 2014; 2015. 
3. Petersen SR, Rayner M, Wolstenholme J. Coronary heart disease statistics: 
Heart Failure Supplement 2002 edition; 2002. 
4. Strömberg A, Mårtensson J, Fridlund B, Levin LÅ, Karlsson J-E, Dahlström U. 
Nurse-led heart failure clinics improve survival and self-care behaviour in 
patients with heart failure: Results from a prospective, randomised trial. 
European Heart Journal. 2003;24(11):1014-23. 
5. van der Wal MHL, Jaarsma T, Moser DK, Veeger N.J.G.M, van Gilst W.H, van 
Velduisen D.J. Compliance in heart failure patients: the importance of 
knowledge and beliefs. European Heart Journal. 2006;27:434-40. 
6. Jaarsma T, Halfens R, Huijer Abu-Saad H, Dracup K, Gorgels T, van Ree J, 
et al. Effects of education and support on self-care and resource utilization in 
patients with heart failure. European Heart Journal. 1999;20(9):673-82. 
7. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of 
chronic heart failure. European Heart Journal. 2001;22(17):1527-60. 
8. Osterberg L, Blaschke T. Adherence to Medication. New England Journal of 
Medicine. 2005;353(5):487-97. 
9. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clinic 
Proceedings. 2011;86(4):304-14. 
10. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and 
medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794 - 
811. 
11. DiMatteo M.R. Variations in patients' adherence to medical recommendations: 




12. Cramer JA. A Systematic Review of Adherence With Medications for Diabetes. 
Diabetes Care. 2004;27(5):1218-24. 
13. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of 
blood pressure in patients with hypertension. The Cochrane database of 
systematic reviews. 2005(1):CD005182. 
14. Lopert R, Shoemaker JS, Davidoff A, Shaffer T, Abdulhalim AM, Lloyd J, et al. 
Medication adherence and Medicare expenditure among beneficiaries with 
heart failure. Am J Manag Care. 2012;18(9):556-63. 
15. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart 
failure in a well-defined older population, 1970-1974 and 1990-1994. 
Circulation. 2006;113(6):799-805. 
16. Nicholson C. Heart Failure: A Clinical Nursing Handbook: John Wiley; 2007. 
17. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SMC, Sutton GC, 
et al. Improving survival in the 6 months after diagnosis of heart failure in the 
past decade: population-based data from the UK. Heart. 2009;95(22):1851-6. 
18. Butler J. Primary Prevention of Heart Failure. ISRN Cardiology 2012;2012:15. 
19. Mehta PA, Cowie MR. Gender and heart failure: a population perspective. 
Heart. 2006;92(suppl 3):iii14-iii8. 
20. Taylor CJ, Ryan R, Nichols L, Gale N, Hobbs FDR, Marshall T. Survival 
following a diagnosis of heart failure in primary care. Family Practice. 
2017;34(2):161-8. 
21. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. 
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection 
Fraction. New England Journal of Medicine. 2006;355:251-9. 
22. Mitchell P, Mindham R. National Heart Failure Audit 2011/12 Public and 
Patient Report: Kings college Hospital; 2013. 





24. Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, et al. Recent National 
Trends in Readmission Rates After Heart Failure Hospitalization. Circulation: 
Heart Failure. 2010;3(1):97-103. 
25. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. 
European Journal of Heart Failure. 2001;3(3):283-91. 
26. Liao L, Allen LA, Whellan DJ. Economic Burden of Heart Failure in the Elderly. 
PharmacoEconomics. 2008;26(6):447-62. 
27. Donkor AC, Hardman S McDonagh T. National Heart Failure Audit. April 2014- 
March 2015; 2016. 
28. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et 
al. The EuroHeart Failure survey programme- a survey on the quality of care 
among patients with heart failure in Europe. Part 1:Patient characteristics and 
diagnosis. Eur Heart J. 2003;24(5):      442-63. 
29. Remme WJ, McMurray JJV, Hobbs FDR, Cohen-Solal A, Lopez-Sendon J, 
Boccanelli A et al. Awareness and perception of heart failure among European 
cardiologists, internists, geriatricians, and primary care physicians. European 
Heart Journal. 2008;29(14):1739-52. 
30. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects 
of simvastatin on the incidence of heart failure in patients with coronary heart 
disease.. Journal of Cardiac Failure. 1997;3(4):249-54. 
31. SOLVD Investigators. Effect of enalapril on mortality and the development of 
heart failure in asymptomatic patients with reduced left ventricular ejection 
fractions. The SOLVD Investigattors. The New England Journal of Medicine. 
1992;327(10):685-91. 
32. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et 
al. Health outcomes associated with antihypertensive therapies used as first-





33. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient 
Characteristics Associated with Medication Adherence. Clinical Medicine & 
Research. 2013;11(2):54-65. 
34. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and 
persistence across 6 chronic medication classes. Journal of Managed Care 
Pharmacy. 2009;15(9):728-40. 
35. Sabate. WHO Adherence to long term therapies Evidence for action Geneva 
2003. 
36. Horowitz CR, Rein SB, Leventhal H. A story of maladies, misconceptions and 
mishaps: effective management of heart failure. Social Science & Medicine. 
2004;58(3):631-43. 
37. Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. 
Circulation. 2010;121(12):1455-8. 
38. O'Carroll R, Dennis M, Johnston M, Sudlow C. Improving adherence to 
medication in stroke survivors (IAMSS): a randomised controlled trial: study 
protocol. BMC Neurology. 2010;10(1):15. 
39. Leventhal H, Brissette I, Leventhal E. The common-sense model of self-
regulation of health and illness. In: Cameron LD, Leventhal H, editors. The self 
regulation of health and illness behaviour: Routledge; 2003. p. 42-65. 
40. Horne R. Representations of medication and treatment: advances in theory 
and measurement. In: Petrie KJ, Weinman J, editors Perceptions of health & 
illness; 1997. p. 155-88. 
41. Bandura A. Self-Efficacy - Toward a unifying theory of behavioral change. 
Psychological Review. 1977;84(2):191-215. 
42. Molloy GJ, O'Carroll RE, Witham MD, McMurdo MET. Interventions to 
enhance adherence to medications in patients with heart failure: a systematic 
review. Circulation Heart failure. 2012;5(1):126-33. 
43. Oosterom-Calo R, van Ballegooijen AJ, Terwee CB, te Velde SJ, Brouwer IA, 
Jaarsma T, et al. Determinants of adherence to heart failure medication: a 




44. Molloy GJ, Gao C, Johnston DW, Johnston M, Witham MD, Struthers AD, et 
al. Adherence to angiotensin-converting-enzyme inhibitors and illness beliefs 
in older heart failure patients. European Journal of Heart Failure. 
2009;11(7):715-20. 
45. Creswell JW. Research design : Qualitative, quantitative, and mixed methods 
approaches. Los Angeles, Calif, London: Sage; 2014. 
46. Sandelowski M. Combining qualitative and quantitative sampling, data 
collection and analysis techniques in mixed-method studies. Research in 
Nursing and Health. 2000;23(3):246-55. 
47. Johnson RB, Anthony JO, Lisa AT. Toward a Definition of Mixed Methods 
Research. Journal of Mixed Methods Research. 2007; 1(2):112-33. 
48. Anguera MT, Blanco-Villaseñor A, Losada JL, Sánchez-Algarra P, 
Onwuegbuzie AJ. Revisiting the difference between mixed methods and 
multimethods: Is it all in the name? Quality & Quantity. 2018; 52(6):2757-2770. 
49. Tashakkori A, Creswell, JW. Editorial: The New Era of Mixed Methods. Journal 
of Mixed Methods Research. 2007;1(1):3-7. 
50. Hanson WC, Creswell JW; Plano Clark VL, Petska KS, Creswell JD. Mixed 
Methods Research Designs in Counseling Psychology. Journal of Counseling 
Psychology. 2005;52(2):224-35. 
51. Muncey T. Does mixed methods constitute a change in paradigm? In: Andrew 
SH editor. Mixed methods research for the nursing and health sciences: Wiley-
Blackwell; 2009. p.13-30. 
52. Florczak K. Purists Need Not Apply:The Case for Pragmatism in Mixed 
Methods Research. Nursing Science Quarterly. 2014;27(4):278-82. 
53. Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods 
designs-principles and practices. Health Services Research. 2013;48(6 Pt 
2):2134-56. 
54. Morgan D. Paradigms Lost and Pragmatism Regained:Methodological 
Implications of Combining Qualitative and Quantitative Methods. Journal of 




55. Farquhar ME, Ewing G, Booth S. Using mixed methods to develop and 
evaluate complex interventions in palliative care research. Palliative Medicine. 
2011;25(8):748-57. 
56. Bressan V, Bagnasco A, Aleo G, Timmins F, Barisone M, Bianchi M, Pellegrini 
R, Sasso L. Mixed-methods research in nursing – a critical review. Journal of 
Clinical Nursing. 2017;26(19-20):2878-90. 
57. Strömberg A. The crucial role of patient education in heart failure. European 
Journal of Heart Failure. 2005;7(3):363-9. 
58. Artinian NT, Magnan M, Christian W, Lange MP. What do patients know about 
their heart failure? Appl Nurs Res. 2002;15(4):200-8 
59. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, 
et al. ESC guidelines for the diagnosis and treatment of acute and chronic 
heart failure 2012:. European journal of Heart Failure. 2012;14(8):803-69. 
60. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 
2013 ACCF/AHA guideline for the management of heart failure. Journal of the 
American College of Cardiology. 2013;62(16):e147-239. 
61. Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of 
heart failure in elderly patients. Clinics in Geriatric Medicine. 2000;16(3):445-
56. 
62. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: 
a population-based case-control study. The American Journal of Medicine. 
2009;122(11):1023-8. 
63. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. 
Obesity and the risk of heart failure. The New England Journal of Medicine. 
2002;347(5):305-13. 
64. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors 
for congestive heart failure in US men and women: NHANES I epidemiologic 
follow-up study. Archives of Internal Medicine. 2001;161(7):996-1002. 





66. Eriksson H, Svardsudd K, Larsson B, Ohlson LO, Tibblin G, Welin L, et al. Risk 
factors for heart failure in the general population: the study of men born in 
1913. European Heart Journal. 1989;10(7):647-56. 
67. Ho KKL, Pinsky JL, Kannel WB, Levy D, Pitt B. The epidemiology of heart 
failure: The Framingham Study. Journal of the American College of 
Cardiology. 1993;22(4s1):A6-A13. 
68. Sundström J, Lind L, Vessby B, Andrén B, Aro A, Lithell HO. Dyslipidemia and 
an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years 
later. Circulation. 2001;103(6):836-41. 
69. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, 
Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for 
Congestive Heart Failure in the Framingham Heart Study. Annals of Internal 
Medicine. 2003;138(1):10-6. 
70. Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K et al. Differences 
in the incidence of congestive heart failure by ethnicity: The multi-ethnic study 
of atherosclerosis. Archives of Internal Medicine. 2008;168(19):2138-45. 
71. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing 
diagnosis in heart failure: which features are any use? QJM. 1997;90(5):335-
9. 
72. Fonseca C, Morais H, Mota T, Matias F, Costa C, Gouveia-Oliveira A, et al. 
The diagnosis of heart failure in primary care: value of symptoms and signs. 
European Journal of Heart Failure. 2004;6(6):795-800. 
73. Stevenson L, Perloff JK. The limited reliability of physical signs for estimating 
hemodynamics in chronic heart failure. JAMA. 1989;261(6):884-8. 
74. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–659.  
75.  National Institute for Health and Care Excellence (2018). Management of 
chronic heart failure in adults: diagnosis and management [NICE Guideline 





76. Cowie MR. The heart failure epidemic: A UK perspective. Echo Research and 
Practice. 2017;4(1):R15-R20. 
77. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito 
JM, Vasan RS. Long-term trends in the incidence of and survival with heart 
failure. New England Journal of Medicine. 2002;347(18):1397-402. 
78. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. 
Temporal trends and patterns in heart failure incidence: A population-based 
study of 4 million individuals. The Lancet. 2018;391(10120):572-80. 
79. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in Comorbidity, 
Disability, and Polypharmacy in Heart Failure. The American Journal of 
Medicine. 2011;124(2):136-43. 
80. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology 
of multimorbidity and implications for health care, research, and medical 
education: a cross-sectional study. Lancet.  2012; 7;380(9836):37-43. 
81. Archana R, Gray D. The quality of life in chronic disease--heart failure is as 
bad as it gets. European Heart Journal. 2002;23(23):1806-8. 
82. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ 
than cancer? Five-year survival following a first admission for heart failure. 
European Journal of Heart Failure. 2001;3(3):315-22. 
83. Townsend N WK, Bhatnagar P, Smolina K, Nichols M, Leal J, Luengo-
Fernandez R, Rayner M. Coronary heart disease statistics 2012 edition. British 
Heart Foundation: London. 2012. 
84. Macintyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, et al. 
Evidence of improving prognosis in heart failure: trends in case fatality in 66 
547 patients hospitalized between 1986 and 1995. Circulation. 
2000;102(10):1126. 
85. Cleland J, Dargie H, Hardman S, McDonagh T, Mitchell P. National Heart  




86. Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Suresh 
V, et al. Incidence and aetiology of heart failure; a population-based study. 
European Heart Journal. 1999;20(6):421-8. 
87. Davies MK, Hobbs FD, Davis RC, Kenkre JE, Roalfe AK, Hare R, et al. 
Prevalence of left-ventricular systolic dysfunction and heart failure in the 
Echocardiographic Heart of England Screening study: a population based 
study. Lancet. 2001;358(9280):439-44. 
88. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme 
inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 
1999: the end of an epidemic? Heart. 2002;87(1):75-6. 
89. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: 
long-term implications on readmission and survival. Circulation. 
2002;105(24):2861-6. 
90. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, 
et al. Hospitalizations after heart failure diagnosis a community perspective. J 
Am Coll Cardiol.  2009;54(18):1695-702. 
91. Nicol ED, Fittall B, Roughton M, Cleland JGF, Dargie H, Cowie MR. NHS heart 
failure survey: a survey of acute heart failure admissions in England, Wales 
and Northern Ireland. Heart. 2008;94(2):172-7. 
92. Krumholz HM. Post-Hospital Syndrome — An Acquired, Transient Condition 
of Generalized Risk. New England Journal of Medicine. 2013;368(2):100-2. 
93. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among Patients in 
the Medicare Fee-for-Service Program. New England Journal of Medicine. 
2009;360(14):1418-28. 
94. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic 
heart failure. Pharmacoeconomics. 1996;9(3):188-97. 
95. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A 
multidisciplinary intervention to prevent the readmission of elderly patients with 




96. Murray SA, Kendall M, Grant E, Boyd K, Barclay S, Sheikh A. Patterns of 
social, psychological, and spiritual decline toward the end of life in lung cancer 
and heart failure. Journal of pain and symptom management. 2007 
1;34(4):393-402 
97. Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in 
the elderly: role of adverse drug reactions and non-compliance. Postgrad Med 
J. 2001;77(913):703-7. 
98. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in 
heart failure: meta-analysis of randomized controlled trials. Journal of the 
American College of Cardiology. 2002;39(3):463-70. 
99. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect 
of spironolactone on morbidity and mortality in patients with severe heart 
failure. Randomized Aldactone Evaluation Study Investigators. The New 
England Journal of Medicine. 1999;341(10):709-17. 
100. de Milliano PAR, Tijssen JGP, van Zwietwn PA, Lie KI. Beta blockers in heart 
failure haemodynamics, clinical effects and modes of action. Neth Heart J. 
2001;9(8). 
101. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et 
al. Quality of life among 5,025 patients with left ventricular dysfunction 
randomized between placebo and enalapril: the Studies of Left Ventricular 
Dysfunction. The SOLVD Investigators. J Am Coll Cardiol. 1994;23(2):393-
400. 
102. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart 
Failure questionnaire as a measure of therapeutic response to enalapril or 
placebo. The American Journal of cardiology. 1993;71(12):1106-7. 
103. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New 





104. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart 
failure: The Task Force for the diagnosis and treatment of acute and chronic 
heart failure of the European Society of Cardiology (ESC). European Journal 
of Heart Failure. 2016;18(8):891-975. 
105.  Zhang Y, &  Li K. Use of Implantable Cardioverter Defibrillators in Heart Failure 
Patients and Risk of Mortality: A Meta-Analysis. Medical science monitor : 
international medical journal of experimental and clinical research. 2015,(21): 
1792–1797 
106. Mahendiran T, Gosling OE, Newton J, Giblett D, Mckenzie D, Dayer M, Newton 
J, Mckenzie D. Latest NICE guidelines on CRT and ICD devices in heart failure 
May significantly increase implant rates. Br J Cardiol. 2015;22:155 
107. National Institute for Health and Care Excellence (2014). Implantable 
cardioverter defibrillators and cardiac resynchronisation therapy for 
arrhythmias and heart failure (NICE Guideline TA314). Available at 
https://www.nice.org.uk/guidance/ta314 [Accessed 01 October 2019]. 
108. Nicholls MG, Richards AM; Christchurch Cardioendocrine Research Group. 
Disease monitoring of patients with chronic heart failure. Heart. 2007;93 
(4):519-23.  
109. Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart 
failure management. Heart. 2018;104(16):1376-82. 
110. Price A. Specialist nurses improve outcomes in heart failure. Nursing times. 
2012;108(40):22-4. 
111. Toukhsati SR, Driscoll A, Hare DL. Patient Self-management in Chronic Heart 
Failure - Establishing Concordance Between Guidelines and Practice. Card 
Fail Rev. 2015;1(2):128–131. 
112. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to 
treatment: three decades of research. A comprehensive review. Journal of 




113. McDonald HP, Garg AX, Haynes RB. Interventions to Enhance Patient 
Adherence to Medication Prescriptions: Scientific Review. JAMA. 
2002;288(22):2868 - 679. 
114. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. 
Assessing medication adherence in the elderly: which tools to use in clinical 
practice? Drugs & Aging.  2005;22(3):231-55. 
115. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: 
recommendations for a call to action. A statement for healthcare professionals. 
Circulation. 1997;95(4):1085-90. 
116. Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: Factors influencing 
compliance with prescribed medication plans. The Case Manager. 
2005;16(2):47-51. 
117. Marinker M. Personal paper: writing prescriptions is easy. BMJ. 
1997;314(7082):747. 
118. Aronson JK. Compliance, concordance, adherence. British Journal of Clinical 
Pharmacology. 2007;63(4):383-4. 
119. Bell JS, Airaksinen MS, Lyles A, Chen TF, Aslani P. Concordance is not 
synonymous with compliance or adherence. Br J Clin Pharmacol. 2007; 
64(5):710-1. 
120. Wu J-R, Moser DK, De Jong MJ, Rayens MK, Chung ML, Riegel B, et al. 
Defining an evidence-based cutpoint for medication adherence in heart failure. 
American Heart Journal. 2009;157(2):285-91. 
121. Nieuwenhuis MMW, Jaarsma T, van Veldhuisen DJ, van der Wal MHL. Self-
reported versus ‘true’ adherence in heart failure patients: a study using the 
Medication Event Monitoring System. Netherlands Heart Journal. 
2012;20(7):313-9. 
122. Struthers AD, Anderson G, MacFadyen RJ, Fraser C, MacDonald TM. 
Nonadherence with ACE Inhibitors Is Common and Can Be Detected in 





123. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and 
improving medication adherence in heart failure patients. Journal of Managed 
Care Pharmacy. 2014;20(7):741-55. 
124. Farmer KC. Methods for measuring and monitoring medication regimen 
adherence in clinical trials and clinical practice. Clinical Therapeutics. 
1999;21(6):1074-90. 
125. Raynor DK. Patient compliance: the pharmacist's role. International Journal of 
Pharmacy Practice. 1992;1(3):126-35. 
126. Dunbar-Jacob J, Sereika SM, Houze M, Luyster FS, Callan JA. Accuracy of 
measures of medication adherence in a cholesterol-lowering regimen. 
Western Journal of Nursing Research. 2012;34(5):578-97. 
127. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in 
cardiovascular outcomes. Circulation. 2009;119(23): 3028 -35. 
128. Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber LS, et al. 
Differences in cardiovascular disease risk when antihypertensive medication 
adherence is assessed by pharmacy fill versus self-report: The Cohort Study 
of Medication Adherence among Older Adults (CoSMO). Journal of 
Hypertension. 2015;33(2):412-20. 
129. Lam WY, Fresco P. Medication Adherence Measures: An Overview. BioMed 
Research International. 2015;2015:12. 
130. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is 
medication taken as prescribed? A novel assessment technique. JAMA. 
1989;261(22):3273-7. 
131. Bond W, Hussar D. Detection methods and strategies for improving medication 
compliance. American Journal of Health-System Pharmacy. 1991;48(9):1978-
88. 
132. Riegel B, Knafl GJ. Electronically monitored medication adherence predicts 





133. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. 
Oman Medical Journal. 2011;26(3):155-9. 
134. Kucukarslan SN. A review of published studies of patients' illness perceptions 
and medication adherence: lessons learned and future directions. Res Social 
Adm Pharm. 2012 Sep-Oct;8(5):371-82. 
135. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review 
of recent research. Clin Pharmacokinet. 1994 Sep;27(3):202-15. 
136. Stehlik J, Taylor DO. And an ARB makes nine: polypharmacy in patients with 
heart failure. Cleveland Clinic Journal of Medicine. 2004;71(8):674-7. 
137. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with 
Congestive-Heart-Failure Therapy in the Elderly. Archives of Internal 
Medicine. 1994;154(4):433-7. 
138. Cline CM, Bjorck-Linne AK, Israelsson BY, Willenheimer RB, Erhardt LR. Non-
compliance and knowledge of prescribed medication in elderly patients with 
heart failure. European Journal of Heart Failure. 1999;1(2):145-9. 
139. O'Neill C, Coughlan D. Importance of Adherence and the Role of Nonfinancial 
Barriers. Clinical Therapeutics.2011;33(9):1222-4. 
140. Hilleman DE, Campbell JA. Medication Adherence in Heart Failure. In: Bakris 
GL, editor. The Kidney in Heart Failure. Boston, MA: Springer US; 2012. p. 
183-202. 
141. Col N, Fanale JE, Kronholm P. The Role of Medication Noncompliance and 
Adverse Drug Reactions in Hospitalizations of the Elderly. Archives of Internal 
Medicine. 1990;150(4):841-5. 
142. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital 







143. Annema C, Luttik ML, Jaarsma T. Reasons for readmission in heart failure: 
Perspectives of patients, caregivers, cardiologists, and heart failure nurses. 
Heart & Lung. 2009;38(5):427-34.144. Ambardekar AV, Fonarow GC, 
Hernandez AF, Pan W, Yancy CW, Krantz MJ, et al. Characteristics and in-
hospital outcomes for nonadherent patients with heart failure: findings from 
Get With The Guidelines-Heart Failure (GWTG-HF). American Heart Journal. 
2009;158(4):644-52. 
145. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch 
P, et al. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure 
Is Associated With Improved Outcomes. Circulation. 2007;116(7):737-44. 
146. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term 
ACE-inhibitor therapy in patients with heart failure or left-ventricular 
dysfunction: a systematic overview of data from individual patients. The 
Lancet. 2000;355(9215):1575-81. 
147. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJV, 
et al. Adherence to candesartan and placebo and outcomes in chronic heart 
failure in the CHARM programme: double-blind, randomised, controlled clinical 
trial. The Lancet. 2005;366(9502):2005-11. 
148. Hughes CM. Medication Non-Adherence in the Elderly. Drugs & Aging. 
2004;21(12):793-811. 
149. van der Wal MHL, Jaarsma T. Adherence in heart failure in the elderly: 
Problem and possible solutions. International Journal of Cardiology. 
2008;125(2):203-8. 
150. Ekman I, Fagerberg B, Lundman B. Health-related quality of life and sense of 
coherence among elderly patients with severe chronic heart failure in 







151. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of 
heart failure and left ventricular systolic dysfunction on quality of life. A cross-
sectional study comparing common chronic cardiac and medical disorders and 
a representative adult population. European Heart Journal. 2002;23(23):1867-
76. 
152. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. 
Health related quality of life in patients with congestive heart failure: 
comparison with other chronic diseases and relation to functional variables. 
Heart. 2002;87(3):235-41. 
153. Coelho R, Ramos S, Prata J, Bettencourt P, Ferreira A, Cerqueira-Gomes M. 
Heart failure and health related quality of life. Clinical Practice and 
Epidemiology in Mental Health. 2005;1:19-. 
154. Holt EW, Muntner P, Joyce CJ, Webber L, Krousel-Wood MA. Health-related 
quality of life and antihypertensive medication adherence among older adults. 
Age and Ageing. 2010;39(4):481-7. 
155. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. 
Baseline Quality of Life as a Predictor of Mortality and Hospitalization in 5,025 
Patients With Congestive Heart Failure. American Journal of Cardiology. 
2017;78(8):890-5. 
156. Unverzagt S, Meyer G, Mittmann S, Samos F-A, Unverzagt M, Prondzinsky R. 
Improving Treatment Adherence in Heart Failure: A Systematic Review and 
Meta-analysis of Pharmacological and Lifestyle Interventions. Deutsches 
Ärzteblatt International. 2016;113(25):423-30. 
157. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. 
The epidemiology of multimorbidity in primary care: a retrospective cohort 
study. Br J Gen Pract. 2018 Apr;68(669):e245-e51. 






159. Nunes V NJ, O’Flynn N, Calvert N, Kuntze S, Smithson H, Benson J, et al. 
Clinical Guidelines and Evidence Review for Medicines Adherence: involving 
patients in decisions about prescribed medicines and supporting adherence. 
Other. NICE: National Institute for Health and Clinical Excellence, London, UK.  
160. Leventhal MJE, Riegel B, Carlson B, De Geest S. Negotiating Compliance in 
Heart Failure: Remaining Issues and Questions. European Journal of 
Cardiovascular Nursing. 2005;4(4):298-307. 
161. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic 
disadvantage and primary non-adherence with medication in Sweden. 
International Journal for Quality in Health Care. 2007;19(3):134-40. 
162. Langley CA, Bush J. The Aston Medication Adherence Study: mapping the 
adherence patterns of an inner-city population. International Journal of Clinical 
Pharmacy. 2014;36(1):202-11. 
163. Dunbar-Jacob J, Bohachick P, Mortimer MK, Sereika SM, Foley SM. 
Medication Adherence in Persons With Cardiovascular Disease. Journal of 
Cardiovascular Nursing. 2003;18(3):209-18. 
164. Rockwell JM, Riegel B. Predictors of self-care in persons with heart failure. 
Heart & Lung. 2001;30(1):18-25. 
165. Simpson SH, Farris KB, Johnson JA, Tsuyuki RT. Using focus groups to 
identify barriers to drug use in patients with congestive heart failure. 
Pharmacotherapy. 2000;20(7):823-9. 
166. Sayers SL, Riegel B, Pawlowski S, Coyne JC, Samaha FF. Social support and 
self-care of patients with heart failure. Ann Behav Med. 2008;35(1):70-9. 
167. Wu J-R, Moser DK, Lennie TA, Peden AR, Chen Y-C, Heo S. Factors 
influencing medication adherence in patients with heart failure. Heart & Lung. 
2008;37(1):8. 
168. Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence 
using a multidimensional adherence model in patients with heart failure. 




169. Simpson SH, Johnson JA, Farris KB, Tsuyuki RT. Development and validation 
of a survey to assess barriers to drug use in patients with chronic heart failure. 
Pharmacotherapy. 2002;22(9):1163-72. 
170. Evangelista LS, Berg J, Dracup K. Relationship between psychosocial 
variables and compliance in patients with heart failure. Heart Lung. 
2001;30(4):294-301. 
171. Rodgers PT, Ruffin DM. Medication nonadherence: Part II-A pilot study in 
patients with congestive heart failure. Manag Care Interface. 1998;11(9):67-9. 
172. Schulz RM, Lingle EW, Chubon SJ, Coster-Schulz MA. Drug use behavior 
under the constraints of a medicaid prescription cap. Clinical Therapeutics. 
1995;17(2):330-40. 
173. Hicks FD, Holm K. Self-Management Decision Influences in Heart Failure: A 
Preliminary Investigation. Clinical Nursing Research. 2003;12(1):69-84. 
174. Wu J-R, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients 
who have heart failure: a review of the literature. The Nursing Clinics of North 
America. 2008;43(1):133-53; vii-viii. 
175. Bagchi AD, Esposito D, Kim M, Verdier J, Bencio D. Utilization of and 
adherence to, drug therapy among medicaid beneficiaries with congestive 
heart failure. Clinical Therapeutics. 2007;29(8):1771-83. 
176. Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, et 
al. Adherence to medication according to sex and age in the CHARM 
programme. Eur J Heart Fail. 2009;11(11):1092-8. 
177. Cholowski K, Cantwell R. Predictors of medication compliance among older 
heart failure patients. International Journal of Older People Nursing. 
2007;2(4):250-62. 
178. Morgan AL, Masoudi FA, Havranek EP, Jones PG, Peterson PN, Krumholz 
HM, et al. Difficulty Taking Medications, Depression, and Health Status in 




179. Tang H, Sayers S, Weissinger G, Riegel B. The Role of Depression in 
Medication Adherence Among Heart Failure Patients. Clinical Nursing 
Research. 2014;23(3):231-44. 
180. Carney RM, Freeland KE, Eisen SA, Rich MW, Jaffe AS. Major depression 
and medication adherence in elderly patients with coronary artery disease. 
Health Psychology. 1995;14(1):88-90. 
181. Evangelista L, Doering LV, Dracup K, Westlake C, Hamilton M, Fonarow GC. 
Compliance behaviors of elderly patients with advanced heart failure. The 
Journal of Cardiovascular Nursing. 2003;18(3):197. 
182. Riegel B, Carlson B. Facilitators and barriers to heart failure self-care. Patient 
Education and Counseling. 2002;46(4):287-95. 
183. Riegel B, Lee CS, Ratcliffe SJ, De Geest S, Potashnik S, Patey M, et al. 
Predictors of objectively measured medication nonadherence in adults with 
heart failure. Circulation Heart failure. 2012;5(4):430-6. 
184. Bohachick P, Burke LE, Sereika S, Murali S, Dunbar-Jacob J. Adherence to 
Angiotensin-Converting Enzyme Inhibitor Therapy for Heart Failure. Progress 
in Cardiovascular Nursing. 2002;17(4):160-6. 
185. Toh CT, Jackson B, Gascard DJ, Manning AR, Tuck EJ. Barriers to medication 
adherence in chronic heart failure patients during home visits. Journal of 
Pharmacy Practice & Research. 2010;40(1):27-30. 
186. Muzzarelli S, Brunner-La Rocca H, Pfister O, Foglia P, Moschovitis G, 
Mombelli G, et al. Adherence to the medical regime in patients with heart 
failure. Eur J Heart Fail. 2010;12(4):389-96. 
187. Stromberg A, Brostrom A, Dahlstrom U, Fridlund B. Factors influencing patient 
compliance with therapeutic regimens in chronic heart failure: A critical incident 
technique analysis. Heart & Lung. 1999;28(5):334-41. 
188. Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication 
Adherence Among Community-Dwelling Patients With Heart Failure. Mayo 




189. Schweitzer RD, Head K, Dwyer JW. Psychological factors and treatment 
adherence behavior in patients with chronic heart failure. Journal of 
Cardiovascular Nursing. 2007;22(1):76-83. 
190. Hawkins LA, Kilian S, Firek A, Kashner TM, Firek CJ, Silvet H. Cognitive 
impairment and medication adherence in outpatients with heart failure. Heart 
& Lung. 2012;41(6):572-82. 
191. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to 
hospital admission with decompensated heart failure. Heart. 1998;80(5):437-
41. 
192. Ni H, Nauman D, Burgess D, Wise K, Crispell K, Hershberger RE. Factors 
Influencing Knowledge of and Adherence to self-care Among Patients With 
Heart Failure. Archives of Internal Medicine. 1999;159(14):1613-9. 
193. Welsh JD, Heiser RM, Schooler MP, Brockopp DY, Parshall MB, Cassidy KB, 
et al. Characteristics and treatment of patients with heart failure in the 
emergency department. Journal Of Emergency Nursing. 2002;28(2):126-31. 
194. Albert NM, Levy P, Langlois E, Nutter B, Yang D, Kumar VA, et al. Heart Failure 
Beliefs and Self-Care Adherence While Being Treated in an Emergency 
Department. The Journal of Emergency Medicine. 2014;46(1):122-9. 
195. Percival M, Cottrell WN, Jayasinghe R. Exploring the beliefs of heart failure 
patients towards their heart failure medicines and self care activities. 
International Journal of Clinical Pharmacy. 2012 ;34(4):618-25. 
196. Sayers SL, White T, Zubritsky C, Oslin DW. Family involvement in the care of 
healthy medical outpatients. Family Practice. 2006;23(3):317-24. 
197. Murbeg TE, Bu E, Svebak S, Tveteras R, Aarsland T. Depressed mood and 
subjective health symptoms as predictors of mortality in patients with 
congestive heart failure a two-years follow-uip study. Int'l J Psychiatry in 
Medicine. 1999;29(3):311-26. 
198. Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb SS. 
Relationship of depression, anxiety, and social isolation to chronic heart failure 




199. DiMatteo MR. Social Support and Patient Adherence to Medical Treatment: A 
Meta-Analysis. Health Psychology. 2004;23(2):207-18. 
200. Chui MA, Deer M, Bennett SJ, Tu W, Oury S, Brater DC, et al. Association 
Between Adherence to Diuretic Therapy and Health Care Utilization in Patients 
with Heart Failure. Pharmacotherapy. 2003;23(3):326-32. 
201. Ratzan SC. Health literacy: communication for the public good. Health 
Promotion International. 2001;16(2):207-14. 
202. Wills J. Health literacy: new packaging for health education or radical 
movement? International Journal of Public Health. 2009;54(1):3-4. 
203. Gazmararian JA, Williams MV, Peel J, Baker DW. Health literacy and 
knowledge of chronic disease. Patient Education and Counseling. 
2003;51(3):267-75. 
204. Wolf MS, Gazmararian JA, Baker DW. Health literacy and functional health 
status among older adults. Archives of Internal Medicine. 2005;165(17):1946-
52. 
205. Baker DW, Gazmararian JA, Williams MV, Scott T, Parker RM, Green D, et al. 
Functional health literacy and the risk of hospital admission among Medicare 
managed care enrollees. Am J Public Health. 2002;92(8):1278-83. 
206. Baker DW, Wolf MS, Feinglass J, Thompson JA, Gazmararian JA, Huang J. 
Health literacy and mortality among elderly persons. Arch Intern Med. 
2007;167(14):1503-9. 
207. Cajita MI, Cajita TR, Han H-R. Health Literacy and Heart Failure: A Systematic 
Review. Journal of Cardiovascular Nursing. 2016;31(2):121-30. 
208. Dewalt DA, Berkman ND, Sheridan S, Lohr KN, Pignone MP. Literacy and 
health outcomes: a systematic review of the literature. J Gen Intern Med. 
2004;19(12):1228-39. 
209. Noureldin M, Plake KS, Morrow DG, Tu W, Wu J, Murray MD. Effect of Health 
Literacy on Drug Adherence in Patients with Heart Failure. Pharmacotherapy: 




210. Mixon AS, Myers AP, Leak CL, Lou Jacobsen JM, Cawthon C, Goggins KM, 
et al. Characteristics Associated With Postdischarge Medication Errors. Mayo 
Clinic Proceedings. 2014;89(8):1042-51. 
211. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a 
review of systematic reviews. Frontiers in Pharmacology. 2013 2013;4(91). 
212. Goold SD, Lipkin M. The Doctor–Patient Relationship: Challenges, 
Opportunities, and Strategies. Journal of General Internal Medicine. 
1999;14(Suppl 1):S26-S33. 
213. Barello S, Graffigna G, Vegni E, Savarese M, Lombardi F, Bosio AC. ‘Engage 
me in taking care of my heart’: a grounded theory study on patient–cardiologist 
relationship in the hospital management of heart failure. BMJ Open. 
2015;5(3)e005582. 
214.  Bradley, E. and Nolan, P. Impact of nurse prescribing: a qualitative study. 
Journal of Advanced Nursing. 2007;59: 120-128 
215. Linn AJ, van Weert JC, van Dijk L, Horne R, Smit EG. The value of nurses’ 
tailored communication when discussing medicines: Exploring the relationship 
between satisfaction, beliefs and adherence. Journal of health psychology. 
2016;21(5):798-807. 
216. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev. 2008 
Feb;13(1):99-106. 
217. Zill JM, Christalle E, Müller E, Härter M, Dirmaier J, Scholl I. Measurement of 
Physician-Patient Communication—A Systematic Review. PLOS One. 
2014;9(12):e112637. 
218. Jerant A, Fenton JJ, Bertakis KD, Franks P. Satisfaction With Health Care 
Providers and Preventive Care Adherence: A National Study. Medical Care. 
2014;52(1):78-85. 
219. Meakin R, Weinman J. The ‘Medical Interview Satisfaction Scale’ (MISS-21) 




220. Britten N, Stevenson FA, Barry CA, Barber N, Bradley CP. Misunderstandings 
in prescribing decisions in general practice: qualitative study. BMJ. 
2000;320(7233):484-8. 
221. Haskard Zolnierek KB, DiMatteo MR. Physician Communication and Patient 
Adherence to Treatment: A Meta-analysis. Medical Care. 2009;47(8):826-34. 
222. Stavropoulou C. Non-adherence to medication and doctor–patient 
relationship: Evidence from a European survey. Patient Education and 
Counseling. 2011;83(1):7-13. 
223. Dharmarajan K, Dunlay SM. Multimorbidity in Older Adults with Heart Failure. 
Clinics in Geriatric Medicine. 2016;32(2):277-89. 
224. Bähler C, Huber CA, Brüngger B, Reich O. Multimorbidity, health care 
utilization and costs in an elderly community-dwelling population: A claims data 
based observational study. BMC Health Services Research. 2015;15(1):23. 
225. Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. 
Journal of Cardiac Failure. 2005;11(6):455-63. 
226. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart 
failure. Journal of the American College of Cardiology. 2006;48(8):1527-37. 
227. Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of 
depression in patients with congestive heart failure: A review of the literature. 
The Primary Care Companion for CNS Disorders. 2013;15(4):PCC.13r01511. 
228. DeWolfe A, Gogichaishvili I, Nozadze N, Tamariz L, Quevedo HC, Julian E, et 
al. Depression and quality of life among heart failure patients in Georgia, 
Eastern Europe. Congestive Heart Failure. 2012;18(2):107-11. 
229. Rumsfeld JS, Havranek E, Masoudi FA, Peterson ED, Jones P, Tooley JF, et 
al. Depressive symptoms are the strongest predictors of short-term declines in 
health status in patients with heart failure. Journal of the American College of 
Cardiology. 2003;42(10):1811-7. 
230. Koenig HG. Depression in hospitalized older patients with congestive heart 




231. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: Meta-analysis of the effects of anxiety 
and depression on patient adherence. Archives of Internal Medicine. 
2000;160(14):2101-7. 
232. Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL, et 
al. Effects of Depression and Anxiety Improvement on Adherence to 
Medication and Health Behaviors in Recently Hospitalized Cardiac Patients. 
The American Journal of Cardiology. 2012;109(9):1266-71. 
233. MacMahon KA, Lip GH. Psychological factors in heart failure: A review of the 
literature. Archives of Internal Medicine. 2002;162(5):509-16. 
234. Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL, 
et al. Prognostic Value of Anxiety and Depression in Patients With Chronic 
Heart Failure. Circulation. 2004;110(22):3452-6. 
235. Haworth JE, Moniz-Cook E, Clark AL, Wang M, Cleland JGF. An evaluation of 
two self-report screening measures for mood in an out-patient chronic heart 
failure population. International Journal of geriatric Psychiatry. 
2007;22(11):1147. 
236. Moser DK, Dracup K, Evangelista LS, Zambroski CH, Lennie TA, Chung ML, 
et al. Comparison of prevalence of symptoms of depression, anxiety, and 
hostility in elderly patients with heart failure, myocardial infarction, and a 
coronary artery bypass graft. Heart & Lung. 2010;39(5):378-85. 
237. Clarke SP, Frasure-Smith N, Lesperance F, Bourassa M. Psychosocial factors 
as predictors of functional status at 1 year in patients with left ventricular 
dysfunction. Res Nurs Health. 2000;23(4):290-300. 
238. Frasure-Smith N, Lesperance F, Talajic M. The Impact of Negative Emotions 
on Prognosis Following Myocardial Infarction: Is It More Than Depression. 
Health Psychology. 1995;14(5):388-98. 
239. Moser DK, Dracup K. Is Anxiety Early after Myocardial Infarction Associated 





240. Rushton C, Kadam UT. Polypharmacy in heart failure: A growing challenge. 
British Journal of Cardiac Nursing. 2011;6(5):214-20. 
241. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing 
frequency and medication adherence in chronic disease. Journal of Managed 
Care Pharmacy 2012;18(7):527. 
242. Coleman CI, Roberts M, Sobieraj D, Lee S, Alam T, Kaur R. Effect of dosing 
frequency on chronic cardiovascular disease medication adherence. Current 
Medical Research and Opinion. 2012; 28(5):669-80. 
243. Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordronneau P, 
Lukas MA, et al. Adherence with once daily versus twice daily carvedilol in 
patients with heart failure: the Compliance And Quality of Life Study 
Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily 
Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) 
Trial. Journal of Cardiac Failure. 2009;15(5):385-93. 
244. Kaplan RM, Simon HJ. Compliance in Medical Care: Reconsideration of Self-
Predictions. Annals of Behavioral Medicine. 1990;12(2):66-71. 
245. Krueger K, Botermann L, Schorr SG, Griese-Mammen N, Laufs U, Schulz M. 
Age-related medication adherence in patients with chronic heart failure: A 
systematic literature review. International Journal Of Cardiology. 
2015;184:728-35. 
246. Manteuffel ME, Steinkellner AR, Williams S, Chen W. Influence of patient sex 
and gender on medication use, adherence and prescribing alignment with 
guidelines. Journal of Womens Health. 2012;21(4):112-9. 
247. Setoguchi S, Choudhry NK, Levin R, Shrank WH, Winkelmayer WC. Temporal 
trends in adherence to cardiovascular medications in elderly patients after 
hospitalization for heart failure. Clinical Pharmacology and Therapeutics. 
2010;88:548-54. 
248. Lee D, Mansi I, Bhushan S, Parish R. Non-adherence in at-risk heart failure 





249. Hajduk AM, Lemon SC, McManus DD, Lessard DM, Gurwitz JH, Spencer FA, 
et al. Cognitive impairment and self-care in heart failure. Clinical Epidemiology. 
2013 23;5(1):407-16. 
250. Cameron J, Worrall-Carter L, Page K, Riegel B, Lo SK, Stewart S. Does 
cognitive impairment predict poor self-care in patients with heart failure? 
European Journal of Heart Failure. 2010;12(5):508-15. 
251. Vogels RLC, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive 
impairment in heart failure: A systematic review of the literature. European 
Journal of Heart Failure. 2007;9(5):440-9. 
252. Huynh QL, Negishi K, Blizzard L, Saito M, De Pasquale CG, Hare JL, et al. 
Mild cognitive impairment predicts death and readmission within 30days of 
discharge for heart failure. International Journal of Cardiology. 
2016;221(Supplement C):212-7. 
253. Dunbar SB, Jacobson LH, Deaton C. Heart failure: strategies to enhance 
patient self-management. AACN Clinical Issues. 1998;9(2):244-56. 
254. Sneed NV, Paul SC. Readiness for behavioral changes in patients with heart 
failure. American Journal of Respiratory and Critical Care Medicine. 
2003;12(5):444-53. 
255. Balkrishnan R. Predictors of medication adherence in the elderly. Clinical 
Therapeutics. 1998;20(4):764-71. 
256. Schüz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, Schwarzer R, et al. 
Medication beliefs predict medication adherence in older adults with multiple 
illnesses. Journal of Psychosomatic Research. 2011;70(2):179-87. 
257. Holt EW, Rung AL, Leon KA, Firestein C, Krousel-Wood MA. Medication 
Adherence in Older Adults: A Qualitative Study. Educ Gerontol. 
2014;40(3):198-211. 
258. McHorney CA, Spain CV. Frequency of and reasons for medication non-
fulfillment and non-persistence among American adults with chronic disease 




259. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for 
enhancing medication adherence. Cochrane Database Syst Rev. 
2008;2(2):CD000011. 
260. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, 
Spiegelhalter D, et al. Framework for design and evaluation of complex 
interventions to improve health. BMJ. 2000;321(7262):694-6. 
261. Leventhal H, Cameron L. Behavioral Theories and the Problem of Compliance. 
Patient Education and Counseling. 1987;10(2):117-38. 
262. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ 
Q. 1984;11(1):1-47. 
263. Janz NK, Champion VL, Strecher VJ. The Health Belief Model In: Glanz K, 
Rimer B, Lewis F, editors. Health behavior and health education: Theory, 
research, and practice. San Francisco: Jossey-Bass; 2002. p. 45-66. 
264. Jones CJ, Smith H, Llewellyn C. Evaluating the effectiveness of health belief 
model interventions in improving adherence: a systematic review. Health 
Psychology Review. 2014;8(3):253-69. 
265. Hershey JC, Morton BG, Davis JB, Reichgott MJ. Patient compliance with 
antihypertensive medication. Am J Public Health.   1980;70(10):1081-9. 
266. Becker MH, Radius SM, Rosenstock IM, Drachman RH, Schuberth KC, Teets 
KC. Compliance with a medical regimen for asthma: a test of the health belief 
model. Public Health Reports. 1978;93(3):268-77. 
267. Alogna M. Perception of Severity of Disease and Health Locus of Control in 
Compliant and Noncompliant Diabetic Patients. Diabetes Care.1980;3(4):533-
4. 
268. Baghianimoghadam MH, Shogafard G, Sanati HR, Baghianimoghadam B, 
Mazloomy SS; Askarshahi M. Application of the Health Belief model in 
Promotion of Self-care in Heart Failure Patients. Acta Medica Iranica. 
2013;51(1):52-8. 
269. George J, Shalansky SJ. Predictors of refill non-adherence in patients with 




270. Weinman JH, R. Appendix 4: Psychological models of treatment adherence: a 
brief overview. Report for the National Co-ordinating Centre for NHS Service 
Delivery and Organisation R & D (NCCSDO); 2005. 
271. Ajzen I. The Theory of Planned Behaviour. Organisational Behaviour and 
Human Decision Processes. 1991;50:179-211. 
272. Rich A, Brandes K, Mullan B, Hagger MS. Theory of planned behavior and 
adherence in chronic illness: a meta-analysis. Journal of Behavioral Medicine. 
2015;38(4):673-88. 
273. Farmer A, Hardeman W, Hughes D, Prevost A, Kim Y, Craven A, et al. An 
explanatory randomised controlled trial of a nurse-led, consultation-based 
intervention to support patients with adherence to taking glucose lowering 
medication for type 2 diabetes. BMC Family Practice. 2012;13(1):30. 
274. Lawrence M, Kerr S, Watson H, Paton G, Ellis G. An exploration of lifestyle 
beliefs and lifestyle behaviour following stroke: findings from a focus group 
study of patients and family members. BMC Family Practice. 2010;11(1):97. 
275. De Bruin M, Hospers HJ, Van Den Borne HW, Kok G, Prins JM. Theory and 
evidence-based intervention to improve adherence to antiretroviral therapy 
among HIV-infected patients in the Netherlands: A pilot study. AIDS Patient 
Care and STDs. 2005;19(6):384-94. 
276. Wu J-R, Lennie TA, Dunbar SB, Pressler SJ, Moser DK. Does the Theory of 
Planned Behavior Predict Dietary Sodium Intake in Patients With Heart 
Failure? Western Journal of Nursing Research. 2017;39(4):568-81. 
277. Wu J-R, Corley DJ, Lennie TA, Moser DK. Effect of a medication-taking 
behavior feedback theory-based intervention on outcomes in patients with 
heart failure. Journal Of Cardiac Failure. 2012;18(1):1-9. 
278. Welsh D, Lennie TA, Marcinek R, Biddle MJ, Abshire D, Bentley B, et al. Low-
sodium diet self-management intervention in heart failure: pilot study results. 




279. McEachan RR, Conner M, Taylor N, Lawton R. Prospective Prediction of 
Health-related Behaviours with the Theory of Planned Behaviour: A Meta-
analysis. Health Psychology Review. 2011;5(2):97-144. 
280. Conner M, Sparks P. Theory of Planned Behaviour and Health Behaviour. In: 
Conner M, Norman P, editors. Predicting Health Behaviour. 2nd ed: Open 
University Press; 2005. p.170-222. 
281. Kaptein A, Scharloo M, Helder D, Kleijn W, vanKorlarr I, Woertman M. 
Representations of chronic illness. In: Cameron LD, Leventhal H, editors. The 
self regulation of health and illness behaviour; 2003. p.97-118. 
282. Petrie KJ, Weinman J. Why illness perceptions matter. Clinical Medicine. 
2006;6(6):536-9. 
283. Zeidner M, Boekaerts M, Pintrich PR. Self regulation: diections and challenges 
for future research. Handbook of self-regulation; 2000. p.750-68. 
284. Cameron L, Leventhal H. Self-regulation, health and illness. In: Cameron L, 
Leventhal H, editors. The self-regulation of health and illness behaviour: 
Routledge; 2003. p.1-14. 
285. deRidder D, deWit J. Self-regulation in health behaviour. John Wiley & Sons; 
2006. 
286. Leventhal HB, Benyamini Y, Brownlee S, Diefenbach M, Leventhal E, Patrick-
Miller L, Robitille C. Illness Representations: Theorectical Foundations. In: 
Petrie KJ, Weinman J, editors. Perceptions of health and illness: Harwood 
academic publishers; 1997. p.19-46 
287. Leventhal H, Halm E, Horowitz C, Leventhal EA, Ozakinci G. Living with 
chronic illness: A contextualized, self-regulation approach. In: Sutton S, Baum 
A, Johnston M, editors. The Sage handbook of health psychology: Thousand 
Oaks; 2004. p.197-240. 





289. Cameron E, Moss-Moris R. Illness-Related cognition and Behaviour. In: 
French D, Vedhara K, Kaptein A, Weinman J, editors. Health Psychology. 
West Sussex: BPS Blackwell; 2010. p.149-61. 
290. Hagger MS, Orbell S. A meta-analytic review of the common-sense model of 
illness representations. Psychology & Health.  2003;18(2):141-84. 
291. MacInnes J. An exploration of illness representations and treatment beliefs in 
heart failure. Journal of Clinical Nursing. 2014;23(9-10): 1249-56. 
292. Voelmeck W. The relationship of illness representation and self-care behaviour 
to health related quality of life in older individuals with heart failure: University 
of Austin TX; 2006. 
293. MacInnes J. Relationships between illness representations, treatment beliefs 
and the performance of self-care in heart failure: a cross-sectional survey. 
European Journal of Cardiovascular Nursing. 2013;12(6):536-43. 
294. Cherrington CC, Lawson TN, Clark KB. Illness representation of patients with 
systolic heart failure. Progress in Cardiovascular Nursing. 2006;21(4):190-5. 
295. Albert NM, Zeller RA. Development and testing of the Survey of Illness Beliefs 
in Heart Failure tool. Progress in Cardiovascular Nursing. 2007;22(2):63-71. 
296. Leventhal H, Phillips LA, Burns E. The Common-Sense Model of Self-
Regulation (CSM): a dynamic framework for understanding illness self-
management. Journal of Behavioral Medicine. 2016;39(6):935-46. 
297. Ekman I, Andersson G, Boman K, Charlesworth A, Cleland JGF, Poole-Wilson 
P, et al. Adherence and perception of medication in patients with chronic heart 
failure during a five-year randomised trial. Patient Education and Counseling. 
2006;61(3):348-53. 
298. Riegel B, Dickson VV. A qualitative secondary data analysis of intentional and 
unintentional medication nonadherence in adults with chronic heart failure. 
Heart & Lung. 2016;45(6):468-74. 
299. Farmer KC. Leventhal's common-sense model and medication adherence. 




300. Bandura A. Theoretical Perspectives. In: Self-efficacy the exercise of control; 
Worth Publishers; 1997. p.1-10.  
301. Rajati F, Sadeghi M, Feizi A, Sharifirad G, Hasandokht T, Mostafavi F. Self-
efficacy strategies to improve exercise in patients with heart failure: A 
systematic review. ARYA atherosclerosis. 2014;10(6):319-33. 
302. Tsay SL, Chao YF. Effects of Perceived Self-Efficacy and Functional Status 
on Depression in Patients With Chronic Heart Failure. Journal of Nursing 
Research. 2002;10(4):271-8. 
303. Bandura A. Health Promotion by Social Cognitive Means. Health Education & 
Behavior. 2004;31(2):143-64. 
304. Yehle KS, Plake KS. Self-efficacy and Educational Interventions in Heart 
Failure: A Review of the Literature. Journal of Cardiovascular Nursing. 
2010;25(3):175-88. 
305. Peters-Klimm F, Freund T, Kunz CU, Laux G, Frankenstein L, Muller-Tasch T, 
et al. Determinants of heart failure self-care behaviour in community-based 
patients: a cross-sectional study. European Journal of Cardiovascular Nursing. 
2013;12(2):167-76. 
306. Schnell-Hoehn KN, Naimark BJ, Tate RB. Determinants of self-care behaviors 
in community-dwelling patients with heart failure. Journal of Cardiovascular 
Nursing. 2009;24(1):40-7. 
307. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping 
patients to follow prescriptions for medications. Cochrane Database Syst Rev. 
2002(2):Cd000011. 
308. Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions 
to improve medication adherence. JAMA. 2013;310(24):2611-2. 
309. Moher D, Tsertsvadze A, Tricco AC, Eccles M, Grimshaw J, Sampson M, et 
al. When and how to update systematic reviews. Cochrane Database Syst 
Rev. 2008(1):Mr000023. 
310. Centre for Reviews and Dissemination UoY. Systematic Reviews: CRD's 




311. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic 
review. Journal of the Royal Society of Medicine. 2003;96(3):118-21. 
312. Wright RW, Brand RA, Dunn W, Spindler KP. How to Write a Systematic 
Review. Clinical Orthopaedics and Related Research. 2007(455):23-9. 
313. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid 
lowering medication. Cochrane Database of Systematic Reviews. 
2010(3):CD004371 
314. Higgins JP, Deeks JJ. Selecting studies and collecting data. In Higgins JP, 
Altman D, editors. Cochrane handbook for systematic reviews of interventions: 
John Wiley & Sons; 2008. 
315. Higgins JP, Altman D. Assessng risk of bias in included srudies. In: Higgins 
JP, Altman D, editors. Cochrane handbook for systematic reviews of 
interventions: John Wiley & Sons Ltd; 2008. p.188-235. 
316. Akobeng AK. Understanding systematic reviews and meta-analysis. Archives 
of Disease in Childhood. 2005;90(8):845-8. 
317.  Fulton RL, Kroll T, McMurdo MET, Molloy G, Witham MD. Interventions to 
Improve medication adherence in heart failure - A systematic review. J Prev 
Card. 2017;6(3):1048-56 
318. GESICAInvestigators. Randomised trial of telephone intervention in chronic 
heart failure: DIAL trial. BMJ (Clinical Research Ed). 2005;331(7514):425-. 
319. Albert NM, Buchsbaum R, Li J. Randomized study of the effect of video 
education on heart failure healthcare utilization, symptoms, and self-care 
behaviors. Patient Education & Counseling. 2007;69(1-3):129-39. 
320. Bondmass MD. Improving outcomes for African Americans with chronic heart 
failure: a comparison of two home care management delivery methods. Home 
Health Care Management & Practice. 2007;20(1):8-20. 
321. Bowles KH, Hanlon AL, Glick HA, Naylor MD, O'Connor M, Riegel B, et al. 
Clinical Effectiveness, Access to, and Satisfaction with Care Using a 




International Journal of Telemedicine and Applications. 2011:540138. 
doi:10.1155/2011/540138 
322. Capomolla SP, Pinna GD, La Rovere MT, Maestri R, Ceresa M, Ferrari M, et 
al. Heart failure case disease management program: A pilot study of home 
telemonitoring versus usual care. European Heart Journal, Supplement. 
2004;6(6):F91-F8. 
323. Copeland LA, Berg GD, Johnson DM, Bauer RL. An intervention for VA 
patients with congestive heart failure. Am J Manag Care. 2010;16(3):158-65. 
324. Davis KK, Mintzer M, Dennison Himmelfarb CR, Hayat MJ, Rotman S, Allen J. 
Targeted intervention improves knowledge but not self-care or readmissions 
in heart failure patients with mild cognitive impairment. European Journal of 
Heart Failure. 2012;14(09):1041-9. 
325. de Lusignan S, Well S, Johnson P, Meredith K, Leatham E. Compliance and 
effectiveness of 1 year's home telemonitoring. The report of a pilot study of 
patients with chronic heart failure. European Journal of Heart Failure. 
2001;3(6):723-30 
326. Del Sindaco D, Pulignano G, Minardi G, Apostoli A, Guerrieri L, Rotoloni M, et 
al. Two-year outcome of a prospective, controlled study of a disease 
management programme for elderly patients with heart failure. Journal Of 
Cardiovascular Medicine. 2007;8(5):324-9. 
327. DeWalt DA, Broucksou KA, Hawk V, Baker DW, Schillinger D, Ruo B, et al. 
Comparison of a one-time educational intervention to a teach-to-goal 
educational intervention for self-management of heart failure: Design of a 
randomized controlled trial. BMC Health Services Research. 2009;9:99 
328. Dunagan WC, Littenberg B, Ewald GA, Jones CA, Emery VB, Waterman BM, 
et al. Randomized trial of a nurse-administered, telephone-based disease 
management program for patients with heart failure. Journal Of Cardiac 
Failure. 2005;11(5):358-65. 
329. Ferrante D, Varini S, Macchia A, Soifer S, Badra R, Nul D, et al. Long-term 




(Randomized Trial of Phone Intervention in Chronic Heart Failure) follow-up. 
Journal of the American College of Cardiology. 2010;56(5):372-8. 
330. Glatz J, Muschalla B, Karger G. Patient Education in Heart Failure Improves 
Disease-Related Knowledge and Behavior during Cardiac Rehabilitation. 
Rehabilitation. 2014;53(3):155-60. 
331. Heisler M, Halasyamani L, Cowen ME, Davis MD, Resnicow K, Strawderman 
RL, et al. Randomized controlled effectiveness trial of reciprocal peer support 
in heart failure. Circulation Heart Failure. 2013;6(2):246-53. 
332. Holst M, Willenheimer R, Mårtensson J, Lindholm M, Strömberg A. Telephone 
follow-up of self-care behaviour after a single session education of patients 
with heart failure in primary health care. European Journal of Cardiovascular 
Nursing. 2007;6(2):153-9. 
333. Hui E, Yang H, Chan LS, Or K, Lee DTF, Yu CM, et al. A community model of 
group rehabilitation for older patients with chronic heart failure: a pilot study. 
Disability & Rehabilitation. 2006;28(23):1491-7. 
334. Iraurgui BA, Muniz J, Rodriguez-Fernandez JA, Vidan-Martinez L, Silva-Cesar 
M, Lamelo-Alfonsin F, et al. Randomized controlled clinical trial of a home care 
unit intervention to reduce readmission and death rates in patients discharged 
from hospital following admission for heart failure. Revista espanola de 
cardiologia. 2007;60(9):914-22. 
335. Jerant AF, Azari R, Martinez C, Nesbitt TS. A randomized trial of telenursing 
to reduce hospitalization for heart failure: patient-centered outcomes and 
nursing indicators. Home Health Care Services Quarterly. 2003;22(1):1-20. 
336. Villani A, Malfatto G, Compare A, Rosa FD, Bellardita L, Branzi G, et al. Clinical 
and psychological telemonitoring and telecare of high risk heart failure 
patients. Journal of Telemedicine & Telecare. 2014;20(8):468-75. 
337. Melin M, Hagglund E, Frie F, Lynga P, Ullman B, Persson H, et al. Patient-
centered home-based management of heart failure, findings from a 
randomized clinical trial evaluating effects on knowledge, self-care and quality 




338. Grancelli HO. Disease management programs in heart failure. Findings of the 
DIAL study. Revista Española De Cardiología. 2007;60 Suppl 3:15-22. 
339. Antonicelli R, Testarmata P, Spazzafumo L, Gagliardi C, Bilo G, Valentini M, 
et al. Impact of telemonitoring at home on the management of elderly patients 
with congestive heart failure. Journal of Telemedicine & Telecare. 
2008;14(6):300-5. 
340. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HGM. 
Guidance improves compliance. Pharmacist stimulates proper use of loop 
diuretics in patient with heart failure. Pharmaceutisch weekblad. 2003;138(41). 
341. Boyne JJJ, Vrijhoef HJM, Spreeuwenberg M, De Weerd G, Kragten J, Gorgels 
APM. Effects of tailored telemonitoring on heart failure patients' knowledge, 
self-care, self-efficacy and adherence: a randomized controlled trial. European 
Journal Of Cardiovascular Nursing. 2014;13(3):243-52. 
342. Powell LH, Calvin JE, Mendes de Leon CF, Richardson D, Grady KL, Flynn 
KJ, et al. The Heart Failure Adherence and Retention Trial (HART): design and 
rationale. American Heart Journal. 2008; 156(3):452-60. 
343. Falces C, López-Cabezas C, Andrea R, Arnau A, Ylla M, Sadurní J. An 
educative intervention to improve treatment compliance and to prevent 
readmissions of elderly patients with heart failure. Medicina Clínica. 
2008;131(12):452-6. 
344. Ashby B. Home teaching: effect on compliance, hospital readmissions and 
days of rehospitalization for patients with chronic congestive heart failure: 
Virgina Commonwealth University; 1988. 
345. Nimpitakpong P. The effects of pharmacist interventions on patient adherence 
and rehospitalization in CHF patients in Thailand: University of Wisconsin - 
Madison; 2002. 
346. Feldman PH, Peng TR, Murtaugh CM, Kelleher C, Donelson SM, McCann ME, 
et al. A randomized intervention to improve heart failure outcomes in 





347. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood 
JT, et al. Improving Evidence-Based Care for Heart Failure in Outpatient 
Cardiology Practices: Primary Results of the Registry to Improve the Use of 
Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE 
HF). Circulation. 2010;122(6):585-96. 
348. Hawkins L, Firek CJ, Silvet H. Testing a Novel Pictorial Medication Sheet to 
Improve Adherence in Veterans with Heart Failure and Cognitive Impairment. 
Heart & Lung. 2013;42(4):294-5. 
349. Mau J, Kolk M, Pelon J, Frauenheim W, Johnson D, Culina J. Nurse-directed 
home-based heart failure management program decreases death/readmission 
rates and increases dietary and medication compliance. Progress in 
Cardiovascular Nursing. 2006; 21(2):112. 
350. Artinian NT, Harden JK, Kronenberg MW, Vander Wal JS, Daher E, Stephens 
Q, et al. Pilot study of a Web-based compliance monitoring device for patients 
with congestive heart failure. Heart & Lung. 2003;32(4):226-33. 
351. Goldstein CM, Gathright EC, Dolansky MA, Gunstad J, Sterns A, Redle JD, et 
al. Randomized controlled feasibility trial of two telemedicine medication 
reminder systems for older adults with heart failure. Journal of Telemedicine & 
Telecare. 2014;20(6):293-9. 
352. Bocchi EA, Cruz F, Guimarães G, Pinho Moreira LF, Issa VS, Ayub Ferreira 
SM, et al. Long-Term Prospective, Randomized, Controlled Study Using 
Repetitive Education at Six-Month Intervals and Monitoring for Adherence in 
Heart Failure Outpatients: The REMADHE Trial. Circulation: Heart Failure. 
2008 July 1, 2008;1(2):115-24. 
353. Powell LH, Calvin JE, Richardson D, Janssen I, Mendes de Leon CF, Flynn 
KJ, et al. Self-management counseling in patients with heart failure: The heart 
failure adherence and retention randomized behavioral trial. JAMA. 
2010;304(12):1331-8. 
354. Gwadry-Sridhar FH, Arnold JMO, Zhang Y, Brown JE, Marchiori G, Guyatt G. 




intervention in patients hospitalized with heart failure. American Heart Journal. 
2005;150(5):982. e1-e9. 
355. Goodyer LI, Miskelly F, Milligan P. Does encouraging good compliance 
improve patients' clinical condition in heart failure? The British Journal of 
Clinical Practice. 1995;49(4):173-6. 
356. Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of a 
multidisciplinary intervention on medication compliance in elderly patients with 
congestive heart failure. Am J Med. 1996;101(3):270-6. 
357 Fulmer TT, Feldman PH, Kim TS, Carty B, Beers M, Molina M, et al. An 
intervention study to enhance medication compliance in community-dwelling 
elderly individuals. J Gerontol Nurs. 1999 Aug;25(8):6-14. 
358. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical 
care of patients with congestive heart failure: interventions and outcomes. 
Pharmacotherapy. 1999;19(7):860-9. 
359. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HGM, 
et al. Effect of a pharmacist-led intervention on diuretic compliance in heart 
failure patients: a randomized controlled study. Journal of Cardiac Failure. 
2003;9(5):404-11. 
360. Laramee AS, Levinsky SK, Sargent J, Ross R, Callas P. Case management in 
a heterogeneous congestive heart failure population: a randomized controlled 
trial. Arch Intern Med. 2003;163(7):809-17. 
361. Ross SE, Moore LA, Earnest MA, Wittevrongel L, Lin CT. Providing a web-
based online medical record with electronic communication capabilities to 
patients with congestive heart failure: randomized trial.   J Med Internet Res. 
2004;6(2):e12. 
362. Tsuyuki RT, Fradette M, Johnson JA, Bungard TJ, Eurich DT, Ashton T, et al. 
A multicenter disease management program for hospitalized patients with 
heart failure. Journal of Cardiac Failure. 2004;10(6):   473-80. 
363. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart 




364. Lopez-Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla 
Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge 
pharmaceutical care program vs regular follow-up in patients with heart failure. 
Farm Hosp. 2006;30(6):328-42. 
365. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist 
Intervention to Improve Medication Adherence in Heart Failure, A Randomized 
Trial. Annals of Internal Medicine. 2007;146(10):714-25. 
366. Wakefield BH, JE; Ray, A; Scherubel, M; Burns, TL; Kienzle, MG; Rosentha,l 
GE. Outcomes of a home telehealth intervention for patients with heart failure. 
Journal of Telemedicine & Telecare. 2009;15(1):46-50. 
367. Antonicelli R, Mazzanti I, Abbatecola AM, Parati G. Impact of home patient 
telemonitoring on use of beta-blockers in congestive heart failure. Drugs 
Aging. 2010;27(10):801-5. 
368. Dunbar SB, Clark PC, Reilly CM, Gary RA, Smith A, McCarty F, et al. A trial of 
family partnership and education interventions in heart failure. Journal Of 
Cardiac Failure. 2013;19(12):829-41. 
369. Mussi CM, Ruschel K, Souza ENd, Lopes ANM, Trojahn MM, Paraboni CC, et 
al. Home visit improves knowledge, self-care and adhesion in heart failure: 
randomized Clinical Trial HELEN-I. Revista Latino-Americana de 
Enfermagem. 2013;21:20-8. 
370. Granger BB, Ekman I, Hernandez AF, Sawyer T, Bowers MT, DeWald TA, et 
al. Results of the Chronic Heart Failure Intervention to Improve MEdication 
Adherence study: A randomized intervention in high-risk patients. American 
Heart Journal. 2015;169(4):539-48. 
371. Jeon Y-HK, S.G; Jowsey, T; Glasgow, N.J. The experience of living with 
chronic heart failure: a narrative review of qualitative studies. BMC Health 






372. Khangura S, Polisena J, Clifford TJ, Farrah K, Kamel C. Rapid Review: An 
emerging approach to evidence sysnthesis in health technology assessment. 
International Journal of Technology Assessment in Health Care. 
2014;30(01):20-7. 
373. Ganann R, Ciliska D, Thomas H. Expediting systematic reviews: methods and 
implications of rapid reviews. Implementation Science. 2010;5(1):56. 
374. Thomas J, Harden A. Methods for the thematic synthesis of qualitative 
research in systematic reviews. BMC Medical Research Methodology. 
2008;8(1):45. 
375. Critical Appraisal Skills Programme (CASP). Critical Appraisal Skills 
Programme (CASP) [online]  [cited 2015; Available at: http://www.casp-
uk.net/#!casp-tools-checklists/c18f8 [Accessed various 2015].]  
376. Rogers A, Addington-Hall JM, McCoy AS, Edmonds PM, Abery AJ, Coats AJ, 
et al. A qualitative study of chronic heart failure patients' understanding of their 
symptoms and drug therapy. European Journal of Heart Failure. 
2002;4(3):283-7. 
377. Scotto CJ. The lived experience of adherence for patients with heart failure. 
Journal of Cardiopulmonary Rehabilitation. 2005;25(3):158-63. 
378. Field K, Ziebland S, McPherson A, Lehman R. 'Can I come off the tablets now?' 
A qualitative analysis of heart failure patients' understanding of their 
medication. Family Practice. 2006;23(6):624-30. 
379. Reid M, Clark A, Murdoch DL, Morrison C, Capewell S, McMurray J. Patients 
strategies for managing medication for chronic heart failure. International 
Journal Of Cardiology. 2006;109(1):66-73. 
380. van der Wal MHL, Jaarsma T, Moser DK, van Gilst WH, van Veldhuisen DJ. 
Qualitative examination of compliance in heart failure patients in The 






381. Ming L, Hassali M, Shafie A, Awaisu A, Hadi M, Al-Haddad M. Perspectives of 
heart failure patients in Malaysia towards medications and disease state 
management: findings from a qualitative study. Journal of Public Health. 
2011;19(6):569-77. 
382. Granger BB, McBroom K, Bosworth HB, Hernandez A, Ekman I. The meanings 
associated with medicines in heart failure patients. European Journal of 
Cardiovascular Nursing. 2013;12(3):276-83. 
383.  Polit DF, Beck CT. Essentials of nursing research : appraising evidence for 
nursing practice. Ninth edition.; International edition. 2017. 
384. Patton MQ. Qualitative Research and Evaluation Methods. 3rd edition. 
Thousand Oaks, Calif, London: Sage; 2002. 
385. Marshall MN. Sampling for qualitative research. Family Practice. 
1996;13(6):522-6. 
386 Mason M. Sample Size and Saturation in PhD Studies Using Qualitative 
Interviews. Forum: Qualitative Social Research. 2010;11(3). 
387. O’Reilly M, Parker N. ‘Unsatisfactory Saturation’: a critical exploration of the 
notion of saturated sample sizes in qualitative research. Qualitative Research. 
2012;13(2):190-7. 
388. Dworkin SL. Sample Size Policy for Qualitative Studies Using In-Depth 
Interviews. Archives of Sexual Behavior. 2012;41(6):1319-20. 
389. Guest, G., Bunce, A., & Johnson, L. How many interviews are enough? An 
experiment with data saturation and variability. Field methods, 2006;18(1), 59-
82. 
390. Childress JF, Beauchamp TL. Principles of biomedical ethics. New York: 
Oxford University Press; 2001. 
391. Doody O, Noonan M. Nursing research ethics, guidance and application in 
practice. British Journal of Nursing. 2016 Jul 28;25(14):803-7. 
392. Holloway I, Wheeler S. Qualitative research in nursing. Oxford: Oxford : 




393. Birt L, Scott S, Cavers D, Campbell C, Walter F. Member checking: a tool to 
enhance trustworthiness or merely a nod to validation?. Qualitative health 
research. 2016;26(13):1802-11. 
394.  Korstjens I, Moser A. Series: Practical guidance to qualitative research. Part 
4: trustworthiness and publishing. European Journal of General Practice. 2018 
Jan 1;24(1):120-4. 
395. Ritchie JL, Lewis J. Qualitative Research Practice: A Guide for Social Science 
Students and Researchers. London: Sage Publications, London; 2003. 
396. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta 
Psychiatr Scand. 1983 Jun;67(6):361-70. 
397. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 
2006;3(2):77-101 
398. Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse 
Researcher. 2011;18(2):52-62.398. 
399. Smith J, Bekker H, Cheater F. Theoretical versus pragmatic design in 
qualitative research. Nurse Researcher. 2011;18(2):39-51. 
400. Pope C, Ziebland S, Mays N. Analysing qualitative data. BMJ. 
2000;320(7227):114-6.400.  
401. Rabiee H. Focus Group interview and data analysis. Proceedings of The 
Nutrition Society 2004;63(4):655-60.400.  
402. Hale ED, Treharne GJ, Kitas GD. The Common-Sense Model of self-regulation 
of health and illness: how can we use it to understand and respond to our 
patients’ needs? Rheumatology. 2007;46(6):904-6. 
403. Chen AMH, Yehle KS, Albert NM, Ferraro KF, Mason HL, Murawski MM, et al. 
Health Literacy Influences Heart Failure Knowledge Attainment but Not Self-
Efficacy for Self-Care or Adherence to Self-Care over Time. Nursing Research 
and Practice. 2013;8. doi.org/10.1155/2013/353290. 
404. Blackman JS, M. Patient understanding of frequently used cardiology 




405. van der Wal MHL, Jaarsma T, Moser DK, van Gilst WH, van Veldhuisen DJ. 
Unraveling the mechanisms for heart failure patients' beliefs about compliance. 
Heart & lung. 2007;36(4):253-61. 
406. Buetow S, Goodyear-Smith F, Coster G. Coping strategies in the self-
management of chronic heart failure. Fam Pract. 2001;18(2):117-22. 
407. Siabani S, Leeder SR, Davidson PM. Barriers and facilitators to self-care in 
patients with chronic heart failure: A review of qualitative studies.SpringerPlus. 
2013;2:320. 
408. Banning M. Older people and adherence with medication: A review of the 
literature. International Journal of Nursing Studies. 2008;45(10):1550-61. 
409. Dowell J, Hudson H. A qualitative study of medication taking behaviour in 
primary care. Family Practice. 1997;14:369-75. 
410. Clark AM, Freydberg CN, McAlister FA, Tsuyuki RT, Armstrong PW, Strain LA. 
Patient and informal caregivers’ knowledge of heart failure: necessary but 
insufficient for effective self-care. European Journal of Heart Failure. 
2009;11(6):617-21. 
411. McKinstry B, Sullivan FM, Vasishta S, Armstrong R, Hanley J, Haughney J, et 
al. Cohort profile: the Scottish Research register SHARE. A register of people 
interested in research participation linked to NHS data sets. BMJ Open. 
2017;7(2) e013351 
412. Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, et al. 
Nonadherence with angiotensin-converting enzyme inhibitor therapy: A 
comparison of different ways of measuring it in patients with chronic heart 
failure. Journal of the American College of Cardiology. 1999;34(7):2072-7. 
413. Rani K. Prescribing diuretics in the management of heart failure. Nurse 
Prescribing. 2011;9(9):436-41. 
414. Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart 
failure. Cochrane Database Syst Rev. 2006 Jan 25(1):CD003838. 





416. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 
2005. European Heart Journal. 2005;26(7):644-9. 
417. Davidson P, Macdonald P, Paull G, Rees D, Howes L, Cockburn J, et al. 
Diuretic therapy in chronic heart failure: Implications for heart failure nurse 
specialists. Australian Critical Care. 2003;16(2):59-69. 
418. Lehmann A, Meslot C, Gauchet A, Roustit M, Baudrant M, Pansu P, et al. 
Development of a self-administered questionnaire to identify levers and barrier 
of adhesion behavior to patient's medication: Quilam. International Journal of 
Clinical Pharmacy. 2016;38 (6):499-500. 
419. Fairman KA. Evaluating Medication Adherence: Which Measure Is Right for 
Your Program? Journal of Managed Care Pharmacy. 2000;6(6):499-506. 
420. Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin 
P-F, et al. Validation of a French Version of the 8-Item Morisky Medication 
Adherence Scale in Hypertensive Adults. The Journal of Clinical Hypertension. 
2012;14(7):429-34. 
421. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication 
Questionnaire: a tool for screening patient adherence and barriers to 
adherence. Patient Educ Couns. 1999 Jun;37(2):113-24. 
422. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for 
measuring medication adherence. Journal of the American Pharmacists 
Association. 2011;51(1):90-4. 
423. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-
reported measure of medication adherence. Med Care. 1986;24(1):67-74. 
424. Culig J, Leppee M. From Morisky to Hill-bone; self-reports scales for 
measuring adherence to medication. Coll Antropol. 2014;38(1):55-62. 
425. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of A 





426. Krousel-Wood M, Islam T, Webber LS, Re R, Morisky DE, Muntner P. New 
medication adherence scale versus pharmacy fill rates in hypertensive seniors. 
The American Journal of Managed Care. 2009;15(1):59-66. 
427. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, et al. Comparison 
of Morisky Medication Adherence Scale with therapeutic drug monitoring in 
apparent treatment–resistant hypertension. Journal of the American Society of 
Hypertension. 2015;9(6):420-6.e2. 
428. Oliveira-Filho AD, Barreto-Filho JA, Neves SJ, Lyra Junior DP. Association 
between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood 
pressure control. Arq Bras Cardiol. 2012;99(1):649-58. 
429. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. 
Medication nonadherence is associated with a broad range of adverse 
outcomes in patients with coronary artery disease. American Heart Journal. 
2008;155(4):772-9. 
430. Dahri K, Shalansky SJ, Jang L, Jung L, Ignaszewski AP, Clark C. Accuracy of 
a provincial prescription database for assessing medication adherence in heart 
failure patients. Annals of Pharmacotherapy. 2008;42(3):361-7. 
431. Clifford S, Barber N, Horne R. Understanding different beliefs held by 
adherers, unintentional nonadherers, and intentional nonadherers: Application 
of the Necessity–Concerns Framework. Journal of Psychosomatic Research. 
2008;64(1):41-6. 
432. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: Development and validation. 
Journal of Chronic Diseases. 1987;40(5):373-83. 
433. Struthers A. Heart Failure. The diagnosis of heart failure. Heart. 2000;    
84:334-8. 
434. Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA 
classes for measuring research outcomes in patients with cardiac disease. 




435. Gov.scot. The Scottish Index of Multiple Deprivation.  [cited 2017; Available 
from:  
436. Cullen B, O’Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests 
for cognitive impairment. Journal of Neurology, Neurosurgery & Psychiatry. 
2007;78(8):790-9. 
437. Aggarwal AK, Kean E. Comparison of the Folstein Mini Mental State 
Examination (MMSE) to the Montreal Cognitive Assessment (MoCA) as a 
Cognitive Screening Tool in an Inpatient Rehabilitation Setting. Neuroscience 
and Medicine. 2010;1(2):39-42. 
438. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A 
Comprehensive Review. Journal of the American Geriatrics Society. 
1992;40(9):922-35. 
439. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin 
I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for 
mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-9. 
440. Leventhal H, Leventhal EA, Contrada RJ. Self-regulation, health, and 
behavior: A perceptual-cognitive approach. Psychology & Health. 
1998;13(4):717-33. 
441. Figueiras MJ, Alves NC. Lay perceptions of serious illnesses: An adapted 
version of the Revised Illness Perception Questionnaire (IPQ-R) for healthy 
people. Psychology & Health. 2007;22(2):143-58. 
442. Weinman J, Petrie KJ, Moss-morris R, Horne R. The illness perception 
questionnaire: A new method for assessing the cognitive representation of 
illness. Psychology & Health. 1996;11(3):431-45. 
443. Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. The 
revised Illness Perception Questionnaire (IPQ-R). Psychology & Health. 2002 
Feb;17(1):1-16. 
444. Jessop DC, Rutter DR. Adherence to Asthma Medication: The Role of Illness 




445. Broadbent E, Petrie KJ, Main J, Weinman J. The Brief Illness Perception 
Questionnaire. Journal of Psychosomatic Research. 2006;60(6):631-7. 
446. Taylor EC, O’Neill M, Hughes LD, Moss-Morris R. An illness-specific version 
of the Revised Illness Perception Questionnaire in patients with atrial fibrillation 
(AF IPQ-R): Unpacking beliefs about treatment control, personal control and 
symptom triggers. Psychology & Health. 2018;33(4):499-517. 
447. Ross S, Walker A, Macleod M. Patient compliance in hypertension: Role of 
illness perceptions and treatment beliefs. J Hum hypertens 2004;18(9):607-
13. 
448. Bandura A. Guide for constructing Self-Efficacy Scales.  Self-Fficacy Beliefs of 
Adolescents: Information Age Publishing; 2006. p. 307-37. 
449. Resnick B, Jenkins LS. Testing the Reliability and Validity of the Self-Efficacy 
for Exercise Scale. Nursing Research. 2000;49(3):154-9. 
450. Sullivan MD, Russo J, Katon WJ, Lacroix AZ. Self-efficacy and self-reported 
functional status in coronary heart disease: A six-month prospective study. 
Psychosomatic Medicine. 1998;60(4):473-8. 
451. O'Neil A, Berk M, Davis J, Stafford L. Cardiac-self efficacy predicts adverse 
outcomes in coronary artery disease (CAD) patients. Health. 2013;5(7A3):6-
14 
452. Arnold R, Ranchor AV, DeJongste MJ, Koeter GH, Ten Hacken NH, Aalbers 
R, et al. The relationship between self-efficacy and self-reported physical 
functioning in chronic obstructive pulmonary disease and chronic heart failure. 
Behav Med. 2005;31(3):107-15. 
453. Smeulders ES, van Haastregt JC, van Hoef EF, van Eijk JT, Kempen GI. 
Evaluation of a self-management programme for congestive heart failure 
patients: design of a randomised controlled trial. BMC Health Serv Res. 
2006;6:91. 
454. Sarkar U, Ali S, Whooley MA. Self-efficacy as a marker of cardiac function and 




coronary heart disease: findings from the Heart and Soul Study. Health 
Psychology. 2009;28(2):166-73. 
455. Loo DWY, Jiang Y, Koh KWL, Lim FP, Wang W. Self-efficacy and depression 
predicting the health-related quality of life of outpatients with chronic heart 
failure in Singapore. Applied Nursing Research. 2016;32:148-55. 
456. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. 
Understanding Patients’ Adherence-Related Beliefs about Medicines 
Prescribed for Long-Term Conditions: A Meta-Analytic Review of the 
Necessity-Concerns Framework. PLOS One. 2013;8(12):e80633. 
457. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: 
The development and evaluation of a new method for assessing the cognitive 
representation of medication. Psychology & Health. 1999;14(1):1-24. 
458. Ruppar TM, Dobbels F, De Geest S. Medication Beliefs and Antihypertensive 
Adherence Among Older Adults: A Pilot Study. Geriatric Nursing. 
2017;33(2):89-95. 
459. Porteous T, Francis J, Bond C, Hannaford P. Temporal stability of beliefs about 
medicines: Implications for optimising adherence. Patient Education and 
Counseling. 2010;79(2):225-30. 
460. Snaith RP. The Hospital Anxiety And Depression Scale. Health and Quality of 
Life Outcomes. 2003;1:29-. 
461. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck 
Depression Inventory: Twenty-five years of evaluation. Clinical Psychology 
Review. 1988;8(1):77-100. 
462. Stern AF. The Hospital Anxiety and Depression Scale.  Occupational 
Medicine. 2014;64(5):393-4. 
463. Michopoulos I, Douzenis A, Kalkavoura C, Christodoulou C, Michalopoulou P, 
Kalemi G, et al. Hospital Anxiety and Depression Scale (HADS): validation in 




464. Herrmann C. International experiences with the Hospital Anxiety and 
Depression Scale-A review of validation data and clinical results. Journal of 
Psychosomatic Research. 1997;42(1):17-41. 
465. Benyamini Y, Medalion B, Garfinkel D. Patient and spouse perceptions of the 
patient's heart disease and their associations with received and provided social 
support and undermining. Psychology & Health. 2007;22(7):765-85. 
466. Figueiras M, Weinman J. Do similar patient and spouse perceptions of 
myocardial infarction predict recovery? Psychology and Health. 
2003;18(2):201-16. 
467. Baker DW, Williams MV, Parker RM, Gazmararian JA, Nurss J. Development 
of a brief test to measure functional health literacy. Patient Educ Couns. 
1999;38(1):33-42. 
468. Robinson S, Moser D, Pelter MM, Nesbitt T, Paul SM, Dracup K. Health 
Literacy in Heart Failure Patients? Journal of Cardiac Failure. 
2011;17(11):887-92. 
469. Bostock S, Steptoe A. Association between low functional health literacy and 
mortality in older adults: longitudinal cohort study. BMJ(Clinical Research ed.). 
2012;344:e1602. 
470. Kirsch I. The International Adult Literacy Survey (IALS): Understanding What 
Was Measured; Educational Testing Service 2001. 
471. Wagner Cv, Knight K, Steptoe A, Wardle J. Functional health literacy and 
health-promoting behaviour in a national sample of British adults. Journal of 
Epidemiology and Community Health. 2007;61(12):1086-90. 
472. Saleem F, Hassali MA, Shafie AA, Awad GA, Atif M, ul Haq N, et al. Does 
treatment adherence correlates with health related quality of life? findings from 
a cross sectional study. BMC Public Health. 2012;12(1):318. 
473. Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, et al. Assessing 
health-related quality of life in patients with heart failure: a systematic, 





474. Riegel B, Moser DK, Glaser D, Carlson B, Deaton C, Armola R, et al. The 
Minnesota Living With Heart Failure Questionnaire: Sensitivity to Differences 
and Responsiveness to Intervention Intensity in a Clinical Population. Nursing 
Research. 2002;51(4):209-18. 
475. Bennett SJ, Oldridge NB, Eckert GJ, Embree JL, Browning S, Hou N, et al. 
Comparison of Quality of Life Measures in Heart Failure. Nursing Research. 
2003;52(4):207-16. 
476. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and 
evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health 
status measure for heart failure. Journal of the American College of 
Cardiology. 2000;35(5):1245-55. 
477. Kosiborod M, Soto GE, Jones PG, Krumholz HM, Weintraub WS, Deedwania 
P, et al. Identifying heart failure patients at high risk for near-term 
cardiovascular events with serial health status assessments. Circulation. 
2007;115(15):1975-81. 
478. Marti CN, Georgiopoulou VV, Giamouzis G, Cole RT, Deka A, Tang WH, et al. 
Patient-reported selective adherence to heart failure self-care 
recommendations: a prospective cohort study. Congestive Heart Failure. 
2013;19(1):16-24. 
479. Kinnersley P, Stott N, Peters T, Harvey I, Hackett P. A comparison of methods 
for measuring patient satisfaction with consultations in primary care. Fam 
Pract. 1996;13(1):41-51. 
480. Baker R. Development of a questionnaire to assess patients' satisfaction with 
consultations in general practice. The British Journal of General Practice. 
1990;40(341):487-90. 
481. Landis JR, Koch GG. The measurement of observer agreement for categorical 
data. Biometrics. 1977;33(1):159-74. 
482. Lang CC, Mancini DM. Management of Comorbidities in Heart Failure. In: 
Baliga RR, Pitt B, Givertz MM, editors. Management of Heart Failure: Volume 




483. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure. European Heart Journal. 2016;37(27):2129-200.484.  
484. NICE. CG108: Chronic heart failure: full guidelines: NICE; 2010. 
485. McMurdo ME, Roberts H, Parker S, Wyatt N, May H, Goodman C, et al. 
Improving recruitment of older people to research through good practice. Age 
and Ageing. 2011;40(6):659-65. 
486. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient 
utilization of angiotensin-converting enzyme inhibitors among heart failure 
patients after hospital discharge. Journal of the American College of 
Cardiology. 2004;43(11):2036-43. 
487. Smith H, Hankins M, Hodson A, George C. Measuring the adherence to 
medication of elderly patients with heart failure: Is there a gold standard? 
International Journal of Cardiology. 2010;145(1):122-3. 
488. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar‐Jacob JM. Medication 
Adherence Interventions Improve Heart Failure Mortality and Readmission 
Rates: Systematic Review and Meta‐Analysis of Controlled Trials. Journal of 
the American Heart Association. 2019;5(6):e002606. 
489. Tsai KT, Chen JH, Wen CJ, Kuo HK, Lu IS, Chiu LS, et al. Medication 
adherence among geriatric outpatients prescribed multiple medications. Am J 
Geriatr Pharmacother. 2012;10(1):61-8. 
490. van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, de Leeuw 
PW, et al. Participation in a clinical trial enhances adherence and persistence 
to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573-8. 
491. Stewart S, Riegel B, Boyd C, Ahamed Y, Thompson DR, Burrell LM, et al. 
Establishing a pragmatic framework to optimise health outcomes in heart 
failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. 





492. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, 
et al. Noncardiac comorbidity increases preventable hospitalizations and 
mortality among Medicare beneficiaries with chronic heart failure. J Am Coll 
Cardiol. 2003;42(7):1226-33. 
493. Triposkiadis FK, Skoularigis J. Prevalence and importance of comorbidities in 
patients with heart failure. Current Heart Failure Reports. 2012;9(4):354-62. 
494.   Clyne B, Cooper JA, Boland F, Hughes CM, Fahey T, Smith SM. Beliefs about 
prescribed medication among older patients with polypharmacy: a mixed 
methods study in primary care. Br J Gen Pract. 2017;67(660):e507-e18. 
495. Dreyer K, Steventon A, Fisher R, Deeny SR. The association between living 
alone and health care utilisation in older adults: a retrospective cohort study of 
electronic health records from a London general practice. BMC Geriatr. 
2018;18(1):269. 
496. Welstand J, Carson A, Rutherford P. Living with heart failure: An integrative 
review. International Journal of Nursing Studies. 2009;46(10):1374-85. 
497. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of Symptom Prevalence 
and Symptom Burden on Quality of Life in Patients with Heart Failure. 
European Journal of Cardiovascular Nursing. 2005;4(3):198-206. 
498. Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: 
the challenges of applying UK clinical guidelines to people with multimorbidity. 
Age and Ageing. 2012;42(1):62-9. 
499. Abu AMD, Gallacher K, Boehmer KR, Hargraves IG, Mair FS. Minimally 
disruptive medicine: the evidence and conceptual progress supporting a new 
era of healthcare. The Journal of the Royal College of Physicians of Edinburgh. 
2015;45(2):114-7. 
500. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients' 
experiences of treatment burden in chronic heart failure using normalization 




501. Jowsey T, Yen L, W PM. Time spent on health related activities associated 
with chronic illness: a scoping literature review. BMC Public Health. 
2012;12(1):1044. 
502. Shippee ND, Allen SV, Leppin AL, May CR, Montori VM. Attaining minimally 
disruptive medicine: context, challenges and a roadmap for implementation. 
The Journal of the Royal College of Physicians of Edinburgh. 2015;45(2):118-
22. 
503. Leppin A, Montori V, Gionfriddo M. Minimally disruptive medicine: a 
pragmatically comprehensive model for delivering care to patients with multiple 
chronic conditions.  Healthcare; 2015: Multidisciplinary Digital Publishing 
Institute; 2015. p. 50-63. 
504. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing 
and evaluating complex interventions: new guidance. Medical Research 
Council; 2006. 
505. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing 
and evaluating complex interventions: the new Medical Research Council 
guidance. BMJ. 2008;337.a1655 
506. Barker F, Atkins L, de Lusignan S. Applying the COM-B behaviour   and 
behaviour change wheel to develop an intervention to improve hearing-aid use 
in adult auditory rehabilitation. International Journal of Audiology. 
2016;55(sup3):S90-S8. 
507. Jackson C, Eliasson L, Barber N, Weinman J. Applying COM-B to medication 
adherence: a suggested framework for research and interventions. European 
Health Psychologist. 2014;16(1):7-17. 
508. Michie S, van Stralen MM, West R. The behaviour change wheel: A new 
method for characterising and designing behaviour change interventions. 
Implementation Science. 2011;6:42-. 
509. Zou H, Chen Y, Fang W, Zhang Y, Fan X. Identification of factors associated 
with self-care behaviors using the COM-B model in patients with chronic heart 






Protocol for systematic review of Interventions to 




Heart Failure (HF) is a major cause of disability, hospitalisation and death, 
particularly amongst older people (1). It currently affects approximately 900,000 
people in the UK. Despite improvements in the prevention and treatment of HF 
the prognosis remains poor with a median survival following a first episode of 
decompensated HF being 2.3 years for men and 1.8 years for women (2). The 
annual cost of heart failure to the NHS is estimated to be 4% (direct costs of 
1.9%) of the total NHS expenditure, with hospitalisation being the predominant 
cost component. 
The improvements, which have been achieved in symptoms and mortality, are 
due in large part to the prescribing of effective medications such as 
angiotensin-converting enzyme inhibitors (ACEi), beta-blockers and 
spironolactone. While there is clear evidence that these medications improve 
survival and reduce hospitalisation rates due to HF, there is also evidence to 




(CHF) patients, especially amongst older HF patients (1, 3). This non-adherence 
to medication remains a significant barrier to optimising outcomes for those 
with CHF and so presents a modifiable target for intervention. 
In observational studies poor adherence to medication is associated with 
worse outcomes for CHF patients. Strategies to improve adherence to drug 
therapy in CHF has the potential to both improve health outcomes and reduce 
the burden on the health budget. One of the largest studies of adherence in 
CHF patients found that only 80% of patients with a prescription for ACEi at 
hospital discharge actually filled the prescription in the following 30 days, with 
this rate dropping further to only 60% of prescriptions being refilled at 12 
months (4). The Candesartan in Heart Failure: Assessment of Reduction in 
Mortality and morbidity study (CHARM) concluded that adherence was 
independently associated with improved clinical outcome, even in the placebo 
group (5) .  This relationship between adherence and improved outcomes in all-
cause mortality, even to placebo, suggests that adherent behaviour itself is 
associated with clinical outcome and highlights the requirement to find ways to 
improve medication adherence.  
In the last few years there have been a number of studies published showing 
that simple well-specified behaviour change strategies that could be 
incorporated into routine nursing care can increase adherence to medications 
in a number of conditions. These include patients with Type 2 diabetes (6) and 
in a recent Chief Scientist Office (CSO) funded study of patients following 




in the context of chronic heart failure, which has similar e.g. complex regimens, 
but also unique challenges e.g. a distinct symptom profile.  
This systematic review is an update on the systematic review carried out by 
Molloy et al (8) and published in 2012. Given that available evidence is 
generally dynamic and evolving, incorporating additional studies into the 
current review will ensure that the best available evidence will be available. 
Objectives 
To systematically review the evidence from randomised controlled trials of 
interventions to enhance medication adherence in patients with chronic heart 
failure. 
Design 
Types of studies 
• Randomised controlled trials where treatment was compared to a 
usual care or a clearly justified comparison group  
• The intervention strategy clearly had a primary or secondary aim to 
increase adherence to heart failure medication 
• Self-administered medication adherence (i.e. medication not 
administered by a health care professional)  was measured as an 
outcome by either –  
▪ pill count 
▪ electronic monitoring 





▪ biochemical measures of drug ingestion specific to heart 
failure medication 
Types of participants 
Studies enrolling adults >=18years, with a clinical with a diagnosis of heart 
failure (confirmed by a physician) will be eligible.  
Types of interventions 
Any intervention designed to enhance medication adherence including the 
following: 
• Patient Education and Information ( such as face to face oral, written 
material, visual aids or mailed instructional materials ) 
• Intensified Patient Care (including direct patient contact interventions 
or telephone / tele monitoring programs)  
• Complex Behavioural Approaches 
• Simplification of the Drug regimen (either pill number or dose timing) 
Control groups or treatment as usual groups should either have received no 
intervention or ’usual care’ and have similar demographic characteristics to the 
intervention groups. Treatment as usual includes ’usual’ dosage medication 
regimens. 
Exclusion criteria 
1. Interventions not aimed at enhancing adherence to heart failure medication. 




3. Interventions not directed at patients (e.g. education of healthcare 
professionals about the importance of adherence). 
4. Studies that do not report the results in full (e.g. conference abstracts), 
where further information (sufficient to make a fair appraisal of the 
methodological quality and results of the study) are not available from the 
authors. 
5. Non-randomised studies 
Primary Outcome 
Adherence to medication including any definition of adherence noting how this 
was defined and measured in each study. 
Search strategy  
A comprehensive search strategy will be used to retrieve all relevant RCT of 
medication adherence in heart Failure.  The following electronic databases will 
be searched: 
Medline (start date to end March 2015) 
CINAHL (start date to end March 2015) 
Embase (start date to end March 2015) 
Cochrane Central Register of Controlled Trials (start date to end March 2015) 
PsychInfo (start date to end March 2015) 
Google Scholar (for grey literature) 
Controlled Clinical Trials.com  




There will be no restrictions on language or publication status 
Search terms: 
Databases will be searched using the same search criteria as used by the 
author of the previous review (see appendix) 
Hand-searching: 
Reference lists of all retrieved articles will be screened to identify any additional 
publications. Where necessary, we will contact the authors of relevant articles. 
Selection of Studies. 
Two reviewer authors (RF and MW) will independently pre-screen all search 
results (titles) for possible inclusion. Each reviewer will then indicate whether  
I. A citation is relevant (i.e. appears to meet the inclusion criteria)  
II. A citation is clearly not relevant   
III. A citation gave insufficient information to make a judgement.  
All discrepancies will be were resolved by discussion and consensus. 
Abstracts for all potentially relevant titles will be obtained and the process 
repeated. 
We will seek full-text paper copies of all potentially relevant abstracts 
(categories I and III). Any discrepancies will be resolved by consensus, 
overseen by a third review author acting as arbiter. 
A detailed PRISMA flowchart will be formulated in which the characteristics of 





Quality assessment of studies 
As recommended by the Cochrane Reviewers Handbook studies will be 
assessed for adequate sequence generation and allocation concealment 
(selection bias), the presence of blinding in outcome assessment 
(performance and detection bias), and whether reporting of losses to follow-up 
and intention-to-treat analysis were specified (attrition bias) using a 
standardised quality checklist. 
The two review authors (RF & MW) will independently assess the risk of bias 
in each of the included studies, with any disagreements resolved by discussion 
and consensus. Assessment will be presented in a Risk of Bias table using 
criteria suggested in the Cochrane Handbook. For each study a summary 
assessment will be made for the primary outcome (high, low or unclear risk of 
bias). The GRADE system will be used to assess the quality of the evidence 
for the primary outcome across studies and a Summary of Findings table will 
be produced. 
Data extraction 
Both authors (RF and MW) will collect data from all papers independently using 
the standardised data extraction form (see appendix 2). Both reviewers will 
extract details concerning:  
e) Study characteristics: including study design, inclusion/exclusion 





f) Patient characteristics: including age, gender, ethnicity, severity of 
illness, co-morbidities; current medication, as well as number of 
participants in each characteristic category for intervention and control 
group 
g) Intervention and setting: including setting in which the intervention is 
delivered; method of delivery; description of the intervention and 
control; duration of treatment period; sample size and description of 
co-interventions if relevant  
h) Outcome data/results: including outcome names; measurement tool or 
method used for outcome measures; length of follow-up number 
and/or times of follow-up measurements; number of withdrawals, 
exclusions, deaths or recorded hospitalisation and results of study 
analysis 
Key findings relating to adherence will be compiled in a ‘summary of findings’ 
table 
Data analysis  
We will conduct a narrative synthesis of the included studies. We will examine 
interventions designed to enhance medication adherence, classing them into 
the same 4 main categories used in the initial review: 
• Patient Education and Information  
• Intensified Patient Care  
• Complex Behavioural Approaches 




Clinical and methodological heterogeneity across the included studies will be 
evaluated by comparing the characteristics of participants, interventions and 
study designs. If study interventions and outcomes are sufficiently similar we 
will consider pooling the data statistically via meta-analysis. If there is sufficient 
cope we aim to identify the specific behaviour change techniques used in each 
study using a behaviour change taxonomy.  
Meta-analysis 
Due to the wide range of possible interventions and outcomes it is not expected 
that there will be scope for meta-analysis. However if studies are sufficiently 
homogeneous in terms of design and measurement of adherence meta-
analysis will be conducted in Revman software using random effects models. 
Continuous variables will be aggregated using inverse-variance analyses; 
odds ratios will be combined using Peto odds ratio analyses. Heterogeneity 
will be assessed using the I2 statistic, and possible publication bias will be 
assessed by means of funnel plots and application of Egger’s test. 
Sensitivity analyses 
In the event that meta-analysis is deemed appropriate, sensitivity analyses will 
be conducted. These will include, but not be limited to: 
- Omitting studies with a high risk of bias 
- Subgrouping studies into those with self-reported adherence vs 






Missing / incomplete data 
If the presented data are insufficient or missing, we will attempt to obtain 
additional information from the authors of the included studies by personal 
communication. If we do not receive correspondence from the authors, we will 
analyse the available data. 
Reporting 
The results will be reported according to the current PRISMA guidelines 
Review Registration 
The review will be registered on the PROSPERO database of systematic 
reviews 
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Systematic Review Protocol – Search terms 
((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR 
(randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR 
(randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT 
humans[mh]))  
AND  
((Patient compliance[mh]) OR (Treatment Refusal[mh]) OR (Patient 
Dropouts[mh]) OR (Attitude to health[mh]) OR (Patient satisfaction[mh]) OR 
(adher* OR nonadherence* OR non-adherence*) OR (compliance* OR 
noncompliance* OR non-compliance*) OR (refusal OR refuse) OR (dropout* 









Systematic review of Interventions to Enhance Adherence to 





Data Extracted by:                                                  Date                       
 
 
Checked by:                                                            Date 
 
Study ID: (surname of first author and year first full report of study was published)  
 
 















Report title  
 
 






Study funding sources 
 
 








































needed/ obtained for 
study 
                       





                        
Yes           No            Unclear 
 
Type of study Randomised Controlled 
Trial 
                           


































Risk of Bias assessment 
Domain Risk of bias 
 






















   
 
Blinding of outcome 
assessment 
(detection bias) 
























required for further study 
information (from whom, 

































 Intervention group Control Group  Overall 
Total no. Randomised     
Withdrawals and 
exclusions 
   
Age (range, mean, SD)    
Sex (%)    
Race/Ethnicity    
Severity of illness  
e.g. NYHA class 
































 Description  
Description of intervention  




Theoretical basis  
Duration of treatment period  
Setting   
Delivery including Providers(e.g. 



















Outcome name    





Method and / or unit of 
measurement  
   
Is outcome/tool 
validated? 
   
Yes     No    Unclear 
   
Yes     No    Unclear 
   









 Intervention Comparison 
No. Missing participants and 
reasons 
  
No. Participants moved from 
other group and reasons 
  
No. recorded deaths   




Mean Change (SD) Number participants Mean Change (SD) Number participants 
Odds Ratio (95% CI) 

















Mean Change (SD) Number 
participants 
Odds Ratio (95% CI) 
 
 














Qualitative Study Protocol 
 




Sponsor University of Dundee / NHS TAYSIDE 
Sponsor R+D Number 2013GR03 
Funder Chief Scientist Office 
Funding Reference Number DTF/13/04 
Chief Investigator 
Principal Investigator 
Prof Marion McMurdo 
Mrs Roberta L Fulton 
REC Number 14/ES/0066 














How do older Heart Failure patients manage their medication? 
  
Signatures 
By signing this document I am confirming that I have read, understood and 
approve the protocol for the above study. 
 
Prof Marion McMurdo    
Chief Investigator Signature  Date 
    
Mrs. Roberta L Fulton    
Principal Investigator Signature  Date 
    
    
    
    
   
    
    
    
    




    
CONTACT DETAILS 
CHIEF INVESTIGATOR 
Professor M.E.T McMurdo 
Ageing & Health 
Mailbox 1  
Medical Research Institute  
Division of Diabetes & Cardiovascular Medicine  
Ninewells Hospital,  
Dundee  
DD1 9SY  
Email: m.e.t.mcmurdo@dundee.ac.uk 
Telephone: 01382 383086 
 
PRINCIPAL INVESTIGATOR           
Mrs. R L Fulton      
Research Fellow        
Ageing & Health      
Mailbox 1        
Medical Research Institute       
Division of Diabetes & Cardiovascular Medicine    
Ninewells Hospital,        
Dundee DD19SY       
Email: r.l.z.fulton@dundee.ac.uk        
Telephone: 01382 383086    




SPONSOR       
University of Dundee & Tayside Health Board 
Sponsor’s representative: 










Dr. M Witham                                            Professor Thilo Kroll          
Ageing & Health                                        Social Dimensions Health Institute 
Mailbox 1                                 School of Nursing          
Medical Research Institute                    11 Airlie Place           
Diabetes & Cardiovascular Medicine        Dundee                 
Ninewells Hospital                                     Email: t.kroll@dundee.ac.uk  
Dundee           Telephone 01382 388655 
DD1 9SY                     
Email:m.witham@dundee.ac.uk  
Telephone: 01382 383086 
                                                
                                            







ACEi: angiotensin-converting enzyme inhibitors  
CHF: chronic heart failure 
CSO: Chief Scientist Office 
ESC: European Society of Cardiology  
GCP: good clinical practice  
HF: heart failure  
NHS R&D: National Health Service Research and Development 
NYHA: New York Heart Association 
REC: Research Ethics Committee 


















Heart Failure (HF) is a major cause of disability, hospitalisation and death, particularly 
amongst older people. Prognosis remains poor despite the improvements in 
prevention and treatment achieved through the prescribing of effective medications. 
Evidence suggests that adherence to medication is sub-optimal but there is a lack of 
current data identifying which modifiable factors are associated with poor adherence 
in older HF patients. This study forms part of a programme of work, which aims to 
address these issues, culminating in the development of a tailored intervention to 
enhance medication adherence in older HF patients. 
This study is the first stage of this programme of work. This qualitative study will use 
a purposive sampling approach to recruit up to 12 older HF patients and their 
nominated carers to participate in a semi-structured interview to explore their 
understanding of heart failure and medication, along with the perceived drivers and 
barriers to adherence. The findings of this study will be used, along with information 
gleaned from the updating of a recent systematic review (1), to guide development of 
the next phase of this programme of work. 
1. INTRODUCTION 
Heart Failure (HF) is a major cause of disability, hospitalisation and death, particularly 
amongst older people (2). It currently affects approximately 900,000 people in the UK. 
Despite improvements in the prevention and treatment of HF the prognosis remains 
poor with a median survival following a first episode of decompensated HF being 2.3 
years for men and 1.8 years for women (3). The annual cost of heart failure to the NHS 
is estimated to be 4% (direct costs of 1.9%) of the total NHS expenditure, with 
hospitalisation being the predominant cost component. 
The improvements, which have been achieved in symptoms and mortality, are due in 
large part to the prescribing of effective medications such as angiotensin-converting 
enzyme inhibitors (ACEi), beta-blockers and spironolactone. While there is clear 
evidence that these medications improve survival and reduce hospitalisation rates due 
to HF, there is also evidence to suggest that adherence to medication is sub-optimal 




non-adherence to medication remains a significant barrier to optimising outcomes for 
those with CHF and so presents a modifiable target for intervention. 
In observational studies poor adherence to medication is associated with worse 
outcomes for CHF patients. Strategies to improve adherence to drug therapy in CHF 
has the potential to both improve health outcomes and reduce the burden on the health 
budget. One of the largest studies of adherence in CHF patients found that only 80% 
of patients with a prescription for ACEi at hospital discharge actually filled the 
prescription in the following 30 days, with this rate dropping further to only 60% of 
prescriptions being refilled at 12 months (5). The Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity study (CHARM) concluded that 
adherence was independently associated with improved clinical outcome, even in the 
placebo group (6) .  This relationship between adherence and improved outcomes in 
all-cause mortality, even to placebo, suggests that adherent behaviour itself is 
associated with clinical outcome and highlights the requirement to find ways to 
improve medication adherence.  
In the last two years there have been a number of studies published showing that 
simple well-specified behaviour change strategies that could be incorporated into 
routine nursing care can increase adherence to medications in a number of conditions. 
These include patients with Type 2 diabetes (7) and in a recent chief Scientist Office 
(CSO) funded study of patients following stroke (8). The potential for these kinds of 
interventions has not been examined in the context of chronic heart failure, which has 
similar e.g. complex regimens, but also unique challenges e.g. a distinct symptom 
profile. 
A recently performed systematic review of interventions to enhance adherence to 
medications in patients with heart failure concluded that limited high quality evidence 
evaluating the effectiveness of specific adherence enhancing interventions currently 
exists and called for further research to identify the optimum strategies for 
implementation into clinical practice (1).  
In order to address this lack of evidence gaps in existing knowledge need addressed, 




a) To understand what are the beliefs which are currently commonly held around HF 
and its management by older HF patients and their nominated carers  
b) To identify which of these commonly held beliefs around HF and medication 
consistently predict medication adherence and which can be modified 
c) To use the information gathered to identify which adherence enhancing strategies 
could be implemented for evaluation at a later date. 
2. RESEARCH QUESTIONS 
This qualitative phase of the study aims to answer the following questions: 
a. What are the beliefs and attitudes older heart failure patients and their informal 
caregivers hold about their disease and its treatment? 
b. What are the barriers and drivers to medication adherence for heart failure patients? 
3. STUDY DESIGN 
The methodology for this qualitative study follows the framework approach based on 
work developed at the National Centre for Social Research by Ritchie and Lewis (9). 
This approach, widely used in healthcare research, draws on characteristics of the 
scientific model while adapting them to suit the nature of qualitative data which is more 
appropriate for exploring the complexities of health and well-being, assisting the 
investigator to achieve a deeper understanding of the patient experience (10). The 
underpinning principles of the framework approach are based on the concepts of 
interpretivism and reflexivity, balancing them with pragmatism and transparency (11). 
This approach is in direct contrast to other entirely inductive approaches, such as 
grounded theory, were the research design is not strictly predefined but developmental 
in response to the data obtained. 
Using this approach the investigator will aim to remain as objective and neutral as 
possible during the collection, interpretation and presentation of the data while 
minimising the extent of their influence on the participant. The use of topic guides to 
facilitate the interview process as advocated by the framework approach will support 
the investigator to identify patterns within the data. While the investigator recognises 




framework approach can be used to undertake qualitative data analysis systematically 
enabling the exploration of the data in depth while simultaneously maintaining an 
effective and transparent audit trail, enhancing the rigour of the analytical processes, 
something that some published qualitative studies often lack (10).  
Study type: This Qualitative study will comprise of the following:    
• Individual semi structured interviews, using structured topic guides, with older 
heart failure patients taking place within their own home or another nominated 
site. 
• Focus groups, using structured topic guides, comprising relatives or other 
nominated informed carers of those who have been diagnosed with heart 
failure.  
4. STUDY POPULATION 
The study is a single site study (NHS Tayside Area) 
Study population:  
a) Community dwelling people ages 70 and over with a diagnosis of chronic 
heart failure according to the European Society of Cardiology (ESC) 
guidelines and with evidence of left ventricular systolic dysfunction. 
b) Nominated informed carers of the participants described above. 
Participants will be recruited from the following various sources: 
• Secondary care via Heart Failure and Medicine for the Elderly outpatient 
clinics. 
• Secondary care via medical wards in Ninewells Hospital 
• Primary care via primary care Heart Failure outpatient clinics. 
• Heart Failure nurse liaison service  
The use of the above range of recruitment methods will ensure that the study 
population includes recently hospitalised patients whose heart failure may not be 
optimally controlled as well as those patients who are being managed successfully 





4.1 INCLUSION CRITERIA 
Age 70 years and over 
Living in own home or sheltered housing 
Existing diagnosis of chronic heart failure according to ESC guidelines:  
• Presence of breathlessness or tiredness on exertion or at rest 
• Presence of structural heart disease on imaging 
Left ventricular systolic dysfunction (on echocardiogram) or other cardiac imaging 
New York Heart Association class II, III or IV 
4.2 EXCLUSION CRITERIA 
Unable to give written informed consent 
Residing in Nursing home or Residential Home Environment 
Currently receiving daily visits from district nursing service to administer medications 
5.  PARTICIPANT SELECTION AND ENROLMENT 
Patients meeting the inclusion criteria, identified from any of the previously identified 
sources, will be considered for enrolment in the study: 
Participants will be recruited to participate in a one using a purposive sampling 
strategy as described by Patton (12)  chosen to provide the researchers with a detailed 
picture of living with heart failure by encompassing a range of demographic variables. 
Using information gleaned from the reading of current literature two key variables have 
been chosen as selection criteria –  
1. Gender  
2. Recent hospital admission following an episode of decompensated heart 
failure. 
Evidence exists to show that different views and beliefs are held by men and women 
regarding their amount of medication use, their adherence to medications, and their 
likelihood of receiving ongoing medication monitoring (13) while a recent systematic 




institutionalisation including hospitalisation  was associated with adherence to 
medication (14).  
Potential participants will be identified within the relevant clinic or inpatient areas my 
members of the medical and nursing team who will supply a copy of the PIS and reply 
slip or seek permission for a member of the research team to send study information 
to the potential participants’ home address. The potential participant will have the 
opportunity to consider the study by reading the PIS and respond by returning the 
reply slip using the prepaid envelope supplied.  This will allow the principle investigator 
to contact potential participants to discuss the study in more detail and establish if they 
meet the selection criteria by referring to the sampling matrix. All participants meeting 
the inclusion criteria will be asked to nominate an informal carer to participate in the 
carer’s interview. Those patients unable to nominate a carer will still be eligible to 
participate in the individual interview should they meet the selection criteria as directed 
by the sampling matrix.  
6.  PLAN OF INVESTIGATION 
This study aims to ensure that while all main elements are covered diversity is also 
included to ensure each element can be explored thoroughly. Purposive sampling of 
eligible participants will be carried out using a sampling matrix. Given the experience 
within the investigating team with this type of research it is anticipated that up to 12 
heart failure patients and 12 nominated carers will be required to achieve data 
saturation. Recruitment will however cease early should saturation be realised at an 
earlier point. 
Participants selected will be invited to participate in the individual interview and will be 
given the opportunity to nominate an alternative setting should they not wish the 
interview to be conducted in their home.  Nominated carers will be asked to participate 
in either an individual interview or a small focus group depending on their preference. 
6.1 CONSENT 
The Principal Investigator will be responsible for ensuring written informed consent is 




Participants will receive adequate oral and written information – appropriate 
Participant Information will be provided at least 48 hours prior to potential participation.   
The oral explanation to the participant will be performed by the Principal Investigator 
and must cover all the elements specified in the Participant Information 
Sheet/Informed Consent, The participant will be given every opportunity to clarify any 
points they do not understand and, if necessary, ask for more information.  Sufficient 
time will be given to each participant to consider the information provided.  It will be 
emphasised that the participant may withdraw their consent to participate at any time 
without it affecting any medical care in the future. 
The participant will be asked to agree to their medical records being inspected by 
regulatory authorities but understand that their name will not be disclosed outside the 
hospital. 
The Investigator or delegated researcher and the participant will sign and date the 
Informed Consent Form(s) to confirm that consent has been obtained.  The participant 
will receive a copy of this document and a copy will be filed in the Trial Master File. 
6.2 DATA COLLECTION 
Prior to commencing the interview the permission will be sought to tape record the 
interview for transcribing by the investigator at a later date. Patient demographics 
including age, sex, home circumstances including postcode and formal help at home 
will be collected along with a list of the patient’s current medication. The interview will 
be conducted using the appropriate topic guide (see appendix) and recorded 
throughout.  
A review of the literature highlighted depression as a common variable in medication 
adherence thus mood will be formally assessed in all participants with the their 
permission using a commonly used assessment tool - the Hospital Anxiety and 
Depressions Scale 
Interviews with participants will continue alongside data analysis with the recruitment 
of participants continuing until data saturation occurs. All interviews will be tape 
recorded by and transcribed from audiotapes by the principal investigator. . A unique 




6.3 DATA ANALYSIS 
Analysis of all the data will be conducted using NVivo software.  The principal 
investigator, in order for familiarisation of the data to occur, will carry out transcribing 
of the taped interviews. The framework approach is based on thematic analysis and 
will be used to underpin all data analysis. Thematic frameworking is an interpretive 
process, which aims to develop meaningful themes representing participants’ 
accounts. The data will be systematically searched and analysised by the investigator 
to identify patterns.   
Using thematic frameworking the investigator will classify and code the data 
transcribed from the interviews according to key themes, concepts and emergent 
categories. The categories will be refined through familiarisation with the raw data and 
the subsequent cross-sectional labeling subdivided by a succession of related sub-
themes or topics.  
Once a comprehensive list of main and sub-themes has been obtained each one will 
be charted in a matrix. The response of each research subject will be allocated a row 
with each column representing a separate subtopic. Finally the investigator will 
summarise or synthesise the original data from each participant. Importantly the key 
terms phrases or expressions used by the research participants will be retained as 
much as possible. Interpretation will be kept to a minimum and material will not be 
dismissed just because it is not immediately obvious where it should be included in 
the analysis. 
7. INSPECTION OF RECORDS 
Chief and Principle Investigators and institutions involved in the study will permit study 
related monitoring, audits, and REC review  In the event of an audit, the Investigator 
agrees to allow the Sponsor, representatives of the Sponsor or regulatory authorities 
direct access to all study records and source documentation. 
8. STUDY MONITORING 
The study may be subject to monitoring by the Sponsor or Research Ethics 





9. RISK ASSESSMENT 
Risks of study: Occasionally when discussing ill health or life events participants may 
become emotionally distressed. 
Minimising the risk: The investigator is an experienced research nurse with many 
years’ experience dealing with older people with heart failure and has undergone 
appropriate training. 
10. ETHICAL CONDUCT OF THE STUDY 
The study will be conducted in accordance with the principles of the good clinical 
practice (GCP). A favourable ethical opinion will be obtained from the appropriate REC 
and local NHS R&D approval will be obtained prior to commencement of the study. 
11. REGULATORY COMPLIANCE OF THE STUDY 
The study will not commence until research sponsor approval, favourable ethics 
opinion and local NHS R+D approval are in place  
12. CONFIDENTIALITY 
All transcribed interviews, field notes, reports, and other records will be identified in a 
manner designed to maintain participant confidentiality.  All records will be kept in the 
allocated secure storage area within Department of Ageing & Health, Ninewells 
Hospital.  Information will not be released without the written permission of the 
participant, except as necessary for monitoring and auditing by the Sponsor, its 
designee, Regulatory Authorities, or the REC.  The Investigator and study site staff 
involved with this study will not disclose or use for any purpose other than performance 
of the study, any data, record, or other unpublished, confidential information disclosed 
to those individuals for the purpose of the study.  Prior written agreement from the 
Sponsor or its designee will be obtained for the disclosure of any said confidential 
information to other parties. 
13. DATA PROTECTION 
All study site staff involved with this study will comply with the requirements of the Data 
Protection Act 1998 with regard to the collection, storage, processing and disclosure 
of personal information and will uphold the Act’s core principles. Access to collated 




Computers used to collate the data will have limited access measures via user names 
and passwords. 
Published results will not contain any personal data that could allow identification of 
individual participants. Quotations will be anonymised and labeled with participant 
study numbers only in published documents 
13.1 Insurance and Indemnity 
The University of Dundee and Tayside Health Board are Co-Sponsoring the study. 
Insurance – The University of Dundee will obtain and hold a policy of Public Liability 
Insurance for legal liabilities arising from the study]. 
Tayside Health Board will maintain its membership of the Clinical Negligence and 
Other Risks Insurance Scheme (“CNORIS”) which covers the legal liability of Tayside 
in relation to the study]. 
Where the study involves University of Dundee staff undertaking clinical research on 
NHS patients, such staff will hold honorary contracts with Tayside Health Board which 
means they will have cover under Tayside’s membership of the CNORIS scheme. 
Indemnity Co-Sponsors do not provide study participants with indemnity in relation to 
participation in the Study but have insurance for legal liability as described above. 
14. STUDY CONDUCT RESPONSIBILITIES 
Protocol Amendments, deviations and breaches 
The CI will seek approval for any amendments to the Protocol or other study 
documents from the Sponsor, REC and NHS R&D Office. Amendments to the protocol 
or other study docs will not be implemented without these approvals.  
In the event that a CI needs to deviate from the protocol, the nature of and reasons for 
the deviation will be documented and submitted to the Sponsor. If this necessitates a 
subsequent protocol amendment, this will be submitted to the Sponsor for approval 
and then to the appropriate REC and lead NHS R&D Office for review and approval.  
In the event that a serious breach of GCP is suspected, this will be reported to the 
Sponsor immediately using the form “Notification to Sponsor of Serious Breach or 




15. STUDY RECORD RETENTION 
All study documentation will be kept for at least 5 years. Archiving will take place 
according to current TASC standard operating procedures. 
16. PUBLICATION 
The information collected by the study will be used for publication and presentation at 
scientific meetings. Investigators have the right to publish orally or in writing the results 
of the study. 
17. PEER REVIEW 
The proposal for this study formed part of a fellowship award which has been 
subjected to external peer review via the CSO, the funding body. 
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Title of Project: How do older Heart Failure patients manage their 
medication? 
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1. I confirm that I have read and understood the information sheet 
dated 10/04/14 (version 1.0) for the above study.  I have had 
the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without any 
medical care or legal rights being affected. 
3. I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by regulatory 
authorities from the University of Dundee or from NHS 
Tayside, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my 
records. 
4. I agree to the audio tape recording of the interview which will 
be anonymised 
5.  I agree to take part in the above study. 
 
 
Participant name (Block Capitals)             Date   Signature  
 
 












                                                                                 
 
PARTICIPANT INFORMATION SHEET 
 
How do older Heart Failure patients manage their 
medication: An Observational Study  
 
Invitation 
My name is Roberta Fulton and I am undertaking a project as 
part of my PhD at the University of Dundee. I invite you to take 
part in the following study. Before you decide to do so, I need to 
be sure that you understand firstly why I am doing it, and 
secondly what it would involve if you agreed. I am therefore 
providing you with the following information. Please read it 
carefully and be sure to ask any questions you might have and, 
if you want, discuss it with others including your friends and 
family. I will do my best to explain the project to you and provide 
you with any further information you may ask for now or later. 
You do not have to make an immediate decision. 
 
Why are we doing this study? 
As researchers we are interested in the views that older people 
with heart failure have about their health, medicines and 
treatment. We are also interested in your day-to- day 
experiences living with your medications. The results of this 
study will help us understand how well people with heart failure 
understand their condition and how they deal with their 




you to take part in this study. This knowledge will help other 
people get the best from their treatments in the future. 
 
We are always interested in the views of your family or those 
people who care for you. We would like you to suggest someone 
you think may want to help us. If so, they will be asked to 
complete a questionnaire relating to heart failure and return it in 
a free-post envelope. This is also voluntary, and they can say 
‘no’ at any time, however you can take part even if you feel you 
do not wish to recommend a friend or carer. 
  
Why Have I Been Invited? 
You have been invited because you are aged 70 years or over 
and are currently prescribed medication commonly used to treat 
people with a condition called heart failure. This condition means 
the heart does not pump enough blood to meet all the needs of 
the body, usually because the heart muscle has been damaged. 
This condition is not uncommon; around 900,000 people in the 
UK have a diagnosis of heart failure, which may result in 
symptoms such as breathlessness and tiredness. Many people 
suffering from heart failure are prescribed daily tablets by their 
doctor to help control their condition. We are asking a minimum 
of 60 older people with heart failure to participate in the study. 
 
How Will The Study Help Me? 
While we cannot promise the study will help you, you may find 
the opportunity to talk about your experience beneficial. The 
information we get will help other older people with heart failure 
in the future, because we will have a better idea of what they 
understand about their heart condition and medication and how 
they manage their medication. We aim to use this information to 
design a programme which may help people with heart failure to 






Do I have to take part? 
It is up to you to decide. Participation in this study is entirely 
voluntary and you are free to refuse to take part or to withdraw 
from the study at any time without having to give a reason and 
without this affecting your future medical care or your 
relationship with medical or nursing staff looking after you. 
Remember you can take part even if you feel you do not wish to 
recommend a friend or carer. 
 
What will happen to me if I take part? 
If you feel you may be able to help us and complete the enclosed 
reply slip, I (Roberta Fulton) will telephone you to discuss the 
study further. 
 
The telephone call 
I will first phone you at home to ask you some short questions 
about your health and current medication. If these questions 
suggest that the study is suitable for you, we will arrange for you 
to visit your local hospital. If you would prefer, I can visit you at 
home or at another place convenient for you. 
  
The study visit 
Should you be happy to travel to the hospital we can pay for a 
taxi or other transport to collect on the day of the visit and take 
you home again. You may ask a friend or relative to accompany 
you to the visit should you wish it. 
At the visit, which should last around 2 hours, we will go over the 
study information; you will have the opportunity to ask any 
questions you want to about the study. If you are happy to take 
part, we will ask you to sign a consent form. You will be given a 





At this visit, we will do the following: 
• We will take a note of your medicines and medical 
conditions 
• Ask you to provide a small sample of urine, this will be 
tested for levels of one of the medications if you are currently 
taking called Furosemide. 
• Test your walking speed and balance 
• Take some blood (about a teaspoonful), this will be sent to 
the laboratory and tested for levels of another of the medications 
if you are currently taking, it may have a name like Ramipril, 
Lisinopril or Perindopril. 
• Ask you to complete nine Questionnaires. These 
questionnaires relate to your health, medication taking, mood 
and memory. I can help you to complete these if you wish. 
 
Will my GP know about this research project? 
If during your study visit we discover anything we feel your GP 
should be aware of, we will ask for your permission to share 
these f indings with your GP. 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course 
of this study will be kept strictly confidential. 
Your research data will be stored using a unique study code 
which does not identify you. All written information will be kept in 
a locked filing cabinet in a locked room. Any web-based data will 
be stored in a secure password protected central database. Only 
individuals directly involved with the study will have access to 
this information. 
 It is a requirement of the regulators that your records in this 




available for scrutiny by appropriate monitors from NHS Tayside. 
This procedure is routine and carried out by fully qualified 
officials, and data confidentiality is preserved at all times. 
 
At the end of the study the confidential records will be kept for 
10 years and then destroyed. The confidential handling, 
processing, storage and disposal of data are in accordance with 
the Data Protection Act 1998. Should you change your mind and 
not wish your information to be stored you may contact the 
research team at any time and ask that it be destroyed. 
 
We will also ask your permission to allow us access your paper 
and electronic medical records for a period of five years. This will 
help us obtain information on your health now and over the next 
five years to investigate the long-term effects of your treatment. 
 
The blood sample will be sent to the local NHS laboratory for 
analysis. The result will be stored indefinitely using your name 
and unique hospital record number within the NHS clinical 
system and can be made available to specialist doctors for your 
future health care needs. The urine sample will be stored until all 
participants have been recruited before being analysed by 
colleagues at the University of Dundee laboratories. The 
samples will be destroyed after they have finished analysing it. 
 
What will happen to the results? 
The results will be examined by the researchers who have 
organised the study and a short report will be produced. You will 
not be identified in this report. The results will be shared with the 
funder for the study (The Scottish Government’s Chief Scientist 
Office.) The results will then be published in scientific journals. 




would like a copy of the full results, please let us know; we will 
give everyone who takes part a summary of the main results. 
 
Who is organising and funding this research? 
The study has been organised by Dr Miles Witham and 
colleagues at the University of Dundee. The study is funded by 
the Scottish Government’s Chief Scientists Office and 
sponsored by the University of Dundee and NHS Tayside. 
  
What are my rights? 
If you have any concerns about your participation in the study 
you have the right to raise your concern with a researcher 
involved in conducting the study or a doctor involved in your 
care. If you have a complaint about your participation in the 
study, you should first talk to a researcher involved in the study.  
However you have the right to raise a formal complaint. 
You can make a complaint to a senior member of the research 
team or to the Complaints Officer for NHS Tayside: 
 
Complaints and Feedback Team 
The Business Unit, Level 7, Laboratory Corridors B and F 
Ninewells Hospital, Dundee DD1 9SY 
Freephone: 0800 027 5507 
Email:feedback.tayside@nhs.net 
 
In the event that you think you have suffered harm as a result of 
your participation in the study there are no automatic financial 
compensation arrangements. However, you may have the right 
to make a claim for compensation against the University of 
Dundee or NHS Tayside. If you wish to make a claim, you should 
consider seeking independent legal advice but you may have to 





The University of Dundee maintains a policy of public liability 
insurance which provides legal liability cover in respect of 
damages, costs and expenses arising out of claims. 
 
Tayside Health Board is a member of the Clinical Negligence 
and Other Risks Insurance Scheme which provides legal liability 
cover. 
 
Who has reviewed the study? 
The East of Scotland Research Ethics Service REC 1, which has 
responsibility for scrutinising all proposals for medical research 
on humans, has examined the proposal and has raised no 
objections from the point of view of medical ethics. It is a 
requirement that your records in this research, together with any 
relevant medical records, be available for scrutiny by monitors 
from University of Dundee and NHS Tayside, whose role is to 
check that research is properly conducted and the interests of 
those taking part are adequately protected. 
  
What to do now: 
Now that you have read the information sheet, please think about 
it and discuss it with friends or family if you wish. If you would 
like to talk to a member of the research team about the study, 
please contact Roberta on the phone number below or return the 
reply slip in the self-addressed envelope and Roberta will contact 
you. 
 
Thank you for reading this Information Sheet and considering 




By returning the form you are only agreeing that the researcher 
may phone you. You can make a decision on whether to take 
part after speaking to her 
 
Mrs Roberta Fulton 
 
 Call on: 01382 383086 
 
 











APPENDIX F  
                            
 
CARERS INFORMATION SHEET 
Study title: How do older Heart Failure patients 
manage their medication? 
Chief Investigator: Prof Marion McMurdo 
INVITATION 
My name is Roberta Fulton and I am required to undertake a 
project as part of my PhD at the University of Dundee. I invite 
you to take part in the following study, however, before you 
decide to do so, I need to be sure that you understand firstly why 
I am doing it, and secondly what it would involve if you agreed. I 
am therefore providing you with the following information. Please 
read it carefully and be sure to ask any questions you might have 
and, if you want, discuss it with others including your friends and 
family. I will do my best to explain the project to you and provide 
you with any further information you may ask for now or later. 




ABOUT THIS RESEARCH 
As researchers we are interested in the views that older people 
with heart failure hold about their health, medication and 
treatment as well as their experiences of day to day life. The 
results of this study will help us understand how well informed 
people with heart failure are about their medical conditions and 
prescribed treatments.  We are also interested in the 
experiences of relatives or carers of people diagnosed with heart 
failure. This knowledge will help other people get the best from 
their treatments in the future. 
To help us understand your views, we are inviting you to 
participate in either a one to one interview with a researcher or a 
small focus group with other people who also care for someone 
diagnosed with heart failure. Your may also find that we have 
already invited someone you know to help us.   
 
WHY HAVE I BEEN INVITED? 
You have been invited because you care for someone aged 70 
years or over who have had a diagnosis of heart failure. This 
means their heart does not pump enough blood to meet all the 
needs of their body, usually because the heart muscle has been 
damaged. They are not alone; around 900,000 people in the UK 




symptoms such as breathlessness and tiredness. Many people 
suffering from heart failure are prescribed daily tablets by their 
doctor to help control their condition. We are asking a total of 12 
older people with heart failure and 12 nominated carers to 
participate in the study. 
 
WHAT WILL TAKING PART INVOLVE? 
If you feel you may be able to help us, and complete the enclosed 
reply slip Roberta Fulton will telephone you to discuss the study 
further. If you are agreeable: 
• Roberta will then arrange to either visit you individually at 
your home or at a place convenient for you or arrange for you to 
attend a venue where you will be part of a small informal group 
sharing your views with other people who may be in a similar 
situation to yourself.  
• Roberta will discuss the carers information sheet with you 
ask you to sign a consent form indicating you wish to take part 
in the study.   
• You will be asked some questions about your 
understanding of heart failure and its treatment and your opinion 





• Roberta will ask your permission to record the interview so 
she can listen to it again to make sure we fully understand your 
views. The researcher will agree a false name with you so that 
what you say can be quoted later without revealing your identity. 
• The interview will last around one hour, everything you tell 
us is confidential and will not be directly fed back to the person 
you care for.   
 
HOW WILL THE STUDY HELP ME? 
While we cannot promise the study will help you, you may find 
the opportunity to talk about your experience beneficial. The 
information we get will help other older people with heart failure 
in the future, because we will have a better idea of what they 
understand about their heart condition and medication.  
 
DO I HAVE TO TAKE PART? 
No.   Participation in this study is entirely voluntary. If you choose 
not to take part, you do not have to give a reason.  You are also 
free to change your mind at any time without having to give a 







We would like to record the discussions. All the information you 
give is strictly confidential. At the start of the study you will be 
assigned an identity (ID) number to protect your anonymity. 
Instead of using your name, the recording and the written copy 
of the discussions will be stored with a code. The information will 
be kept in a locked room and held on a secure computer. Only 
the researchers involved in the study will have access to this 
information.  At the end of the study the recordings and any other 
identifiable information held on our computer will be destroyed. 
You will never be identified in any study report or publication.  
 
WHAT WILL HAPPEN AT THE END OF THE STUDY? 
The results will help us design the next phase of our research. 
This will look at how well older people with heart failure manage 
to take their medication as it has been prescribed. The 
information we collect will also be used to write up the results 
from the study as a publication in a medical journal. The Scottish 
Government, which funds the research, will receive a report of 
our overall findings. None of your personal details will appear in 
any report, presentation or publication arising from the research 
and  all collected data will be destroyed 5 years from the end of 




WHAT IF THERE IS A PROBLEM? 
In the event that something goes wrong and you are harmed 
during the study there are no special compensation 
arrangements.  If you are harmed and this is due to someone’s 
negligence then you may have grounds for a legal action for 
compensation against the University of Dundee or NHS Tayside 
but you may have to pay your legal costs.  The normal National 
Health Service complaints mechanisms will still be available to 
you (if appropriate). 
If you have a complaint about your participation in the study you 
should first talk to a researcher involved in your care. You can 
ask to speak to a senior member of the research team or the 
Complaints Officer for NHS Tayside: 
Complaints and Claims Manager 
Complaints and Advice Team 
Level 7, Ninewells Hospital 
Dundee DD1 9SY 








WHO HAS REVIEWED THE STUDY? 
The study has been looked at by an independent group of people 
called a Research Ethics committee, who are there to protect 
your interests. The study has been reviewed and approved by 
East of Scotland Research Ethics Committee. It is a requirement 
that your records in this research, together with any relevant 
medical records, are made available for scrutiny by monitors 
from the University of Dundee and NHS Tayside. Their role is to 
check that research is properly conducted and the interests of 
those taking part are adequately protected. 
 
WHAT DO I DO NOW? 
Now that you have read the information sheet, please think about 
it and discuss it with friends or family if you wish. If you would 
like to talk to a member of the research team about the study, 
please contact Roberta on the phone number below or return the 










Mrs Roberta Fulton 
Research Fellow 
Ageing and Health 




Telephone: 01382 383086 
Email: r.l.z.fulton@dundee.ac.uk 
Professor Marion McMurdo 
Division of Diabetes & Cardiovascular Medicine 
Ninewells hospital and Medical School 
Dundee DD1 9SY 
Telephone 01382 383086 
Thank you for reading this Information Sheet and considering 
taking part in this study. 
By returning the form you are only agreeing that the researcher 
may phone you. You can make a decision on whether to take 




CARER REPLY SLIP 
Study title: How do older Heart Failure patients 
manage their medication? 
CI: Prof Marion McMurdo   PI: Roberta Fulton 
Yes, I would like to take part in this study, and I am happy to be 
contacted by the research team to make arrangements  





Home telephone number(s): 
………………………………………………………………. 




When would be a good time for us to call? 








Carers Identification Number  
 
Title of Project: How do older Heart Failure patients manage 
their medication? 
 
                                                                                                                                            Please initial box 
1. I confirm that I have read and understood the information 
sheet dated 10/04/14 (version 1.0) for the above study.  I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without giving any 
reason, without any medical care or legal rights being 
affected. 
 
3. I agree to the audio tape recording of the interview which 
will be anonymised. 
 
4. I agree to take part in the above study. 
 
 














How do older Heart Failure patients manage their 
medication? 
 
Topic Guide Discussion for interviews with Patients  
1. Present Circumstances 
• Age 
• Current living arrangements including: who lives with them, 
postcode and area, supportive network, previous occupation? 
2. Just to get started, can you tell me a little bit 
about any medical conditions you have? –  
• Names 
• How long you have had them, 
• What is the prognosis for each of them,  
3.  Tell me a bit about long you have suffered from 
your heart condition 
(Symptoms; Cause; timeline; consequences i.e. physical social 
emotional; cure and controllability) 
• Can you remember when and who told you about the 




• Are you able to describe what you thought when they told 
you 
• Can you explain to me what the problem with your heart 
actually is 
• Are you able to describe to me any symptoms you may 
have which you feel are related to your heart problem,  
• Can you tell me does anything help you with these 
symptoms? 
• Tell me about any regular heath checkups you may be 
having (who, when what where) 
• What effect do these appointments have? If anything 
4. Let’s focus specifically on your general health for 
now.  When it comes    specifically to health issues – 
what would you say are the biggest problems that 
you face? 
• Which condition do you think is most serious,  
• Why do you think that? 
• Which condition, if any, causes you more problems than the 
others  




• Tell me how do you overcome theses problems? Is there 
anything you do? 
• Do any of your medical conditions make you worry, which 
ones, why  
5. Now, let’s talk about your medicines for a few 
minutes.  
(necessity & concerns; medication knowledge; social influences; 
impact of medication on lifestyle)  
• Can you tell me a little about the medications you are 
taking? – Names, dose, how often you take them 
• In which way do you think these tablets help your condition? 
-  
• Sometimes people who take tablets long term say they 
have problems with their medication. Can you tell me about any 
problems you may be having with these tablets. 
• Would you say any of your medications cause any side 
effects? – If so which tablets, what are the symptoms, what do 
you do to deal with these side effects? 
• Can you tell me about any issues about taking your 






6.    Overall can you describe to me how do you think 
your health will affect    your life over the next few 
years? 
• Physically, emotionally, financially, relationships with 
friends and family 
7.  Are there any questions that you want to ask us, 
or final words you like to tell me about what health 
professionals need to know about patients with heart 














How do older Heart Failure patients manage their 
medication? 
Topic Guide Discussion for interviews with 
Nominated Carers 
 
1. Present Circumstances 
• Age 
• Current living arrangements including: who lives with them, 
employment status, postcode and area, supportive network,  
• How often they visit xx, hours per week, help they require 
to give 
2. Just to get started, can you tell me a little bit 
about what you know about the medical conditions 
xxx has?  
• List, Prognosis for each, how long they have had them, how 







3. Tell me a bit about long they have suffered from 
their heart conditions 
(Symptoms; Cause; timeline; consequences i.e. physical social 
emotional; cure and controllability) 
• Can you remember who told you that xxx had a problem 
with their heart 
• Are you able to describe what you thought when they told 
you 
• Can you explain to me what the problem with their heart 
actually is 
• Are you able to describe to me any symptoms you may 
have which you feel are related to their heart problem,  
• Can you tell me of anything, which helps xxx cope with 
these symptoms? 
• Tell me about any regular heath checkups they may be 
having (who, when what where) 
• Can you tell me in what way if any these appointments help 






4. Let’s focus specifically on xxx’s general health for 
now.  When it comes specifically to health issues – 
what would you say are the biggest problems that 
they face? 
• Which condition do you think is most serious  
• Do you think one condition causes them more problems 
than the others and if so in what way 
• Tell me about the things they do to overcome these 
problems 
5. Now, let’s talk about xxx’s medicines for a few 
minutes.  Can you tell me anything about the 
medications they are taking? – Names, dose, how 
often? 
(necessity & concerns; medication knowledge; social influences; 
impact of medication on lifestyle) 
• In which way do you think these tablets help their condition 
• Sometimes people who take tablets long term say they 
have problems with their medication. Can you tell me about any 
problems you may think xx’s may be having with their tablets? 
• Can you tell me about any issues about their medication, 




6. Overall can you describe to me how you think 
xx’s health will affect their life over the next few 
years? 
• Can you describe to me if in any way, xx’s health affects 
you? 
• How do you think their health conditions will impact on your 
life over the next few years? 
7.  We have talked about xx health, are you currently 
having any issues with your own health? 
Conditions? Medications? Impact on your life? How 
do you see your own health and personal 
circumstances impacting on xx over the next few 
years? 
8. Are there any questions that you want to ask us, 
or final words you like to tell me about what health 








How do older Heart Failure patients manage their 
medication? 
Focus Group Topic Guide 
 
• What does everybody understand by the term ‘Heart 
Failure?’ 
 
• What treatments are available – medication and others 
and how well are these managed – what help is available to 
patients and carers? 
 
• What is the day to day effect of heart failure on patient 
and carers – how does it fit in with other illnesses? 
 
• What does the future hold for both patient and family 
because of heart failure? 
 













                        
 
PARTICIPANT INFORMATION SHEET 
How do older Heart Failure patients manage their 
medication: An Observational Study 
Invitation 
My name is Roberta Fulton and I am undertaking a project as 
part of my PhD at the University of Dundee. I invite you to take 
part in the following study. Before you decide to do so, I need to 
be sure that you understand firstly why I am doing it, and 
secondly what it would involve if you agreed. I am therefore 
providing you with the following information. Please read it 
carefully and be sure to ask any questions you might have and, 
if you want, discuss it with others including your friends and 
family. I will do my best to explain the project to you and provide 
you with any further information you may ask for now or later. 





Why are we doing this study? 
As researchers we are interested in the views that older people 
with heart failure have about their health, medicines and 
treatment. We are also interested in your day-to-day experiences 
living with your medications. The results of this study will help us 
understand how well people with heart failure understand their 
condition and how they deal with their treatments. To help us 
understand these views, we are inviting you to take part in this 
study. This knowledge will help other people get the best from 
their treatments in the future. 
 
We are always interested in the views of your family or those 
people who care for you. We would like you to suggest someone 
you think may want to help us.  If so, they will be asked to 
complete a questionnaire relating to heart failure and return it in 
a free-post envelope. This is also voluntary, and they can say 
‘no’ at any time, however you can take part even if you feel you 
do not wish to recommend a friend or carer. 
 
Why Have I Been Invited? 
You have been invited because you are aged 70 years or over 
and are currently prescribed medication commonly used to treat 




the heart does not pump enough blood to meet all the needs of 
the body, usually because the heart muscle has been damaged.  
This condition is not uncommon; around 900,000 people in the 
UK have a diagnosis of heart failure, which may result in 
symptoms such as breathlessness and tiredness. Many people 
suffering from heart failure are prescribed daily tablets by their 
doctor to help control their condition. We are asking a minimum 
of 60 older people with heart failure to participate in the study.  
 
How Will The Study Help Me? 
While we cannot promise the study will help you, you may find 
the opportunity to talk about your experience beneficial. The 
information we get will help other older people with heart failure 
in the future, because we will have a better idea of what they 
understand about their heart condition and medication and how 
they manage their medication. We aim to use this information to 
design a programme which may help people with heart failure to 
manage their medication and condition more effectively in the 
future. 
 
Do I have to take part? 
It is up to you to decide. Participation in this study is entirely 




from the study at any time without having to give a reason and 
without this affecting your future medical care or your 
relationship with medical or nursing staff looking after you. 
Remember you can take part even if you feel you do not wish to 
recommend a friend or carer. 
 
What will happen to me if I take part? 
If you feel you may be able to help us and complete the enclosed 
reply slip, I (Roberta Fulton) will telephone you to discuss the 
study further.  
 
The telephone call 
I will first phone you at home to ask you some short questions 
about your health and current medication. If these questions 
suggest that the study is suitable for you, we will arrange for you 
to visit your local hospital. If you would prefer, I can visit you at 
home or at another place convenient for you.  
 
The study visit 
Should you be happy to travel to the hospital we can pay for a 




you home again. You may ask a friend or relative to accompany 
you to the visit should you wish it. 
At the visit, which should last around 2 hours, we will go over the 
study information; you will have the opportunity to ask any 
questions you want to about the study. If you are happy to take 
part, we will ask you to sign a consent form. You will be given a 
copy of this along with this Participant Information Sheet to keep. 
At this visit, we will do the following: 
• We will take a note of your medicines and medical 
conditions 
• Ask you to provide a small sample of urine, this will be 
tested for levels of one of the medications you are currently 
taking called Furosemide. 
• Test your walking speed and balance  
• Take some blood (about a teaspoonful), this will be sent to 
the laboratory and tested for levels of another of the medications 
you are currently taking, it may have a name like Ramipril, 
Lisinopril or Perindopril. 
• Ask you to complete nine Questionnaires. These 
questionnaires relate to your health, medication taking, mood 





Will my GP know about this research project? 
If during your study visit we discover anything we feel your GP 
should be aware of,   we will ask for your permission to share 
these findings with your GP. 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course 
of this study will be kept strictly confidential.  
Your research data will be stored using a unique study code 
which does not identify you. All written information will be kept in 
a locked filing cabinet in a locked room. Any web-based data will 
be stored in a secure password protected central database. Only 
individuals directly involved with the study will have access to 
this information. 
It is a requirement of the regulators that your records in this 
study, together with any other relevant medical records, be made 
available for scrutiny by appropriate monitors from NHS Tayside. 
This procedure is routine and carried out by fully qualified 
officials, and data confidentiality is preserved at all times. 
At the end of the study the confidential records will be kept for 
10 years and then destroyed. The confidential handling, 
processing, storage and disposal of data are in accordance with 




not wish your information to be stored you may contact the 
research team at any time and ask that it be destroyed.  
We will also ask your permission to allow us access your paper 
and electronic medical records for a period of five years. This will 
help us obtain information on your health now and over the next 
five years to investigate the long-term effects of your treatment. 
The blood sample will be sent to the local NHS laboratory for 
analysis. The result will be stored indefinitely using your name 
and unique hospital record number within the NHS clinical 
system and can be made available to specialist doctors for your 
future health care needs.  The urine sample will be stored until 
all participants have been recruited before being analysed by 
colleagues at the University of Dundee laboratories. The 
samples will be destroyed after they have finished analysing it. 
 
What will happen to the results? 
The results will be examined by the researchers who have 
organised the study and a short report will be produced. You will 
not be identified in this report.  The results will be shared with the 
funder for the study (The Scottish Government’s Chief Scientist 
Office.) The results will then be published in scientific journals. 




would like a copy of the full results, please let us know; we will 
give everyone who takes part a summary of the main results. 
 
Who is organising and funding this research? 
The study has been organised by Dr Miles Witham and 
colleagues at the University of Dundee. The study is funded by 
the Scottish Government’s Chief Scientists Office and 
sponsored by the University of Dundee and NHS Tayside. 
 
What are my rights? 
If you have any concerns about your participation in the study 
you have the right to raise your concern with a researcher 
involved in conducting the study or a doctor involved in your 
care. If you have a complaint about your participation in the 
study, you should first talk to a researcher involved in the study. 
However you have the right to raise a formal complaint. 
You can make a complaint to a senior member of the research 
team or to the Complaints Officer for NHS Tayside: 
Complaints and Feedback Team 
The Business Unit, Level 7, Laboratory Corridors B and F 
Ninewells Hospital, Dundee DD1 9SY 





In the event that you think you have suffered harm as a result of 
your participation in the study there are no automatic financial 
compensation arrangements.  However, you may have the right to 
make a claim for compensation against the University of Dundee or 
NHS Tayside. If you wish to make a claim, you should consider 
seeking independent legal advice but you may have to pay for 
your legal costs. 
The University of Dundee maintains a policy of public liability 
insurance which provides legal liability cover in respect of 
damages, costs and expenses arising out of claims. 
Tayside Health Board is a member of the Clinical Negligence 
and Other Risks Insurance Scheme which provides legal liability 
cover. 
 
Who has reviewed the study? 
The East of Scotland Research Ethics Service REC 1, which has 
responsibility for scrutinising all proposals for medical research 
on humans, has examined the proposal and has raised no 
objections from the point of view of medical ethics. It is a 
requirement that your records in this research, together with any 
relevant medical records, be available for scrutiny by monitors 




check that research is properly conducted and the interests of 
those taking part are adequately protected. 
 
What to do now: 
Now that you have read the information sheet, please think about 
it and discuss it with friends or family if you wish. If you would 
like to talk to a member of the research team about the study, 
please contact Roberta on the phone number below or return the 
reply slip in the self-addressed envelope and Roberta will contact 
you. 
Thank you for reading this Information Sheet and considering 
taking part in this study. 
By returning the form you are only agreeing that the researcher 
may phone you. You can make a decision on whether to take 
part after speaking to her 
 
Mrs Roberta Fulton 
     Call on:  01382 383086 





APPENDIX K                                           
 
Study title: How do older Heart Failure patients manage their 
medication - an observational study. 
 
Chief Investigator: Dr Miles Witham 
This form must be completed and signed by the research 
participant in the presence of Principal Investigator or someone 
from the research team designated by the Principal Investigator.   
 
 
PARTICIPANT INFORMED CONSENT FORM 
  Initials 
1. I have read and understood the Participant Information Sheet for 
the study V1.0, 04-09-15 
Yes No  
   
2. I have had the opportunity to discuss the study and to ask 
questions which have been answered to my satisfaction. 




3. I agree to my GP being informed of my participation in this study.  
 
Yes No  
   
4. I understand that my participation in the study is voluntary and 
that I am free to withdraw from the study at any time without 
having to give a reason and that this will not affect my medical 
care in any way. 
 
Yes No  
   
5. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by the research team 
or from the regulatory authorities or appropriate staff from the 
University of Dundee or NHS Tayside, where it is relevant to my 
taking part in this study.  I give permission for these individuals to 
have access to my records. 
Yes No  
   
   
6. I agree that if I withdraw or I am withdrawn from the study that 
data already collected can be retained and included in the data 
analysis.  











After initialling the boxes above please now initial the appropriate box below. 
 









Name of person taking consent Date Signature 
 












   
7. I agree that the research team can access my medical records, in 
both paper and electronic form, to obtain information on my 
health now and over the next five years to investigate the long-
term effects of the study treatment. 
 






   
8.  I agree to take part in the above study. Yes      No  








Dear    
RE: “How do older Heart Failure patients manage their medication: An 
Observational Study” 
Thank you for taking the time to read this information pack about a study 
that I am carrying out with colleagues at the University of Dundee. The 
results of this study will help us understand how well people with heart 
failure understand their condition and how they deal with their 
treatments. We are also interested in the experiences of relatives or 
carers of people diagnosed with heart failure. 
You have been nominated by [                         ] as their informal carer. 
Your participation is completely voluntary and you are free to decide to 
take part.  Before you decide I would be grateful if you could take some 
time to read the enclosed participant information sheet. 
After reading the information, if you feel you can help please complete 
the enclosed questionnaire and consent form and return them in the 
freepost envelope. 
If you would like to ask further questions or are interested in taking part 
please contact me using the details below  
 Call on:  01382 383086 
 E-mail:  r.l.z.fulton@dundee.ac.uk 
 
With kind regards 





                       
 
CARER/FAMILY MEMBERS INFORMATION SHEET 
 
  
How do older Heart Failure patients manage their 




My name is Roberta Fulton and I am undertaking a project as 
part of my PhD at the University of Dundee. I invite you to take 
part in the following study. Before you decide to do so, I need to 
be sure that you understand firstly why I am doing it, and 
secondly what it would involve if you agreed. I am therefore 
providing you with the following information. Please read it 
carefully and be sure to ask any questions you might have and, 
if you want, discuss it with others including your friends and 
family. I will do my best to explain the project to you and provide 
you with any further information you may ask for now or later. 
You do not have to make an immediate decision. 
 
Why are we doing this study? 
As researchers we are interested in the views that older people 
with heart failure have about their health, medicines and 
treatment. We are also interested in people’s day-to-day 
experiences living with medications. The results of this study will 
help us understand how well people with heart failure understand 
their condition and how they deal with their treatments. We are 
also interested in the experiences of relatives or carers of people 




we are inviting you to take part in this study. This knowledge will 
help other people get the best from their treatments in the future. 
 
Why Have I Been Invited? 
You have been invited because you care for someone aged 70 
years or over who are currently prescribed medication commonly 
used to treat people with a condition called heart failure. This 
condition means the heart does not pump enough blood to meet 
all the needs of the body, usually because the heart muscle has 
been damaged.  This condition is not uncommon; around 
900,000 people in the UK have a diagnosis of heart failure, which 
may result in symptoms such as breathlessness and tiredness. 
Many people suffering from heart failure are prescribed daily 
tablets by their doctor to help control their condition.  We are 
asking a minimum of 60 older people with heart failure and their 
informal carers to participate in the study.  
  
How Will The Study Help Me? 
While we cannot promise the study will help you or your relative 
personally the information we get will be used to help other older 
people with heart failure in the future.  We will have a better idea 
of what people understand about their heart condition and 
medication and how they manage their medication. We aim to 
use this information to design a programme that may help people 
with heart failure to manage their medication and condition more 
effectively in the future. 
 
Do I have to take part? 
It is up to you to decide. Participation in this study is entirely 
voluntary and you are free to refuse to take part from the study 
without having to give a reason and without and without it 
affecting any future medical care. 
 
What will happen to me if I take part? 
If you feel you may be able to help us please make sure you 




talk to a member of the research team about the study, please 
contact me on the phone number below. 
 
If you feel happy to participate please complete the enclosed 
questionnaire and the informed consent form and return them in 
the freepost envelope supplied. 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the 
course of this study will be kept strictly confidential.  
 
Your responses will be stored using a unique study code that 
does not identify you. All written information will be kept in a 
locked filing cabinet in a locked room. Any web-based data will 
be stored in a secure password protected central database. 
Only individuals directly involved with the study will have access 
to this information. 
 
 
It is a requirement of the regulators that your records in this study 
be made available for scrutiny by appropriate monitors from 
NHS Tayside. This procedure is routine and carried out by fully 




At the end of the study the confidential records will be kept for 
10 years and then destroyed. The confidential handling, 
processing, storage and disposal of data are in accordance 
with the Data Protection Act 1998. Should you change your 
mind and not wish your information to be stored you may 







What will happen to the results? 
The researchers who have organised the study will examine the 
results and a short report will be produced. You will not be 
identified in this report.  The results will be shared with the 
funder for the study (The Scottish Government’s Chief Scientist 
Office.) The results will then be published in scientific journals. 
Again, you will not be identified in any journal articles. If you 
would like a copy of the full results, please let us know. 
 
Who is organising and funding this research? 
The study has been organised by Dr Miles Witham and 
colleagues at the University of Dundee. The study is funded by 
the Scottish Government’s Chief Scientists Office and 
sponsored by the University of Dundee and NHS Tayside. 
 
 
What are my rights? 
If you have any concerns about your participation in the study 
you have the right to raise your concern with a researcher 
involved in conducting the study or a doctor involved in your 
care. If you have a complaint about your participation in the 
study, you should first talk to a researcher involved in the 
study. However you have the right to raise a formal complaint. 
 
You can make a complaint to a senior member of the research 
team or to the Complaints Officer for NHS Tayside: 
 
Complaints and Feedback Team 
The Business Unit,  
Level 7, Laboratory Corridors B and F  
Ninewells Hospital,  
Dundee  
DD1 9SY  







In the event that you think you have suffered harm as a result 
of your participation in the study there are no automatic financial 
compensation arrangements.  However, you may have the right 
to make a claim for compensation against the University of 
Dundee or NHS Tayside. Where you wish to make a claim, you 
should consider seeking independent legal advice but you may 
have to pay for your legal costs. 
 
The University of Dundee maintains a policy of public liability 
insurance which provides legal liability cover in respect of 
damages, costs and expenses arising out of claims. 
 
Tayside Health Board is a member of the Clinical Negligence 
and Other Risks Insurance Scheme which provides legal 
liability cover. 
 
Who has reviewed the study? 
The East of Scotland Research Ethics Service REC 2, which 
has the responsibility for scrutinising all proposals for medical 
research on humans in the UK, has examined this study and 
has raised no objections from the point of view of medical ethics. 
 
What to do now: 
Now that you have read the information sheet, please think 
about it and feel free to discuss it with friends or family if you 
wish. If you would like to talk to a member of the research team 
about the study, please contact me on the phone number below. 
If you feel you are able to help us please return the enclosed 
questionnaire and consent form in the self-addressed envelope. 
 
Thank you for reading this Information Sheet and 
considering taking part in this study. 





APPENDIX N                                          
 
Study title: How do older Heart Failure patients manage their medication 
- an observational study. 
 
Chief investigator: Dr Miles Witham  
 
 
After initialling the boxes above please now initial the appropriate box below. 
 
This research is approved by The East of Scotland Research Ethics Service REC 2  
 
   
Name of Participant Date Signature 
   
Name of person taking consent Date Signature 
 
1 copy for participant and 1 copy to be kept in the ISF. 
CARER/FAMILY MEMBER  INFORMED CONSENT FORM 
  Initials 
9. I have read and understood the Participant Information Sheet for 
the study dated 18-09-15 (Version 1.0) 
Yes No  
   
10. I have had the opportunity to discuss the study and to ask 
questions which have been answered to my satisfaction. 
Yes No  
   
11. I understand that my participation in the study is voluntary 
and that I am free to withdraw from the study at any time without 
having to give a reason, without any medical care or legal rights 
being affected 
 
Yes No  
   
12.  I agree to take part in the above study. Yes      No  
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